Derivative having ppar agonistic activity

Abstract
A compound of the formula (I):
Description
FIELD OF THE INVENTION

The present invention relates to compounds which have an agonistic activity of a peroxisome proliferator-activated receptor (referred to below as PPAR) and which are useful as a medicine.


BACKGROUND ART

Peroxisome which is an intracellular granule is a small granule in the cytoplasm containing catalase and a group of oxidases. Peroxisome proliferators which proliferate peroxisome are thought as important controlling elements of lipid metabolism in the body. A nuclear receptor, PPAR, which is activated by the peroxisome proliferator has turned out to be a multifunctional receptor concerning incretion, metabolism, inflammation or the like. Therefore, the ligand is thought to be able to apply as various medicines and the number of researches is recently increasing.


The subtype genes of PPARs are found from various animal organs and formed a family. In mammals, PPARs are classified into three subtypes of PPARα, PPARδ (also referred to as PPARγ and PPARγ.


The drugs of the fibrate group used as an antihyperlipemic drug are thought to show the activity by PPARα activation-mediated transcriptional enhancement of the gene group which improves serum lipid. Additionally, it is suggested that PPARα may relate to bone metabolism and expression of the activity of non-steroidal anti-inflammatory drugs.


The thiazolidindion compounds, which are improving drugs for insulin resistance, are ligands of PPARγ. As these compounds show hypoglycemic action, hypolipidemic action, adipocyte differentiation-inducing action or the like, PPARγ agonists are expected to develop as therapeutic agents for diabetes, hyperlipidemia, obesity or the like. Furthermore, PPARγ agonists are expected to be therapeutic agents for chronic pancreatitis, inflammatory colitis, glomerulosclerosis, Alzheimer's disease, psoriasis, parkinsonism, Basedow's disease, chronic rheumatoid arthritis, cancer (breast cancer, colonic cancer, prostatic cancer or the like), sterility or the like.


It was reported that transgenic mice in which PPARδ is overexpressed specifically in adipocyte were difficult to get fat or the like. Therefore, PPARδ agonists can be used as an antiobesity or antidiabetic drug. Additionally, PPARδ agonists are suggested the possibility as therapeutic agents for colonic cancer, osteoporosis, sterility, psoriasis, multiple sclerosis or the like.


Based on these findings, PPAR agonists are expected to be useful for treatment or prevention of hyperlipidemia, diabetes, hyperglycosemia, insulin resistance, obesity, arteriosclerosis, atherosclerosis, hypertension, syndrome X, inflammation, allergic disease (inflammatory colitis, chronic rheumatoid arthritis, chronic pancreatitis, multiple sclerosis, glomerulosclerosis, psoriasis or the like), osteoporosis, sterility, cancer, Alzheimer's disease, parkinsonism, Basedow's disease or the like (Non-Patent Document 1).


Patent Document 1 disclosed benzothiazole derivatives containing piperazine which can be used as antiobesity drugs or the like. However, it did not disclose the PPAR agonistic activity at all.


Patent Document 2 disclosed benzothiazole or benzoxazole derivatives containing piperazine or piperidine as antiviral drugs. However, it did not disclose the PPAR agonistic activity at all.


Patent Document 3 disclosed benzoxazole derivatives containing pyrrolidine as PPARγ agonists. However, it did not disclose a compound containing piperazine or piperidine.


Patent Document 4 and 5 disclosed that compounds containing piperazine have antiallergic action or the like. Non-patent Document 2 disclosed compounds containing piperazine as glycoprotein IIb/IIIa antagonists. Patent Document 6 disclosed compounds containing piperazine as CB1 antagonists. However, they did not disclose the PPAR agonistic activity at all.


Patent Document 7 and 8 disclosed compounds containing piperazine or piperidine as PPAR modulators. However, these compounds are characterized by having a sulfonyl group between piperazine and a phenyl group as a linker.


[Patent Document 1] WO 00/006558
[Patent Document 2] EP 398425
[Patent Document 3] WO 97/31907
[Patent Document 4] JP1992-345765
[Patent Document 5] JP1997-208570
[Patent Document 6] WO 2006/060461
[Patent Document 7] WO 2004/092117
[Patent Document 8] WO 2005/115983
[Non-patent Document 1]
Current Medicinal Chemistry, 2003, Vol. 10, p.p. 267-280
[Non-patent Document 2]
Bioorganic & Medical Chemistry Letters, 1998, Vol. 8, p.p. 1531-1536
DISCLOSURE OF INVENTION
Problems to be solved by the Invention

The objection of the present invention is to provide good PPAR agonists.


Means for Solving the Problem

The present inventors have intensively studied to synthesize excellent PPAR agonists and carried out search for compounds having desired pharmacological activities by using computerized molecular design technology as a means to discover candidate compounds. The inventors carried out an automatic search program of a compound from a three-dimensional compound database based on the three-dimensional structure of peroxisome proliferator-activated receptors whose structures are registered in PDB (Protein Data Bank), and by virtual screenings, they selected compounds having potentials as PPAR agonists from compounds registered in databases of commercial compounds. The inventors synthesized a lot of derivatives on the basis of the skeletons of the selected compounds and carried out tests of the synthesized derivatives such as assays for transcriptional activation of PPAR δ, α and ≡, assays for cell toxicity and the like. The inventors selected compounds having strong and desired pharmacological activities, and further prepared their derivatives to achieve the present invention. Additionally, the inventors found that compounds of the present invention have PPAR transcriptional activity, less inhibition of drug-metabolizing enzymes and good metabolic stability and solubility. Furthermore, compounds of the present invention are less toxic and thought to be safe enough for pharmaceutical use.


The present invention includes the followings.


(1) A compound of the formula (I):







a pharmaceutically acceptable salt or solvate thereof,


wherein


Ring Q is optionally substituted monocyclic aryl, optionally substituted monocyclic heteroaryl, optionally substituted fused aryl or optionally substituted fused heteroaryl provided that Ring Q is not unsubstituted 11H-dibenz[b,e]-azepine-6-yl,


Y1 is a bond, —NR6— or —NR6—CO— wherein R6 is hydrogen or optionally substituted lower alkyl,


provided that Y1 is —NR6—CO— when Ring Q is unsubstituted monocyclic aryl, and Ring Q is phenyl substituted with alkyl halide when Ring Q is monocyclic aryl and Y1 is a bond,


Ring A is optionally substituted nonaromatic heterocyclediyl, provided that Ring Q binds with a nitrogen atom of Ring A when Y1 is a bond,


a group of the formula: -Y2 Z1- is a group of the formula:







provided that a group of the formula: -Y2 Z1- is not —SO2— and, a group of the formula: -Y2 Z1- is not —CH2—CH2—O— or —O— when Ring Q is unsubstituted benzothiazole-2-yl or unsubstituted benzoxazole-2-yl,


R7 are each independently hydrogen, optionally substituted lower alkyl or optionally substituted cycloalkyl,


R8 and R9 are each independently hydrogen or optionally substituted lower alkyl,


n is an integer between 0 and 3,


Z1 is a bond, —O—, —S— or —NR9— wherein R9 is hydrogen, optionally substituted lower alkyl, optionally substituted acyl, optionally substituted lower alkylsulfonyl or optionally substituted arylsulfonyl,


Ring B is optionally substituted aromatic carbocyclediyl or optionally substituted aromatic heterocyclediyl,


Y3 is a bond, optionally substituted lower alkylene optionally intervened by —O—, cycloalkylene optionally intervened by —O— or optionally substituted lower alkenylene,


Z2 is COOR3, C(═NR1)NR14OR15, CONHCN or a group of the formula:







R3, R14 and R15 are each independently hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted aryl or optionally substituted heteroaryl, and


provided that a compound wherein a group of the formula: -Y2 Z1- is a group of the formula:







n is 0 and Z1 is a bond is excluded.


(2) The compound, pharmaceutically acceptable salt or solvate thereof according to (1),


wherein


Ring A is a group of the formula:







wherein


X4 is N or CR5 wherein R5 is hydrogen or optionally substituted lower alkyl, X5 is O, S, NR16 or CR17R18 wherein R16 to R18 are each independently hydrogen, optionally substituted lower alkyl, cyano, optionally substituted nonaromatic heterocycle, optionally substituted heteroaryl, optionally substituted amino, optionally substituted lower alkoxy, aryl lower alkyl or optionally substituted cycloalkyl, provided that a compound wherein X4 is CR5 and X5 is CR17R18 is excluded,


R4 are each independently halogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy or optionally substituted aryl,


m is an integer between 0 and 2,


the bond from X4 binds with Y1 and the other bond binds with Y2, and the other bond can bind with X5 when X5 is NR16 or CR17R18.


(3) The compound, pharmaceutically acceptable salt or solvate thereof according to (1), wherein


Ring A is a group of the formula:







X4 is N or CR5 wherein R5 is hydrogen or optionally substituted lower alkyl,


X5 is NR16 or CR17R18 wherein R16 to R18 are each independently hydrogen, optionally substituted lower alkyl, cyano, optionally substituted nonaromatic heterocycle, optionally substituted heteroaryl, optionally substituted amino, optionally substituted lower alkoxy, aryl lower alkyl or optionally substituted cycloalkyl,


R4 are each independently halogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy or optionally substituted aryl,


m is an integer between 0 and 2,


the bond from X4 binds with Y1 and the other bond binds with Y2, and the other bond can bind with X5.


(4) The compound, pharmaceutically acceptable salt or solvate thereof according to (1), wherein


Ring A is a group of the formula:







R4 are each independently halogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl or optionally substituted lower alkoxy, and


m is an integer of 1 or 2.


(5) The compound, pharmaceutically acceptable salt or solvate thereof according to (1), wherein


Ring A is a group of the formula:







R17 is optionally substituted lower alkyl, cyano, optionally substituted nonaromatic heterocycle, optionally substituted heteroaryl, optionally substituted amino, optionally substituted lower alkoxy, aryl lower alkyl or optionally substituted cycloalkyl, the bond from N binds with Y1 and the bond from C binds with Y2.


(6) The compound, pharmaceutically acceptable salt or solvate thereof according to (1), wherein


Ring A is a group of the formula:







X4 is N or CR5 wherein R5 is hydrogen or optionally substituted lower alkyl,


X5 is NR16 or CR17R18 wherein R16 to R18 are each independently hydrogen, optionally substituted lower alkyl, cyano, optionally substituted nonaromatic heterocycle, optionally substituted heteroaryl, optionally substituted amino, optionally substituted lower alkoxy, aryl lower alkyl or optionally substituted cycloalkyl, provided that a compound wherein X4 is CR5 and X5 is CR17R18 is excluded,


R4 are each independently halogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy or optionally substituted aryl,


m is an integer between 0 and 2,


the bond from X4 binds with Y1 and the other bond binds with Y2, and the other bond can bind with X5.


(7) The compound, pharmaceutically acceptable salt or solvate thereof according to (1) or (2), wherein Ring Q is substituted fused heteroaryl.


(8) The compound, pharmaceutically acceptable salt or solvate thereof according to (1) or (2), wherein Ring Q is substituted benzofuryl, substituted benzothienyl, substituted benzopyrolyl, substituted benzoxazolyl, substituted benzoisoxazolyl, substituted benzothiazolyl, substituted benzoisothiazolyl, substituted benzoimidazolyl or substituted benzopyrazolyl.


(9) The compound, pharmaceutically acceptable salt or solvate thereof according to (1) or (2), wherein


a group of the formula:







is a group of the formula:







R1 is hydrogen, halogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy or optionally substituted aryl,


R2 is halogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio or optionally substituted heteroaryl, or


R1 and R2 can be taken together with the neighboring carbon atom and 5-membered ring including X1 and X3 as the constructive atoms to form a substituted fused heteroaryl,


X1 is N or CR10, and


X3 is NR11, O or S wherein R10 and R11 are each independently hydrogen or optionally substituted lower alkyl.


(11) The compound, pharmaceutically acceptable salt or solvate thereof according to (1) or (2), wherein


a group of the formula:







is a group of the formula:







R1 is hydrogen, halogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl or optionally substituted lower alkoxy,


R2 is halogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio or optionally substituted heteroaryl, or


R1 and R2 can be taken together with the neighboring carbon atom and 5-membered ring including X1 and X3 as the constructive atoms to form a substituted fused heteroaryl, X1 is N or CR12, and


X3 is NR13, O or S wherein R12 and R13 are each independently hydrogen or optionally substituted lower alkyl.


(12) The compound, pharmaceutically acceptable salt or solvate thereof according to (1) or (2), wherein


a group of the formula:







is a group of the formula:







R1 are each independently hydrogen, halogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl or optionally substituted lower alkoxy,


R2 is halogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio or optionally substituted heteroaryl,


X1 is N or CR19, and


X3 is N or CR20 wherein R19 and R20 are each independently hydrogen or optionally substituted lower alkyl, provided that either X1 or X3 is N.


(13) The compound, pharmaceutically acceptable salt or solvate thereof according to (1) or (2), wherein


a group of the formula: -Y2Z1- is a group of the formula:







R8 and R9 are each independently hydrogen or lower alkyl,


n is an integer between 0 and 2, and


Z1 is a bond, —O— or —S—.


(14) The compound, pharmaceutically acceptable salt or solvate thereof according to (1) or (2), wherein Ring B is optionally substituted phenylene, optionally substituted indolediyl, optionally substituted benzofurandiyl, optionally substituted benzothiophenediyl, optionally substituted furandiyl or optionally substituted thiophenediyl.


(15) The compound, pharmaceutically acceptable salt or solvate thereof according to (1) or (2), wherein Y3 is a bond, optionally substituted lower alkylene, —O-optionally substituted lower alkylene or optionally substituted lower alkenylene.


(16) The compound, pharmaceutically acceptable salt or solvate thereof according to (1) or (2), wherein Z2 is COOR3 wherein R3 is hydrogen or optionally substituted lower alkyl.


(17) The compound, pharmaceutically acceptable salt or solvate thereof according to (1), wherein


a group of the formula:







is a group of the formula:







R1 is hydrogen,


R2 is optionally substituted aryl or


R1 and R2 can be taken together with the neighboring carbon atom and 5-membered ring including X1 and X3 as the constructive atoms to form a substituted fused heteroaryl,


X1 is N or CR10 wherein R10 is hydrogen,


X3 is O or S,


Y1 is a bond,


Ring A is a group of the formula:







X4 is N,


X5 is NR16 or CR17R18 wherein R16 to R18 are each independently hydrogen, optionally substituted lower alkyl, cyano, optionally substituted nonaromatic heterocycle, optionally substituted heteroaryl, optionally substituted amino, optionally substituted lower alkoxy, aryl lower alkyl or optionally substituted cycloalkyl,


R4 are each independently halogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy or optionally substituted aryl,


m is an integer between 0 and 2,


the bond from X4 binds with Y1 and the other bond binds with Y2, and the other bond can bind with X5,


a group of the formula: -Y2Z1- is a group of the formula:







R8 and R9 are each independently hydrogen or lower alkyl,


n is an integer between 0 and 2, Z1 is a bond, —O— or —S—,


Ring B is optionally substituted phenylene, optionally substituted furandiyl or optionally substituted thiophendiyl,


the substituent(s) of said phenylene, furandiyl or thiophendiyl of Ring B is/are selected from a group consisting of halogen, lower alkyl and lower alkoxy,


Y3 is a bond, optionally substituted lower alkylene, —O— optionally substituted lower alkylene or optionally substituted lower alkenylene,


the substituent(s) of said lower alkylene or lower alkenylene of Y3 is/are selected from a group consisting of halogen and lower alkylene, and


Z2 is COOR3 wherein R3 is hydrogen or lower alkyl.


(18) The compound, pharmaceutically acceptable salt or solvate thereof according to (1), wherein


a group of the formula:







is a group of the formula:







R1 are each independently hydrogen, halogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl or optionally substituted lower alkoxy,


R2 is optionally substituted alkyl or optionally substituted aryl,


X1 is N or CR19,


X3 is N or CR20 wherein R19 and R20 are each independently hydrogen or optionally substituted lower alkyl, provided that either X1 or X3 is N,


Y1 is a bond,


Ring A is a group of the formula:







X4 is N,


X5 is NR16 or CR17R18 wherein R16 to R18 are each independently hydrogen, optionally substituted lower alkyl, cyano, optionally substituted nonaromatic heterocycle, optionally substituted heteroaryl, optionally substituted amino, optionally substituted lower alkoxy, aryl lower alkyl or optionally substituted cycloalkyl,


R4 are each independently halogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy or optionally substituted aryl,


m is an integer between 0 and 2, the bond from X4 binds with Y1 and the other bond binds with Y2, and the other bond can bind with X5,


a group of the formula: -Y2 Z1- is a group of the formula:







R8 and R9 are each independently hydrogen or lower alkyl,


n is an integer between 0 and 2,


Z1 is a bond, —O— or —S—,


Ring B is optionally substituted phenylene, optionally substituted furandiyl or optionally substituted thiophendiyl,


the substituent(s) of said phenylene, furandiyl or thiophendiyl of Ring B is/are selected from a group consisting of halogen, lower alkyl and lower alkoxy,


Y3 is a bond, optionally substituted lower alkylene, —O— optionally substituted lower alkylene or optionally substituted lower alkenylene,


the substituent(s) of said lower alkylene or lower alkenylene of Y3 is/are selected from a group consisting of halogen and lower alkylene, and


Z2 is COOR3 wherein R3 is hydrogen or lower alkyl.


(19) The compound, pharmaceutically acceptable salt or solvate thereof according to (1), wherein


Y1 is a bond,


Ring A is a group of the formula:







R4 are each independently halogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl or optionally substituted lower alkoxy,


m is an integer of 1 or 2,


a group of the formula: -Y2 Z1- is a group of the formula:







R8 and R9 are each independently hydrogen or lower alkyl,


n is an integer of 1 or 2,


Z1 is a bond or —O—,


Ring B is optionally substituted phenylene,


Y3 is optionally substituted lower alkylene or —O— optionally substituted lower alkylene,


the substituent(s) of said lower alkylene of Y3 is/are selected from a group consisting of halogen and lower alkylene, and


Z2 is COOR3 wherein R3 is hydrogen or lower alkyl.


(20) The compound, pharmaceutically acceptable salt or solvate thereof according to (1),


wherein


Y1 is a bond,


Ring A is a group of the formula:







R17 is optionally substituted lower alkyl, cyano, optionally substituted nonaromatic heterocycle, optionally substituted heteroaryl, optionally substituted amino, optionally substituted lower alkoxy, aryl lower alkyl or optionally substituted cycloalkyl,


the bond from N binds with Y1 and the bond from C binds with Y2,


a group of the formula: Y2 Z1- is a group of the formula:







R8 and R9 are each independently hydrogen or lower alkyl,


n is 2,


Z1 is —O—,


Ring B is optionally substituted phenylene,


Y3 is optionally substituted lower alkylene or —O— optionally substituted lower alkylene, and the substituent(s) of said lower alkylene of Y3 is/are selected from a group consisting of halogen and lower alkylene, and


Z2 is COOR3 wherein R3 is hydrogen or lower alkyl.


(21) A pharmaceutical composition comprising the compound, pharmaceutically acceptable salt or solvate thereof according to any one of (1) to (20) as an active ingredient.


(22) A pharmaceutical composition for prevention and/or treatment for a disease concerning peroxisome proliferator-activated receptor(s), which comprises the compound, pharmaceutically acceptable salt or solvate thereof according to any one of (1) to (20) as active ingredient.


(23) A compound of the formula:







a salt or solvate thereof,


wherein


Ring Q has the same meaning as defined in (1), and


R4 is halogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl or optionally substituted lower alkoxy.


(24) A compound of the formula:







salt or solvate thereof,


wherein


Y2, Z1, Ring B, Y3 and Z2 have the same meanings as defined in (1),


R4 are each independently halogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy or optionally substituted aryl, and


RX is hydrogen or amino protecting group.


(25) A compound of the formula:







a salt or solvate thereof,


wherein


Ring Q has the same meaning as defined in (1),


R17 is optionally substituted lower alkyl, cyano, optionally substituted nonaromatic heterocycle, optionally substituted heteroaryl, optionally substituted amino, optionally substituted lower alkoxy, aryl lower alkyl or optionally substituted cycloalkyl,


R8 and R9 are each independently hydrogen or lower alkyl,


n is an integer between 1 and 3, and


X10 is halogen or hydroxy.


(26) A compound of the formula:







a salt or solvate thereof,


wherein


R4 are each independently halogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl or optionally substituted lower alkoxy,


m is 1 or 2, and


Rx is hydrogen or amino protecting group.


(27) A compound of the formula:







a salt or solvate thereof,


wherein


R4 are each independently halogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl or optionally substituted lower alkoxy,


R8 and R9 are each independently hydrogen or lower alkyl,


n is an integer between 1 and 3,


RX is hydrogen or amino protecting group, and


X10 is hydroxy or halogen.


(28) A compound of the formula:







a salt or solvate thereof,


wherein


R17 is optionally substituted lower alkyl, cyano, optionally substituted nonaromatic heterocycle, optionally substituted heteroaryl, optionally substituted amino, optionally substituted lower alkoxy, aryl lower alkyl or optionally substituted cycloalkyl,


R8 and R9 are each independently hydrogen or lower alkyl,


n is an integer between 1 and 3,


X10 is halogen or hydroxy, and


RX is hydrogen or amino protecting group.


Furthermore, the present invention provides a process for PPAR activation characterized by administrating the above compound, pharmaceutically acceptable salt or solvate thereof. In details, it is the treatment process and/or prevention process for hyperlipidemia, diabetes, obesity, arteriosclerosis, atherosclerosis, hyperglycemia and/or syndrome X.


As the other embodiment, the present invention provides use of the above compound, pharmaceutically acceptable salt or solvate thereof to produce medicines for PPAR activation, for example, medicines for treatment and/or prevention for hyperlipidemia, diabetes, obesity, arteriosclerosis, atherosclerosis, hyperglycemia and/or syndrome X.


EFFECT OF THE INVENTION

As the following test results show, compounds of the present invention have PPAR agonistic activity and are very useful as medicine and especially medicine for treatment and/or prevention for hyperlipidemia, diabetes, obesity, arteriosclerosis, atherosclerosis, hyperglycemia and/or syndrome X.







BEST MODE FOR CARRYING OUT THE INVENTION

Each term used in this description is explained below. The each term has the same meaning in this description both when it is used alone each term and when it is used with the other term.


The term “monocyclic aryl” means C6 to C12 monocyclic aromatic carbon ring. Examples include phenyl and the like.


The term “fused aryl” means aromatic carbon ring which 1 to 4 monocyclic aromatic carbon ring(s) (C6 to C12 monocyclic aromatic carbon ring(s)) is condensed with C6 to C12 monocyclic aromatic carbon ring. Examples include naphthyl, anthryl, phenanthryl and the like. The bonds can be attached to any of the rings. Naphthyl is preferable.


The term “aryl” means the above “monocyclic aryl” and “fused aryl”.


The term “aralkyl” means the above “alkyl” substituted with 1 to 3 of the above “aryl”. Examples include benzyl, phenethyl, phenylpropyl, trityl and the like.


The term “monocyclic heteroaryl” means 4- to 8-membered monocyclic aromatic heterocycle having 1 or more hetero atom(s) selected from O, S and N in the ring. Examples include pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazolyl, triazinyl, tetrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, isothiazolyl, thiazolyl, thiadiazolyl, furyl, thienyl and the like. 5- or 6-membered monocyclic aromatic heterocycle is especially preferable.


The term “fused heteroaryl” means a group derived from condensed aromatic heterocycle which aromatic carbon ring (aromatic carbon ring derived from the above “aryl”) or aromatic heterocycle (4- to 8-membered aromatic heterocycle having 1 or more hetero atom(s) selected from O, S and N in the ring) is condensed with monocyclic aromatic heterocycle derived from the above “monocyclic heteroaryl”. Examples include indolyl, isoindolyl, indazolyl, indolizinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, quinoxalinyl, prinyl, pteridinyl, benzopyranyl, benzimidazolyl, benzisoxazolyl, benzoxazolyl, benzoxadiazolyl, benzisothiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, imidazopyridyl, triazolopyridyl, imidazothiazolyl, pyradinopyridazinyl, quinazolinyl, tetrahydroquinolyl, tetrahydrobenzothienyl, carbazolyl, acridinyl, xanthenyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, dibenzofuryl and the like. In case of “fused heteroaryl”, the bonds can be attached to any of the rings. A condensed fused heteroaryl which benzene ring is condensed with 5- or 6-membered monocyclic aromatic heterocycle is especially preferable.


The term “heteroaryl” means the above “monocyclic heteroaryl” and “fused heteroaryl”.


The term “heteroaralkyl” means the above “alkyl” substituted with 1 to 3 of the above “heteroaryl”.


The term “nonaromatic heterocycle” means a condensed nonaromatic heterocycle which aromatic carbon ring (aromatic carbon ring derived from the above “aryl”), aromatic heterocycle (4- to 8-membered aromatic heterocycle having 1 or more hetero atom(s) selected from O, S and N in the ring), monocyclic nonaromatic heterocycle (monocyclic nonaromatic heterocycle derived from the above “monocyclic nonaromatic heterocycle”) or cycloalkane (a ring derived from the below “cycloalkyl”) is condensed with 4- to 8-membered monocyclic nonaromatic heterocycle having 1 or more hetero atom(s) selected from O, S and N in the ring or the above “monocyclic nonaromatic heterocycle”. Examples include indolinyl, dioxanyl, thiiranyl, oxyranyl, oxathiolanyl, azetidinyl, thianyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperidino, piperazinyl, piperadino, morpholinyl, morpholino, oxadiadinyl, dihydropyridyl and the like.


The term “heterocycle” include the above “heteroaryl” and “nonaromatic heterocycle”. Examples include morpholino, piperidino, piperadino, furyl, thienyl, pyridyl and the like.


The term “nonaromatic heterocyclediyl” includes a bivalent group derived by removing 2 hydrogen atoms from 4- to 10-membered nonaromatic heterocycle having 1 or more hetero atom(s) selected from O, S and N in the ring. The nonaromatic heterocycle can be bridged by alkylene. The preferable examples include piperidinediyl, piperadinediyl, morpholinediyl, dioxanediyl, pyrrolidinediyl, pyrrolinediyl, imidazolinediyl, imidazolidinediyl and the like. Examples of “nonaromatic heterocyclediyl” of Ring A include the following groups.


A group of the formula:







wherein


X4 is N or CR5 wherein R5 is hydrogen or optionally substituted lower alkyl,


X5 is O, S, NR16 or CR17R18 wherein R16 to R18 are each independently hydrogen, optionally substituted lower alkyl, optionally substituted nonaromatic heterocycle, optionally substituted heteroaryl, optionally substituted amino, optionally substituted lower alkoxy, aryl lower alkyl or optionally substituted cycloalkyl, provided that a compound wherein X4 is CR5 and X5 is CR17R18 is excluded,


R4 are each independently halogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy or optionally substituted aryl, and


m is an integer between 0 and 2,


the bond from X4 binds with Y1 and the other bond binds with Y2, and the other bond can bind with X5 when X5 is NR16 or CR17R18. The other bond preferably binds with X5.


“The other bond can bind with X5 when X5 is NR16” means the below.







wherein each symbol has the same meaning as defined above.


“The other bond can bind with X5 when X5 is CR17R18” means the below.







wherein each symbol has the same meaning as defined above.


The term “aromatic carbocyclediyl” includes a bivalent group derived by removing a hydrogen atom from the above “aryl”. Examples include phenylene, naphthylene and the like. Phenylene is preferable.


The term “aromatic heterocyclediyl” includes a bivalent group derived by removing a hydrogen atom from the above “heteroaryl”. Examples includes pyrroldiyl, imidazolediyl, pyrazolediyl, pyridinediyl, pyridazinediyl, pyrimidinediyl, pyrazinediyl, triazolediyl, triazinediyl, isoxazolediyl, oxazolediyl, oxadiazolediyl, isothiazolediyl, thiazolediyl, thiadiazolediyl, furandiyl, thiophenediyl, indolediyl, benzofurandiyl, benzothiophenediyl and the like. Indolediyl, benzofurandiyl, benzothiophenediyl, furandiyl or thiophenediyl is preferable. Monocyclic aromatic heterocyclediyl is especially preferable. Furandiyl (especially furan-2,5-diyl) or thiophenediyl (especially thiophene-2,5-diyl) is more preferable.


The term “lower alkyl” means C1 to C10, preferably C1 to C6 and more preferably C1 to C4 straight or branched alkyl group. Examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-buthyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl, isooctyl, n-nonyl, n-decyl and the like.


The term “lower alkenyl” means C2 to C10, preferably C2 to C6 and more preferably C2 to C4 straight or branched alkenyl having one or more double bond(s) at arbitrary position(s). Examples include vinyl, propenyl, isopropenyl, butenyl, isobutenyl, prenyl, butadienyl, pentenyl, isopentenyl, pentadienyl, hexenyl, isohexenyl, hexadienyl, heptenyl, octenyl, nonenyl, decenyl and the like.


The term “lower alkynyl” means C2 to C10, preferably C2 to C6 and more preferably C2 to C4 straight or branched alkynyl. Examples include ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decenyl and the like. These have one or more triple bond(s) at arbitrary position(s) and can have double bond(s).


The term “cycloalkyl” includes C3 to C9 and preferably C3 to C6 cycloalkyl. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cycloctyl and the like.


The term “cycloalkylene” includes C3 to C9 and preferably C3 to C6 cycloalkylene. Examples include cyclopropylene, cyclobutylene, cyclopenthylene, cyclohexylene, cycloheptylene, cycloethylene and the like. Cyclopropylene is especially preferable.


“Cycloalkylene optionally intervened by —O—” means cycloalkylene which is the above “cycloalkylene” optionally intervened by 1 or 2-O—. Examples include a group of the formula:







The term “acyl” includes (a) carbonyl substituted with the above “alkyl” or “alkenyl”, (b) carbonyl substituted with the above “cycloalkyl”, (c) carbonyl substituted with the above “aryl” or (d) formyl. Examples include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, pivaloyl, hexanoyl, acryloyl, propioloyl, methacryloyl, crotonoyl, cyclopropylcarbonyl, cyclohexylcarbonyl, cyclooctylcarbonyl, benzoyl and the like.


The term “lower alkylene” includes C1 to 10, preferably C1 to 6 and more preferably C1 to 3 straight or branched alkylene. Examples include methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, methylmethylene, propylene, dimethylmethylene, 1,1-dimethylethylene, 1,2-dimethylethylene and the like. Methylene, ethylene or dimethylmethylene is especially preferable.


“Lower alkylene optionally intervened by —O—” means alkylene which is the above “alkylene” optionally intervened by 1 to 3-O—. Alkylene which —O— is intervened at the end is also included. Examples include —O—CH2—, —CH2—O—, —CH2—O—CH2—, —O—CH2—CH2—, —CH2—CH2—O—, —O—CH(CH3)—, —O—C(CH3)2—, —O—CH2—CH2—O—, —O—CH(CH3)—O—, —O—C(CH3)2—O— and the like.


“—O-optionally substituted lower alkylene” means alkylene which —O— is intervened at the end.


The term “lower alkenylene” includes C2 to 10, preferably C2 to C6 and more preferably C2 to C4 straight or branched alkenylene having one or more double bond(s) at arbitrary position(s). Examples include vinylene, propenylene and the like.


The term “halogen” means fluorine, chlorine, bromine or iodine. Especially, fluorine, chlorine or bromine is preferable.


An alkyl part of “lower alkoxy” is the same as the above “lower alkyl”.


Examples of the substituent of “optionally substituted lower alkyl”, “optionally substituted lower alkylsulfonyl”, “optionally substituted lower alkenyl”, “optionally substituted lower alkynyl”, “optionally substituted lower alkylene”, “optionally substituted lower alkenylene”, “optionally substituted lower alkoxy” or “optionally substituted acyl” include halogen, hydroxy, optionally substituted lower alkoxy, optionally substituted lower alkynyloxy, optionally substituted amino, mercapto, optionally substituted lower alkylthio, acyl, acyloxy, optionally substituted imino, carboxy, optionally substituted lower alkoxycarbonyl, optionally substituted carbamoyl, optionally substituted thiocarbamoyl, optionally substituted carbamoyloxy, optionally substituted thiocarbamoyloxy, optionally substituted sulfamoyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylsulfonyloxy, cyano, nitro, optionally substituted cycloalkyl, optionally substituted cycloalkyloxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heterocycle, optionally substituted heterocycleoxy, optionally substituted lower alkylene, optionally substituted lower alkylenedioxy and oxo. They can be substituted at arbitrary position(s) with one or more group(s) selected from the above. In case that optionally substituted lower alkylene or optionally substituted lower alkylenedioxy is the substituent, the two bonds bind with one carbon atom to form a spiro ring, or bind with different atoms and are taken together with the neighboring carbon atom to form a ring.


A heterocycle part of “heterocycleoxy” is the same as the above “heterocycle”.


Examples of the substituent of “optionally substituted monocyclic aryl”, “optionally substituted monocyclic heteroaryl”, “optionally substituted aryl”, “optionally substituted aralkyl”, “optionally substituted aryloxy”, “optionally substituted arylthio”, “optionally substituted heteroaryl”, “optionally substituted hetroaralkyl”, “optionally substituted heteroaryloxy”, “optionally substituted heteroarylthio”, “substituted fused aryl”, “substituted fused heteroaryl”, “optionally substituted arylsulfonyl”, “optionally substituted aromatic carbocyclediyl”, “optionally substituted aromatic heterocyclediyl” or “optionally substituted nonaromatic heterocyclediyl” include optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkenyl, optionally substituted lower alkenyloxy, halogen, hydroxy, optionally substituted lower alkoxy, optionally substituted lower alkynyloxy, optionally substituted amino, mercapto, optionally substituted lower alkylthio, acyl, acyloxy, optionally substituted imino, carboxy, optionally substituted lower alkoxycarbonyl, optionally substituted carbamoyl, optionally substituted thiocarbamoyl, optionally substituted carbamoyloxy, optionally substituted thiocarbamoyloxy, optionally substituted sulfamoyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylsulfonyloxy, cyano, nitro, optionally substituted cycloalkyl, optionally substituted cycloalkyloxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heterocycle, optionally substituted heterocycleoxy, optionally substituted lower alkylene and optionally substituted lower alkylenedioxy. They can be substituted at arbitrary position(s) with one or more group(s) selected from the above. In case that optionally substituted lower alkylene or optionally substituted lower alkylenedioxy is the substituent, the bonds can bind with different atoms and be taken together with the neighboring carbon atom to form a ring.


Preferable examples in the above substituents include halogen, hydroxy, optionally substituted lower alkyl (the substituent is halogen or hydroxy), optionally substituted lower alkenyl (the substituent is halogen or hydroxy), optionally substituted lower alkoxy (the substituent is halogen or aryl), carboxy, lower alkoxycarbonyl, optionally substituted carbamoyl (the substituent is lower alkyl or aryl), optionally substituted amino (the substituent is acyl or lower alkyl), mercapto, lower alkylthio, acyl, acyloxy, cyano, nitro, aryl, heterocycle, lower alkylene and lower alkylenedioxy. Halogen or optionally substituted lower alkyl (the substituent is halogen) is especially preferable.


A substituent of “substituted benzofuryl”, “substituted benzothienyl”, “substituted benzopyronyl”, “substituted benzoxazolyl”, “substituted benzisoxazolyl”, “substituted benzothiazolyl”, “substituted benzisothiazolyl”, “substituted benzimidazolyl” or “substituted benzopyrazolyl” is the same as the substituent of the above “substituted fused heteroaryl”.


A substituent of “optionally substituted phenylene” is the same as the substituent of “optionally substituted aromatic carbocyclediyl”.


A substituent of “optionally substituted indolediyl”, “optionally substituted benzofurandiyl”, “optionally substituted benzothiophenediyl”, “optionally substituted furandiyl” or “optionally substituted thiophenediyl” is the same as the substituent of the above “optionally substituted aromatic heterocyclediyl”.


Examples of a substituent of “optionally substituted nonaromatic heterocyclediyl” include halogen, hydroxy, optionally substituted lower alkoxy, optionally substituted lower alkynyloxy, optionally substituted amino, mercapto, optionally substituted lower alkylthio, acyl, acyloxy, optionally substituted imino, carboxy, optionally substituted lower alkoxycarbonyl, optionally substituted carbamoyl, optionally substituted thiocarbamoyl, optionally substituted carbamoyloxy, optionally substituted thiocarbamoyloxy, optionally substituted sulfamoyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylsulfonyloxy, cyano, nitro, optionally substituted cycloalkyl, optionally substituted cycloalkyloxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heterocycle, optionally substituted heterocycleoxy, optionally substituted lower alkylene, optionally substituted lower alkylenedioxy and oxo. It can be optionally substituted at arbitrary position(s) with one or more group(s) selected from the above. In case that optionally substituted lower alkylene or optionally substituted lower alkylenedioxy is a substituent, the two bonds bind with one carbon atom to form a spiro ring, or bind with different atoms and are taken together to with the neighboring carbon atom to form a ring.


A substituent of “optionally substituted lower alkynyloxy”, “optionally substituted lower alkylthio”, “optionally substituted lower alkoxycarbonyl”, “optionally substituted lower alkylsulfonyloxy”, “optionally substituted cycloalkyl”, “optionally substituted cycloalkyloxy”, “optionally substituted arylsulfonyl”, “optionally substituted arylsulfonyloxy”, “optionally substituted heterocycle”, “optionally substituted heterocycleoxy” or “optionally substituted lower alkylenedioxy” is the same as the substituent of the above “optionally substituted lower alkyl”.


A substituent of “optionally substituted amino”, “optionally substituted imino”, “optionally substituted carbamoyl”, “optionally substituted thiocarbamoyl”, “optionally substituted carbamoyloxy”, “optionally substituted thiocarbamoyloxy” or “optionally substituted sulfamoyl” is the same as the substituent of the above “optionally substituted lower alkyl”. These substituents can be mono- or di-substituted on a nitrogen atom. Lower alkyl, aryl, heterocycle, acyl, lower alkoxycarbonyl, lower alkylsulfonyl or arylsulfonyl is especially preferable.


Preferable embodiments of each substituent for a compound of the formula (I) are explained below.


Ring Q is optionally substituted monocyclic aryl, optionally substituted monocyclic heteroaryl, optionally substituted fused aryl or optionally substituted fused heteroaryl. Preferable examples include monocyclic aryl substituted with one or more of R2 and optionally substituted with other group(s), monocyclic heteroaryl substituted with one or more of R2 and optionally substituted with other group(s) wherein each R2 is halogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaryloxy or optionally substituted heteroarylthio, substituted fused aryl or substituted fused heteroaryl. Monocyclic heteroaryl substituted with one of R2 and optionally substituted with other group(s) wherein R2 is halogen, optionally substituted alkyl or optionally substituted aryl, substituted fused aryl or substituted fused heteroaryl is especially preferable.


“and optionally substituted with other group(s)” means to be optionally substituted except for the substituent, R2. The substituent(s) can be the same substituent as R2.


Examples of substituted fused heteroaryl include substituted benzofuryl, substituted benzothienyl, substituted benzopyronyl, substituted benzoxazolyl, substituted benzisoxazolyl, substituted benzothiazolyl, substituted benzisothiazolyl, substituted benzimidazolyl, substituted benzopyrazolyl and the like. Substituted benzothiazolyl wherein the substituent is halogen, optionally substituted lower alkyl, optionally substituted lower alkoxy, aryl, lower alkylsulfonyl or optionally substituted carbamoyl is especially preferable.


Especially preferable examples of Ring Q include below.


A group of the formula:







R1 is hydrogen, halogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy or optionally substituted aryl,


R2 is halogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio or optionally substituted heteroaryl, or


R1 and R2 can be taken together with the neighboring carbon atom to form optionally substituted ring,


X1 is N or CR10, and


X3 is NR11, O or S wherein R10 and R11 are each independently hydrogen or optionally substituted lower alkyl,


a group of the formula:







R1 is hydrogen, halogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl or optionally substituted lower alkoxy,


R2 is halogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio or optionally substituted heteroaryl, or


R1 and R2 can be taken together with the neighboring carbon atom to form optionally substituted ring,


X1 is N or CR12, and


X3 is NR13, O or S wherein R12 and R13 are each independently hydrogen or optionally substituted lower alkyl, or


a group of the formula:







R1 are each independently hydrogen, halogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl or optionally substituted lower alkoxy,


R2 is halogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio or optionally substituted heteroaryl,


X1 is N or CR19, and


X3 is N or CR20 wherein R19 and R20 are each independently hydrogen or optionally substituted lower alkyl, provided that either X1 or X3 is N.


The following embodiments are preferable as “substituted fused heteroaryl” of Ring Q.







R is optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkenyl, optionally substituted lower alkenyloxy, halogen, hydroxy, optionally substituted lower alkoxy, optionally substituted lower alkynyloxy, optionally substituted amino, mercapto, optionally substituted lower alkylthio, acyl, acyloxy, optionally substituted imino, carboxy, optionally substituted lower alkoxycarbonyl, optionally substituted carbamoyl, optionally substituted thiocarbamoyl, optionally substituted carbamoyloxy, optionally substituted thiocarbamoyloxy, optionally substituted sulfamoyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylsulfonyloxy, cyano, nitro, optionally substituted cycloalkyl, optionally substituted cycloalkyloxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heterocycle, optionally substituted heterocycleoxy,

    • R′ is hydrogen or has the same meaning as the above R, and provided that R can be hydrogen when R′ has the same meaning as the above R.


The following embodiments are also preferable as “monocyclic heteroaryl substituted with one or more of R2 and optionally substituted with other group(s)” for ring Q.







R1 is hydrogen, halogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy or optionally substituted aryl, and


R and R′ are each independently hydrogen, halogen, hydroxy, optionally substituted lower alkoxy, optionally substituted lower alkynyl oxy, optionally substituted amino, mercapto, optionally substituted lower alkylthio, acyl, acyloxy, optionally substituted imino, carboxy, optionally substituted lower alkoxycarbonyl, optionally substituted carbamoyl, optionally substituted thiocarbamoyl, optionally substituted carbamoyloxy, optionally substituted thiocarbamoyloxy, optionally substituted sulfamoyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylsulfonyloxy, cyano, nitro, optionally substituted cycloalkyl, optionally substituted cycloalkyloxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heterocycle, optionally substituted heterocyclyloxy or the like.


Y1 is a bond, —NR6— or —NR6—CO— wherein R6 is hydrogen or optionally substituted lower alkyl. A bond is especially preferable.


Ring A is optionally substituted nonaromatic heterocyclediyl, provided that Ring Q binds with a nitrogen atom of Ring A when Y1 is a bond. Especially preferable examples include a group of the formula:







wherein


X4 is N or CR5 wherein R5 is hydrogen or optionally substituted lower alkyl,


X5 is O, S, NR16 or CR18R18 wherein R16 to R18 are each independently hydrogen, optionally substituted lower alkyl, cyano, optionally substituted nonaromatic heterocycle, optionally substituted heteroaryl, optionally substituted amino, optionally substituted lower alkoxy, aryl lower alkyl or optionally substituted cycloalkyl, provided that a compound wherein X4 is CR5 and X5 is CR17R18 is excluded,


R4 are each independently halogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy or optionally substituted aryl, and


m is an integer between 0 and 2,


the bond from X4 binds with Y1 and the other bond binds with Y2, and the other bond can bind with X5 when X5 is NR16 or CR17R18.


More preferable examples include a group of the formula:







wherein


X4 is N or CR5 wherein R5 is hydrogen or optionally substituted lower alkyl,


X5 is NR16 or CR17R18 wherein R16 to R18 are each independently hydrogen, optionally substituted lower alkyl, cyano, optionally substituted nonaromatic heterocycle, optionally substituted heteroaryl, optionally substituted amino, optionally substituted lower alkoxy, aryl lower alkyl or optionally substituted cycloalkyl, provided that a compound wherein X4 is CR5 and X5 is CR17R18 is excluded,


R4 are each independently halogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy or optionally substituted aryl,


m is an integer between 0 and 2,


the bond from X4 binds with Y1 and the other bond binds with Y2, and the other bond can bind with X5 when X5 is NR16 or CR17R18.


Much more preferable examples include a group of the formula:







wherein


X4 is N,


X5 is NR16 or CR17R18 wherein R16 to R18 are each independently hydrogen, optionally substituted lower alkyl, cyano, optionally substituted nonaromatic heterocycle, optionally substituted heteroaryl, optionally substituted amino, optionally substituted lower alkoxy, aryl lower alkyl or optionally substituted cycloalkyl,


R4 are each independently halogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy or optionally substituted aryl,


m is an integer between 0 and 2,


the bond from X4 binds with Y1 and the other bond binds with Y2.


Especially preferable examples of m include 1 and 2. R4 are especially each independently optionally substituted lower alkyl and the preferable examples include C1 to C4 straight or branched alkyl. Much more preferable examples include a group of the formula:







R4 are each independently halogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl or optionally substituted lower alkoxy, and


m is an integer of 1 or 2, or


a group of the formula:







R17 is optionally substituted lower alkyl, cyano, optionally substituted nonaromatic heterocycle, optionally substituted heteroaryl, optionally substituted amino, optionally substituted lower alkoxy, aryl lower alkyl or optionally substituted cycloalkyl,


the bond from N binds with Y1 and the bond from C binds with Y2.


A group of the formula: -Y2 Z1- is a group of the formula:







R7 are each independently hydrogen, optionally substituted lower alkyl or optionally substituted cycloalkyl,


R8 and R9 are each independently hydrogen or optionally substituted lower alkyl,


n is an integer between 0 and 3,


Z1 is a bond, —O—, —S— or —NR9— wherein R9 is hydrogen, optionally substituted lower alkyl, optionally substituted acyl, optionally substituted lower alkylsulfonyl or optionally substituted arylsulfonyl. Especially preferable examples include a group of the formula:







R8 and R9 are each independently hydrogen or lower alkyl,


n is an integer between 0 and 2, and


Z1 is a bond, —O— or —S—.


The following embodiments are also preferable as a group of the formula: -Y1-Ring A-Y2-Z1










R17 is hydrogen, optionally substituted lower alkyl, cyano, optionally substituted nonaromatic heterocycle, optionally substituted heteroaryl, optionally substituted amino, optionally substituted lower alkoxy, aryl lower alkyl or optionally substituted cycloalkyl,


R6 is hydrogen or optionally substituted lower alkyl,


R7 is hydrogen, optionally substituted lower alkyl or optionally substituted cycloalkyl,


R4 are each independently halogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy or optionally substituted aryl,


Z1 is a bond, O, S or NR9 wherein R9 is hydrogen, optionally substituted lower alkyl, optionally substituted acyl, optionally substituted lower alkylsulfonyl or optionally substituted arylsulfonyl,


n is an integer between 0 and 3.


R17 is especially nonaromatic heterocycle. Preferable examples include pyrrolidinyl, piperidyl, azepanyl, morpholinyl and the like.


Ring B is optionally substituted aromatic carbocyclediyl or optionally substituted aromatic heterocyclediyl. Especially preferable examples include optionally substituted phenylene, optionally substituted furandiyl and optionally substituted thiophenediyl, and the substituent(s) of said phenylene, furandiyl or thiophendiyl is/are selected from a group consisting of halogen, lower alkyl and lower alkoxy.


Y3 is a bond, optionally substituted lower alkylene optionally intervened by —O—, cycloalkylene optionally intervened by —O— or optionally substituted lower alkenylene. Especially preferable examples include a bond, optionally substituted lower alkylene, —O-optionally substituted lower alkylene and optionally substituted lower alkenylene, and the substituent(s) of said lower alkylene or lower alkenylene is/are selected from a group consisting of lower alkylene and halogen.


Z1 is COOR3, C(═NR3)NR14OR15, CONHCN or a group of the formula:







R3, R14 and R15 are each independently hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted aryl or optionally substituted heteroaryl. Especially preferable examples include COOR3 wherein R3 is hydrogen or optionally substituted lower alkyl.


The following embodiments are also preferable as a group of the formula: -Z1-Ring B—Y3-Z2.







Z1 is a bond, —O—, —S— or —NR9— wherein R9 is hydrogen, optionally substituted lower alkyl, optionally substituted acyl, optionally substituted lower alkylsulfonyl or optionally substituted arylsulfonyl, and


R, R′ and R″ are each independently hydrogen, halogen, hydroxy, optionally substituted lower alkoxy, optionally substituted lower alkynyloxy, optionally substituted amino, mercapto, optionally substituted lower alkylthio, acyl, acyloxy, optionally substituted imino, carboxy, optionally substituted lower alkoxycarbonyl, optionally substituted carbamoyl, optionally substituted thiocarbamoyl, optionally substituted carbamoyloxy, optionally substituted thiocarbamoyloxy, optionally substituted sulfamoyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylsulfonyloxy, cyano, nitro, optionally substituted cycloalkyl, optionally substituted cycloalkyloxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heterocycle, optionally substituted heterocyclyloxy, optionally substituted lower alkylene, optionally substituted lower alkylenedioxy or oxo.


A compound of the present invention includes producible and pharmaceutically acceptable salts of each compound. Examples of “a pharmaceutically acceptable salt” include salts of inorganic acid such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid or the like; salts of organic acid such as paratoluenesulfonic acid, methanesulfonic acid, oxalic acid, citric acid or the like; salts of organic salt group such as ammonium, trimethylammonium or triethylammonium; salts of alkali metal such as sodium or potassium; and alkaline-earth metal salts such as calcium, magnesium or the like.


A compound of the present invention includes a solvate thereof and can be coordinate any number of solvent molecules to Compound (I). Hydrate is preferable.


When Compound (I) of the present invention has an asymmetric carbon atom, it contained racemic body and all stereoisomers (a diastereoisomer, an antipode or the like). When Compound (I) of the present invention has a double bond and there is geometrical isomer at a substituent position of the double bond, it includes both type of the isomers.


The popular methods for production of compounds of the present invention are described below.


Step A






wherein X is halogen or the like, and the other symbols have the same meaning as defined in the above (1).


This step is a method for production of Compound (C) by reacting Compound (A) and (B).


This step is especially preferably carried out especially under the presence of base. Examples of the base include potassium carbonate, sodium carbonate, sodium hydrogencarbonate, sodium hydroxide, sodium hydride, triethylamine, N,N-diisopropylethylamine and the like. Examples of the reaction solvent include N,N-dimethylformamide, tetrahydrofuran, dioxane, methylene chloride, acetonitrile, dimethylsulfoxide and the like. The reaction can be performed at room temperature to 100° C.


The acid addition salt can be used as Compound (B). In that case, the value of the base used in the reaction is increased.


Step B






wherein X is halogen or the like, and the other symbols have the same meaning as defined in the above (1).


This step is a method for production of Compound (C) by reacting Compound (D) and (E).


This step can be carried out under the same conditions as Step B.


Step C






wherein X is halogen or the like, and the other symbols have the same meaning as defined in the above (1).


This step is a method for production of Compound (H) by reacting Compound (F) and (G).


This step can be carried out under the same conditions as Step A and B.


Step D






wherein X is halogen or the like, and the other symbols have the same meaning as defined in the above (1).


This step is a method for production of Compound (L) by reacting Compound (J) and (K).


This step can be carried out under the same conditions as Step A, B and C.


Step E






wherein each symbol has the same meaning as defined in the above (1).


This step is a method for production of Compound (O) by reacting Compound (M) and (N).


This step can be carried out by Mitsunobu reaction under the presence of azodicarboxylate and triphenylphosphine. Instead of azodicarboxylate, 1,1-azodicarbonyldipiperidine, N,N,N′N′-tetramethylazodicarboxamide or the like can be used. Instead of triphenylphosphine, tributyl phosphine or the like can be used. Examples of the reaction solvent include tetrahydrofuran, toluene, benzene and the like. The reaction can be carried out at room temperature.


Step F






wherein X is halogen or the like, and the other symbols have the same meaning as defined in the above (1).


This step is a method for production of Compound (R) by reacting Compound (P) and (Q).


This step can be carried out under the same conditions as Step A, B, C and D.


Step G






wherein X is halogen or the like, and the other symbols have the same meaning as defined in the above (1).


This step is a method for production of Compound (O) by reacting Compound (P) and (S).


This step can be carried out under the same conditions as Step A, B, C, D and F.


When the compound obtained by the above any step is ester of COOR3, this compound is hydrolyze by the usual method to give carboxylic acid of COOH.


If necessary, at an appropriate step in the above method for production, any substituent can be transform to a different substituent by the well-known organic synthesized reaction.


For example, when any compound has halogen, it is reacted with alcohol in a solvent such as DMF, tetrahydrofuran or the like under the presence of base such as sodium hydride, potassium hydride or the like and deacid reagent such as alkali metal hydroxide, alkali metal hydrogencarbonate, alkali metal carbonate, organic base or the like at −20° C. to 100° C. to give a compound whose substituent is transformed to lower alkoxy.


When any compound has alkyl hydroxy, it is reacted with oxidizing agent such as pyridinium dichromate, Jones reagent, manganese dioxide, potassium permanganate, ruthenium tetroxide or the like in a solvent such as dimethyl formamide, tetrahydrofuran, dichloromethane, benzene, acetone or the like to give a compound whose substituent is transformed to carboxy.


If necessary, after amino or hydroxy of a compound is protected by the usual process at an appropriate step, it is subjected to the reaction and then deprotected by treatment with acid or base at an appropriate step.


As an amino protecting group, phthalimide, lower alkoxycarbonyl (e.g., butoxycarbonyl (Boc)), lower alkenyloxycarbonyl, halogenoalkoxycarbonyl, aryl lower alkoxycarbonyl, trialkylsilyl, lower alkylsulfonyl, halogeno lower alkylsulfonyl, arylsulfonyl, lower alkylcarbonyl, arylcarbonyl, aryl lower alkyl (e.g., benzyl) or the like can be used.


As a hydroxy protecting group, alkyl (e.g., t-butyl), aralkyl (triphenylmethyl or benzyl), trialkylsilyl (e.g., t-butyldimethylsilyl or triisopropylsilyl), alkyldiarylsilyl (e.g., t-butyldiphenylsilyl), triaralkylsilyl (e.g., tribenzylsilyl), alkoxyalkyl (e.g., methoxymethyl, 1-ethoxyethyl or 1-methyl-1-methoxyethyl), alkoxyalkoxyalkyl (e.g., methoxyethoxymethyl), alkylthioalkyl (e.g., methylthiomethyl), tetrahydropyranyl (e.g., tetrahydropyran-2-yl or 4-methoxytetrahydropyran-4-yl), tetrahydrothiopyranyl (e.g., tetrahydrothiopyran-2-yl), tetrahydrofuranyl (e.g., tetrahydrofuran-2-yl), tetrahydrothiofuranyl (e.g., tetrahydrothiofuran-2-yl), aralkyloxyalkyl (e.g., benzyloxymethyl)alkylsulfonyl, acyl, p-toluenesulfonyl or the like can be used.


Deprotection reaction is carried out in a solvent such as tetrahydrofuran, dimethylformamide, diethylether, dichloromethane, toluene, benzene, xylene, cyelohexane, hexane, chloroform, ethyl acetate, butyl acetate, pentane, heptane, dioxane, acetone, acetonitrile or a mixed solvent thereof, by using base such as hydrazine, pyridine, sodium hydroxide, potassium hydroxide or the like or acid such as hydrochloric acid, trifluoroacetic acid, hydrofluoric acid or the like.


Step H






wherein RX is an amino protecting group (e.g., benzyl or tert-butoxycarbonyl) or the like, X10 is halogen, and the other symbols have the same meanings as above.


Compound (O1) is reacted with a derivative having Ring Q under the presence of a base to give Compound (O2). The protecting group of the obtained Compound (O2) is removed and the compound is reacted with Compound (O4) to give Compound (O5).


Step I






wherein RX is an amino protecting group (e.g., benzyl or tert-butoxycarbonyl) or the like, RY is lower alkyl or the like, X10 is hydroxy, Z1 is O, S or NR9, and the other symbols have the same meanings as above.


A compound of the formula: X—C(R8R9)n-1—COORY is reacted to Compound (P1) under the presence of the base (e.g., potassium carbonate) to give Compound (P2). As the solvent, dimethylformamide or the like can be used.


The obtained Compound (P2) is reduced to give Compound (P3). The reduction can be used with lithium aluminium hydride or the like.


The obtained Compound (P3) is reacted with mesyl chloride or the like to transform X10 to a leaving group and coupled with a compound having Ring B.


After that, Compound (P5) is obtained by deprotection of RX and reacted with phenylisocyanate derivatives or the like to give Compound (P6).


Compound (P7) can be also obtained by reacting with a compound having Ring Q.


A compound wherein Z1 is —S— or —NR9— can be obtained by transforming X10 of Compound (P3) to halogen and reacting with a compound having Ring B.


Step J






wherein RX is an amino protecting group (e.g., benzyl or tert-butoxycarbonyl) or the like, RY is lower alkyl or the like, X10 is hydroxy or halogen, Z1 is —O—, —S— or —NR9—, and the other symbols have the same meanings as above.


COORY is reduced by introducing from Compound (Q1) to Compound (Q2). The reduction can be carried out with lithium aluminium hydride or the like. Next, the deprotection of RX is carried out. When the protecting group is benzyl, the deprotection is carried out by a catalytic reduction or the like. After the deprotection, a compound having Ring Q is reacted under the presence of base (e.g., potassium carbonate) to give Compound (Q4). Next, a compound having Ring B is reacted to the obtained Compound (Q4) to give Compound (Q5). A compound wherein Z1 is —S— or —NR9— can be also obtained by transforming X10 of Compound (Q4) to halogen and reacting with a compound having Ring B.


A pharmaceutical composition for PPAR agonist of the present invention can be effectively acted on all diseases concerning PPAR and especially for prevention and/or treatment of hyperlipidemia, dyslipidosis, disorder of lipid metabolism, Low HDL, High LDL, High VLDL, High TG, diabetes, hyperglycosemia, insulin resistance, obesity, bulimia, arteriosclerosis, atherosclerosis, hypertension, syndrome X, ischemic disease, inflammation, allergic disease (e.g., inflammatory bowel disease, rheumatoid arthritis, chronic pancreatitis, multiple sclerosis, glomerulosclerosis, psoriasis or eczema), osteoporosis, sterility, cancer (e.g., breast cancer, colonic cancer, colon cancer, ovarian cancer or lung cancer), Alzheimer's disease, parkinsonism or Basedow's disease. Especially, a compound having PPARδ selective agonistic activity in compounds of the present invention having PPAR agonistic activity can be a good medicine. The reason is, for example, that it can be expected to have a high HDL increasing activity or that the side effect can be lightened.


Furthermore, a compound of the present invention has the good characters, for example,


a) weak CYP enzyme inhibition


b) high water solubility


c) good drug disposition such as high bioavailability


d) low toxicity of anemia-inducing activity or the like, or


e) high metabolic stability.


When administering a compound of the present invention as a pharmaceutical composition for PPAR agonist, it can be administered orally or parenterally. For oral administration, the compound of the present invention can be used in any form of usual formulations, for example, tablets, granules, powders, capsules, pills, solutions, syrup, buccals, sublingual tablets or the like which are made by the usual process. For parenteral administration, the compound of the present invention can be used in any form of usual formulations, for example, injections such as intramuscular administration and intravenous administration, suppository, transdermal therapeutic agent, insufflation or the like. A compound of the present invention can be preferably used as an oral agent because it has high oral bioavailability.


The formulation according to the present invention may be manufactured by combining a curatively effective amount of a compound of the present invention with various pharmaceutically acceptable excipients such as binder, moistening agent, disintegrating agents, lubricant, diluents or the like, if necessary. When the formulation is injection, the compound of the present invention may be manufactured by sterilization treatment with an appropriate carrier.


For example, the excipient is lactose, saccharose, glucose, starch, calcium carbonate, crystalline cellulose or the like. The binder is methylcellulose, carboxy methylcellulose, hydroxy propylcellulose, gelatin, polyvinylpyrrolidone or the like. The disintegrating agent is carboxy methyl cellulose, carboxymethylcellulose sodium, starch, sodium alginate, powdered agar, sodium lauryl sulfate or the like. The lubricant is talc, magnesium stearate, macrogol or the like. As a basis for suppository, cocoa butter, macrogol, methylcellulose or the like can be used. When the present invention is manufactured as liquid medicine, emulsion injection or suspension injection, solubilizing agent, suspending agent, emulsifying agent, stabilizing agent, preservatives, isotonic agent or the like which is usually used can be appropriately added. In case of oral administration, sweetening agent, flavoring agent or the like can be added.


The dose as a pharmaceutical composition for PPAR agonist of a compound of the present invention is preferably established depending on age, body weight, kind of disease, conditions of the patient, the administration route or the like. In case of the oral administration for an adult, it is usually 0.05 to 100 mg/kg/day and preferably 0.1 to 10 mg/kg/day. In case of the parenteral administration, although it is very different depending on route of administration, it is usually 0.005 to 10 mg/kg/day and preferably 0.01 to 1 mg/kg/day. This can be separated and administrated at 1 time to few times a day.


Example

The following examples are provided to explain in more detail and do not restrict the present invention.


Compounds in Reference Examples 1 to 6 were obtained by the methods described in US patent application publication no. US2004-0224997 or WO 95/22531.


Reference Example 1






Yield: 88%, 1H-NMR (CDCl3): δ7.41 (1H, dd, J=8.5, 2.0 Hz), 7.45 (1H, d, J=8.5 Hz), 7.95 (1H, d, J=2.0 Hz).


Reference Example 2






Yield: 90%, 1H-NMR (CDCl3): δ7.60 (1H, dd, J=8.5, 2.0 Hz), 7.82 (1H, d, J=8.5 Hz), 7.93 (1H, d, J=2.0 Hz).


Reference Example 3






Yield: 76%, 1H-NMR (CDCl3): δ7.23 (1H, td, J=8.0, 2.5 Hz), 7.48 (1H, dd, J=8.0, 2.5 Hz), 7.91 (1H, dd, J=8.0, 4.0 Hz).


Reference Example 4






Yield: 65%, 1H-NMR (CDCl3): δ7.73 (1H, d, J=7.0 Hz), 7.82 (1H, d, J=9.0 Hz).


Reference Example 5






Yield: 89%, 1H-NMR (CDCl3): δ7.78 (1H, d, J=6.5 Hz), 8.06 (1H, d, J=10.5 Hz).


Reference Example 6






Yield: 66%, 1H-NMR (CDCl3): δ8.00 (1H, d, J=8.5 Hz), 8.17 (1H, d, J=8.5 Hz), 8.45 (1H, s), 8.89 (1H, s).


Reference Example 7
Preparation of 2-chloro-5-phenylthiazole






To a mixture of 2-amino-5-phenylthiazole described in Journal of Medicinal Chemistry, 1983, Vol. 26 (8), 1158-1163, (1.00 g; 5.67 mmol), copper (II) chloride dihydrate (1.94 g; 11.3 mmol), concentrated hydrochloric acid (8 ml) and acetic acid (8 ml) was added sodium nitrite (0.47 g; 6.80 mmol) under ice-cooling. The mixture was stirred at 40° C. for 1 hour. After returning the reaction solution to room temperature, water and chloroform were added and extracted. The organic layer was washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure. The residue was purified by column chromatograph on silica gel (methylene chloride) to give 2-chloro-5-phenylthiazole as pale yellow crystal (0.68 g; 62%).



1H-NMR (CDCl3): δ7.32-7.53 (5H, m), 7.71 (1H, s).


Reference Example 8
Preparation of [3-(methoxymethoxy)-4-methylphenyl]acetonitrile






To a mixture of 3-(methoxymethoxy)-4-methylbenzyl alcohol described in WO2004/022551 (9.80 g; 53.78 mmol), triethylamine (7.90 ml; 56.47 mmol) and anhydrous THF (50 ml) was added dropwise methanesulfonyl chloride (4.40 ml; 56.47 mmol) under ice-cooling. The mixture was stirred at the same temperature for 1.5 hours. The precipitate was collected and condensed under reduced pressure. Then, to the residue were added sodium cyanide (7.91 g; 0.161 mol) and anhydrous N,N-dimethylformamide (50 ml). The mixture was stirred at room temperature for 3 days. Water and ethyl acetate were added to the reaction solution. The organic layer was separated, washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure. The residue was purified by column chromatograph on silica gel (hexane:ethyl acetate=3:1) to give [3-(methoxymethoxy)-4-methylphenyl]acetonitrile as blackish brown oil (7.87 g; 77%).



1H-NMR (CDCl3): δ2.23 (3H, s), 3.49 (3H, s), 3.70 (2H, s), 5.21 (2H, s), 6.89 (1H, dd, J=7.5, 1.5 Hz), 6.98 (1H, d, J=1.5 Hz), 7.14 (1H, d, J=7.5 Hz).


Reference Example 9
Preparation of 3-(methoxymethoxy)-4-methylphenylacetate






A mixture of [3-(methoxymethoxy)-4-methylphenyl]acetonitrile (7.87 g; 41.2 mmol), sodium hydroxide (8.30 g; 210 mmol), water (30 ml) and ethanol (70 ml) was refluxed for 5 hours. The reaction solution was condensed under reduced pressure. Water and ethyl acetate were added thereto and back-extracted. The water layer became pH=7 by adding 2N-aqueous hydrochloric acid. Ethyl acetate was added thereto and extracted. The organic layer was washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure to give 3-(methoxymethoxy)-4-methylphenylacetate as pale blackish brown oil (5.52 g; 64%).



1H-NMR (CDCl3): δ2.22 (3H, s), 3.48 (3H, s), 3.59 (2H, s), 5.19 (2H, s), 6.83 (1H, dd, J=7.5, 1.5 Hz), 6.95 (1H, d, J=1.5 Hz), 7.13 (1H, d, J=7.5 Hz), 9.83 (1H, brs).


Reference Example 10
Preparation of [3-hydroxy-4-methylphenyl]ethyl acetate






A mixture of [3-(methoxymethoxy)-4-methyl]phenylacetate (5.52 g; 26.3 mmol), concentrated hydrochloric acid (2 ml) and ethanol (20 ml) was refluxed for 3 hours. After cooling, the reaction solution was concentrated under reduced pressure. To the residue was added saturated aqueous sodium hydrogencarbonate to become pH=7. Ethyl acetate was added thereto and extracted. The organic layer was washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure. The residue was purified by column chromatograph on silica gel (hexane:ethyl acetate=3:1) to give 3-hydroxy-4-methylphenylethyl acetate as pale yellow oil (2.40 g; 47%).



1H-NMR (CDCl3): δ1.26 (3H, t, J=7 Hz), 2.21 (3H, s), 3.53 (2H, s), 4.14 (2H, q, J=7 Hz), 5.13 (1H, s), 6.72 (1H, s), 6.74 (1H, d, J=7.5 Hz), 7.05 (1H, d, J=7.5 Hz).


Reference Example 11
Preparation of 2-chloro-5-(methoxyethoxy)toluene






To a mixture of 4-chloro-3-methylcresol (15.0 g; 0.105 mol), N,N-diisopropylethylamine (23.3 ml; 0.137 mol) and THF (150 ml), was added dropwise chloromethylmethyl ether (9.50 ml; 0.126 mol) at room temperature. The mixture was stirred at 60° C. for 27.5 hours. The reaction solution was poured into ice water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure. The residue was purified by column chromatograph on silica gel (hexane:ethyl acetate=5:1) to give 2-chloro-5-(methoxyethoxy)toluene as dark reddish-brown oil (17.7 g; 90%).



1H-NMR (CDCl3): δ2.34 (3H, s), 3.47 (3H, s), 5.13 (2H, s), 6.81 (1H, dd, J=8.5, 3.0 Hz), 6.92 (1H, d, J=3.0 Hz), 7.22 (1H, d, J=8.5 Hz).


Reference Example 12
Preparation of [2-chloro-5-(methoxymethoxy)phenyl]acetonitrile






A mixture of 2-chloro-5-(methoxyethoxy)toluene (5.00 g; 26.8 mmol), N-bromosuccinimide (4.77 g; 26.8 mmol) and 2,2-azobis(isobutyronitrile) (0.09 g; 0.53 mmol) in carbon tetrachloride (25 ml) was refluxed for 2 hours. After air cooling and filtration the precipitate, the filtrate was condensed under reduced pressure. To the residue were added sodium cyanide (2.77 g; 80.4 mol) and anhydrous N,N-dimethylformamide (30 ml). The mixture was stirred at room temperature for 2 hours. Water and ethyl acetate were added to the reaction solution and extracted. The organic layer was washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure. The residue was purified by column chromatograph on silica gel (hexane:ethyl acetate=6:1→4:1) to give [2-chloro-5-(methoxymethoxy)phenyl]acetonitrile as colorless oil (2.64 g; 47%).



1H-NMR (CDCl3): δ3.48 (3H, s), 3.80 (2H, s), 5.17 (2H, s), 6.99 (1H, dd, J=9.0, 3.0 Hz), 7.19 (1H, d, J=3.0 Hz), 7.32 (1H, d, J=9.0 Hz).


Reference Example 13
Preparation of [2-chloro-5-hydroxyphenyl]ethyl acetate






To a mixture of [2-chloro-5-(methoxymethoxy)phenyl]acetonitrile (2.60 g; 12.3 mmol), sodium hydroxide (2.46 g; 61.5 mmol), water (10.4 ml) and ethanol (33.8 ml) was stirred at 80° C. for 3 hours. After cooling, the solvent was evaporated under reduced pressure. To the residue was added water and 2N-aqueous hydrochloric acid to become acid and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure. To the residue, were added concentrated hydrochloric acid (0.65 ml) and ethanol (15 ml). The mixture was stirred at 80° C. for 8 hours. After cooling, the reaction solution was condensed under reduced pressure. The residue was purified by column chromatograph on silica gel (hexane:ethyl acetate=2:1) to give [2-chloro-5-hydroxyphenyl]ethyl acetate as colorless oil (0.69 g; 26%).



1H-NMR (CDCl3): δ1.28 (3H, t, J=7.0 Hz), 3.70 (2H, s), 4.20 (2H, q, J=7.0 Hz), 5.66 (1H, s), 6.64 (1H, dd, J=8.5, 3.0 Hz), 6.73 (1H, d, J=3.0 Hz), 7.18 (1H, d, J=8.5 Hz).


Reference Example 14
Preparation of [3-bromomethyl-5-methyl]phenoxy acetate






It was synthesized by the method described in Reference Example 77 of WO2004/022551.



1H-NMR (CDCl3); δ2.29 (3H, s), 2.35 (3H, s), 4.44 (2H, s), 6.85 (1H, s), 6.94 (1H, s), 7.08 (1H, s).


Reference Example 15
Preparation of 3-bromomethyl-5-methylmethyl benzoate






A mixture of 3,5-dimethylmethyl benzoate (5.00 g; 30.5 mmol), N-bromosuccinimide (5.69 g; 32.0 mmol) and 2,2-azobis(isobutyronitrile) (0.10 g; 0.61 mmol) in carbon tetrachloride (25 ml) was refluxed for 1 hour. After cooling and filtration of the precipitate, the filtrate was concentrated under reduced pressure. The residue was purified by column chromatograph on silica gel (hexane:ethyl acetate=10:1) to give 3-bromomethyl-5-methylmethyl benzoate as colorless oil (3.78 g; 51%).



1H-NMR (CDCl3): δ2.40 (3H, s), 3.92 (3H, s), 4.49 (2H, s), 7.40 (1H, s), 7.79 (1H, s), 7.89 (1H, s).


Compounds in Reference Examples 16 and 17 were obtained by similar methods as Reference Example 15.


Reference Example 16






Yield: 56%, 1H-NMR (CDCl3): δ3.93 (3H, s), 4.61 (2H, s), 7.47 (1H, d, J=8.5 Hz), 7.91 (1H, dd, J=8.5, 2 Hz), 8.11 (1H, d, J=2 Hz).


Reference Example 17






Yield: 75%, 1H-NMR (CDCl3): δ2.33 (3H, s), 4.40 (2H, s), 7.08 (1H, s), 7.10 (1H, s), 7.18 (1H, s).


Reference Example 18
Preparation of [(3-chloro-5-methyl)phenyl]acetonitrile






A mixture of (3-bromomethyl-5-chloro) toluene (1.67 g; 7.62 mmol), sodium cyanide (0.42 g; 8.51 mmol) and anhydrous N,N-dimethylformamide (15 ml) were stirred at 40° C. for 2 hours. Water and ethyl acetate were added to the reaction solution and extracted. The organic layer was washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure. The residue was purified by column chromatograph on silica gel (methylene chloride) to give [(3-chloro-5-methyl)phenyl]acetonitrile as pale yellow oil (0.75 g; 59%).



1H-NMR (CDCl3): δ2.35 (3H, s), 3.69 (2H, s), 7.04 (1H, s), 7.12 (1H, s), 7.14 (1H, s).


Reference Example 19
Preparation of (3-chloro-5-methyl)phenylethyl acetate






To [(3-chloro-5-methylphenyl)]acetonitrile (0.38 g; 2.29 mmol) were added 2N aqueous sodium hydroxide solution (2.1 ml) and ethanol (5 ml). The mixture was stirred at 80° C. for 1 hour. The reaction solution was concentrated under reduced pressure. To the residue were added water and 2N-aqueous HCl to become neutral. Ethyl acetate was added thereto and extracted. The organic layer was washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure to give colorless crystal. Concentrated sulfuric acid (0.02 ml) and ethanol (2 ml) were added thereto, and the mixture was refluxed for 5 hours. The reaction solution was concentrated under reduced pressure. To the residue were added water and 2N-aqueous sodium hydroxide solution to become neutral. Ethyl acetate was added thereto and extracted. The organic layer was washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure. The residue was purified by column chromatograph on silica gel (hexane:ethyl acetate=6:1) to give 3-chloro-5-methylphenylethyl acetate as colorless oil (0.31 g; 63%).



1H-NMR (CDCl3): δ1.26 (3H, t, J=7.2 Hz), 2.32 (3H, s), 3.53 (2H, s), 4.16 (2H, q, J=7.2 Hz), 6.97 (1H, s), 7.08 (2H, s).


Reference Example 20
Preparation of [3-bromomethyl-5-chloro]phenylethyl acetate






A mixture of 3-chloro-5-methylphenylethyl acetate (0.20 g; 0.958 mol), N-bromosuccinimide (0.21 g; 1.21 mmol) and 2,2-azobis(isobutyronitrile) (0.01 g; 0.037 mmol) in carbon tetrachloride (2 ml) were refluxed for 2 hours. After cooling and filtration of the precipitate, the filtrate was condensed under reduced pressure. The residue was purified by column chromatograph on silica gel (hexane:ethyl acetate=20:1) to give 3-bromomethyl-5-chlorophenylethyl acetate as colorless oil (0.16 g; 57%).



1H-NMR (CDCl3): δ1.27 (3H, t, J=7.2 Hz), 3.58 (2H, s), 4.17 (2H, t, J=7.2 Hz), 4.42 (2H, s), 7.20 (1H, s), 7.22 (1H, s), 7.30 (1H, s).


Compounds in Reference Examples 21 and 22 were synthesized as above.


Reference Example 21






Yield: 56%, 1H-NMR (CDCl3): δ1.26 (3H, t, J=7.0 Hz), 3.61 (2H, s), 4.16 (2H, q, J=7.0 Hz), 4.48 (2H, s), 7.18-7.38 (4H, m).


Reference Example 22






Yield: 70%, 1H-NMR (CDCl3): δ1.28 (3H, t, J=7 Hz), 3.51 (3H, s), 3.59 (2H, s), 4.17 (2H, q, J=7 Hz), 4.45 (2H, s), 7.04 (1H, s), 7.12 (2H, s).


Reference Example 23
Preparation of 4-hydroxy-3-methylethyl benzoate






A mixture of 4-hydroxy-3-methyl benzoic acid (3.01 g; 19.78 mmol), concentrated sulfuric acid (0.20 ml) and ethanol (40 ml) was refluxed for 6 hours. The reaction solution was concentrated under reduced pressure. To the residue were added water and 2N-aqueous sodium hydroxide solution to become neutral. Ethyl acetate was added and extracted. The organic layer was washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure to give 4-hydroxy-3-methylethyl benzoate as yellow crystal (3.40 g; 95



1H-NMR (CDCl3): δ1.38 (3H, t, J=7.2 Hz), 2.28 (3H, s), 4.35 (2H, q, J=7.2 Hz), 5.75 (1H, s), 6.81 (1H, d, J=8.1 Hz), 8.40 (1H, d, J=8.1 Hz), 7.84 (1H, s).


Reference Example 24
Preparation of 4-(methoxymethoxy)-3-methylethyl benzoate






A mixture of 4-hydroxy-3-methylethyl benzoate (2.15 g; 11.93 mmol), methoxymethoxychloride (1.60 ml; 21.2 mmol), diisopropylethylamine (4.10 ml; 23.9 mmol) and THF (40 ml) was refluxed at 60° C. for 9 hours. After cooling, water and ethyl acetate were added to the reaction solution and extracted. The organic layer was washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure. The residue was purified by column chromatograph on silica gel (hexane:ethyl acetate=20:1) to give 4-(methoxymethoxy)-3-methylethyl benzoate as colorless oil (1.94 g; 73%).



1H-NMR (CDCl3): δ1.38 (3H, t, J=7.2 Hz), 2.27 (3H, s), 3.49 (3H, s), 4.34 (2H, q, J=7.2 Hz), 5.26 (2H, s), 7.05 (1H, d, J=9.3 Hz), 7.84-7.86 (2H, m).


Reference Example 25
Preparation of [4-(methoxymethoxy)-3-methyl]benzyl alcohol






To a suspension of lithium aluminium hydride (0.26 g; 6.76 mmol) in anhydrous THF (5 ml) were added dropwise a mixture of 4-(methoxymethoxy)-3-methylethyl benzoate (1.02 g; 4.55 mmol) and anhydrous THF (10 ml) at 0° C. After stirring at the same temperature for 1 hour, 2N-aqueous sodium hydroxide solution was added dropwise to the reaction solution. The residue was filtrated. To the filtrate were added ethyl acetate and brine. The organic layer was separated and dried over anhydrous sodium sulphate and the solvent was evaporated under reduced pressure. The residue was purified by column chromatograph on silica gel (hexane:ethyl acetate=3:1) to give [4-(methoxymethoxy)-3-methyl]benzyl alcohol as colorless oil (0.80 g; 97%).



1H-NMR (CDCl3): δ1.63 (1H, brs), 2.25 (3H, s), 3.48 (3H, s), 4.59 (2H, d, J=3.9 Hz), 5.20 (2H, s), 7.01-7.17 (3H, m)


Reference Example 26
Preparation of 5-chloromethyl-2-(methoxymethoxy)toluene






To a mixture of [4-(methoxymethoxy)-3-methyl]benzyl alcohol (0.49 g; 2.69 mmol), triethylamine (0.42 ml; 3.01 mmol) and methylene chloride (14 ml) was added dropwise methanesulfonyl chloride (0.23 ml; 2.97 mmol) under ice-cooling. The mixture was stirred for 4.5 hours. The reaction solution was concentrated under reduced pressure. The residue was purified by column chromatograph on silica gel (hexane:ethyl acetate=6:1) to give 5-chloromethyl-2-(methoxymethoxy)toluene as pale blackish brown oil (0.53 g; 99%).



1H-NMR (CDCl3): δ2.25 (3H, s), 3.48 (3H, s), 4.54 (2H, s), 5.20 (2H, s), 7.02 (1H, d, J=8.4 Hz), 7.14-7.18 (2H, m).


Reference Example 27

The following compound was synthesized by referring to Synthetic Communications, 2004, Vol. 34, 4111 to 4118.


Synthesis of 2-(N-chloroacetamide)methyl butanoate






To a solution of 2-aminobutanoic acid (10.0 g; 96.97 mmol) in methanol (65 ml) was added dropwise thionyl chloride (30 ml; 411.28 mmol) under ice-cooling. The mixture was stirred at room temperature for 18 hours. The reaction solution was concentrated under reduced pressure. Diisopropyl ether (20 ml) was added to the residue. The mixture was azeotroped under reduced pressure to give colorless crystal.


To the above crystal (5.00 g) were added water (15 ml) and sodium hydrogencarbonate (6.66 g; 79.28 mmol) and added dropwise a solution of chloroacetylchloride (2.6 ml; 32.64 mmol) in toluene (10 ml) under ice-cooling. The mixture was stirred at room temperature for 18 hours. The reaction solution was separated and the organic layer was dried over anhydrous sodium sulphate. The solvent was evaporated under reduced pressure. The residue was purified by column chromatograph on silica gel (hexane:ethyl acetate=2:1) to give 2-(N-chloroacetamide)methyl butanoate as colorless oil (4.75 g; 75%).


1H-NMR (CDCl3): δ0.94 (3H, t, J=7.2 Hz), 1.74-1.86 (1H, m), 1.8-2.02 (1H, m), 3.78 (3H, s), 4.08 (2H, s), 4.59 (1H, q, J=6.6 Hz), 7.07 (1H, s).


Compounds in Reference Examples 28 to 37 were obtained as above.


Reference Example 28






Yield: 74%, 1H-NMR (CDCl3): δ0.94 (3H, t, J=7.5 Hz), 1.70-2.00 (2H, m), 3.78 (3H, s), 4.09 (2H, s), 4.54-4.63 (1H, m), 7.10 (1H, brs).


Reference Example 29






Yield: 70%, 1H-NMR (CDCl3): δ0.94 (3H, t, J=7.5 Hz), 1.65-2.00 (2H, m), 3.78 (3H, s), 4.11 (2H, s) 4.50-4.65 (1H, m), 7.09 (1H, brs).


Reference Example 30






Yield: 97%, 1H-NMR (CDCl3): δ0.95 (3H, t, J=7.2 Hz), 1.26-1.41 (2H, m), 1.66-1.78 (1H, m), 1.81-1.89 (1H, m), 3.77 (3H, s), 4.08 (2H, s), 4.62 (1H, dt, J=7.8 Hz), 7.03 (1H, s)


Reference Example 31






Yield: 91%, 1H-NMR (CDCl3): δ0.95 (3H, t, J=7.5 Hz), 1.24-1.43 (2H, m), 1.66-1.78 (1H, m), 1.81-1.93 (1H, m), 3.77 (3H, s), 4.08 (2H, s), 4.62 (1H, q, J=7.5 Hz), 7.02 (1H, s)


Reference Example 32






Yield: 99%, 1H-NMR (CDCl3): δ0.91 (3H, t, J=7 Hz), 1.23-1.40 (4H, m), 1.67-1.80 (1H, m), 1.81-1.96 (1H, m), 3.77 (3H, s), 4.08 (2H, s), 4.57-4.65 (1H, m), 7.03 (1H, brs).


Reference Example 33






Yield: 86%, 1H-NMR (CDCl3): δ0.91 (3H, t, J=7 Hz), 1.23-1.40 (4H, m), 1.65-1.80 (1H, m), 1.82-1.95 (1H, m), 3.77 (3H, s), 4.08 (2H, s), 4.55-4.65 (1H, m), 7.02 (1H, brs).


Reference Example 34






Yield: 93%, 1H-NMR (CDCl3): δ0.96 (6H, d, J=6.0 Hz), 1.58-1.74 (3H, m), 3.76 (3H, s), 4.08 (2H, s), 4.66 (1H, t, J=8.4 Hz), 6.90 (1H, br)


Reference Example 35






Yield: quant. %, 1H-NMR (CDCl3): δ0.96 (6H, d, J=6.0 Hz), 1.54-1.78 (3H, m), 3.76 (3H, s), 4.08 (2H, s), 4.60-4.70 (1H, m), 6.83-6.95 (1H, m).


Reference Example 36






Yield: 93%, 1H-NMR (CDCl3): δ0.95 (6H, d, J=6 Hz), 1.56-1.75 (3H, m), 3.76 (3H, s), 4.08 (2H, s), 4.60-4.70 (1H, m), 6.93 (1H, brs).


Reference Example 37






Yield: 90%, 1H-NMR (CDCl3): δ0.96 (6H, t, J=6.5 Hz), 2.16-2.30 (1H, m), 3.77 (3H, s), 4.10 (2H, s), 4.51-4.60 (1H, m), 7.04 (1H, brs).


Reference Example 38
Synthesis of 1-benzyl-3-ethylpiperazine-2,5-dion






A mixture of 2-(N-chloroacetamide)methyl butanoate (4.00 g; 20.71 mmol), triethylamine (8.8 ml; 63.14 mmol), benzylamine (2.8 ml; 25.64 mmol) and methanol (45 ml) was refluxed for 16 hours. The reaction solution was concentrated under reduced pressure. Water and ethyl acetate were added to the residue and extracted. To the organic layer was added 1N aqueous hydrochloric acid to separate. To the organic layer was added aqueous sodium hydrogencarbonate water solution to become neutral. The organic layer was washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure. The residue was washed with diisopropyl ether to give 1-benzyl-3-ethylpiperazine-2,5-dion as colorless crystal (1.58 g; 33%).


1H-NMR (CDCl3): δ0.98 (3H, t, J=7.2 Hz), 1.71-2.02 (2H, m), 3.84 (2H, dd, J=0.9, 5.1 Hz), 4.03-4.08 (1H, m), 4.51 (1H, d, J=14.4 Hz), 4.71 (1H, d, J=14.4 Hz), 7.25-7.36 (5H, m)


Compounds in Reference Examples 39 to 48 were obtained as above.


Reference Example 39






Yield: 44%, 1H-NMR (CDCl3): δ0.98 (3H, t, J=7.5 Hz), 1.83-2.03 (2H, m), 3.83 (2H, d, J=5.5 Hz), 4.00-4.10 (1H, m), 4.50 (1H, d, J=14.5 Hz), 4.71 (1H, d, J=14.5 Hz), 7.05 (1H, brs), 7.23-7.40 (5H, m).


Reference Example 40






Yield: 32%, 1H-NMR (CDCl3): δ0.98 (3H, t, J=7.5 Hz), 1.85-2.05 (2H, m), 3.83 (2H, dd, J=6, 1 Hz), 4.02-4.10 (1H, m), 4.50 (1H, d, J=14.5 Hz), 4.71 (1H, d, J=14.5 Hz), 6.95 (1H, brs), 7.20-7.40 (5H, m).


Reference Example 41






Yield: 41%, 1H-NMR (CDCl3): δ0.97 (3H, t, J=7.2 Hz), 1.36-1.48 (2H, m), 1.82-1.90 (2H, m), 3.83 (2H, dd, J=0.9, 5.4 Hz), 4.07 (1H, td, J=2.6, 5.7 Hz), 4.60 (2H, dd, J=14.1, 39.9 Hz), 7.24-7.38 (5H, m)


Reference Example 42






Yield: 45%, 1H-NMR (CDCl3): δ0.97 (3H, t, J=7.2 Hz), 1.36-1.48 (2H, m), 1.82-1.90 (2H, m), 3.83 (2H, dd, J=0.9, 5.4 Hz), 4.04-4.09 (1H, m), 4.53 (1H, d, J=14.4 Hz), 4.67 (1H, d, J=14.4 Hz), 7.24-7.39 (5H, m)


Reference Example 43






Yield: 49%, 1H-NMR (CDCl3): δ0.85-1.00 (3H, m), 1.24-1.45 (4H, m), 1.80-1.96 (2H, m), 3.83 (2H, d, J=6 Hz), 4.02-4.12 (1H, m), 4.53 (1H, d, J=14.5 Hz), 4.67 (1H, d, J=14.5 Hz), 6.68 (1H, brs), 7.21-7.40 (5H, m).


Reference Example 44






Yield: 43%, 1H-NMR (CDCl3): δ0.85-0.95 (3H, m), 1.30-1.50 (4H, m), 1.80-1.98 (2H, m), 3.72-3.91 (2H, m), 4.04-4.10 (1H, m), 4.53 (1H, d, J=14.5 Hz), 4.67 (1H, d, J=14.5 Hz), 6.45 (1H, brs), 7.23-7.40 (5H, m).


Reference Example 45






Yield: 34%, 1H-NMR (CDCl3): δ0.97 (6H, dd, J=6.0, 8.1 Hz), 1.61-1.73 (2H, m), 1.76-1.88 (1H, m), 3.83 (2H, d, J=6.3 Hz), 4.02-4.07 (1H, m), 4.59 (2H, q, J=14.7 Hz), 6.65 (1H, s), 7.23-7.35 (5H, m)


Reference Example 46






Yield: 55%, 1H-NMR (CDCl3): δ0.96 (3H, d, J=6.5 Hz), 0.98 (3H, d, J=6.5 Hz), 1.58-1.89 (3H, m), 3.80 (1H, d, J=17.5 Hz), 3.83 (1H, d, J=17.5 Hz), 4.01-4.10 (1H, m), 4.55 (1H, d, J=14.5 Hz), 4.65 (1H, d, J=14.5 Hz), 6.66 (1H, s), 7.21-7.40 (5H, m).


Reference Example 47






Yield: 50%, 1H-NMR (CDCl3): δ0.90-1.05 (6H, m), 1.58-1.90 (3H, m), 3.83 (2H, d, J=6.5 Hz), 4.02-4.10 (1H, m), 4.54 (1H, d, J=14.5 Hz), 4.65 (1H, d, J=14.5 Hz), 6.75 (1H, brs), 7.20-7.40 (5H, m).


Reference Example 48






Yield: 12%, 1H-NMR (CDCl3): δ0.88 (3H, d, J=6.5 Hz), 1.02 (3H, d, J=6.5 Hz), 2.42-2.55 (1H, m), 3.83 (2H, d, J=11 Hz), 3.90-3.96 (1H, m), 4.45 (1H, d, J=14 Hz), 4.77 (1H, d, J=14 Hz), 6.43 (1H, brs), 7.21-7.45 (5H, m).


Reference Example 49
Synthesis of 1-benzyl-3-ethylpiperazine






To a suspension of lithium aluminium hydride (0.87 g; 22.9 mmol) in anhydrous THF (20 ml) was added dropwise a solution of 1-benzyl-3-ethylpiperazine-2,5-dion (1.50 g; 6.46 mmol) in anhydrous THF (10 ml) under ice-cooling. After stirring at room temperature for 18 hours, a mixture of water (0.25 ml) and THF (5 ml) and 2N-aqueous sodium hydroxide solution (0.5 ml) were added dropwise sequentially under ice-cooling. The mixture was stirred at room temperature for 1 hour. After filtration of aluminium hydroxide, the filtrate was condensed under reduced pressure. To the residue were added ethyl acetate and brine to separate. The organic layer was dried over anhydrous sodium sulphate. The solvent was evaporated under reduced pressure to give 1-benzyl-3-ethylpiperazine as pale yellow oil (1.29 g; 98%).


1H-NMR (CDCl3): δ0.90 (3H, t, J=7.5 Hz), 1.30-1.40 (2H, m), 1.70 (1H, t, J=10.8 Hz), 2.01 (1H, dt, J=3.6, 10.8 Hz), 2.61-2.70 (1H, m), 2.73-2.89 (2H, m), 2.92-3.00 (1H, m), 3.49 (2H, dt, J=6.9 Hz), 3.68 (1H, t, J=5.7 Hz), 7.23-7.31 (5H, m)


Compounds in Reference Examples 50 to 60 were obtained as above.


Reference Example 50






Yield: 96%, 1H-NMR (CDCl3): δ0.90 (3H, t, J=7.5 Hz), 1.29-1.36 (2H, m), 1.70 (1H, t, J=10.5 Hz), 2.01 (1H, td, J=11, 3.5 Hz), 2.60-3.00 (5H, m), 3.46 (1H, d, J=13 Hz), 3.53 (1H, d, J=13 Hz), 7.20-7.40 (5H, m).


Reference Example 51






Yield: 89%, 1H-NMR (CDCl3): δ0.90 (3H, t, J=7.5 Hz), 1.35 (2H, quant, J=7.5 Hz), 1.70 (1H, t, J=10.5 Hz), 2.01 (1H, td, J=11, 3.5 Hz), 2.60-3.00 (5H, m), 3.46 (1H, d, J=13 Hz), 3.53 (1H, d, J=13 Hz), 7.20-7.40 (5H, m).


Reference Example 52






Yield: 73%, 1H-NMR (CDCl3): δ0.89 (3H, t, J=6.9 Hz), 1.29-1.40 (4H, m), 1.69 (1H, t, J=9.9 Hz), 2.00 (1H, td, J=3.6, 10.5 Hz), 2.73-2.99 (5H, m), 3.49 (2H, d, J=5.4 Hz), 7.21-7.35 (5H, m)


Reference Example 53






Yield: 68%, 1H-NMR (CDCl3): δ0.89 (3H, t, J=6.8 Hz), 1.26-1.40 (4H, m), 1.69 (1H, t, J=9.9 Hz), 2.00 (1H, td, J=3.6, 10.8 Hz), 2.72-2.95 (5H, m), 3.49 (2H, d, J=5.1 Hz), 7.23-7.32 (5H, m)


Reference Example 54






Yield: quant. %, 1H-NMR (CDCl3): δ0.88 (3H, t, J=6.5 Hz), 1.20-1.40 (6H, m), 1.50 (1H, brs), 1.70 (1H, t, J=10 Hz), 2.00 (1H, td, J=11, 4 Hz), 2.65-3.00 (5H, m), 3.46 (1H, d, J=13 Hz), 3.52 (1H, d, J=13 Hz), 7.20-7.40 (5H, m).


Reference Example 55






Yield: quant. %, 1H-NMR (CDCl3): δ0.88 (3H, d, J=6.5 Hz), 1.20-1.39 (6H, m), 1.70 (1H, t, J=10 Hz), 2.00 (1H, td, J=11, 4 Hz), 2.65-3.00 (5H, m), 3.46 (1H, d, J=13 Hz), 3.52 (1H, d, J=13 Hz), 7.20-7.40 (5H, m).


Reference Example 56






Yield: 88%, 1H-NMR (CDCl3): δ0.88 (6H, dd, J=5.1, 6.6 Hz), 1.09-1.26 (2H, m), 1.59-1.72 (3H, m), 2.00 (1H, dt, J=3.9, 10.8 Hz), 2.74-2.84 (3H, m), 2.88-2.94 (2H, m), 3.49 (2H, d, J=7.5 Hz), 7.31 (3H, s), 7.32 (2H, s)


Reference Example 57






Yield: quant. %, 1H-NMR (CDCl3): δ0.87 (3H, d, J=6.5 Hz), 0.89 (3H, d, J=6.5 Hz), 1.05-1.29 (2H, m), 1.57-1.74 (2H, m), 2.00 (1H, td, J=10.5, 4.0 Hz), 2.70-2.99 (5H, m), 3.43 (1H, d, J=13.0 Hz), 3.50 (1H, d, J=13.0 Hz), 7.20-7.38 (5H, m).


Reference Example 58






Yield: 90%, 1H-NMR (CDCl3): δ0.87 (3H, d, J=5 Hz), 0.89 (3H, d, J=5 Hz), 1.16-1.30 (2H, m), 1.58-1.74 (2H, m), 2.00 (1H, td, J=11, 4 Hz), 2.70-3.00 (5H, m), 3.45 (1H, d, J=13 Hz), 3.52 (1H, d, J=13 Hz), 7.20-7.40 (5H, m).


Reference Example 59






Yield: 92%, 1H-NMR (CDCl3): δ0.88 (3H, d, J=6.5 Hz), 0.93 (3H, d, J=6.5 Hz), 1.55 (1H, sextet, J=6.5 Hz), 1.78 (1H, t, J=10.5 Hz), 1.97 (1H, td, J=11, 3.5 Hz), 2.67-3.03 (5H, m), 3.44 (1H, d, J=13 Hz), 3.56 (1H, d, J=13 Hz), 7.20-7.40 (5H, m).


Reference Example 60






Yield: 80%, 1H-NMR (CDCl3): δ0.91 (3H, d, J=7.0 Hz), 0.94 (3H, d, J=7.0 Hz), 1.43-1.60 (1H, m), 2.27-2.37 (1H, m), 2.38-2.48 (1H, m), 2.65-2.85 (2H, m), 2.86-2.94 (1H, m), 2.96-3.06 (2H, m).


Reference Example 61
Synthesis of 3-ethylpiperazine ditrifluoroacetate






A mixture of 1-benzyl-3-ethylpiperazine (1.16 g; 5.68 mmol), 5% palladium carbon (0.11 g), trifluoroacetic acid (1.1 ml; 14.8 mmol) and methanol (30 ml) was stirred at room temperature under the presence of hydrogen gas for 17 hours. The reaction solution was filtrated and the filtrate was condensed under reduced pressure. The residue was washed with diisopropyl ether to give 3-ethylpiperazine ditrifluoroacetate as colorless crystal (1.65 g; 85%).


1H-NMR (D2O): δ0.74 (3H, t, J=7.5 Hz), 1.44-1.54 (2H, m), 2.90 (1H, dd, J=12.0 Hz), 3.07-3.15 (2H, m), 3.20-3.34 (1H, m), 3.43-3.51 (3H, m)


Compounds in Reference Examples 62 to 71 were obtained as above.


Reference Example 62






Yield: 88%, 1H-NMR (DMSO-d6): δ0.94 (3H, t, J=7.5 Hz), 1.60 (2H, quant, J=7.5 Hz), 2.93 (1H, t, J=12.5 Hz), 3.00-3.65 (6H, m), 9.24 (2H, brs).


Reference Example 63






Yield: 80%, 1H-NMR (DMSO-d6): δ0.94 (3H, t, J=7.5 Hz), 1.61 (2H, quant, J=7.5 Hz), 2.93 (1H, t, J=12.5 Hz), 3.00-3.60 (6H, m), 9.27 (2H, brs).


Reference Example 64






Yield: 59%, 1H-NMR (D2O): δ0.76 (3H, t, J=7.5 Hz), 1.25 (2H, m), 1.53 (2H, q, J=7.5 Hz), 3.00 (1H, t, J=12.9 Hz), 3.13-3.29 (2H, m), 3.39-3.48 (1H, m), 3.52-3.59 (3H, m)


Reference Example 65






Yield: 61%, 1H-NMR (D2O): δ0.79 (3H, t, J=7.2 Hz), 1.22-1.35 (2H, m), 1.52-1.60 (2H, m), 3.03 (1H, dd, J=12.2 Hz), 3.16-3.32 (2H, m), 3.40-3.51 (1H, m), 3.55-3.63 (3H, m)


Reference Example 66






Yield: 76%, 1H-NMR (DMSO-d6): δ0.88 (3H, t, J=7 Hz), 1.20-1.40 (4H, m), 1.48-1.70 (2H, m), 2.96 (1H, t, J=12.5 Hz), 3.05-3.28 (2H, m), 3.30-3.44 (1H, m), 3.45-3.60 (3H, m), 9.39 (2H, brs).


Reference Example 67






Yield: 74%, 1H-NMR (DMSO-d6): δ0.87 (3H, t, J=7.5 Hz), 1.20-1.40 (4H, m), 1.45-1.67 (2H, m), 2.94 (1H, t, J=7 Hz), 3.16 (2H, quant, J=12.5 Hz), 3.29-2.65 (4H, m), 9.35 (2H, brs).


Reference Example 68






Yield: 78%, 1H-NMR (D2O): δ0.82 (6H, dd, J=1.8, 6.0 Hz), 1.49 (2H, t, J=6.9 Hz), 1.54-1.65 (1H, m), 3.06 (1H, dd, J=11.7 Hz), 3.20-3.37 (2H, m), 3.48-3.55 (1H, m), 3.57-3.66 (3H, m)


Reference Example 69






1H-NMR (CDCl3): δ0.87 (3H, d, J=6.5 Hz), 0.89 (3H, d, J=6.5 Hz), 1.44 (2H, t, J=7.0 Hz), 1.61-1.78 (1H, m), 2.85-3.00 (1H, m), 3.03-3.32 (2H, m), 3.35-3.59 (4H, m), 9.34 (2H, brs).


Reference Example 70






Yield: 82%, 1H-NMR (DMSO-d6): 0.88 (6H, t, J=6.5 Hz), 1.43 (2H, t, J=6.5 Hz), 1.70 (1H, quant, J=6.5 Hz), 2.90 (1H, t, J=13 Hz), 3.00-3.28 (2H, m), 3.35-3.55 (4H, m), 9.17 (2H, brs).


Reference Example 71






Yield: 49%, 1H-NMR (DMSO-d6): 0.94 (3H, d, J=7 Hz), 0.98 (3H, d, J=7 Hz), 1.84-1.98 (1H, m), 2.94 (1H, t, J=12.5 Hz), 3.05-3.25 (3H, m), 3.47 (2H, d, J=10.5 Hz), 3.52 (1H, d, J=15 Hz), 9.12 (2H, brs).


Reference Example 72
Synthesis of 1-tert-butoxycarbonyl-3-ethylpiperazine






To a mixture of 3-ethylpiperazine ditrifluoroacetate (0.51 g; 1.47 mmol) and acetonitrile (10 ml) were added triethylamine (0.62 ml; 4.45 mmol) and di-t-butyldicarbonate (0.35 g; 1.59 mmol) under ice-cooling. The mixture was stirred at room temperature for 17 hours. The reaction solution was concentrated under reduced pressure. To the residue were added ethyl acetate and water and extracted. The organic layer was washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure. The residue was purified by column chromatograph on silica gel (chloroform:methanol=20:1) to give 1-tert-butoxycarbonyl-3-ethylpiperazine as colorless crystal (0.27 g; 85%).


1H-NMR (CDCl3): δ 1.03 (3H, t, J=7.5 Hz), 1.47 (9H, s), 1.60-1.81 (2H, m), 2.96 (3H, br), 3.26 (2H, d, J=12.6 Hz), 4.08 (2H, d, J=14.1 Hz)


Compounds in Reference Examples 73 to 83 were obtained as above.


Reference Example 73






Yield: 99%, 1H-NMR (CDCl3): 0.95 (3H, t, J=7.5 Hz), 1.30-1.45 (2H, m), 1.46 (9H, s), 1.67 (1H, brs), 2.30-2.55 (2H, m), 2.68-2.90 (2H, m), 2.91-3.01 (1H, m), 3.80-4.05 (2H, m).


Reference Example 74






Yield: 80%, 1H-NMR (CDCl3): 0.95 (3H, t, J=7.5 Hz), 1.30-1.45 (2H, m), 1.46 (9H, s), 1.69 (1H, brs), 2.30-2.55 (2H, m), 2.68-2.88 (2H, m), 2.90-3.00 (1H, m), 3.85-4.02 (2H, m).


Reference Example 75






Yield: quant. %, 1H-NMR (CDCl3, 328K): 0.94 (3H, t, J=6.9 Hz), 1.29-1.46 (4H, m), 1.46 (9H, s), 2.64-2.86 (3H, m), 2.96-3.14 (2H, m), 3.64-4.04 (2H, m)


Reference Example 76






Yield: quant. %, 1H-NMR (CDCl3, 328K): 0.94 (3H, t, J=6.9 Hz), 1.36-1.60 (4H, m), 1.47 (9H, s), 2.82-2.93 (3H, m), 3.12-3.21 (2H, m), 3.99-4.10 (2H, m)


Reference Example 77






Yield: 96%, 1H-NMR (CDCl3): 0.90 (3H, t, J=6 Hz), 1.25-1.40 (6H, m), 1.46 (9H, s), 1.54 (1H, brs), 2.30-2.60 (2H, m), 2.67-2.86 (2H, m), 2.90-2.99 (1H, m), 3.80-4.05 (2H, m).


Reference Example 78






Yield: 94%, 1H-NMR (CDCl3): 0.85-0.95 (3H, m), 1.25-1.40 (6H, m), 1.46 (9H, s), 1.56 (1H, brs), 2.30-3.00 (5H, m), 3.80-4.05 (2H, m).


Reference Example 79






Yield: 90%, 1H-NMR (CDCl3): 0.94 (6H, dd, J=3.3, 6.3 Hz), 1.47 (9H, s), 1.43-1.54 (2H, m), 1.68-1.79 (1H, m), 2.97 (2H, dt, J=3.3, 12.3 Hz), 3.08 (1H, br), 3.22-3.28 (2H, m), 4.08 (2H, d, J=13.8 Hz)


Reference Example 80






Yield: 74%, 1H-NMR (CDCl3): 0.90 (3H, d, J=6.5 Hz), 0.93 (3H, d, J=6.5 Hz), 1.11-1.30 (2H, m), 1.47 (9H, s), 1.60-1.78 (1H, m), 2.41 (1H, brs), 2.56-2.87 (3H, m), 2.90-3.00 (1H, m), 3.82-4.03 (2H, m).


Reference Example 81






Yield: 99%, 1H-NMR (CDCl3): 0.92 (6H, t, J=7 Hz), 1.15-1.30 (2H, m), 1.46 (9H, s), 1.47 (1H, brs), 1.62-1.76 (1H, m), 2.30-2.52 (1H, m), 2.58-3.00 (4H, m), 3.82-4.04 (2H, m).


Reference Example 82






Yield: 59%, 1H-NMR (CDCl3): 0.95 (3H, d, J=13.5 Hz), 0.96 (3H, d, J=13.5 Hz), 1.46 (9H, s), 1.47-1.69 (1H, m), 2.22-2.35 (1H, m), 2.38-2.63 (1H, brs), 2.65-2.86 (2H, m), 2.93-3.04 (1H, m), 3.80-4.17 (2H, m).


Reference Example 83






Yield: 75%, 1H-NMR (CDCl3): 0.94 (3H, d, J=2.5 Hz), 0.96 (3H, d, J=2.5 Hz), 1.46 (9H, s), 1.53-1.70 (2H, m), 2.24-2.35 (1H, m), 2.36-2.65 (1H, m), 2.66-2.86 (2H, m), 2.93-3.04 (1H, m), 3.80-4.16 (2H, m).


Reference Example 84
Preparation of 4-(6-chlorobenzothiazole-2-yl)piperazine-1-carboxylic acid tert-butyl ester






A mixture of 2,6-dichlorobenzothiazole (1.00 g; 4.90 mmol), 1-piperazine-tert-butyl ester (0.96 g; 5.15 mmol), potassium carbonate (0.71 g; 5.15 mmol) and anhydrous N,N-dimethylformamide (10 ml) was stirred at room temperature for 14 hours and at 50° C. for 3 hours. Water was added to the reaction solution. The precipitate was collected and washed with diisopropyl ether to give 4-(6-chlorobenzothiazole-2-yl)piperazine-1-carboxylic acid tert-butyl ester as pale blackish brown crystal (1.50 g; 87%).



1H-NMR (DMSO-d6): δ1.43 (9H, s), 3.44-3.53 (4H, m), 3.55-3.60 (4H, m), 7.30 (1H, dd, J=8, 2 Hz), 7.44 (1H, d, J=8 Hz), 7.93 (1H, d, J=2 Hz).


Compounds in Reference Examples 85 to 154 were obtained by similar methods as Reference Example 84.


Reference Example 85






Yield: 97%, 1H-NMR (CDCl3); δ1.42 (9H, d, J=8.4 Hz), 2.01-2.07 (2H, m), 3.36 (1H, t, J=6.0 Hz), 3.44 (1H, t, J=5.7 Hz) 3.63-3.76 (6H, m) 7.24 (1H, dd, J=8.7, 2.1 Hz), 7.43 (1H, d, J=8.4 Hz), 7.55 (1H, d, J=2.4 Hz).


Reference Example 86






Yield: 51%, 1H-NMR (DMSO-d6): δ1.43 (9H, s), 3.44-3.53 (4H, m), 3.55-3.65 (4H, m), 7.58 (2H, s), 8.27 (1H, s)


Reference Example 87






Yield: 47%, 1H-NMR (CDCl3): δ1.44 (9H, s), 2.06 (2H, quant, J=6 Hz), 3.35-3.50 (2H, m), 3.60-3.85 (6H, m), 7.50-7.60 (2H, m), 7.85 (1H, s).


Reference Example 88






Yield: 43%, 1H-NMR (CDCl3): δ1.29 (3H, d, J=7 Hz), 1.49 (9H, s), 2.85-3.10 (1H, m), 3.10-3.30 (1H, m), 3.40 (1H, td, J=13, 3.5 Hz), 3.75-4.25 (4H, m), 7.24 (1H, dd, J=8.5, 2 Hz), 7.44 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=2 Hz).


Reference Example 89






Yield: 69%, 1H-NMR (CDCl3): δ1.16 (3H, d, J=6 Hz), 1.76 (1H, brs), 2.80 (1H, dd, J=12, 12 Hz), 2.90-2.95 (1H, m), 3.00 (1H, dd, J=12, 3 Hz), 3.15 (1H, td, J=12, 3 Hz), 3.21 (1H, dd, J=12, 3 Hz), 3.84-4.00 (2H, m), 7.24 (1H, dd, J=8.5, 2.5 Hz), 7.44 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=2.5 Hz).


Reference Example 90






Yield: 90%, 1H-NMR (CDCl3): δ1.15 (6H, d, J=6 Hz), 1.61 (1H, brs), 2.73 (2H, dd, J=12.5, 10 Hz), 2.95-3.10 (2H, m), 3.94 (2H, dd, J=12.5, 2.5 Hz), 7.23 (1H, dd, J=8.5, 2 Hz), 7.42 (1H, d, J=2 Hz), 7.55 (1H, d, J=8.5 Hz).


Reference Example 91






Yield: 40%, 1H-NMR (CDCl3): δ1.27 (3H, d, J=7 Hz), 1.37 (3H, d, J=7 Hz), 2.64 (1H, dd, J=12, 2.5 Hz), 3.20-3.35 (1H, m), 3.42 (1H, dd, J=12, 4.5 Hz), 3.50-3.65 (2H, m), 4.10-4.25 (1H, m), 7.23 (1H, dd, J=8.5, 2 Hz), 7.42 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2 Hz).


Reference Example 92






Yield: 87%, 1H-NMR (CDCl3): δ1.16 (3H, d, J=6 Hz), 1.62 (1H, brs), 2.84 (1H, t, J=10.5 Hz), 2.90-3.00 (1H, m), 3.01 (1H, dd, J=12, 3 Hz), 3.14 (1H, dt, J=12, 2.5 Hz), 3.25 (1H, td, J=12, 3.5 Hz), 4.01 (2H, t, J=12 Hz), 7.52 (1H, d, J=8.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.85 (1H, s).


Reference Example 93






Yield: 8%, 1H-NMR (CDCl3): δ1.27 (3H, d, J=6.5 Hz), 1.40 (3H, d, J=6.5 Hz), 1.65 (1H, brs), 2.66 (1H, dd, J=13, 2 Hz), 3.25-3.40 (1H, m), 3.43 (1H, dd, J=13, 4.5 Hz), 3.61 (2H, d, J=3 Hz), 4.20-4.28 (1H, m), 7.51 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Reference Example 94






Yield: 38%, 1H-NMR (CDCl3): δ1.16 (6H, d, J=6.5 Hz), 1.54 (1H, brs), 2.76 (1H, d, J=12.5 Hz), 2.80 (1H, d, J=12.5 Hz), 2.95-3.08 (2H, m), 3.95-4.03 (2H, m), 7.52 (1H, d, J=8.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.85 (1H, s).


Reference Example 95






Yield: 71%, 1H-NMR (CDCl3): δ1.15 (3H, d, J=6.3 Hz), 2.80 (1H, dd, J=12.3 Hz), 2.88-3.02 (2H, m), 3.08-3.23 (2H, m), 3.94 (2H, dd, J=12.3 Hz), 7.24 (1H, dd, J=2.1, 8.7 Hz), 7.43 (1H, d, J=8.7 Hz), 7.56 (1H, d, J=2.1 Hz)


Reference Example 96






Yield: 77%, 1H-NMR (CDCl3): δ1.15 (3H, d, J=6.0 Hz), 2.80 (1H, dd, J=12.3 Hz), 2.89-3.02 (2H, m), 3.10-3.23 (2H, m), 3.95 (2H, t, J=12.3 Hz), 7.24 (1H, dd, J=2.4, 8.4 Hz), 7.44 (1H, d, J=8.4 Hz), 7.56 (1H, d, J=2.4 Hz)


Reference Example 97






Yield: 48%, 1H-NMR (CDCl3): δ1.16 (3H, d, J=6.0 Hz), 2.86 (1H, d, J=12.0 Hz), 2.88-3.03 (2H, m), 3.11-3.16 (1H, m), 3.23 (1H, dt, J=3.3, 12.0 Hz), 4.01 (2H, t, J=12.6 Hz), 7.51-7.59 (2H, m), 7.85 (1H, s)


Reference Example 98






Yield: 63%, 1H-NMR (CDCl3): δ1.01 (3H, t, J=7.2 Hz), 1.44-1.53 (2H, m), 2.67-2.76 (1H, m), 2.80-2.88 (1H, m), 2.91-3.00 (1H, m), 3.10-3.20 (2H, m), 3.91-4.01 (2H, m), 7.24 (1H, dd, J=2.1, 8.7 Hz), 7.43 (1H, d, J=8.7 Hz), 7.55 (1H, d, J=2.1 Hz), 8.02 (1H, s)


Reference Example 99






Yield: quant. %, 1H-NMR (CDCl3): δ1.16 (3H, d, J=6 Hz), 1.75 (1H, brs), 2.80-3.05 (3H, m), 3.08-3.18 (1H, m), 3.25 (1H, dd, J=12, 3.5 Hz), 4.00 (2H, t, J=12 Hz), 7.53 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=8.5 Hz), 7.85 (1H, s).


Reference Example 100






Yield: quant. %, 1H-NMR (CDCl3): δ1.98 (1H, brs), 3.06-3.30 (3H, m), 3.38 (1H, dd, J=12, 3.5 Hz), 3.93 (1H, dd, J=10.5, 3 Hz), 4.05-4.18 (2H, m), 7.30-7.60 (7H, m), 7.86 (1H, s).


Reference Example 101






Yield: quant. %, 1H-NMR (CDCl3): δ1.02 (3H, t, J=7.5 Hz), 1.38-1.60 (2H, m), 1.75 (1H, brs), 2.65-2.80 (1H, m), 2.85-3.00 (2H, m), 3.10-3.20 (1H, m), 3.25 (1H, td, J=12, 3.5 Hz), 3.95-4.10 (2H, m), 7.52 (1H, dd, J=8.5, 1.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.85 (1H, d, J=1.5 Hz).


Reference Example 102






Yield: 93%, 1H-NMR (CDCl3): δ1.02 (3H, t, J=7.5 Hz), 1.38-1.60 (2H, m), 1.78 (1H, brs), 2.67-2.78 (1H, m), 2.82-3.03 (2H, m), 3.09-3.32 (2H, m), 3.95-4.10 (2H, m), 7.52 (1H, d, J=8.5 Hz), 7.70 (1H, d, J=8.5 Hz), 7.85 (1H, s).


Reference Example 103






Yield: quant. %, 1H-NMR (CDCl3): δ1.02 (3H, t, J=7.5 Hz), 1.38-1.60 (2H, m), 1.83 (1H, brs), 2.65-2.78 (1H, m), 2.85-3.03 (2H, m), 3.10-3.18 (1H, m), 3.24 (1H, td, J=12, 3.5 Hz), 3.93-4.10 (2H, m), 7.52 (1H, dd, J=8.5, 1.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.85 (1H, d, J=1.5 Hz).


Reference Example 104






Yield: 84%, 1H-NMR (CDCl3): δ0.90-1.05 (3H, m), 1.35-1.54 (4H, m), 1.55-1.66 (2H, m), 2.75-3.02 (3H, m), 3.14 (1H, dt, J=12, 2 Hz), 3.25 (1H, td, J=12.5, 3.5 Hz), 4.01 (1H, t, J=11.5 Hz), 7.52 (1H, dd, J=8.5, 1.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.85 (1H, d, J=1.5 Hz).


Reference Example 105






Yield: 87%, 1H-NMR (CDCl3): δ0.96-0.99 (3H, m), 1.42-1.50 (4H, m), 2.83-3.01 (3H, m), 3.12-3.29 (2H, m), 4.01 (2H, t, J=9.9 Hz), 7.51-7.59 (2H, m), 7.85 (1H, s), 8.02 (1H, s)


Reference Example 106






Yield: quant. %, 1H-NMR (CDCl3): δ0.94 (3H, t, J=7.5 Hz), 1.29-1.54 (6H, m), 1.56-1.70 (2H, m), 2.73-3.05 (3H, m), 3.13 (1H, dt, J=12, 2 Hz), 3.25 (1H, td, J=12, 3.5 Hz), 4.01 (1H, t, J=10 Hz), 7.52 (1H, dd, J=8.5, 1.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.85 (1H, d, J=1.5 Hz).


Reference Example 107






Yield: 56%, 1H-NMR (CDCl3): δ0.95 (6H, dd, J=6.6, 8.4 Hz), 1.25-1.33 (2H, m), 1.71-1.80 (1H, m), 2.77-2.92 (2H, m), 2.96-3.00 (1H, m), 3.10-3.24 (2H, m), 3.95 (2H, d, J=10.5 Hz), 7.24 (1H, dd, J=2.1, 8.4 Hz), 7.44 (1H, d, J=8.4 Hz), 7.56 (1H, d, J=2.1 Hz)


Reference Example 108






Yield: quant. %, 1H-NMR (CDCl3): δ0.93 (3H, d, J=6.5 Hz), 0.96 (3H, d, J=6.5 Hz), 1.26-1.35 (2H, m), 1.68 (1H, brs), 1.69-1.83 (1H, m), 2.73-3.03 (3H, m), 3.07-3.25 (2H, m), 3.90-4.00 (2H, m), 7.23 (1H, dd, J=8.5, 2 Hz), 7.44 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Reference Example 109






Yield: quant. %, 1H-NMR (CDCl3): δ0.93 (3H, d, J=6.5 Hz), 0.96 (3H, d, J=6.5 Hz), 1.20-1.38 (2H, m), 1.60-1.84 (2H, m), 2.72-3.03 (2H, m), 3.05-3.26 (2H, m), 3.87-4.02 (2H, m), 7.23 (1H, dd, J=8.5, 2.0 Hz), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2.0 Hz).


Reference Example 110






Yield: quant. %, 1H-NMR (CDCl3): δ0.94 (3H, d, J=6.5 Hz), 0.97 (3H, d J=6.5 Hz), 1.27-1.37 (2H, m), 1.66 (1H, brs), 1.70-1.83 (1H, m), 2.80-3.03 (3H, m), 3.09-3.30 (2H, m), 3.95-4.05 (2H, m), 7.52 (1H, d, J=8.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.85 (1H, s).


Reference Example 111






Yield 91%, 1H-NMR (CDCl3): δ0.94 (3H, d, J=6.5 Hz), 0.97 (3H, d, J=6.5 Hz), 1.27-1.36 (2H, m), 1.62-1.84 (2H, m), 2.81-3.03 (2H, m), 3.09-3.30 (2H, m), 3.94-4.07 (2H, m), 7.52 (1H, d, J=8.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.85 (1H, s).


Reference Example 112






Yield: 91%, 1H-NMR (CDCl3): δ1.16 (3H, d, J=6 Hz), 1.58 (1H, brs), 2.80-3.03 (3H, m), 3.07-3.17 (1H, m), 3.24 (1H, td, J=12, 3.5 Hz), 3.99 (2H, t, J=11 Hz), 7.26 (1H, d, J=12 Hz), 7.75 (1H, d, J=6.5 Hz).


Reference Example 113






Yield: 91%, 1H-NMR (CDCl3): δ1.02 (3H, t, J=7.5 Hz), 1.37-1.62 (2H, m), 1.90 (1H, brs), 2.64-2.78 (1H, m), 2.84-3.03 (2H, m), 3.10-3.20 (1H, m), 3.21-3.32 (1H, m), 3.92-4.09 (2H, m), 7.27 (1H, d, J=12.5 Hz), 7.76 (1H, d, J=6.5 Hz).


Reference Example 114






Yield: 75%, 1H-NMR (CDCl3): δ1.32 (3H, d, J=6.5 Hz), 1.50 (9H, s), 2.90-3.30 (2H, m), 3.44 (1H, td, J=12.5, 3.5 Hz), 3.80-4.40 (4H, m), 7.53 (1H, dd, J=8.5, 1.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.86 (1H, d, J=1.5 Hz).


Reference Example 115






Yield: 61%, 1H-NMR (CDCl3): δ1.29 (3H, d, J=6 Hz), 1.49 (9H, s), 2.90-3.30 (2H, m), 3.34-3.48 (1H, m), 3.80-4.30 (4H, m), 7.25 (1H, dd, J=8.5, 2 Hz), 7.44 (1H, d, J=8.5 Hz), 7.57 (1H, d, J=2 Hz).


Reference Example 116






Yield: 31%, 1H-NMR (CDCl3): δ1.30 (3H, d, J=6.5 Hz), 1.49 (9H, s), 2.91-3.29 (2H, m), 3.33-3.47 (1H, m), 3.76-4.34 (4H, m), 7.25 (1H, dd, J=8.5, 2.0 Hz), 7.44 (1H, d, J=8.5 Hz), 7.57 (1H, d, J=2.0 Hz).


Reference Example 117






Yield: 65%, 1H-NMR (CDCl3): δ1.31 (3H, d, J=6.5 Hz), 1.50 (9H, s), 2.90-3.30 (2H, m), 3.44 (1H, td, J=12.5, 3.5 Hz), 3.85-4.35 (4H, m), 7.53 (1H, dd, J=8.5, 1.5 Hz), 7.58 (1H, d, J=8.5 Hz), 7.86 (1H, d, J=1.5 Hz).


Reference Example 118






Yield: 50%, 1H-NMR (CDCl3): δ1.32 (3H, d, J=6.5 Hz), 1.50 (9H, s), 2.85-3.27 (2H, m), 3.32-3.52 (1H, m), 3.82-4.38 (4H, m), 7.54 (1H, d, J=8.5 Hz), 7.58 (1H, d, J=8.5 Hz), 7.86 (1H, s).


Reference Example 119






Yield: 22%, 1H-NMR (CDCl3): δ1.00 (3H, t, J=7.5 Hz), 1.49 (9H, s), 1.63-1.78 (2H, m), 2.83-3.17 (2H, m), 3.26-3.41 (1H, m), 3.82-4.31 (4H, m), 7.23 (1H, dd, J=8.5, 2.0 Hz), 7.41 (1H, d, J=8.5 Hz), 7.53 (1H, d, J=2.0 Hz).


Reference Example 120






Yield: 41%, 1H-NMR (CDCl3): δ1.00 (3H, t, J=7.5 Hz), 1.49 (9H, s), 1.72 (2H, quant, J=7.5 Hz), 2.90-3.20 (3H, m), 3.26-3.42 (1H, m), 3.85-4.00 (2H, m), 4.10-4.30 (1H, m), 7.24 (1H, dd, J=8.5, 2 Hz), 7.41 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Reference Example 121






Yield: 25%, 1H-NMR (CDCl3): δ1.00 (3H, t, J=7.5 Hz), 1.49 (9H, s), 1.63-1.78 (2H, m), 2.82-3.19 (2H, m), 3.26-3.43 (1H, m), 3.80-4.30 (4H, m), 7.23 (1H, dd, J=8.5, 2.0 Hz), 7.41 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2.0 Hz).


Reference Example 122






Yield: 67%, 1H-NMR (CDCl3): δ1.01 (3H, t, J=7.5 Hz), 1.49 (9H, s), 1.68-1.80 (2H, m), 2.90-3.20 (2H, m), 3.32-3.46 (1H, m), 3.90-4.32 (4H, m), 7.54 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=8.5 Hz), 7.85 (1H, s).


Reference Example 123






Yield: 60%, 1H-NMR (CDCl3): δ1.01 (3H, t, J=7.5 Hz), 1.49 (9H, s), 1.74 (2H, quant, J=7.5 Hz), 2.90-3.20 (2H, m), 3.33-3.46 (1H, m), 3.92-4.31 (4H, m), 7.50-7.58 (2H, m), 7.85 (1H, s).


Reference Example 124






Yield: 43%, 1H-NMR (CDCl3): δ0.96 (3H, t, J=7.0 Hz), 1.25-1.75 (4H, m), 1.49 (9H, s), 2.84-3.18 (2H, m), 3.36 (1H, td, J=12.5, 3.0 Hz), 3.85-4.32 (4H, m), 7.24 (1H, dd, J=8.5, 2.0 Hz), 7.41 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2.0 Hz).


Reference Example 125






Yield: 33%, 1H-NMR (CDCl3, 328K): δ0.96 (3H, t, J=7.2 Hz), 1.36-1.49 (2H, m), 1.49 (9H, s), 1.59-1.71 (2H, m), 2.98 (1H, t, J=11.1 Hz), 3.10 (1H, d, J=11.1 Hz), 3.36 (1H, dt, J=3.3, 13.2 Hz), 3.93-4.12 (4H, m), 7.22 (1H, s), 7.41 (1H, d, J=8.4 Hz), 7.54 (1H, s)


Reference Example 126






Yield: 40%, 1H-NMR (CDCl3): δ0.97 (3H, t, J=7.0 Hz), 1.20-1.55 (2H, m), 1.50 (9H, s), 1.56-1.77 (2H, m), 2.83-3.21 (2H, m), 3.40 (1H, td, J=13.0, 3.0 Hz), 3.88-4.35 (4H, m), 7.52 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Reference Example 127






Yield: 64%, 1H-NMR (CDCl3, 328K): δ0.97 (3H, t, J=7.2 Hz), 1.27-1.49 (2H, m), 1.49 (9H, s), 1.69 (2H, br), 2.99 (1H, t, J=11.7 Hz), 3.11 (1H, d, J=12.6 Hz), 3.39 (1H, td, J=12.6 Hz), 3.97-4.14 (4H, m), 7.53 (2H, s, J=Hz), 7.83 (1H, s)


Reference Example 128






Yield: 18%, 1H-NMR (CDCl3): δ0.85-0.97 (3H, m), 1.30-1.45 (4H, m), 1.49 (9H, s), 1.59-1.75 (2H, m), 2.86-3.19 (2H, m), 3.30-3.43 (1H, m), 3.90-4.30 (4H, m), 7.24 (1H, dd, J=8.5, 2 Hz), 7.42 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Reference Example 129






Yield: 50%, 1H-NMR (CDCl3): δ0.84-0.98 (3H, m), 1.25-1.75 (15H, m), 2.85-3.20 (2H, m), 3.30-3.45 (1H, m), 3.90-4.30 (4H, m), 7.24 (1H, dd, J=9, 2 Hz), 7.42 (1H, d, J=9 Hz), 7.55 (1H, d, J=2 Hz).


Reference Example 130






Yield: 58%, 1H-NMR (CDCl3): δ0.85-0.97 (3H, m), 1.30-1.45 (4H, m), 1.50 (9H, s), 1.63-1.78 (2H, m), 2.85-3.20 (2H, m), 3.33-3.43 (1H, m), 3.95-4.35 (4H, m), 7.50-7.58 (2H, m), 7.85 (1H, s).


Reference Example 131






Yield: 11%, 1H-NMR (CDCl3): δ0.92 (3H, d, J=6.5 Hz), 1.13 (3H, d, J=6.5 Hz), 1.49 (9H, s), 2.07-2.27 (1H, m), 2.70-3.15 (2H, m), 3.25-3.44 (1H, m), 3.59-3.75 (1H, m), 3.95-4.46 (3H, m), 7.52 (1H, s), 7.53 (1H, s), 7.83 (1H, s).


Reference Example 132






Yield: 31%, 1H-NMR (CDCl3): δ0.91 (3H, d, J=6.5 Hz), 1.13 (3H, d, J=6.5 Hz), 1.49 (9H, s), 2.12-2.24 (1H, m), 2.84-3.13 (2H, m), 3.27-3.43 (1H, m), 3.60-3.75 (1H, m), 4.02-4.40 (3H, m), 7.53 (2H, s), 7.83 (1H, s).


Reference Example 133






Yield: 26%, 1H-NMR (CDCl3): δ0.98 (3H, d, J=6.5 Hz), 1.00 (3H, d, J=6.5 Hz), 1.33-1.75 (3H, m), 1.49 (9H, s), 2.84-3.22 (2H, m), 3.37 (1H, td, J=13.0, 3.5 Hz), 3.88-4.32 (4H, m), 7.24 (1H, dd, J=8.5, 2.0 Hz), 7.42 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=2.0 Hz).


Reference Example 134






Yield: 54%, 1H-NMR (CDCl3): δ0.90-1.05 (6H, m), 1.35-1.48 (2H, m), 1.49 (9H, s), 1.58-1.73 (1H, m), 2.85-3.20 (2H, m), 3.30-3.43 (1H, m), 3.90-4.30 (4H, m), 7.35 (1H, dd, J=8.5, 2 Hz), 7.41 (1H, d, J=8.5 Hz), 7.57 (1H, d, J=2 Hz).


Reference Example 135






Yield: 43%, 1H-NMR (CDCl3): δ0.99 (3H, d, J=6.5 Hz), 1.00 (3H, d, J=6.5 Hz), 1.37-1.52 (1H, m), 1.49 (9H, s), 1.57-1.75 (2H, m), 2.84-3.23 (2H, m), 3.40 (1H, td, J=13.0, 3.5 Hz), 3.94-4.35 (4H, m), 7.48-7.58 (2H, m), 7.85 (1H, s).


Reference Example 136






Yield: 57%, 1H-NMR (CDCl3, 328K): δ1.00 (6H, t, J=6.0 Hz), 1.40-1.52 (1H, m), 1.49 (9H, s), 1.60-1.69 (2H, m), 2.99 (1H, t, J=10.8 Hz), 3.12 (1H, d, J=10.8 Hz), 3.40 (1H, dt, J=3.6, 12.9 Hz), 3.98-4.13 (4H, m), 7.49-7.56 (2H, m), 7.84 (1H, s)


Reference Example 137






Yield: 46%, 1H-NMR (CDCl3): δ1.10 (3H, d, J=7.0 Hz), 1.26 (3H, d, J=7.0 Hz), 2.98 (1H, td, J=12.5, 3.5 Hz), 3.06-3.17 (2H, m), 3.35 (1H, td, J=12.5, 3.5 Hz), 3.75-3.93 (1H, m), 4.00-4.18 (1H, m), 7.46-7.62 (2H, m), 7.85 (1H, s).


Reference Example 138






Yield: 96%, 1H-NMR (CDCl3): δ1.49 (9H, s), 3.54-3.70 (8H, m), 7.29 (1H, d, J=7.0 Hz), 7.78 (1H, d, J=11.5 Hz).


Reference Example 139






Yield: 90%, 1H-NMR (CDCl3): δ1.43 (9H, s), 2.00-2.13 (2H, m), 3.32-3.54 (2H, m), 3.62-3.89 (6H, m), 7.28 (1H, d, J=7.0 Hz), 7.75 (1H, d, J=11.5 Hz).


Reference Example 140






Yield: 64%, 1H-NMR (CDCl3): δ1.32 (3H, d, J=7.0 Hz), 1.50 (9H, s), 2.94-3.15 (2H, m), 3.44 (1H, td, J=12.5, 3.5 Hz), 3.77-4.42 (4H, m), 7.28 (1H, d, J=12.0 Hz), 7.77 (1H, d, J=7.0 Hz).


Reference Example 141






Yield: 57%, 1H-NMR (CDCl3): δ1.32 (3H, d, J=7.0 Hz), 1.50 (9H, s), 2.88-3.32 (2H, m), 3.45 (1H, td, J=12.5, 3.5 Hz), 3.75-4.36 (4H, m), 7.29 (1H, d, J=12.0 Hz), 7.77 (1H, d, J=7.0 Hz).


Reference Example 142






Yield: 93%, 1H-NMR (CDCl3): δ1.17 (6H, d, J=6.0 Hz), 2.76 (1H, d, J=12.5 Hz), 2.81 (1H, d, J=12.5 Hz), 2.94-3.08 (2H, m), 3.97 (2H, d, J=12.5 Hz), 7.27 (1H, d, J=11.5 Hz), 7.75 (1H, d, J=7.0 Hz).


Reference Example 143






Yield: 55%, 1H-NMR (CDCl3): δ1.49 (9H, s), 3.43-3.66 (8H, m), 7.22 (1H, t, J=7.5 Hz), 7.33 (2H, t, J=7.5 Hz), 7.41 (1H, s), 7.43 (2H, d, J=7.5 Hz).


Reference Example 144






Yield: 78%, 1H-NMR (CDCl3): δ1.49 (9H, s), 3.55-3.67 (8H, m), 7.10 (1H, td, J=8.0, 1.0 Hz), 7.31 (1H, td, J=8.0, 1.0 Hz), 7.57 (1H, dd, J=8.0, 1.0 Hz), 7.61 (1H, dd, J=8.0, 1.0 Hz).


Reference Example 145






Yield: 42%, H-NMR (CDCl3): δ1.00 (3H, t, J=7.5 Hz), 1.49 (9H, s), 1.64-1.79 (2H, m), 2.85-3.19 (2H, m), 3.28-3.44 (1H, m), 3.83-4.33 (4H, m), 7.27 (1H, d, J=10.0 Hz), 7.55 (1H, d, J=7.0 Hz).


Reference Example 146






Yield: 60%, 1H-NMR (CDCl3): δ1.50 (9H, s), 3.55-3.68 (4H, m), 3.73-3.85 (4H, m), 7.37-7.47 (1H, m), 7.59 (1H, td, J=8.0, 1.0 Hz), 7.69 (1H, dd, J=8.0, 1.0 Hz), 7.89 (1H, dd, J=8.0, 1.0 Hz), 8.58 (1H, s).


Reference Example 147






Yield: 60%, 1H-NMR (CDCl3): δ1.50 (9H, s), 3.56-3.67 (4H, m), 3.73-3.84 (4H, m), 7.53 (1H, dd, J=9.0, 2.0 Hz), 7.62 (1H, d, J=9.0 Hz), 7.88 (1H, d, J=2.0 Hz), 8.57 (1H, s).


Reference Example 148






Yield: 70%, 1H-NMR (CDCl3): δ1.20 (3H, d, J=6.5 Hz), 2.68 (1H, dd, J=13.0, 10.5 Hz), 2.86-3.22 (4H, m), 4.37-4.48 (2H, m), 7.35-7.44 (1H, m), 7.53-7.62 (1H, m), 7.68 (1H, dd, J=8.5, 1.5 Hz), 7.88 (1H, dd, J=8.5, 1.5 Hz), 8.58 (1H, s).


Reference Example 149






Yield: 27%, 1H-NMR (CDCl3): δ1.50 (9H, s), 3.53-3.64 (4H, m), 3.68-3.78 (4H, m), 6.98 (1H, d, J=9.0 Hz), 7.25 (1H, td, J=8.0, 1.5 Hz), 7.55 (1H, td, J=8.0, 1.5 Hz), 7.61 (1H, d, J=8.0 Hz), 7.71 (1H, d, J=8.0 Hz), 7.92 (1H, d, J=9.0 Hz)


Reference Example 150






Yield: 51%, 1H-NMR (CDCl3): δ1.20 (6H, d, J=6.0 Hz), 2.58 (1H, d, J=12.5 Hz), 2.62 (1H, d, J=12.5 Hz), 2.93-3.07 (2H, m), 4.43 (2H, dd, J=12.5, 2.0 Hz), 7.38 (1H, td, J=8.5, 1.5 Hz), 7.57 (1H, td, J=8.5, 1.5 Hz), 7.68 (1H, dd, J=8.5, 1.5 Hz), 7.87 (1H, dd, J=8.5, 1.5 Hz), 8.58 (1H, s).


Reference Example 151






Yield: 88%, 1H-NMR (CDCl3): δ1.20 (6H, d, J=6.5 Hz), 2.58 (1H, d, J=13.0 Hz), 2.62 (1H, d, J=13.0 Hz), 2.92-3.07 (2H, m), 4.42 (2H, dd, J=13.0, 2.0 Hz), 7.50 (1H, dd, J=9.0, 2.0 Hz), 7.60 (1H, d, J=9.0 Hz), 7.85 (1H, d, J=2.0 Hz), 8.57 (1H, s).


Reference Example 152






Yield: quant. %, 1H-NMR (CDCl3): δ1.21 (6H, d, J=6.0 Hz), 2.62 (1H, d, J=12.5 Hz), 2.66 (1H, d, J=12.5 Hz), 2.92-3.06 (2H, m), 4.49 (2H, dd, J=12.5, 2.0 Hz), 7.71-7.75 (2H, m), 8.14 (1H, s), 8.63 (1H, s).


Reference Example 153






Yield: 52%, 1H-NMR (CDCl3): δ1.31 (3H, d, J=6.5 Hz), 1.51 (9H, s), 2.95-3.19 (1H, m), 3.21-3.31 (1H, m), 3.32-3.45 (1H, m), 3.92-4.41 (3H, m), 4.68-4.82 (1H, m), 7.72 (1H, s), 7.73 (1H, s), 8.17 (1H, s), 8.60 (1H, s).


Reference Example 154






Yield: 72%, 1H-NMR (CDCl3): δ1.50 (9H, s), 2.73 (3H, s), 3.37-3.46 (4H, m), 3.62-3.70 (4H, m), 7.76 (1H, d, J=9.0 Hz), 7.89 (1H, d, J=9.0 Hz), 8.19 (1H, s).


Reference Example 155
Preparation of 4-(6-chlorobenzothiazole-2-yl)piperazine dihydrochloride






To 4N solution of hydrochloric acid-dioxane was added 4-(6-chlorobenzothiazole-2-yl)piperazine-1-carboxylic acid tert-butyl ester (1.50 g; 4.239 mmol). The mixture was stirred at 60° C. for 1 hour. The reaction solution was concentrated under reduced pressure and the residue was washed with ethyl acetate to give 4-(6-chlorobenzothiazole-2-yl)piperazine dihydrochloride as colorless crystal (1.40 g; 100%).



1H-NMR (DMSO-d6): δ3.15-3.25 (4H, m), 3.84 (4H, t, J=5 Hz), 6.88 (1H, brs), 7.34 (1H, dd, J=8.5, 2 Hz), 7.50 (1H, d, J=8.5 Hz), 7.99 (1H, d, J=2 Hz), 9.71 (2H, brs).


Compounds in Reference Examples 156 to 194 were obtained by similar methods as Reference Example 155.


Reference Example 156






Yield: 100%, 1H-NMR (DMSO-d6): δ2.13-2.20 (2H, m), 3.20-3.22, (2H, m), 3.33-3.35 (2H, m), 3.68-3.72 (2H, m), 3.98-4.00 (2H, m), 7.33 (1H, dd, J=8.7 Hz, 2.4 Hz), 7.47 (1H, d, J=9.0 Hz), 7.97 (1H, d, J=2.1 Hz), 9.35 (2H, br-s).


Reference Example 157






Yield: 99%, 1H-NMR (DMSO-d6): δ3.26 (4H, t, J=5 Hz), 3.90 (4H, t, J=5 Hz), 7.64 (2H, s), 8.34 (1H, s), 8.65 (1H, brs), 9.77 (2H, s).


Reference Example 158






Yield: 99%, 1H-NMR (DMSO-d6): δ2.10-2.25 (2H, m), 3.20-3.30 (2H, m), 3.30-3.40 (2H, m), 3.70-3.80 (2H, m), 4.00-4.10 (2H, m), 6.64 (1H, brs), 7.60 (2H, s), 8.30 (1H, s), 9.47 (2H, s).


Reference Example 159






Yield: 91%, 1H-NMR (DMSO-d6): δ1.39 (3H, d, J=7 Hz), 3.03-3.18 (1H, m), 3.25-3.40 (4H, m), 3.95-4.05 (1H, m), 4.44-4.55 (1H, m), 7.34 (1H, dd, J=8.5, 2 Hz), 7.49 (1H, d, J=8.5 Hz), 7.96 (1H, d, J=2 Hz), 9.09 (1H, brs), 9.55 (2H, brs).


Reference Example 160






Yield: 82%, 1H-NMR (CDCl3): δ1.40 (3H, d, J=6.5 Hz), 1.67 (1H, brs), 2.77-2.95 (2H, m), 3.05-3.15 (2H, m), 3.40 (1H, td, J=12.5, 3.5 Hz), 3.87 (1H, dd, J=12.5, 3.5 Hz), 4.15-4.30 (1H, m), 7.51 (1H, dd, J=8.5, 1 Hz), 7.56 (1H, d, J=8.5 Hz), 7.84 (1H, d, J=1 Hz).


Reference Example 161






Yield: quant. %, 1H-NMR (DMSO-d6): δ1.42 (3H, d, J=7 Hz), 2.95-3.15 (1H, m), 3.15-3.40 (3H, m), 3.48-3.65 (1H, m), 3.95 (1H, m), 4.40-4.55 (1H, m), 7.33 (1H, dd, J=8.5, 2 Hz), 7.48 (1H, d, J=8.5 Hz), 7.98 (1H, d, J=2 Hz), 8.16 (1H, brs), 9.51 (1H, brs), 9.94 (1H, brs).


Reference Example 162






Yield: 94%, 1H-NMR (DMSO-d6): δ1.42 (3H, d, J=7.0 Hz), 2.98-3.15 (1H, m), 3.16-3.38 (3H, m), 3.47-3.63 (1H, m), 3.96-4.08 (1H, m), 4.40-4.53 (1H, m), 5.10 (1H, s), 7.33 (1H, dd, J=8.5, 2.0 Hz), 7.49 (1H, d, J=8.5 Hz), 7.97 (1H, d, J=2.0 Hz), 9.35-9.53 (1H, br), 9.82-9.98 (1H, br).


Reference Example 163






Yield: 100%, 1H-NMR (CDCl3): δ1.40 (3H, d, J=7 Hz), 2.84-2.96 (2H, m), 3.05-3.15 (2H, m), 3.39 (1H, dt, J=12.5, 3.5 Hz), 3.88 (1H, dd, J=12.5, 2.5 Hz), 4.15-4.25 (1H, m), 7.52 (1H, dd, J=8.5, 1.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.85 (1H, d, J=1.5 Hz).


Reference Example 164






Yield: 80%, 1H-NMR (DMSO-d6): δ1.41 (3H, d, J=7.0 Hz), 3.00-3.17 (1H, m), 3.18-3.38 (3H, m), 3.49-3.64 (1H, m), 4.05-4.14 (1H, m), 4.45-4.58 (1H, m), 6.03 (1H, brs) 7.61 (2H, m), 8.31 (1H, s), 9.25-9.50 (1H, m), 9.73-9.92 (1H, m).


Reference Example 165






Yield: 71%, 1H-NMR (DMSO-d6): δ0.91 (3H, t, J=7.5 Hz), 1.80-1.96 (2H, m), 3.01-3.16 (1H, m), 3.17-3.42 (3H, m), 3.43-3.59 (1H, m), 4.08-4.27 (2H, m), 4.43 (1H, s), 7.33 (1H, dd, J=8.5, 2.0 Hz), 7.46 (1H, d, J=8.5 Hz), 7.94 (1H, d, J=2.0 Hz), 9.22-9.44 (1H, m), 9.60-9.75 (1H, m).


Reference Example 166






Yield: 99%, 1H-NMR (CDCl3): δ0.98 (3H, t, J=7.5 Hz), 1.63 (1H, brs), 1.88 (2H, quant, J=7.5 Hz), 2.88 (1H, td, J=12, 3.5 Hz), 2.95-3.10 (3H, m), 3.34 (1H, td, J=12.5, 3.5 Hz), 3.77-3.86 (1H, m), 3.90-4.00 (1H, m), 7.22 (1H, dd, J=8.5, 2 Hz), 7.40 (1H, d, J=8.5 Hz), 7.53 (1H, d, J=2 Hz).


Reference Example 167






Yield: quant. % 1H-NMR (DMSO-d6): δ0.90 (3H, t, J=7.5 Hz), 1.84-2.05 (2H, m), 2.94-3.62 (5H, m), 4.07-4.26 (2H, m), 6.71 (1H, brs), 7.32 (1H, dd, J=8.5, 2.0 Hz), 7.46 (1H, d, J=8.5 Hz), 7.96 (1H, d, J=2.0 Hz), 9.35-9.58 (1H, m), 9.73-9.95 (1H, m).


Reference Example 168






Yield: quant. %, 1H-NMR (CDCl3): δ0.98 (3H, t, J=7.5 Hz), 1.61 (1H, brs), 1.90 (2H, quant, J=7.5 Hz), 2.89 (1H, td, J=12, 3.5 Hz), 2.95-3.13 (3H, m), 3.37 (1H, td, J=12.5, 3.5 Hz), 3.83-3.94 (1H, m), 3.95-4.06 (1H, m), 7.45-7.56 (2H, m), 7.83 (1H, s).


Reference Example 169






Yield: quant. %, 1H-NMR (CDCl3): δ0.98 (3H, t, J=7.5 Hz), 1.72 (1H, brs), 1.91 (2H, quant, J=7.5 Hz), 2.89 (1H, td, J=12.5, 3.5 Hz), 2.95-3.13 (3H, m), 3.38 (1H, td, J=12.5, 3.5 Hz), 3.84-3.95 (1H, m), 3.95-4.08 (1H, m), 7.50 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=8.5 Hz), 7.83 (1H, s).


Reference Example 170






Yield: quant. %, 1H-NMR (DMSO-d6): δ0.92 (3H, t, J=7.0 Hz), 1.20-1.45 (2H, m), 1.78-1.92 (2H, q, J=7.5 Hz), 2.97-3.38 (4H, m), 3.42-3.59 (1H, m), 4.04-4.17 (1H, m), 4.22-4.34 (1H, m), 5.64 (1H, br), 7.31 (1H, dd, J=8.5, 2.5 Hz), 7.45 (1H, d, J=8.5 Hz), 7.96 (1H, d, J=2.5 Hz), 9.04-9.20 (1H, m), 9.50-9.64 (1H, m).


Reference Example 171






Yield: quant. %, 1H-NMR (CDCl3): δ0.99 (3H, t, J=6.6 Hz), 1.26-1.49 (4H, m), 2.11 (2H, br), 3.63-3.83 (3H, m), 4.10 (1H, br), 4.51 (1H, br), 4.64 (1H, br), 7.22 (1H, s), 7.56-7.63 (2H, m)


Reference Example 172






Yield: quant. %, 1H-NMR (DMSO-d6): δ0.93 (3H, t, J=7.5 Hz), 1.18-1.46 (2H, m), 1.80-1.95 (2H, m), 3.00-3.40 (4H, m), 3.45-3.62 (1H, m), 4.12-4.24 (1H, m), 4.29-4.42 (1H, m), 7.54-7.65 (2H, m), 8.31 (1H, s), 9.14-9.32 (1H, m), 9.60-9.72 (1H, m).


Reference Example 173






Yield: quant. %, 1H-NMR (CDCl3): δ1.00 (3H, t, J=6.0 Hz), 1.26-1.54 (4H, m), 2.17 (2H, br), 3.63-3.86 (3H, m), 4.11 (1H, br), 4.54 (1H, br), 4.70 (1H, br), 7.50 (1H, d, J=7.5 Hz), 7.72 (1H, d, J=7.5 Hz), 7.91 (1H, s)


Reference Example 174






Yield: quant. %, 1H-NMR (DMSO-d6): δ0.87 (3H, t, J=7 Hz), 1.20-1.39 (4H, m), 1.78-1.95 (2H, m), 3.00-3.15 (1H, m), 3.15-3.40 (3H, m), 3.42-3.55 (1H, m), 4.07-4.20 (1H, m), 4.20-4.30 (1H, m), 4.55 (1H, brs), 7.31 (1H, dd, J=8.5, 2 Hz), 7.44 (1H, d, J=8.5 Hz), 7.95 (1H, d, J=2 Hz), 9.00 (1H, brs), 9.48 (1H, brs).


Reference Example 175






Yield: quant. %, 1H-NMR (DMSO-d6): δ0.87 (3H, t, J=7 Hz), 1.18-1.40 (4H, m), 1.77-1.98 (2H, m), 2.95-3.14 (1H, m), 3.14-3.37 (3H, m), 3.40-3.51 (1H, m), 4.08-4.20 (1H, m), 4.20-4.31 (1H, m), 6.89 (1H, brs), 7.31 (1H, dd, J=8.5, 2 Hz), 7.44 (1H, d, J=8.5 Hz), 7.95 (1H, d, J=2 Hz), 9.25 (1H, brs), 9.62 (1H, brs).


Reference Example 176






Yield: quant. %, 1H-NMR (DMSO-d6): δ0.85-0.90 (3H, m), 1.20-1.40 (4H, m), 1.85-2.00 (2H, m), 3.00-3.59 (5H, m), 4.15-4.23 (1H, m), 4.24-4.35 (1H, m), 7.60 (2H, s), 8.29 (1H, s), 9.36 (2H, brs), 9.75 (1H, s).


Reference Example 177






Yield: quant. %, 1H-NMR (DMSO-d6): δ0.86 (3H, d, J=6.5 Hz), 1.04 (3H, d, J=6.5 Hz), 3.00-3.35 (4H, m), 3.38-3.60 (2H, m), 3.87-4.02 (1H, m), 4.16-4.31 (1H, m), 5.20 (1H, br), 7.57 (1H, d, J=8.5 Hz), 7.61 (1H, d, J=8.5 Hz), 8.29 (1H, s), 9.05-9.22 (1H, m), 9.37-9.50 (1H, m).


Reference Example 178






Yield: 93%, H-NMR (DMSO-d6): δ0.86 (3H, d, J=6.5 Hz), 1.00 (3H, d, J=6.5 Hz), 2.50-2.60 (1H, m), 3.03-3.31 (3H, m), 3.44-3.60 (2H, m), 3.90-4.00 (1H, m), 4.20-4.30 (1H, m), 7.54-7.63 (2H, m), 8.29 (1H, s), 9.23 (1H, brs), 9.48 (2H, brs).


Reference Example 179






Yield: 96%, 1H-NMR (DMSO-d6): δ0.95 (6H, d, J=6.5 Hz), 1.50-1.90 (3H, m), 2.96-3.37 (4H, m), 3.40-3.60 (1H, m), 4.03-4.16 (1H, m), 4.27-4.40 (1H, m), 6.30 (1H, br), 7.32 (1H, dd, J=8.5, 2.0 Hz), 7.45 (1H, d, J=8.5 Hz), 7.97 (1H, d, J=2.0 Hz), 9.10-9.32 (1H, m), 9.52-9.75 (1H, m).


Reference Example 180






Yield: quant. %, 1H-NMR (DMSO-d6): δ0.94 (6H, d, J=6.5 Hz), 1.52-1.94 (3H, m), 2.95-3.35 (4H, m), 3.45-3.57 (1H, m), 4.04-4.16 (1H, m), 4.29-4.40 (1H, m), 7.32 (1H, dd, J=8.5, 2 Hz), 7.45 (1H, d, J=8.5 Hz), 7.97 (1H, d, J=2 Hz), 9.45 (1H, brs), 9.81 (1H, brs), 9.84 (1H, brs).


Reference Example 181






Yield: quant. %, 1H-NMR (DMSO-d6): δ0.96 (6H, d, J=6.5 Hz), 1.50-1.90 (3H, m), 2.99-3.39 (4H, m), 3.46-3.63 (1H, m), 4.08-4.22 (1H, m), 4.35-4.48 (1H, m), 6.11 (1H, brs), 7.60 (2H, s), 8.31 (1H, s), 9.10-9.29 (1H, m), 9.54-9.67 (1H, m).


Reference Example 182






Yield: 97%, 1H-NMR (CDCl3): δ1.04 (6H, s), 1.68 (1H, br), 1.98 (1H, br), 2.07 (1H, br), 3.54 (3H, br), 3.71 (1H, br), 3.98 (1H, s), 4.46 (2H, br), 7.52 (1H, d, J=7.5 Hz), 7.65 (1H, d, J=7.5 Hz), 7.90 (1H, s)


Reference Example 183






Yield: 94%, 1H-NMR (DMSO-d6): δ3.24 (4H, t, J=5.0 Hz), 3.74 (4H, t, J=5.0 Hz), 5.12 (1H, s), 7.26 (1H, t, J=7.5 Hz), 7.39 (2H, t, J=7.5 Hz), 7.51 (2H, d, J=7.5 Hz), 7.71 (1H, s), 9.58 (2H, s).


Reference Example 184






Yield: 96%, 1H-NMR (DMSO-d6): δ3.17-3.34 (4H, m), 3.83-3.96 (4H, m), 5.12 (1H, brs), 7.55 (1H, d, J=12.5 Hz), 8.36 (1H, d, J=7.5 Hz), 9.69 (2H, brs).


Reference Example 185






Yield: 92%, 1H-NMR (DMSO-d6): δ2.14-2.27 (2H, m), 3.16-3.30 (2H, m), 3.31-3.43 (2H, m), 3.66-3.84 (2H, m), 3.97-4.13 (2H, m), 4.78 (1H, brs), 7.53 (1H, d, J=12.5 Hz), 8.32 (1H, d, J=7.5 Hz), 9.53 (2H, brs).


Reference Example 186






Yield: 89%, 1H-NMR (CDCl3): δ1.44 (3H, d, J=7.0 Hz), 3.00-3.13 (1H, m), 3.14-3.40 (3H, m), 3.53-3.69 (1H, m), 4.02-4.15 (1H, m), 4.46-4.60 (1H, m), 6.90 (1H, brs), 7.55 (1H, d, J=12.5 Hz), 8.35 (1H, d, J=7.0 Hz), 9.50 (1H, br), 9.94 (1H, br).


Reference Example 187






Yield: 83%, 1H-NMR (DMSO-d6): δ1.44 (3H, d, J=7.0 Hz), 3.01-3.19 (1H, m), 3.20-3.45 (3H, m), 3.51-3.70 (1H, m), 4.01-4.16 (1H, m), 4.45-4.62 (1H, m), 5.95 (1H, brs), 7.55 (1H, d, J=12.5 Hz), 8.35 (1H, d, J=7.5 Hz), 9.49 (1H, br), 9.89 (1H, br).


Reference Example 188






Yield: 83%, 1H-NMR (DMSO-d6): δ0.90 (3H, t, J=7.5 Hz), 1.80-2.00 (2H, m), 2.97-3.40 (4H, m), 3.41-3.56 (1H, m), 4.06-4.26 (2H, m), 7.49 (1H, d, J=10.5 Hz), 8.10 (1H, d, J=7.5 Hz), 9.02-9.25 (1H, m), 9.43-9.65 (1H, m).


Reference Example 189






Yield: quant. %, 1H-NMR (DMSO-d6): δ3.16-3.32 (4H, m), 3.98-4.12 (4H, m), 7.42-7.51 (1H, m), 7.60-7.72 (2H, m), 7.88 (1H, d, J=8.0 Hz), 8.90 (1H, s), 9.54 (2H, s).


Reference Example 190






Yield: 92%, 1H-NMR (DMSO-d6): δ2.19-3.32 (4H, m), 3.80-3.90 (4H, m), 7.15 (1H, td, J=8.0, 1.0 Hz), 7.34 (1H, td; J=8.0, 1.0 Hz), 7.54 (1H, dd, J=8.0, 1.0 Hz), 7.85 (1H, dd, J=8.0, 1.0 Hz), 9.65 (2H, s).


Reference Example 191






Yield: 91%, 1H-NMR (DMSO-d6): δ3.30 (4H, s), 3.80 (1H, br), 4.16 (4H, s), 7.38-7.60 (2H, m), 7.68-7.81 (1H, m), 7.84-7.97 (1H, m), 8.16 (1H, br), 8.32-8.52 (1H, m), 9.57 (2H, brs).


Reference Example 192






Yield: 63%, 1H-NMR (DMSO-d6): δ3.24 (4H, s), 3.87 (1H, brs), 4.03 (4H, s), 7.66 (2H, s), 7.93 (1H, s), 8.92 (1H, s), 9.38 (2H, brs).


Reference Example 193






Yield: 82%, 1H-NMR (DMSO-d6): δ2.71 (3H, s), 3.24-3.35 (4H, m), 3.62-3.73 (4H, m), 7.91 (1H, d, J=9.0 Hz), 7.97 (1H, d, J=9.0 Hz), 8.23 (1H, s), 9.32 (2H, brs).


Reference Example 194






Yield: 80%, 1H-NMR (DMSO-d6): δ1.39 (3H, d, J=7.0 Hz), 3.00-3.16 (1H, m), 3.18-3.54 (5H, m), 4.68 (1H, d, J=14.0 Hz), 5.05-5.17 (1H, m), 7.79 (1H, d, J=8.5 Hz), 7.89 (1H, d, J=8.5 Hz), 8.20 (1H, s), 8.97 (1H, s), 9.19 (1H, brs), 9.53 (1H, brs).


Example 1
Preparation of 3-[[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl]benzoic acid methyl ester






A mixture of 4-(6-chlorobenzothiazole-2-yl)piperazine dihydrochloride (3.00 g; 9.18 mmol), 3-(bromomethyl)methyl butanoate (2.31 g; 10.1 mmol), potassium carbonate (3.81 g; 27.6 mmol) and anhydrous N,N-dimethylformamide (30 ml) was stirred at room temperature for 14 hours. Water was added to the reaction solution. The precipitate was collected and washed with diisopropyl ether to give 3-[[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl]benzoic acid methyl ester as colorless crystal (3.06 g; 83%).



1H-NMR (CDCl3): δ2.58 (4H, t, J=5 Hz), 3.61 (2H, s), 3.64 (4H, t, J=5 Hz), 3.93 (3H, s), 7.23 (1H, dd, J=8.5, 2 Hz), 7.35-7.45 (1H, m), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz), 7.55-7.60 (1H, m), 7.96 (1H, d, J=7.5 Hz), 8.01 (1H, s).


Compounds in Example 2 to 127 were obtained by similar methods as Example 1.


Example 2






Yield: 88%, 1H-NMR (CDCl3): δ2.01-2.05 (2H, m), 2.69 (2H, t, J=5.4 Hz), 2.80-2.83 (2H, m), 3.67 (2H, s) 3.72-3.78 (4H, m), 3.92 (3H, s), 7.23 (1H, dd, J=8.7 Hz, 2.1 Hz), 7.37-7.44 (2H, m), 7.53 (1H, s), 7.55 (1H, d, J=2.1 Hz), 7.94 (1H, d, J=7.5 Hz), 7.99 (1H, s).


Example 3






Yield: 73%, 1H-NMR (CDCl3): δ2.60 (4H, t, J=5 Hz), 3.62 (2H, s), 3.67 (4H, t, J=5 Hz), 3.97 (3H, s), 7.43 (1H, t, J=7.5 Hz), 7.50-7.60 (3H, m), 7.85 (1H, s), 7.97 (1H, d, J=7.5 Hz), 8.02 (1H, s).


Example 4






Yield: q.y, 1H-NMR (CDCl3): δ2.00-2.20 (2H, m), 2.70 (2H, t, J=5.5 Hz), 2.83 (2H, t, J=5.5 Hz), 3.69 (2H, s), 3.70-3.85 (4H, m), 3.92 (3H, s), 7.40 (1H, t, J=7.5 Hz), 7.50-7.60 (3H, m), 7.84 (1H, s), 7.94 (1H, d, J=7.5 Hz), 7.99 (1H, s).


Example 5






Yield: 97%, 1H-NMR (CDCl3): δ1.41 (3H, d, J=6 Hz), 2.28 (1H, td, J=11.5, 3.5 Hz), 2.36 (1H, dd, J=11.5, 3.5 Hz), 2.69 (1H, d, J=11.5 Hz), 2.90 (1H, d, J=11.5 Hz), 3.40-3.55 (2H, m), 3.63 (1H, d, J=12.5 Hz), 3.80-3.90 (1H, m), 3.93 (3H, s), 4.10-4.25 (1H, m), 7.22 (1H, dd, J=8.5, 2 Hz), 7.42 (1H, d, J=8.5 Hz), 7.43 (1H, t, J=7.5 Hz), 7.54 (1H, d, J=2 Hz), 7.58 (1H, d, J=7.5 Hz), 7.95 (1H, d, J=7.5 Hz), 8.02 (1H, s).


Example 6






Yield: q.y, 1H-NMR (CDCl3): δ1.23 (3H, d, J=6 Hz), 2.25-2.35 (1H, m), 2.60-2.73 (1H, m), 2.73-2.82 (1H, m), 3.17 (1H, dd, J=12.5, 9 Hz), 3.33 (1H, d, J=13.5 Hz), 3.35-3.45 (1H, m), 3.65-3.75 (1H, m), 3.85-3.90 (1H, m), 3.93 (3H, s), 4.08 (1H, d, J=13.5 Hz), 7.22 (1H, dd, J=8.5, 2 Hz), 7.41 (1H, t, J=7.5 Hz), 7.43 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2 Hz), 7.56 (1H, d, J=7.5 Hz), 7.94 (1H, d, J=7.5 Hz), 8.01 (1H, s).


Example 7






Yield: 83%, 1H-NMR (CDCl3): δ1.15 (6H, d, J=6 Hz), 2.75-2.85 (2H, m), 3.06 (2H, dd, J=13, 12.5 Hz), 3.80-3.92 (4H, m), 3.92 (3H, s), 7.24 (1H, dd, J=8.5, 2 Hz), 7.37 (1H, d, J=7.5 Hz), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz), 7.62 (1H, d, J=7.5 Hz), 7.89 (1H, d, J=7.5 Hz), 8.04 (1H, s).


Example 8






Yield: 79%, 1H-NMR (CDCl3): δ1.10 (3H, d, J=6.5 Hz), 1.38 (3H, d, J=6.5 Hz), 2.31 (1H, d, J=12 Hz), 2.91 (1H, dd, J=12.4 Hz), 3.10-3.20 (1H, m), 3.59 (2H, t, J=14 Hz), 3.71 (2H, t, J=14 Hz), 3.93 (3H, s), 4.16-4.28 (1H, m), 7.22 (1H, dd, J=8.5, 2 Hz), 7.42 (1H, d, J=8.5 Hz), 7.43 (1H, d, J=7.5 Hz), 7.53 (1H, d, J=2 Hz), 7.61 (1H, d, J=7.5 Hz), 7.95 (1H, d, J=7.5 Hz), 8.06 (1H, s).


Example 9






Yield 92%, 1H-NMR (CDCl3): δ2.45 (3H, s), 2.58 (4H, t, J=5 Hz), 3.55 (2H, s), 3.61 (4H, t, J=5 Hz), 3.91 (3H, s), 7.23 (1H, dd, J=8.5, 2 Hz), 7.24 (1H, d, J=8 Hz), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz), 7.87 (1H, dd, J=8, 1.5 Hz), 7.92 (1H, d, J=1.5 Hz).


Example 10






Yield 93%, 1H-NMR (CDCl3): δ2.66 (4H, t, J=5 Hz), 3.66 (4H, t, J=5 Hz), 3.71 (2H, s), 3.96 (3H, s), 7.24 (1H, dd, J=8.5, 2 Hz), 7.44 (1H, d, J=8.5 Hz), 7.45 (1H, d, J=8 Hz), 7.55 (1H, d, J=2 Hz), 7.88 (1H, dd, J=8.2 Hz), 8.15 (1H, d, J=2 Hz).


Example 11






Yield 79%, 1H-NMR (CDCl3): δ1.99-2.05 (2H, m), 2.40 (3H, s), 2.69 (2H, t, J=5.1 Hz), 2.79-2.82 (2H, m), 3.61 (2H, s), 3.71-3.75 (4H, m), 3.90 (3H, s), 7.21-7.25 (2H, m), 7.42 (1H, d, J=8.4 Hz), 7.55 (1H, d, J=2.4 Hz), 7.38-7.87 (1H, m), 7.92 (1H, s).


Example 12






Yield 79%, 1H-NMR (CDCl3): δ2.03-2.10 (2H, m), 2.75 (2H, t, J=5.4 Hz), 2.87-2.90 (2H, m), 3.73-3.80 (6H, m), 3.92 (3H, s), 7.22-7.26 (1H, m), 7.41 (1H, s), 7.44 (1H, s), 7.55 (1H, d, J=2.1 Hz), 7.87 (1H, dd, J=8.4 Hz, 2.1 Hz), 8.15 (1H, d, J=2.1 Hz).


Example 13






Yield 90%, 1H-NMR (CDCl3): δ2.38 (3H, s), 2.57 (4H, t, J=5 Hz), 3.51 (2H, s), 3.64 (4H, t, J=5 Hz), 3.92 (3H, s), 7.23 (1H, dd, J=8.5, 2 Hz), 7.37 (1H, s), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz), 7.78 (1H, s), 7.80 (1H, s).


Example 14






Yield 90%, 1H-NMR (CDCl3): δ1.59 (3H, s), 2.00-2.06 (2H, m), 2.39 (3H, s), 2.69 (2H, t, J=5.4 Hz), 2.79-2.82 (2H, m), 3.64 (2H, s) 3.74-3.77 (4H, m), 7.23 (1H, dd, J=8.4 Hz, 1.8 Hz), 7.35 (1H, s), 7.42 (1H, d, J=8.4 Hz), 7.55 (1H, d, J=1.8 Hz), 7.75 (1H, s), 7.78 (1H, s).


Example 15







1H-NMR (CDCl3): δ2.65 (4H, t, J=5.1 Hz), 3.64-3.67 (4H, m), 3.78 (2H, s), 3.88 (3H, s), 6.93 (1H, d, J=3.3 Hz), 7.24 (1H, dd, J=8.7, 2.1 Hz), 7.44 (1H, d, J=8.7 Hz), 7.56 (1H, d, J=2.1 Hz), 7.67 (1H, d, J=3.3 Hz).


Example 16






Yield 65%, 1H-NMR (CDCl3): δ2.01-2.08 (2H, m), 2.71-2.75 (2H, m), 2.85-2.89 (2H, m), 3.72-3.76 (2H, m), 3.79-3.82 (2H, m), 3.86 (2H, s), 3.87 (3H, s), 6.89 (1H, d, J=3.9 Hz), 7.23 (1H, dd, J=8.7 Hz, 2.1 Hz), 7.42 (1H, d, J=8.7 Hz), 7.55 (1H, d, J=2.4 Hz), 7.65 (1H, d, J=3.9 Hz).


Example 17







1H-NMR (CDCl3): δ1.37 (3H, t, J=7 Hz), 2.65 (4H, t, J=5 Hz), 3.65 (4H, t, J=5 Hz), 3.69 (2H, s), 4.36 (2H, q, J=7 Hz), 6.37 (1H, d, J=3.5 Hz), 7.13 (1H, d, J=3.5 Hz), 7.24 (1H, dd, J=8.5, 2 Hz), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Example 18







1H-NMR (CDCl3): δ2.56-2.60 (4H, m), 3.62-3.66 (6H, m), 3.92 (3H, s), 7.24 (1H, dd, J=8.7, 2.1 Hz), 7.42-7.44 (3H, m), 7.55 (1H, d, J=2.1 Hz), 8.01 (2H, d, J=8.4 Hz).


Example 19






Yield 76%, 1H-NMR (CDCl3): δ2.41 (3H, s), 2.59 (4H, t, J=5 Hz), 3.58 (2H, s), 3.69 (4H, t, J=5 Hz), 3.96 (3H, s), 7.37 (1H, s), 7.50-7.60 (2H, m), 7.79 (1H, s), 7.80 (1H, s), 7.85 (1H, s).


Example 20






Yield 74%, 1H-NMR (CDCl3): δ2.00-2.10 (2H, m), 2.38 (3H, s), 2.70 (2H, t, J=5 Hz), 2.82 (2H, t, J=5 Hz), 3.65 (2H, s), 3.70-3.90 (4H, m), 3.91 (3H, s), 7.34 (1H, s), 7.50-7.60 (2H, m), 7.75 (1H, s), 7.79 (1H, s), 7.85 (1H, s).


Example 21






Yield 98%, 1H-NMR (CDCl3): δ1.24 (3H, d, J=6.5 Hz), 2.25-2.37 (1H, m), 2.64-2.75 (1H, m), 2.75-2.83 (1H, m), 3.23 (1H, dd, J=13, 9 Hz), 3.29 (1H, d, J=13.5 Hz), 3.40-3.50 (1H, m), 3.70-3.80 (1H, m), 3.87-3.95 (1H, m), 3.93 (3H, s), 4.08 (1H, d, J=13.5 Hz), 7.42 (1H, t, J=7.5 Hz), 7.50-7.60 (3H, m), 7.84 (1H, s), 7.95 (1H, d, J=8 Hz), 8.01 (1H, s).


Example 22






Yield 85%, 1H-NMR (CDCl3): δ1.24 (3H, d, J=6.5 Hz), 2.23-2.35 (1H, m), 2.41 (3H, s), 2.60-2.73 (1H, m), 2.80 (1H, dt, J=12, 3.5 Hz), 3.21 (1H, d, J=13 Hz), 3.24 (1H, d, J=13.5 Hz), 3.39-3.50 (1H, m), 3.70-3.80 (1H, m), 3.91 (3H, s), 3.91-3.95 (1H, m), 4.05 (1H, d, J=13.5 Hz), 7.36 (1H, s), 7.51 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=8.5 Hz), 7.77 (1H, s), 7.80 (1H, s), 7.84 (1H, s).


Example 23






Yield 96%, 1H-NMR (CDCl3): δ1.24 (3H, d, J=6.3 Hz), 2.24-2.32 (1H, m), 2.40 (3H, s), 2.63-2.68 (1H, m), 2.78 (1H, dt, J=3.6, 12.0 Hz), 3.17 (1H, dd, J=9.0 Hz), 3.22 (1H, d, J=13.2 Hz), 3.35-3.43 (1H, m), 3.71 (1H, dt, J=3.3, 12.6 Hz), 3.88 (1H, dd, J=3.0, 15.0 Hz), 3.91 (3H, s), 4.05 (1H, d, J=13.2 Hz), 7.23 (1H, dd, J=2.4, 8.4 Hz), 7.36 (1H, s), 7.43 (1H, d, J=8.4 Hz), 7.54 (1H, d, J=2.4 Hz, 7.76 (1H, s), 7.79 (1H, s)


Example 24






Yield 98%, 1H-NMR (CDCl3): δ1.24 (3H, d, J=6.3 Hz), 2.28 (1H, ddd, J=3.3, 8.7, 9.6 Hz), 2.40 (3H, s), 2.62-2.68 (1H, m), 2.78 (1H, dt, J=3.6, 12.0 Hz), 3.17 (1H, dd, J=8.7, 12.6 Hz), 3.22 (1H, d, J=12.9 Hz), 3.39 (1H, m), 3.71 (1H, d, 12.3 Hz), 3.88 (1H, dd, 3.3, 13.2 Hz), 3.92 (3H, s), 4.05 (1H, d, J=13.2 Hz), 7.23 (1H, dd, J=2.1, 8.4 Hz), 7.36 (1H, s), 7.43 (1H, d, J=8.4 Hz), 7.54 (1H, d, J=2.1 Hz), 7.76 (1H, s), 7.79 (1H, s)


Example 25






Yield 86%, 1H-NMR (CDCl3): δ1.11 (6H, d, J=6 Hz), 2.40 (3H, s), 2.70-2.85 (2H, m), 3.00-3.15 (2H, m), 3.83 (2H, s), 3.83-3.90 (2H, m), 3.91 (3H, s), 7.23 (1H, dd, J=8.5, 2 Hz), 7.40 (1H, s), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz), 7.72 (1H, s), 7.84 (1H, s).


Example 26






Yield 67%, 1H-NMR (CDCl3): δ1.13 (6H, d, J=6.5 Hz), 2.40 (3H, s), 2.75-2.88 (2H, m), 3.05-3.18 (2H, m), 3.84 (2H, s), 3.91 (3H, s), 3.91-3.95 (2H, m), 7.40 (1H, s), 7.52 (1H, d, J=8.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.72 (1H, s), 7.84 (2H, s).


Example 27






Yield 75%, 1H-NMR (CDCl3): δ1.42 (3H, d, J=6.5 Hz), 2.26 (1H, td, J=11.5, 3.5 Hz), 2.36 (1H, dd, J=11.5, 3.5 Hz), 2.41 (3H, s), 2.65-2.75 (1H, m), 2.85-2.95 (1H, m), 3.47 (1H, d, J=13.5 Hz), 3.48-3.55 (1H, m), 3.60 (1H, d, J=13.5 Hz), 3.80-3.90 (1H, m), 3.91 (3H, s), 4.20-4.30 (1H, m), 7.38 (1H, s), 7.51 (1H, dd, J=8.5, 2 Hz), 7.56 (1H, d, J=8.5 Hz), 7.77 (1H, s), 7.83 (1H, d, J=2 Hz), 7.84 (1H, s).


Example 28






Yield 78%, 1H-NMR (CDCl3): δ1.24 (3H, t, J=6.0 Hz), 2.24-2.36 (1H, m), 2.41 (3H, s), 2.61-2.73 (1H, m), 2.75-2.84 (1H, m), 3.21 (1H, d, J=13.0 Hz), 3.24 (1H, d, J=13.5 Hz), 3.38-3.51 (1H, m), 3.71-3.82 (1H, m), 3.88-3.98 (1H, m), 3.92 (3H, s), 4.05 (1H, d, J=13.0 Hz), 7.36 (1H, s), 7.51 (1H, d, J=8.5), 7.56 (1H, d, J=8.5 Hz), 7.77 (1H, s), 7.80 (1H, s), 7.84 (1H, s).


Example 29






Yield 58%, 1H-NMR (DMSO-d6): δ2.25 (3H, s), 2.31 (3H, s), 2.51 (4H, t, J=5 Hz), 3.51 (2H, s), 3.57 (4H, t, J=5 Hz), 6.85 (1H, s), 6.89 (1H, s), 7.04 (1H, s), 7.28 (1H, dd, J=8.5, 2.5 Hz), 7.42 (1H, d, J=8.5 Hz), 7.91 (1H, d, J=2.5 Hz).


Example 30






Yield 89%, 1H-NMR (CDCl3): δ1.99-2.06 (2H, m), 2.29 (3H, s), 2.34 (3H, s), 2.68 (2H, t, J=5.7 Hz), 2.78-2.82 (2H, m), 3.61 (2H, s), 3.72-3.78 (4H, m), 6.79 (1H, s), 6.88 (1H, s), 6.98 (1H, s), 7.22 (1H, dd, J=7.5 Hz, 3.3 Hz), 7.42 (1H, d, J=6.3 Hz), 7.54 (1H, d, J=2.1 Hz).


Example 31






Yield 71%, 1H-NMR (CDCl3): δ2.30 (3H, s), 2.36 (3H, s), 2.59 (4H, t, J=5 Hz), 3.53 (2H, s), 3.68 (4H, t, J=5 Hz), 6.83 (1H, s), 6.90 (1H, s), 7.02 (1H, s), 7.50-7.60 (2H, m), 7.85 (1H, s).


Example 32






Yield 65%, 1H-NMR (CDCl3): δ1.95-2.10 (2H, m), 2.28 (3H, s), 2.34 (3H, s), 2.69 (2H, t, J=5 Hz), 2.83 (2H, t, J=5 Hz), 3.61 (2H, s), 3.70-3.85 (4H, m), 6.80 (1H, s), 6.89 (1H, s), 6.99 (1H, s), 7.48-7.60 (2H, m), 7.85 (1H, s).


Example 33






Yield 69%, 1H-NMR (CDCl3): δ2.31 (3H, s), 2.57 (4H, t, J=5.1 Hz), 3.55 (2H, s), 3.63 (4H, t, J=5.1 Hz), 7.06 (2H, d, J=8.1 Hz), 7.24 (1H, dd, J=8.4, 2.1 Hz), 7.35 (2H, d, J=8.1 Hz), 7.43 (1H, d, J=8.4 Hz), 7.55 (1H, d, J=2.1 Hz).


Example 34






Yield 56%, 1H-NMR (CDCl3): δ1.22 (3H, d, J=6 Hz), 2.24-2.35 (1H, m), 2.29 (3H, s), 2.35 (3H, s), 2.62-2.72 (1H, m), 2.83 (1H, dt, J=12, 4 Hz), 3.15-3.25 (2H, m), 3.40-3.50 (1H, m), 3.70-3.80 (1H, m), 3.87-3.95 (1H, m), 4.03 (1H, d, J=13.5 Hz), 6.81 (1H, s), 6.90 (1H, s), 7.01 (1H, s), 7.52 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 35






Yield 41%, 1H-NMR (CDCl3): δ1.10 (6H, d, J=6 Hz), 2.29 (3H, s), 2.34 (3H, s), 2.70-2.85 (2H, m), 3.00-3.10 (2H, m), 3.79 (2H, s), 3.80-3.90 (2H, m), 6.76 (1H, s), 6.95 (1H, s), 7.02 (1H, s), 7.23 (1H, dd, J=8.5, 2 Hz), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Example 36






Yield 63%, 1H-NMR (CDCl3): δ1.11 (6H, d, J=6 Hz), 2.30 (3H, s), 2.35 (3H, s), 2.70-2.86 (2H, m), 3.00-3.15 (2H, m), 3.80 (2H, s), 3.85-3.95 (2H, m), 6.77 (1H, s), 6.95 (1H, s), 7.02 (1H, s), 7.52 (1H, d, J=8.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.85 (1H, s).


Example 37






Yield 53%, 1H-NMR (CDCl3): δ1.02 (3H, t, J=7.5 Hz), 1.55-1.78 (2H, m), 2.30 (3H, s), 2.30-2.35 (1H, m), 2.36 (3H, s), 2.49-2.60 (1H, m), 2.78-2.90 (1H, m), 3.26 (1H, d, J=13.5 Hz), 3.38-3.46 (1H, m), 3.46-3.58 (1H, m), 3.63-3.72 (1H, m), 3.85 (1H, dd, J=13, 3.5 Hz), 3.98 (1H, d, J=13.5 Hz), 6.81 (1H, s), 6.91 (1H, s), 7.02 (1H, s), 7.51 (1H, dd, J=8.5, 1.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.84 3 (1H, d, J=1.5 Hz)


Example 38






Yield 69%, 1H-NMR (CDCl3): δ2.25-2.35 (1H, m), 2.30 (3H, s), 2.34 (3H, s), 2.86 (1H, d, J=13.5 Hz), 3.02 (1H, d, J=11.5 Hz), 3.25-3.50 (3H, m), 3.82 (1H, d, J=13.5 Hz), 4.00-4.10 (2H, m), 6.79 (1H, s), 6.82 (1H, s), 6.93 (1H, s), 7.30-7.45 (3H, m), 7.48-7.55 (4H, m), 7.84 (1H, d, J=0.5 Hz).


Example 39






Yield 48%, 1H-NMR (CDCl3): δ1.40 (3H, d, J=6.5 Hz), 2.15-2.30 (2H, m), 2.31 (3H, s), 2.36 (3H, s), 2.68-2.75 (1H, m), 2.85-2.95 (1H, m), 3.38-3.60 (3H, m), 3.80-3.90 (1H, m), 4.15-4.25 (1H, m), 6.81 (1H, s), 6.92 (1H, s), 7.02 (1H, s), 7.23 (1H, dd, J=8.5, 2 Hz), 7.42 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2 Hz).


Example 40






Yield 81%, 1H-NMR (CDCl3): δ1.42 (3H, d, J=6.5 Hz), 2.18-2.29 (1H, m), 2.30 (3H, s), 2.30-2.35 (1H, m), 2.36 (3H, s), 2.75 (1H, d, J=11.5 Hz), 2.92 (1H, d, J=11.5 Hz), 3.43 (1H, d, J=13.5 Hz), 3.52 (1H, td, J=12.5, 3.5 Hz), 3.57 (1H, d, J=13.5 Hz), 3.91 (1H, d, J=12.5 Hz), 4.17-4.30 (1H, m), 6.81 (1H, s), 6.92 (1H, s), 7.02 (1H, s), 7.51 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 41






Yield 57%, 1H-NMR (CDCl3): δ1.42 (3H, d, J=6.5 Hz), 2.18-2.38 (2H, m), 2.30 (3H, s), 2.36 (3H, s), 2.70-2.80 (1H, m), 2.86-2.97 (1H, m), 3.38-3.61 (3H, m), 3.85-3.97 (1H, m), 4.17-4.30 (1H, m), 6.82 (1H, s), 6.92 (1H, s), 7.03 (1H, s), 7.48-7.59 (2H, m), 7.84 (1H, s).


Example 42






Yield 63%, 1H-NMR (CDCl3): δ1.02 (3H, t, J=7.5 Hz), 1.60-1.75 (2H, m), 2.30 (3H, s), 2.30-2.35 (1H, m), 2.36 (3H, s), 2.48-2.58 (1H, m), 2.79-2.90 (1H, m), 3.26 (1H, d, J=13.5 Hz), 3.38-3.58 (2H, m), 3.63-3.73 (1H, m), 3.80-3.90 (1H, m), 3.98 (1H, d, J=13.5 Hz), 6.81 (1H, s), 6.91 (1H, s), 7.02 (1H, s), 7.51 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 43






Yield 79%, 1H-NMR (CDCl3): δ1.02 (3H, t, J=7.5 Hz), 1.57-1.80 (2H, m), 2.21 (3H, s), 2.21-2.35 (1H, m), 2.36 (3H, s), 2.50-2.60 (1H, m), 2.80-2.90 (1H, m), 3.26 (1H, d, J=13.5 Hz), 3.38-3.60 (2H, m), 3.63-3.74 (1H, m), 3.85 (1H, dd, J=12.5, 3.5 Hz), 3.98 (1H, d, J=13.5 Hz), 6.81 (1H, s), 6.91 (1H, s), 7.02 (1H, s), 7.53 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 44






Yield 63%, 1H-NMR (CDCl3): δ1.20 (3H, t, J=7.5 Hz), 1.30-1.70 (4H, m), 2.29 (3H, s), 2.29-2.35 (1H, m), 2.36 (3H, s), 2.55-2.65 (1H, m), 2.79-2.89 (1H, m), 3.28 (1H, d, J=13.5 Hz), 3.41 (1H, dd, J=13, 7.5 Hz), 3.50-3.60 (1H, m), 3.60-3.70 (1H, m), 3.84 (1H, dd, J=13, 3 Hz), 3.97 (1H, d, J=13.5 Hz), 6.81 (1H, s), 6.90 (1H, s), 7.02 (1H, s), 7.51 (1H, dd, J=8.5, 1.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.83 (1H, d, J=1.5 Hz).


Example 45






Yield 62%, 1H-NMR (CDCl3): δ0.95 (3H, t, J=7.2 Hz), 1.36-1.43 (2H, m), 1.50-1.66 (2H, m), 2.30 (3H, s), 2.35 (3H, s), 2.32-2.39 (1H, m), 2.58-2.63 (1H, m), 2.80-2.87 (1H, m), 3.28 (1H, d, J=13.5 Hz), 3.41 (1H, dd, J=7.5, 12.6 Hz), 3.50-3.59 (1H, m), 3.62-3.68 (1H, m), 3.84 (1H, dd, J=3.0, 12.6 Hz), 3.97 (1H, d, J=13.5 Hz), 6.81 (1H, s), 6.90 (1H, s), 7.01 (1H, s), 7.53-7.55 (2H, m), 7.83 (1H, s)


Example 46






Yield 70%, 1H-NMR (CDCl3): δ0.93 (3H, t, J=7.5 Hz), 1.23-1.75 (6H, m), 2.30 (3H, s), 2.30-2.34 (1H, m), 2.35 (3H, s), 2.54-2.64 (1H, m), 2.79-2.89 (1H, m), 3.27 (1H, d, J=13.5 Hz), 3.41 (1H, dd, J=12.5, 7.5 Hz), 3.49-3.60 (1H, m), 3.61-3.71 (1H, m), 3.84 (1H, dd, J=12.5, 2.5 Hz), 3.97 (1H, d, J=13.5 Hz), 6.81 (1H, s), 6.90 (1H, s), 7.02 (1H, s), 7.51 (1H, dd, J=8.5, 1.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.84 (1H, d, J=1.5 Hz).


Example 47






Yield 69%, 1H-NMR (CDCl3): δ0.91 (3H, d, J=6.5 Hz), 0.95 (3H, d, J=6.5 Hz), 1.33-1.45 (1H, m), 1.45-1.58 (1H, m), 1.62-1.77 (1H, m), 2.29 (3H, s), 2.35 (3H, s), 2.36-2.45 (1H, m), 2.62-2.73 (1H, m), 2.77-2.88 (1H, m), 3.33 (1H, d, J=13.5 Hz), 3.35 (1H, dd, J=13, 7 Hz), 3.58 (2H, t, J=5.5 Hz), 3.75 (1H, dd, J=13, 3.5 Hz), 3.90 (1H, d, J=13.5 Hz), 6.80 (1H, s), 6.90 (1H, s), 7.02 (1H, s), 7.23 (1H, dd, J=8.5, 2 Hz), 7.42 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2 Hz).


Example 48






Yield 49%, 1H-NMR (CDCl3): δ0.92 (3H, d, J=6.5 Hz), 0.95 (3H, d, J=6.5 Hz), 1.32-1.60 (2H, m), 1.62-1.78 (1H, m), 2.29 (3H, s), 2.31-2.46 (1H, m), 2.35 (3H, s), 2.62-2.72 (1H, m), 2.75-2.88 (1H, m), 3.29-3.42 (2H, m), 3.58 (2H, t, J=5.0 Hz), 3.75 (1H, dd, J=13.0, 3.5 Hz), 3.90 (1H, d, J=13.5 Hz), 6.80 (1H, s), 6.91 (1H, s), 7.02 (1H, s), 7.23 (1H, dd, J=8.5, 2.0 Hz), 7.43 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2.0 Hz).


Example 49






Yield 72%, 1H-NMR (CDCl3): δ0.92 (3H, d, J=7.5 Hz), 0.95 (3H, d, J=7.5 Hz), 1.33-1.45 (1H, m), 1.46-1.60 (1H, m), 1.64-1.78 (1H, m), 2.30 (3H, s), 2.35 (3H, s), 2.36-2.46 (1H, m), 2.63-2.75 (1H, m), 2.77-2.88 (1H, m), 3.35 (1H, d, J=13.5 Hz), 3.40 (1H, dd, J=13, 6.5 Hz), 3.55-3.70 (2H, m), 3.79 (1H, dd, J=12, 3 Hz), 3.90 (1H, d, J=13.5 Hz), 6.81 (1H, s), 6.91 (1H, s), 7.02 (1H, s), 7.51 (1H, dd, J=8.5, 1.5 Hz), 7.55 (1H, d, J=8.5 Hz), 7.83 (1H, d, J=1.5 Hz).


Example 50






Yield 65%, 1H-NMR (CDCl3): δ1.98-2.08 (2H, m), 2.28 (3H, s), 2.34 (3H, s), 2.65-2.74 (2H, m), 2.78-2.85 (2H, m), 3.61 (2H, s), 3.65-3.88 (4H, m), 6.80 (1H, s), 6.88 (1H, s), 6.99 (1H, s), 7.27 (1H, d, J=12.0 Hz), 7.75 (1H, d, J=7.0 Hz).


Example 51






Yield 57%, 1H-NMR (CDCl3): δ1.11 (6H, d, J=6.0 Hz), 2.29 (3H, s), 2.34 (3H, s), 2.71-2.86 (2H, m), 3.07 (1H, d, J=13.0 Hz), 3.10 (1H, d, J=13.0 Hz), 3.79 (2H, s), 3.88 (2H, d, J=13.0 Hz), 6.77 (1H, s), 6.96 (1H, s), 7.01 (1H, s), 7.26 (1H, d, J=11.5 Hz), 7.73 (1H, d, J=7.0 Hz).


Example 52






Yield 57%, 1H-NMR (CDCl3): δ1.21 (3H, d, J=6 Hz), 2.24-2.29 (1H, m), 2.30 (3H, s), 2.36 (3H, s), 2.60-2.72 (1H, m), 2.83 (1H, dt, J=12, 3.5 Hz), 3.18 (1H, d, J=13.5 Hz), 3.18-3.25 (1H, m), 3.48-3.51 (1H, m), 3.67-3.80 (1H, m), 3.85-3.95 (1H, m), 4.02 (1H, d, J=13.5 Hz), 6.81 (1H, s), 6.90 (1H, s), 7.01 (1H, s), 7.26 (1H, d, J=12 Hz), 7.73 (1H, d, J=7 Hz).


Example 53






Yield 65%, 1H-NMR (CDCl3): δ1.02 (3H, t, J=7.5 Hz), 1.50-1.78 (2H, m), 2.26-2.42 (1H, m), 2.30 (3H, s), 2.36 (3H, s), 2.48-2.59 (1H, m), 2.78-2.89 (1H, m), 3.27 (1H, d, J=13.5 Hz), 3.38-3.58 (2H, m), 3.61-3.72 (1H, m), 3.78-3.89 (1H, m), 3.98 (1H, d, J=13.5 Hz), 6.81 (1H, s), 6.90 (1H, s), 7.01 (1H, s), 7.26 (1H, d, J=12.0 Hz), 7.74 (1H, d, J=7.0 Hz).


Example 54






Yield 61%, 1H-NMR (CDCl3): δ2.29 (3H, s), 2.36 (3H, s), 2.58 (4H, t, J=5.0 Hz), 3.52 (2H, s), 3.53 (4H, t, J=5.0 Hz), 6.82 (1H, s), 6.90 (1H, s), 7.02 (1H, s), 7.17-7.24 (1H, m), 7.27-7.37 (2H, m), 7.38-7.47 (3H, m).


Example 55






Yield 49%, 1H-NMR (CDCl3): δ1.15 (6H, d, J=6.0 Hz), 2.30 (3H, s), 2.35 (3H, s), 2.68-2.83 (2H, m), 2.94 (1H, d, J=13.0 Hz), 2.97 (1H, d, J=13.0 Hz), 3.80 (2H, s), 4.33 (2H, d, J=14.0 Hz), 6.76 (1H, s), 6.97 (1H, s), 7.04 (1H, s), 7.34-7.43 (1H, m), 7.52-7.61 (1H, m), 7.67 (1H, d, J=8.0, 1.5 Hz), 7.87 (1H, dd, J=8.0, 1.5 Hz), 8.56 (1H, s)


Example 56






Yield 56%, 1H-NMR (CDCl3): δ1.21 (3H, d, J=6.0 Hz), 1.18-2.30 (1H, m), 2.28 (3H, s), 2.35 (3H, s), 2.52-2.65 (1H, m), 2.78-2.89 (1H, m), 3.05-3.20 (2H, m), 3.27-3.41 (1H, m), 3.97-4.12 (2H, m), 4.15-4.25 (1H, m), 6.80 (1H, s), 6.92 (1H, s), 7.01 (1H, s), 7.32-7.40 (1H, m), 7.50-7.59 (1H, m), 7.67 (1H, dd, J=8.0, 1.5 Hz), 7.87 (1H, dd, J=8.0, 1.5 Hz), 8.53 (1H, s).


Example 57






Yield 55%, 1H-NMR (CDCl3): δ1.14 (6H, d, J=6.0 Hz), 2.29 (3H, s), 2.35 (3H, s), 2.68-2.82 (2H, m), 2.94 (1H, d, J=13.0 Hz), 2.98 (1H, d, J=13.0 Hz), 3.80 (2H, s), 4.30 (2H, d, J=13.0 Hz), 6.76 (1H, s), 6.97 (1H, s), 7.03 (1H, s), 7.50 (1H, dd, J=9.0, 2.5 Hz), 7.59 (1H, d, J=9.0 Hz), 7.85 (1H, d, J=2.5 Hz), 8.54 (1H, s).


Example 58






Yield 34%, 1H-NMR (CDCl3): δ1.13 (6H, d, J=6.0 Hz), 2.28 (3H, s), 2.34 (3H, s), 2.65-2.79 (2H, m), 2.95 (1H, d, J=13.0 Hz), 2.98 (1H, d, J=13.0 Hz), 3.78 (2H, s), 4.34 (2H, d, J=13.0 Hz), 6.77 (1H, s), 6.98 (1H, s), 7.02 (1H, s), 7.67-7.73 (2H, m), 8.13 (1H, s), 8.58 (1H, s).


Example 59






Yield 92%, 1H-NMR (CDCl3): δ2.25 (3H, s), 2.56 (4H, t, J=5.1 Hz), 3.48 (2H, s), 3.50 (3H, s), 3.63 (4H, t, J=5.1 Hz), 5.20 (2H, s), 7.00 (1H, d), 7.08 (1H, d, 8.1 Hz), 7.12 (1H, s), 7.23 (1H, dd, J=8.7, 2.1 Hz), 7.43 (1H, d, J=8.7 Hz), 7.53 (1H, d, 2.1 Hz).


Example 60






Yield 90%, 1H-NMR (CDCl3): δ1.98-2.05 (2H, m), 2.24 (3H, s), 2.68 (2H, t, J=5.4 Hz), 2.79 (2H, t, J=4.8 Hz), 3.49 (3H, s), 3.55 (2H, s), 3.71-3.78 (4H, m), 5.19 (2H, s), 6.98 (1H, s), 7.07 (2H, m), 7.22 (1H, dd, 8.7, 2.1 Hz), 7.42 (1H, d, J=8.7 Hz), 7.54 (1H, d, J=2.1 Hz).


Example 61






Yield 60%, 1H-NMR (CDCl3): δ2.57 (4H, t, J=5.1 Hz), 3.48 (3H, s), 3.50 (2H, s), 3.64 (4H, t, J=5.1 Hz), 5.17 (2H, s), 6.91 (1H, s), 6.97-7.01 (2H, m), 7.24 (1H, dd, 8.7, 2.1 Hz), 7.44 (1H, d, J=8.7 Hz), 7.56 (1H, d, J=2.1 Hz).


Example 62






Yield 70%, 1H-NMR (CDCl3): δ1.22 (3H, d, J=6.5 Hz), 2.24 (3H, s), 2.24-2.35 (1H, m), 2.60-2.70 (1H, m), 2.78-2.88 (1H, m), 3.19 (1H, dt, J=13, 4.5 Hz), 3.24 (1H, d, J=13 Hz), 3.38-3.50 (1H, m), 3.50 (3H, s), 3.70-3.80 (1H, m), 3.85-3.93 (1H, m), 4.01 (1H, d, J=13 Hz), 5.21 (2H, s), 6.89 (1H, d, J=7.5 Hz), 7.02 (1H, s), 7.10 (1H, d, J=7.5 Hz), 7.50 (1H, d, J=8.5 Hz), 7.53 (1H, d, J=8.5 Hz), 7.83 (1H, s).


Example 63






Yield 92%, 1H-NMR (CDCl3): δ1.22 (3H, d, J=6.0 Hz), 2.23-2.33 (1H, m), 2.33 (3H, s), 2.60-2.67 (1H, m), 2.83 (1H, dt, J=3.3, 12.0 Hz), 3.16 (2H, dd, J=4.2, 13.2 Hz), 3.44-3.35 (1H, m), 3.49 (3H, s), 3.71 (1H, d, J=12.0 Hz), 3.86 (1H, dd, J=2.1, 12.6 Hz), 3.99 (1H, d, J=13.2 Hz), 5.17 (2H, s), 6.77 (1H, s), 6.80 (1H, s), 6.83 (1H, s), 7.23 (1H, dd, J=2.1, 8.7 Hz), 7.42 (1H, d, J=8.7 Hz), 7.54 (1H, d, J=2.1 Hz)


Example 64






Yield 95%, 1H-NMR (CDCl3): δ1.22 (3H, d, J=6.0 Hz), 2.25-2.31 (1H, m), 2.33 (3H, s), 2.60-2.67 (1H, m), 2.83 (1H, dt, J=3.6, 12.0 Hz), 3.16 (2H, dt, J=3.6, 13.5 Hz), 3.44-3.35 (1H, m), 3.49 (3H, s), 3.71 (1H, dt, J=3.0, 12.3 Hz), 3.86 (1H, ddd, J=1.5, 3.6, 12.6 Hz), 3.99 (1H, d, J=13.5 Hz), 5.16 (2H, s), 6.77 (1H, s), 6.80 (1H, s), 6.83 (1H, s), 7.23 (1H, dd, J=2.1, 8.7 Hz), 7.42 (1H, d, J=8.7 Hz), 7.54 (1H, d, J=2.1 Hz),


Example 65






Yield 38%, 1H-NMR (CDCl3): δ1.27 (3H, t, J=7.2 Hz), 2.57 (4H, t, J=4.8 Hz), 3.52 (2H, s), 3.59 (2H, s), 3.64 (4H, t, J=4.8 Hz), 4.17 (2H, q, J=7.2 Hz), 7.14 (1H, s), 7.20 (1H, s), 7.23 (1H, dd, J=7.8, 2.4 Hz), 7.26 (1H, s), 7.43 (1H, d, J=7.8 Hz), 7.56 (1H, d, J=2.4 Hz).


Example 66






Yield 60%, 1H-NMR (CDCl3): δ1.26 (3H, t, J=7.2 Hz), 1.98-2.06 (2H, m), 2.68 (2H, t, J=5.4 Hz), 2.80 (2H, t, J=5.4 Hz), 3.56 (2H, s), 3.60 (2H, s), 3.71-3.78 (4H, m), 4.16 (2H, q, J=7.2 Hz), 7.12 (1H, s), 7.18 (1H, s), 7.23 (1H, dd, J=8.4, 2.1 Hz), 7.25 (1H, s), 7.42 (1H, d, J=8.4 Hz), 7.55 (1H, d, J=2.1 Hz)


Example 67






Yield 89%, 1H-NMR (CDCl3): δ1.26 (3H, t, J=7 Hz), 2.57 (4H, t, J=5 Hz), 3.55 (2H, s), 3.61 2H, s), 3.62 (4H, t, J=5 Hz), 4.15 (2H, q, J=7 Hz), 7.23 (1H, dd, J=8.5, 2 Hz), 7.25-7.35 (4H, m), 7.42 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Example 68






Yield 79%, 1H-NMR (CDCl3): δ1.13 (6H, d, J=6 Hz), 1.25 (3H, t, J=7 Hz), 2.73-2.90 (2H, m), 3.05-3.15 (2H, m), 3.61 (2H, s), 3.85 (2H, s), 3.85-3.95 (2H, m), 4.14 (2H, q, J=7 Hz), 7.10-7.35 (4H, m), 7.52 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 69






Yield 54%, 1H-NMR (CDCl3): δ1.09 (6H, d, J=6.5 Hz), 1.26 (3H, t, J=7 Hz), 2.70-2.95 (2H, m), 3.10 (2H, dd, J=13, 13 Hz), 3.58 (2H, s), 3.78 (2H, s), 3.86-3.96 (2H, m), 4.15 (2H, q, J=7 Hz), 7.14 (1H, s), 7.17 (1H, s), 7.33 (1H, s), 7.53 (1H, d, J=8.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.85 (1H, s).


Example 70






Yield 71%, 1H-NMR (CDCl3): δ1.08 (3H, d, J=6.5 Hz), 1.25 (3H, t, J=7 Hz), 1.40 (3H, d, J=6.5 Hz), 2.25-2.35 (1H, m), 2.90 (1H, dd, J=12, 4 Hz), 3.10-3.20 (1H, m), 3.52 (1H, d, J=13.5 Hz), 3.62 (2H, s), 3.63-3.78 (3H, m), 4.16 (2H, q, J=7 Hz), 4.20-4.35 (1H, m), 7.20-7.35 (4H, m), 7.45-7.56 (2H, m), 7.82 (1H, s).


Example 71






Yield 92%, 1H-NMR (CDCl3): δ1.23 (3H, d, J=6 Hz), 1.25 (3H, t, J=7 Hz), 2.23-2.35 (1H, m), 2.60-2.75 (1H, m), 2.83 (1H, dt, J=12, 4 Hz), 3.20 (1H, d, J=12.5 Hz), 3.22 (1H, d, J=13 Hz), 3.38-3.50 (1H, m), 3.62 (2H, s), 3.70-3.80 (1H, m), 3.85-3.95 (1H, m), 4.05 (1H, d, J=13 Hz), 4.16 (2H, q, J=7 Hz), 7.15-7.35 (4H, m), 7.45-7.60 (2H, m), 7.84 (1H, s).


Example 72






Yield 88%, 1H-NMR (CDCl3): δ1.23 (3H, t, J=7.2 Hz), 1.26 (3H, t, J=6.9 Hz), 2.27 (1H, ddd, J=3.3, 8.7, 9.9 Hz), 2.61-2.67 (1H, m), 2.80 (1H, dt, J=3.3, 11.7 Hz), 3.21 (2H, d, J=13.5 Hz), 3.34-3.43 (1H, m), 3.62 (2H, s), 3.71 (1H, d, J=12.6 Hz), 3.87 (1H, dd, J=2.1, 12.6 Hz), 4.05 (1H, d, J=13.5 Hz), 4.16 (2H, q, J=7.2 Hz), 7.18-7.32 (5H, m), 7.42 (1H, d, J=8.7 Hz), 7.54 (1H, d, J=2.4 Hz)


Example 73






Yield 93%, 1H-NMR (CDCl3): δ1.24 (3H, t, J=6.0 Hz), 1.26 (3H, t, J=7.2 Hz), 2.27 (1H, ddd, J=3.3, 8.7, 9.9 Hz), 2.62-2.67 (1H, m), 2.80 (1H, dt, J=3.6, 12.0 Hz), 3.21 (2H, d, J=13.5 Hz), 3.39-3.42 (1H, m), 3.62 (2H, s), 3.71 (1H, dt, J=12.0 Hz), 3.87 (1H, dd, J=2.1, 12.6 Hz), 4.06 (1H, d, J=13.5 Hz), 4.16 (2H, q, J=7.2 Hz), 7.18-7.32 (5H, m), 7.42 (1H, d, J=8.4 Hz), 7.54 (1H, d, J=2.1 Hz)


Example 74






Yield 82%, 1H-NMR (CDCl3): δ1.23 (3H, d, J=6 Hz), 1.26 (3H, t, J=7 Hz), 2.20-2.35 (1H, m), 2.34 (3H, s), 2.58-2.71 (1H, m), 2.82 (1H, dt, J=12, 4 Hz), 3.16 (1H, d, J=13.5 Hz), 3.16-3.25 (1H, m), 3.38-3.50 (1H, m), 3.58 (2H, s), 3.70-3.80 (1H, m), 3.86-3.96 (1H, m), 4.03 (1H, d, J=13.5 Hz), 4.15 (2H, q, J=7 Hz), 7.01 (1H, s), 7.05 (2H, s), 7.51 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 75






Yield 92%, 1H-NMR (CDCl3): δ1.02 (3H, t, J=7.2 Hz), 1.26 (3H, t, J=7.2 Hz), 1.61-1.74 (2H, m), 2.29-2.37 (1H, m), 2.50-2.55 (1H, m), 2.79-2.84 (1H, m), 3.29 (1H, d, J=13.5 Hz), 3.37 (1H, dd, J=8.1, 12.9 Hz), 3.40-3.50 (1H, m), 3.62 (3H, s), 3.80 (1H, dd, J=3.3, 12.9 Hz), 4.01 (1H, d, J=13.5 Hz), 4.16 (2H, t, J=7.2 Hz), 7.18 (5H, m), 7.42 (1H, d, J=8.7 Hz), 7.54 (1H, d, J=2.1 Hz)


Example 76






Yield 90%, 1H-NMR (CDCl3): δ0.93 (6H, dd, J=6.3, 11.7 Hz), 1.26 (3H, t, J=7.2 Hz), 1.35-1.44 (1H, m), 1.50-1.56 (1H, m), 1.65-1.76 (1H, m), 2.37-2.44 (1H, m), 2.67-2.72 (1H, m), 2.78-2.85 (1H, m), 3.36 (1H, d, J=12.9 Hz), 3.39 (1H, d, J=13.2 Hz), 3.58 (2H, t, J=4.8 Hz), 3.61 (2H, s), 3.75 (1H, dd, J=3.3, 12.9 Hz), 3.93 (1H, d, J=13.2 Hz), 4.16 (2H, q, J=7.2 Hz), 7.17-7.31 (5H, m), 7.42 (1H, d, J=8.7 Hz), 7.54 (1H, d, J=1.8 Hz)


Example 77






Yield 68%, 1H-NMR (CDCl3): δ1.26 (3H, t, J=7 Hz), 1.42 (3H, d, J=6.5 Hz), 2.25 (1H, td, J=11.5, 3.5 Hz), 2.32 (1H, dd, J=11.5, 4 Hz), 2.74 (1H, d, J=11.5 Hz), 2.91 (1H, dt, J=11.5, 2 Hz), 3.46 (1H, d, J=13.5 Hz), 3.52 (1H, td, J=11.5, 4 Hz), 3.59 (1H, d, J=13.5 Hz), 3.62 (2H, s), 3.85-4.00 (1H, m), 4.15 (2H, q, J=7 Hz), 4.20-4.30 (1H, m), 7.15-7.33 (4H, m), 7.51 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 78






Yield 86%, 1H-NMR (CDCl3): δ1.25 (3H, t, J=7 Hz), 1.40 (3H, d, J=6.5 Hz), 2.24 (1H, td, J=11.5, 3.5 Hz), 2.33 (1H, dd, J=11.5, 3.5 Hz), 2.72 (1H, d, J=11 Hz), 2.91 (1H, d, J=11 Hz), 3.43 (1H, d, J=13.5 Hz), 3.49 (1H, td, J=11.5, 3.5 Hz), 3.59 (1H, d, J=13.5 Hz), 3.62 (2H, s), 3.80-3.90 (1H, m), 4.10-4.18 (1H, m), 4.19 (2H, q, J=7 Hz), 7.15-7.35 (5H, m), 7.42 (1H, d, J=7.5 Hz), 7.54 (1H, d, J=2 Hz).


Example 79






Yield 71%, 1H-NMR (CDCl3): δ1.26 (3H, t, J=7.0 Hz), 1.40 (3H, d, J=7.0 Hz), 2.17-2.38 (2H, m), 2.68-2.77 (1H, m), 2.88-2.96 (1H, m), 3.41-3.67 (5H, m), 3.82-3.92 (1H, m), 4.07-4.23 (1H, m), 4.16 (2H, q, J=7.0 Hz), 7.16-7.34 (5H, m), 7.42 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2.0 Hz).


Example 80






Yield 85%, 1H-NMR (CDCl3): δ1.26 (3H, t, J=7 Hz), 1.40 (3H, d, J=6.5 Hz), 2.23 (1H, td, J=11.5, 3.5 Hz), 2.27-2.33 (1H, m), 2.34 (3H, s), 2.72 (1H, d, J=11.5 Hz), 2.90 (1H, d, J=11.5 Hz), 3.41 (1H, d, J=13.5 Hz), 3.45-3.54 (1H, m), 3.55 (1H, d, J=13.5 Hz), 3.58 (2H, s), 3.85 (1H, d, J=12 Hz), 4.10-4.15 (1H, m), 4.16 (2H, q, J=7 Hz), 7.01 (1H, s), 7.07 (1H, s), 7.08 (1H, s), 7.22 (1H, dd, J=8.5, 2 Hz), 7.42 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2 Hz).


Example 81






Yield 74%, 1H-NMR (CDCl3): δ1.26 (3H, t, J=7.0 Hz), 1.40 (3H, d, J=7.0 Hz), 2.16-2.37 (5H, m), 2.68-2.77 (1H, m), 2.86-2.96 (1H, m), 3.36-3.62 (5H, m), 3.80-3.90 (1H, m), 4.15 (3H, m), 7.01 (1H, s), 7.04-7.10 (2H, m), 7.23 (1H, dd, J=8.5, 2.0 Hz), 7.42 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2.0 Hz).


Example 82






Yield 83%, 1H-NMR (CDCl3): δ1.26 (3H, t, J=7 Hz), 1.42 (3H, d, J=6.5 Hz), 2.25 (1H, dt, J=12.5, 3.5 Hz), 2.33 (1H, dd, J=11, 3.5 Hz), 2.73 (1H, d, J=11 Hz), 2.93 (1H, d, J=11 Hz), 3.42-3.60 (3H, m), 3.62 (2H, s), 3.85-3.97 (1H, m), 4.16 (2H, q, J=7 Hz), 4.18-4.28 (1H, m), 7.18-7.35 (4H, m), 7.51 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 83






Yield 72%, 1H-NMR (CDCl3): δ1.26 (3H, t, J=7.0 Hz), 1.42 (3H, d, J=6.5 Hz), 2.25 (1H, td, J=11.5, 3.5 Hz), 2.34 (1H, dd, J=11.5, 3.5 Hz), 2.74 (1H, d, J=11.5 Hz), 2.93 (1H, d, J=11.5 Hz), 3.42-3.66 (5H, m), 3.91 (1H, d, J=11.5 Hz), 4.08-4.29 (3H, m), 7.16-7.35 (4H, m), 7.47-7.60 (2H, m), 7.84 (1H, s).


Example 84






Yield 74%, 1H-NMR (CDCl3): δ1.26 (3H, t, J=7 Hz), 1.42 (3H, d, J=6.5 Hz), 2.18-2.34 (2H, m), 2.35 (3H, s), 2.74 (1H, d, J=11 Hz), 2.92 (1H, d, J=11.5 Hz), 3.42 (1H, d, J=13.5 Hz), 3.53 (1H, td, J=11.5, 3.5 Hz), 3.56 (1H, d, J=13.5 Hz), 3.58 (2H, s), 3.91 (1H, d, J=12 Hz), 4.15 (2H, q, J=7 Hz), 4.15-4.30 (1H, m), 7.02 (1H, s), 7.07 (1H, s), 7.09 (1H, s), 7.51 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 85






Yield 69%, 1H-NMR (CDCl3): δ1.26 (3H, t, J=7.0 Hz), 1.43 (3H, d, J=6.5 Hz), 2.17-2.39 (5H, m), 2.70-2.79 (1H, m), 2.87-2.97 (1H, m), 3.43 (1H, d, J=13.0 Hz), 3.46-3.62 (4H, m), 3.85-3.97 (1H, m), 4.16 (2H, q, J=7.0 Hz), 4.17-4.29 (1H, m), 7.02 (1H, s), 7.05-7.11 (2H, m), 7.47-7.59 (2H, m), 7.84 (1H, s).


Example 86






Yield 86%, 1H-NMR (CDCl3): δ1.27 (3H, t, J=7 Hz), 1.43 (3H, d, J=6.5 Hz), 2.26 (1H, td, J=12, 3.5 Hz), 2.36 (1H, dd, J=11, 3.5 Hz), 2.72 (1H, d, J=11 Hz), 2.91 (1H, d, J=11 Hz), 3.44 (1H, d, J=13.5 Hz), 3.52 (1H, td, J=12.5, 3.5 Hz), 3.55 (1H, d, J=13.5 Hz), 3.59 (2H, s), 3.86-3.96 (1H, m), 4.16 (2H, q, J=7 Hz), 4.20-4.30 (1H, m), 7.17 (1H, s), 7.20 (1H, s), 7.29 (1H, s), 7.51 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 87






Yield 41%, 1H-NMR (CDCl3): δ0.87 (3H, t, J=7.5 Hz), 1.26 (3H, t, J=7.0 Hz), 1.80-2.02 (2H, m), 2.16-2.30 (2H, m), 2.79-2.94 (2H, m), 3.38-3.52 (2H, m), 3.54-3.65 (3H, m), 3.76-3.88 (1H, m), 3.94-4.06 (1H, m), 4.15 (2H, q, J=7.0 Hz), 7.15-7.34 (5H, m), 7.39 (1H, d, J=8.5 Hz), 7.52 (1H, d, J=2.0 Hz).


Example 88






Yield 79%, 1H-NMR (CDCl3): δ0.87 (3H, t, J=7.5 Hz), 1.26 (3H, t, J=7 Hz), 1.85-2.00 (2H, m), 2.18-2.29 (2H, m), 2.80-2.84 (2H, m), 3.42 (1H, d, J=13.5 Hz), 3.44 (1H, td, J=12.5, 3.5 Hz), 3.59 (1H, d, J=13.5 Hz), 3.62 (2H, s), 3.70-3.86 (1H, m), 3.95-4.05 (1H, m), 4.15 (2H, q, J=7 Hz), 7.15-7.33 (5H, m), 7.39 (1H, d, J=8.5 Hz), 7.52 (1H, d, J=2 Hz).


Example 89






Yield 25%, 1H-NMR (CDCl3): δ0.88 (3H, t, J=7.5 Hz), 1.26 (3H, t, J=7 Hz), 1.83-2.03 (2H, m), 2.22 (2H, td, J=12.5, 3.5 Hz), 2.34 (3H, s), 2.80-2.92 (2H, m), 3.38 (1H, d, J=13.5 Hz), 3.45 (1H, td, J=12.5, 3.5 Hz), 3.55 (1H, d, J=13.5 Hz), 3.57 (2H, s), 3.75-3.88 (1H, m), 3.95-4.03 (1H, m), 4.15 (2H, q, J=7 Hz), 7.01 (1H, s), 7.05 (1H, s), 7.06 (1H, s), 7.21 (1H, dd, J=8.5, 2 Hz), 7.39 (1H, d, J=8.5 Hz), 7.52 (1H, d, J=2 Hz).


Example 90






Yield 67%, 1H-NMR (CDCl3): δ0.88 (3H, t, J=7.5 Hz), 1.26 (3H, t, J=7.0 Hz), 1.80-2.03 (2H, m), 2.22 (2H, td, J=11.5, 3.5 Hz), 2.34 (3H, s), 2.80-2.93 (2H, m), 3.38 (1H, d, J=13.0 Hz), 3.46 (1H, td, J=12.5, 3.0 Hz), 3.56 (1H, d, J=13.0 Hz), 3.57 (2H, s), 3.76-3.87 (1H, m), 3.94-4.05 (1H, m), 4.15 (2H, q, J=7.0 Hz), 7.01 (1H, s), 7.06 (2H, s), 7.22 (1H, dd, J=8.5, 2.0 Hz), 7.39 (1H, d, J=8.5 Hz), 7.52 (1H, d, J=2.0 Hz).


Example 91






Yield 80%, 1H-NMR (CDCl3): δ0.88 (3H, t, J=7.5 Hz), 1.26 (3H, t, J=7 Hz), 1.96 (2H, quant, J=7.5 Hz), 2.19-2.30 (2H, m), 2.82-2.95 (2H, m), 3.44 (1H, d, J=13.5 Hz), 3.49 (1H, td, J=12.5, 3.5 Hz), 3.59 (1H, d, J=13.5 Hz), 3.62 (2H, s), 3.73-3.83 (1H, m), 4.00-4.10 (1H, m), 4.17 (2H, q, J=7 Hz), 7.15-7.33 (4H, m), 7.48-7.55 (2H, m), 7.82 (1H, s).


Example 92






Yield 53%, 1H-NMR (CDCl3): δ0.89 (3H, t, J=7.5 Hz), 1.20 (3H, t, J=7 Hz), 1.87-2.03 (2H, m), 2.24 (2H, td, J=11, 3.5 Hz), 2.34 (3H, s), 2.82-2.95 (2H, m), 3.38 (1H, d, J=13 Hz), 3.49 (1H, td, J=13, 3.5 Hz), 3.56 (1H, d, J=13 Hz), 3.57 (2H, s), 3.80-3.95 (1H, m), 4.00-4.10 (1H, m), 4.16 (2H, q, J=7 Hz), 7.01 (1H, s), 7.05 (1H, s), 7.06 (1H, s), 7.48-7.55 (2H, m), 7.82 (1H, s).


Example 93






Yield 74%, 1H-NMR (CDCl3): δ0.90 (3H, t, J=7.5 Hz), 1.27 (3H, t, J=7 Hz), 1.94 (2H, quant, J=7.5 Hz), 2.20-2.32 (2H, m), 2.80-2.93 (2H, m), 3.41 (1H, d, J=13.5 Hz), 3.49 (1H, td, J=12.5, 3.5 Hz), 3.55 (1H, d, J=13.5 Hz), 3.59 (2H, s), 3.85-3.95 (1H, m), 4.00-4.10 (1H, m), 4.17 (2H, q, J=7 Hz), 7.14 (1H, s), 7.20 (1H, s), 7.28 (1H, s), 7.45-7.56 (2H, m), 7.82 (1H, s).


Example 94






Yield 85%, 1H-NMR (CDCl3): δ0.88 (3H, t, J=7.5 Hz), 1.20 (3H, t, J=7 Hz), 1.94 (2H, quant, J=7.5 Hz), 2.19-2.30 (2H, m), 2.80-2.95 (2H, m), 3.43 (1H, d, J=13.5 Hz), 3.51 (1H, td, J=12.5, 3.5 Hz), 3.59 (1H, d, J=13.5 Hz), 3.62 (2H, s), 3.80-3.95 (1H, m), 4.00-4.10 (1H, m), 4.15 (2H, q, J=7 Hz), 7.15-7.33 (4H, m), 7.50 (1H, d, J=8.5 Hz), 7.52 (1H, d, J=8.5 Hz), 7.82 (1H, s).


Example 95






Yield 73%, 1H-NMR (CDCl3): δ0.88 (3H, t, J=7.5 Hz), 1.26 (3H, t, J=7 Hz), 1.95 (2H, quant, J=7.5 Hz), 2.15-2.28 (2H, m), 2.34 (3H, s), 2.82-2.93 (2H, m), 3.39 (1H, d, J=13.5 Hz), 3.48 (1H, td, J=12.5, 3.5 Hz), 3.55 (1H, d, J=13.5 Hz), 3.57 (2H, s), 3.80-3.95 (1H, m), 3.98-4.10 (1H, m), 4.15 (2H, q, J=7 Hz), 7.01 (1H, s), 7.06 (2H, s), 7.52 (2H, s), 7.82 (1H, s).


Example 96






Yield 67%, 1H-NMR (CDCl3): δ0.93 (3H, t, J=7.5 Hz), 1.19-1.35 (2H, m), 1.26 (3H, t, J=7.0 Hz), 1.73-2.00 (2H, m), 2.15-2.30 (2H, m), 2.81 (1H, d, J=11.5 Hz), 2.88 (1H, d, J=11.0 Hz), 3.42 (1H, d, J=13.5 Hz), 3.46 (1H, td, J=12.5, 3.5 Hz), 3.58 (1H, d, J=13.5 Hz), 3.61 (2H, s), 3.84-4.05 (2H, m), 4.16 (2H, q, J=7.0 Hz), 7.14-7.34 (5H, m), 7.39 (1H, d, J=8.5 Hz), 7.52 (1H, d, J=2.0 Hz).


Example 97






Yield 64%, 1H-NMR (CDCl3): δ0.93 (3H, t, J=7.2 Hz), 1.21-1.31 (5H, m), 1.78-1.96 (2H, m), 2.19-2.28 (2H, m), 2.81 (1H, d, J=11.4 Hz), 2.88 (1H, d, J=11.4 Hz), 3.42 (1H, d, J=13.2 Hz), 3.47 (1H, td, J=3.3, 12.6 Hz), 3.59 (1H, d, J=13.2 Hz), 3.62 (2H, s), 3.90 (1H, s), 4.00 (1H, d, J=12.6 Hz), 4.16 (2H, q, J=7.2 Hz), 7.19-7.33 (5H, m), 7.39 (1H, d, J=8.4 Hz), 7.53 (1H, d, J=2.1 Hz)


Example 98






Yield 58%, 1H-NMR (CDCl3): δ0.34 (3H, t, J=7.0 Hz), 1.19-1.35 (2H, m), 1.26 (3H, t, J=7.0 Hz), 1.72-2.02 (2H, m), 2.15-2.29 (2H, m), 2.34 (3H, s), 2.81 (1H, d, J=11.5 Hz), 2.89 (1H, d, J=11.5 Hz), 3.37 (1H, d, J=13.5 Hz), 3.47 (1H, td, J=13.5, 3.0 Hz), 3.57 (1H, d, J=13.5 Hz), 3.57 (2H, s), 3.83-3.93 (1H, m), 3.94-4.04 (1H, m), 4.16 (2H, q, J=7.0 Hz), 7.01 (1H, s), 7.05 (2H, s), 7.22 (1H, dd, J=8.5, 2.0 Hz), 7.39 (1H, d, J=8.5 Hz), 7.52 (1H, d, J=2.0 Hz).


Example 99






Yield 68%, 1H-NMR (CDCl3): δ0.94 (3H, t, J=7.5 Hz), 1.24-1.31 (5H, m), 1.73-1.85 (1H, m), 1.89-2.01 (1H, m), 2.17-2.27 (2H, m), 2.34 (3H, s), 2.81 (1H, d, J=11.4 Hz), 2.88 (1H, d, J=11.1 Hz), 3.37 (1H, d, J=13.5 Hz), 3.47 (1H, dt, J=3.3, 12.6 Hz), 3.57 (1H, d, J=13.5 Hz), 3.57 (2H, s), 3.89 (1H, s), 3.99 (1H, d, J=12.0 Hz), 4.16 (2H, q, J=7.2 Hz), 7.01 (1H, s), 7.06 (2H, s), 7.22 (1H, dd, J=2.1, 8.4 Hz), 7.39 (1H, d, J=8.4 Hz), 7.52 (1H, d, J=2.1 Hz)


Example 100






Yield 69%, 1H-NMR (CDCl3): δ0.93 (3H, t, J=7.0 Hz), 1.18-1.35 (2H, m), 1.26 (3H, t, J=7.0 Hz), 1.76-1.99 (2H, m), 2.16-2.29 (2H, m), 2.82 (1H, d, J=11.5 Hz), 2.89 (1H, d, J=11.5 Hz), 3.42 (1H, d, J=13.5 Hz), 3.49 (1H, td, J=13.0, 3.5 Hz), 3.59 (1H, d, J=13.5 Hz), 3.62 (2H, s), 3.90-4.09 (2H, m), 4.16 (2H, q, J=7.0 Hz), 7.15-7.34 (4H, m), 7.49 (1H, d, J=8.5 Hz), 7.53 (1H, d, J=8.5 Hz), 7.81 (1H, s).


Example 101






Yield 80%, 1H-NMR (CDCl3): δ0.94 (3H, t, J=7.2 Hz), 1.24-1.31 (5H, m), 1.83-1.91 (2H, m), 2.20-2.29 (2H, m), 2.83 (1H, d, J=11.4 Hz), 2.90 (1H, d, J=11.4 Hz), 3.34 (1H, d, J=13.5 Hz), 3.50 (1H, td, J=3.6, 12.6 Hz), 3.60 (1H, d, J=13.5 Hz), 3.62 (2H, s), 3.97 (1H, s), 4.05 (1H, d, J=12.6 Hz), 4.16 (2H, q, J=7.2 Hz), 7.19-7.33 (4H, m), 7.51 (2H, s), 7.82 (1H, s)


Example 102






Yield 79%, 1H-NMR (CDCl3): δ0.87 (3H, t, J=7 Hz), 1.15-1.40 (7H, m), 1.74-2.00 (2H, m), 2.17-2.29 (2H, m), 2.77-2.94 (2H, m), 3.41 (1H, d, J=13.5 Hz), 3.46 (1H, td, J=13, 3.5 Hz), 3.59 (1H, d, J=13.5 Hz), 3.61 (2H, s), 3.80-3.93 (1H, m), 3.95-4.08 (1H, m), 4.16 (2H, q, J=7 Hz), 7.15-7.32 (5H, m), 7.39 (1H, d, J=9 Hz), 7.52 (1H, d, J=2 Hz).


Example 103






Yield 75%, 1H-NMR (CDCl3): δ0.87 (3H, t, J=7 Hz), 1.15-1.40 (7H, m), 1.76-2.01 (2H, m), 2.20-2.30 (2H, m), 2.77-2.93 (2H, m), 3.42 (1H, d, J=13.5 Hz), 3.46 (1H, td, J=13, 3.5 Hz), 3.59 (1H, d, J=13.5 Hz), 3.61 (2H, s), 3.80-3.92 (1H, m), 3.95-4.06 (1H, m), 4.16 (2H, q, J=7 Hz), 7.16-7.33 (5H, m), 7.39 (1H, d, J=9 Hz), 7.52 (1H, d, J=2 Hz).


Example 104






Yield 75%, 1H-NMR (CDCl3): δ0.88 (3H, t, J=7 Hz), 1.15-1.40 (7H, m), 1.75-2.03 (2H, m), 2.17-2.30 (2H, m), 2.34 (3H, s), 2.80-2.96 (2H, m), 3.37 (1H, d, J=13.5 Hz), 3.50 (1H, td, J=13, 3.5 Hz), 3.57 (2H, s), 3.58 (1H, d, J=13.5 Hz), 3.85-4.00 (1H, m), 4.00-4.10 (1H, m), 4.15 (2H, q, J=7 Hz), 7.01 (1H, s), 7.05 (1H, s), 7.07 (1H, s), 7.45-7.55 (2H, m), 7.82 (1H, s).


Example 105






Yield 44%, 1H-NMR (CDCl3): δ0.90 (3H, d, J=6.5 Hz), 0.91 (3H, d, J=6.5 Hz), 1.26 (3H, t, J=7.0 Hz), 2.12 (1H, dd, J=11.5, 3.5 Hz), 2.23 (1H, td, J=11.5, 3.5 Hz), 2.34 (3H, s), 2.56-2.72 (1H, m), 2.88 (1H, d, J=11.5 Hz), 2.98 (1H, d, J=11.5 Hz), 3.34 (1H, d, J=13.0 Hz), 3.40-3.65 (2H, m), 3.56 (1H, d, J=13.0 Hz), 3.57 (2H, s), 4.08-4.22 (1H, m), 4.15 (2H, q, J=7.0 Hz), 7.01 (1H, s), 7.05 (2H, s), 7.49 (2H, s), 7.79 (1H, s).


Example 106






Yield 70%, 1H-NMR (CDCl3): δ0.90 (3H, d, J=2.5 Hz), 0.91 (3H, d, J=2.5 Hz), 1.26 (3H, t, J=7 Hz), 2.12 (1H, dd, J=11.5, 3.5 Hz), 2.23 (1H, td, J=11.5, 3.5 Hz), 2.34 (3H, s), 2.55-2.73 (1H, m), 2.88 (1H, d, J=9.5 Hz), 2.98 (1H, d, =9.5 Hz), 3.34 (1H, d, J=13 Hz), 3.40-3.54 (1H, m), 3.56 (1H, d, J=13 Hz), 3.57 (2H, s), 3.57-3.60 (1H, m), 4.11-4.15 (1H, m), 4.16 (2H, q, J=7 Hz), 7.01 (1H, s), 7.04 (1H, s), 7.05 (1H, s), 7.49-7.50 (2H, m), 7.79 (1H, s).


Example 107






Yield 73%, 1H-NMR (CDCl3): δ0.93 (6H, d, J=6.5 Hz), 1.26 (3H, t, J=7.0 Hz), 1.32-1.53 (1H, m), 1.54-1.67 (1H, m), 1.85-1.98 (1H, m), 2.24 (2H, td, J=11.5, 3.5 Hz), 2.79 (1H, d, J=11.5 Hz), 2.89 (1H, d, J=11.5 Hz), 3.40 (1H, d, J=13.5 Hz), 3.47 (1H, td, J=13.0, 3.5 Hz), 3.61 (1H, d, J=13.5 Hz), 3.61 (2H, s), 3.88-4.08 (2H, m), 4.16 (2H, q, J=7.0 Hz), 7.15-7.33 (5H, m), 7.39 (1H, d, J=8.5 Hz), 7.53 (1H, d, J=2.0 Hz).


Example 108






Yield 81%, 1H-NMR (CDCl3): δ0.93 (6H, d, J=6.5 Hz), 1.26 (3H, t, J=7 Hz), 1.38-1.47 (1H, m), 1.55-1.67 (1H, m), 1.85-1.96 (1H, m), 2.19-2.30 (2H, m), 2.78 (1H, d, J=11.5 Hz), 2.88 (1H, d, J=11.5 Hz), 3.40 (1H, d, J=13.5 Hz), 3.47 (1H, td, J=13, 3.5 Hz), 3.60 (1H, d, J=13.5 Hz), 3.61 (2H, s), 3.90-4.08 (2H, m), 4.15 (2H, q, J=7 Hz), 7.15-7.35 (5H, m), 7.39 (1H, d, J=8.5 Hz), 7.53 (1H, d, J=2 Hz).


Example 109






Yield 63%, 1H-NMR (CDCl3): δ0.93 (3H, d, J=6.5 Hz), 0.94 (3H, d, J=6.5 Hz), 1.26 (3H, t, J=7.0 Hz), 1.36-1.64 (2H, m), 1.88-2.02 (1H, m), 2.13-2.44 (2H, m), 2.34 (3H, s), 2.79 (1H, d, J=11.0 Hz), 2.89 (1H, d, J=11.0 Hz), 3.35 (1H, d, J=13.5 Hz), 3.41-3.68 (2H, m), 3.57 (2H, s), 3.86-4.09 (2H, m), 4.16 (2H, q, J=7.0 Hz), 7.01 (1H, s), 7.04 (1H, s), 7.06 (1H, s), 7.22 (1H, dd, J=8.5, 2.0 Hz), 7.39 (1H, d, J=8.5 Hz), 7.53 (1H, d, J=2.0 Hz).


Example 110






Yield 81%, 1H-NMR (CDCl3): δ0.92 (3H, d, J=3 Hz), 0.95 (3H, d, J=3 Hz), 1.26 (3H, t, J=7 Hz), 1.39-1.65 (2H, m), 1.90-2.02 (1H, m), 2.15-2.32 (2H, m), 2.34 (3H, s), 2.78 (1H, d, J=11.5 Hz), 2.89 (1H, d, J=11.5 Hz), 3.35 (1H, d, J=13.5 Hz), 3.48 (1H, td, J=13, 3.5 Hz), 3.57 (2H, s), 3.59 (1H, d, J=13.5 Hz), 3.86-4.08 (2H, m), 4.15 (2H, q, J=7 Hz), 7.01 (1H, s), 7.04 (1H, s), 7.06 (1H, s), 7.21 (1H, dd, J=8.5, 2 Hz), 7.39 (1H, d, J=8.5 Hz), 7.53 (1H, d, J=2 Hz).


Example 111






Yield 47%, 1H-NMR (CDCl3): δ0.94 (3H, d, J=6.5 Hz), 0.95 (3H, d, J=6.5 Hz), 1.27 (3H, t, J=7.0 Hz), 1.38-1.67 (2H, m), 1.89-2.04 (1H, m), 2.14-2.38 (2H, m), 2.34 (3H, s), 2.80 (1H, d, J=11.5 Hz), 2.90 (1H, d, J=11.5 Hz), 3.35 (1H, d, J=13.5 Hz), 3.44-3.64 (2H, m), 3.57 (2H, s), 3.94-4.21 (2H, m), 4.16 (2H, q, J=7.0 Hz), 7.01 (1H, s), 7.06 (2H, s), 7.49 (1H, d, J=8.5 Hz), 7.53 (1H, d, J=8.5 Hz), 7.82 (1H, s).


Example 112






Yield 80%, 1H-NMR (CDCl3): δ0.94 (6H, dd, J=3.0, 6.3 Hz), 1.26 (3H, t, J=7.2 Hz), 1.44-1.48 (1H, m), 1.56-1.62 (1H, m), 1.91-2.00 (1H, m), 2.18-2.26 (2H, m), 2.34 (3H, s), 2.80 (1H, d, J=11.4 Hz), 2.91 (1H, d, J=11.4 Hz), 3.36 (1H, d, J=13.2 Hz), 3.52 (1H, dt, J=3.6, 12.6 Hz), 3.57 (2H, s), 3.60 (1H, d, J=13.2 Hz), 4.04 (2H, br), 4.16 (2H, q, J=7.2 Hz), 7.01 (1H, s), 7.04 (1H, s), 7.06 (1H, s), 7.2 (2H, s), 7.83 (1H, s)


Example 113






Yield 69%, 1H-NMR (CDCl3): δ1.26 (3H, t, J=7.0 Hz), 2.59 (4H, t, J=5.0 Hz), 3.57 (2H, s), 3.62 (2H, s), 3.68 (4H, t, J=5.0 Hz), 4.16 (2H, q, J=7.0 Hz), 7.18-7.34 (5H, m), 7.75 (1H, d, J=7.0 Hz).


Example 114






Yield 72%, 1H-NMR (CDCl3): δ1.26 (3H, t, J=7.0 Hz), 2.34 (3H, s), 2.58 (4H, t, J=5.0 Hz), 3.52 (2H, s), 3.58 (2H, s), 3.68 (4H, t, J=5.0 Hz), 4.16 (2H, q, J=7.0 Hz), 7.00-7.12 (3H, m), 7.26 (1H, d, J=11.5 Hz), 7.75 (1H, d, J=7.0 Hz).


Example 115






Yield 41%, 1H-NMR (CDCl3): δ1.25 (3H, t, J=7.0 Hz), 1.96-2.08 (2H, m), 2.32 (3H, s), 2.69 (2H, t, J=5.0 Hz), 2.75-2.85 (2H, m), 3.56 (2H, s), 3.60 (2H, s), 3.61-3.89 (4H, m), 4.15 (2H, q, J=7.0 Hz), 6.50-7.07 (3H, m), 7.26 (1H, d, J=12.0 Hz), 7.73 (1H, d, J=7.0 Hz).


Example 116






Yield 80%, 1H-NMR (CDCl3): δ1.23 (3H, d, J=6 Hz), 1.26 (3H, t, J=7 Hz), 2.23-2.33 (1H, m), 2.34 (3H, s), 2.69-2.70 (1H, m), 2.82 (1H, dt, J=12, 4 Hz), 3.17 (1H, d, J=13 Hz), 3.18-3.26 (1H, m), 3.36-3.48 (1H, m), 3.58 (2H, s), 3.70-3.80 (1H, m), 3.85-3.95 (1H, m), 4.02 (1H, d, J=13 Hz), 4.13 (2H, q, J=7 Hz), 7.01 (1H, s), 7.04 (1H, s), 7.05 (1H, s), 7.26 (1H, d, J=12 Hz), 7.73 (1H, d, J=7 Hz).


Example 117






Yield 63%, 1H-NMR (CDCl3): δ1.26 (3H, t, J=7.0 Hz), 1.43 (3H, d, J=7.0 Hz), 2.17-2.37 (2H, m), 2.34 (3H, s), 2.71-2.79 (1H, m), 2.87-2.98 (1H, m), 3.43 (1H, d, J=13.0 Hz), 3.46-3.60 (2H, m), 3.58 (2H, s), 3.83-3.94 (1H, m), 4.15-4.28 (1H, m), 4.16 (2H, q, J=7.0 Hz), 7.02 (1H, s), 7.06 (1H, s), 7.08 (1H, s), 7.26 (1H, d, J=11.5 Hz), 7.74 (1H, d, J=7.0 Hz).


Example 118






Yield 60%, 1H-NMR (CDCl3): δ1.26 (3H, t, J=7.0 Hz), 1.43 (3H, d, J=7.0 Hz), 2.16-2.36 (2H, m), 2.34 (3H, s), 2.70-2.79 (1H, m), 2.87-2.98 (1H, m), 3.43 (1H, d, J=13.0 Hz), 3.45-3.61 (4H, m), 3.84-3.94 (1H, m), 4.14-4.28 (1H, m), 4.16 (2H, q, J=7.0 Hz), 7.01 (1H, s), 7.04-7.12 (2H, m), 7.26 (1H, d, J=11.5 Hz), 7.74 (1H, d, J=7.0 Hz).


Example 119






Yield 90%, 1H-NMR (CDCl3): δ0.87 (3H, t, J=7.5 Hz), 1.25 (3H, t, J=7.0 Hz), 1.82-2.03 (2H, m), 2.14-2.53 (2H, m), 2.33 (3H, s), 2.78-2.93 (2H, m), 3.37 (1H, d, J=13.5 Hz), 3.45 (1H, td, J=12.5, 3.5 Hz), 3.55 (1H, d, J=13.5 Hz), 3.57 (2H, s), 3.76-3.88 (1H, m), 3.90-4.03 (1H, m), 4.15 (2H, q, J=7.0 Hz), 7.00 (1H, s), 7.03-7.09 (2H, m), 7.24 (1H, d, J=10.5 Hz), 7.49 (1H, d, J=7.0 Hz).


Example 120






Yield 18%, 1H-NMR (CDCl3): δ1.20 (3H, d, J=6.5 Hz), 1.25 (3H, t, J=7.0 Hz), 1.36 (3H, d, J=6.5 Hz), 2.15 (1H, td, J=12.0, 3.5 Hz), 2.60-2.72 (1H, m), 2.74-2.84 (1H, m), 2.98 (1H, d, J=13.5 Hz), 3.40 (1H, td, J=12.5, 3.5 Hz), 3.62 (2H, s), 3.67-3.81 (1H, m), 4.03-4.22 (4H, m), 7.13-7.34 (4H, m), 7.50 (1H, dd, J=8.5, 1.5 Hz), 7.55 (1H, d, J=8.5 Hz), 7.82 (1H, d, J=1.5 Hz).


Example 121






Yield 73%, 1H-NMR (CDCl3): δ1.26 (3H, t, J=7.0 Hz), 2.58 (4H, t, J=5.0 Hz), 3.54 (4H, t, J=5.0 Hz), 3.56 (2H, s), 3.62 (2H, s), 4.16 (2H, q, J=7.0 Hz), 7.17-7.24 (2H, m), 7.25-7.37 (5H, m), 7.39-7.45 (2H, m), 7.40 (1H, s).


Example 122






Yield 56%, 1H-NMR (CDCl3): δ1.26 (3H, t, J=7.0 Hz), 2.61 (4H, t, J=5.0 Hz), 3.57 (2H, s), 3.63 (2H, s), 3.81 (4H, t, J=5.0), 4.16 (2H, q, J=7.0 Hz), 7.14-7.34 (4H, m), 7.35-7.43 (1H, m), 7.53-7.62 (1H, m), 7.68 (1H, dd, J=8.0, 1.5 Hz), 7.87 (1H, dd, J=8.0, 1.5 Hz), 8.57 (1H, s).


Example 123






Yield 70%, 1H-NMR (CDCl3): δ1.26 (3H, t, J=7.0 Hz), 2.58 (4H, t, J=5.0 Hz), 3.56 (2H, s), 3.62 (2H, s), 3.65 (4H, t, J=5.0 Hz), 4.16 (2H, q, J=7.0 Hz), 7.07 (1H, t, J=7.5 Hz), 7.16-7.34 (5H, m), 7.55 (1H, d, J=8.0 Hz), 7.59 (1H, d, J=8.0 Hz).


Example 124






Yield 66%, 1H-NMR (CDCl3): δ1.26 (3H, t, J=7.0 Hz), 2.59 (4H, t, J=5.0 Hz), 3.57 (2H, s), 3.63 (2H, s), 3.76 (4H, t, J=5.0 Hz), 4.16 (2H, q, J=7.0 Hz), 6.97 (1H, d, J=9.0 Hz), 7.17-7.38 (5H, m), 7.48-7.64 (2H, m), 7.69 (1H, d, J=8.5 Hz), 7.88 (1H, d, J=9.0 Hz).


Example 125






Yield 88%, 1H-NMR (CDCl3): δ1.26 (3H, t, J=7.0 Hz), 2.60 (4H, t, J=5.0 Hz), 3.57 (2H, s), 3.63 (2H, s), 3.80 (4H, t, J=5.0 Hz), 4.16 (2H, q, J=7.0 Hz), 7.16-7.35 (4H, m), 7.50 (1H, dd, J=90, 2.5 Hz), 7.59 (1H, d, J=9.0 Hz), 7.85 (1H, d, J=2.5 Hz), 8.55 (1H, s).


Example 126






Yield 80%, 1H-NMR (CDCl3): δ1.26 (3H, t, J=7.0 Hz), 1.39 (3H, d, J=7.0 Hz), 2.20 (1H, t, J=11.5, 3.5 Hz), 2.25-2.37 (4H, m), 2.82 (1H, d, J=11.5 Hz), 3.00 (1H, d, J=11.5 Hz), 3.31-3.46 (2H, m), 3.53-3.63 (3H, m), 4.16 (2H, q, J=7.0 Hz), 4.33-4.43 (1H, m), 4.64-4.77 (1H, m), 7.02 (1H, s), 7.09 (1H, s), 7.11 (1H, s), 7.70 (2H, s), 8.14 (1H, s), 8.58 (1H, s).


Example 127






Yield 90%, 1H-NMR (CDCl3): δ1.26 (3H, t, J=7.0 Hz), 2.66 (4H, t, J=5.0 Hz), 2.70 (3H, s), 3.47 (4H, t, J=5.0 Hz), 3.60 (2H, s), 3.63 (2H, s), 4.16 (2H, q, J=7.0 Hz), 7.16-7.34 (4H, m), 7.74 (1H, d, J=8.5 Hz), 7.87 (1H, d, J=8.5 Hz), 8.16 (1H, s).


Example 128
Preparation of 6-chloro-2-[4-(3-methoxymethoxy-4-methylbenzyl)piperazine-1-yl]benzothiazole






To a mixture of [3-(methoxymethoxy)-4-methyl]benzyl alcohol described in Reference Example 68 of WO2004/022551 (1.23 g; 6.75 mmol), triethylamine (0.55 ml; 7.09 mmol) and THF (12 ml) was added dropwise methanesulfonyl chloride (0.55 ml; 7.09 mmol) under ice-cooling. The mixture was stirred for 1 hour, and the reaction solution was concentrated under reduced pressure. To the residue were added 4-(6-chlorobenzothiazole-2-yl)piperazine dihydrochloride (2.10 g; 6.43 mmol), potassium carbonate (2.67 g; 19.3 mmol) and anhydrous N,N-dimethylformamide (20 ml). The mixture was stirred at room temperature for 14 hours. Water was added to the reaction solution, and the precipitate was collected and washed with diisopropyl ether to give 6-chloro-2-[4-(3-methoxymethoxy-4-methylbenzyl)piperazine-1-yl]benzothiazole as colorless crystal (1.70 g; 63%).



1H-NMR (CDCl3): δ2.24 (3H, s), 2.57 (4H, t, J=5 Hz), 3.50 (3H, s), 3.52 (2H, s), 3.63 (4H, t, J=5 Hz), 5.22 (2H, s), 6.89 (1H, d, J=7.5 Hz), 7.03 (1H, s), 7.10 (1H, d, J=7.5 Hz), 7.23 (1H, dd, J=8.5, 2 Hz), 7.45 (1H, d, J=8.5 Hz), 7.59 (1H, d, J=2 Hz).


Example 129
Preparation of 3-[4-[(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl]benzyl alcohol






To a suspension of lithium aluminium hydride (0.52 g; 13.7 mmol) in anhydrous THF (27 ml) was added dropwise a solution of 3-[[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl]methyl butanoate (2.76 g; 6.87 mmol) in anhydrous THF (27 ml) under ice-cooling. After stirring at room temperature for 1 hour, a mixture of water/THF (0.25 ml/5 mL) and 2N-aqueous sodium hydroxide solution (0.5 ml) was sequentially added dropwise thereto under ice-cooling. The mixture was stirred at room temperature for 1 hour. After filtration of aluminium hydroxide, the filtrate was concentrated under reduced pressure. To the residue were added ethyl acetate and brine to separate. The organic layer was dried over anhydrous sodium sulphate. The solvent was evaporated under reduced pressure to give yellow crystal. The crystal was washed with diisopropyl ether to give 3-[4-[(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl]benzyl alcohol as pale yellow crystal (2.35 g; 92%).



1H-NMR (CDCl3): 1.83 (1H, t, J=5.5 Hz), 2.57 (4H, t, J=5 Hz), 3.51 (2H, s), 3.63 (4H, t, J=5 Hz), 4.71 (2H, d, J=5.5 Hz), 7.23 (1H, dd, J=8.5, 2 Hz), 7.25-7.38 (4H, m), 7.42 (1H, d, J=8.5 Hz), 7.55 (1H, d. J=2 Hz).


Compounds in Example 130 to 153 were obtained by similar methods as Example 129.


Example 130






Yield: 100%, 1H-NMR (CDCl3); δ1.65 (1H, brs), 1.98-2.05 (2H, m), 2.70 (2H, t, J=5.1 Hz), 2.79-2.82 (2H, m), 3.65 (2H, s), 3.71-3.77 (4H, m), 4.69 (2H, s), 7.23 (1H, dd, J=8.7 Hz, 2.4 Hz), 7.26-7.34 (4H, m), 7.43 (1H, d, J=8.4 Hz), 7.55 (1H, d, J=2.1 Hz).


Example 131






Yield: 100%, 1H-NMR (CDCl3); δ1.26 (1H, brs), 2.59 (4H, t, J=5 Hz), 3.58 (2H, s), 3.68 (4H, t, J=5 Hz), 4.72 (2H, s), 7.20-7.40 (4H, m), 7.50-7.60 (2H, m), 7.84 (1H, s).


Example 132






Yield: 60%, 1H-NMR (DMSO-d6): δ1.88-1.99 (2H, m), 2.58-2.67 (2H, m), 2.74-2.84 (2H, m), 3.62 (2H, s), 3.63-3.85 (4H, m), 4.47 (2H, d, J=5.5 Hz), 5.16 (1H, t, J=5.5 Hz), 7.13-7.20 (2H, m), 7.22-7.30 (2H, m), 7.52-7.57 (2H, m), 8.22 (1H, s).


Example 133






Yield: 96% 1H-NMR (CDCl3); δ1.41 (3H, d, J=6.5 Hz), 1.63 (1H, brs), 2.25 (1H, td, J=11.5, 3.5 Hz), 2.33 (1H, dd, J=11.5, 3.5 Hz), 2.72 (1H, d, J=11.5 Hz), 2.86-2.95 (1H, m), 3.47 (1H, td, J=12.5, 3.5 Hz), 3.48 (1H, d, J=13.5 Hz), 3.60 (1H, d, J=13.5 Hz), 3.85 (1H, d, J=12.5 Hz), 4.10-4.25 (1H, m), 4.72 (2H, s), 7.22 (1H, dd, J=8.5, 2 Hz), 7.25-7.40 (4H, m), 7.42 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2 Hz).


Example 134






Yield: 98%, 1H-NMR (CDCl3); δ1.23 (3H, d, J=6.5 Hz), 1.55-1.70 (1H, m), 2.22-2.32 (1H, m), 2.60-2.70 (1H, m), 2.75-2.85 (1H, m), 3.10-3.20 (1H, m), 3.22 (1H, d, J=13.5 Hz), 3.35-3.45 (1H, m), 3.65-3.75 (1H, m), 3.83-3.90 (1H, m), 4.06 (1H, d, J=13.5 Hz), 4.71 (2H, s), 7.20-7.35 (5H, m), 7.42 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2 Hz).


Example 135






Yield: q.y., 1H-NMR (CDCl3); δ1.12 (6H, d, J=6 Hz), 1.64 (1H, brs), 2.75-2.85 (2H, m), 3.05 (2H, dd, J=13, 12.5 Hz), 3.85 (2H, s), 3.80-3.90 (2H, m), 4.70 (2H, s), 7.23 (1H, dd, J=8.5, 2 Hz), 7.25-7.28 (1H, m), 7.30-7.35 (2H, m), 7.38 (1H, s), 7.42 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Example 136






Yield: q.y., 1H-NMR (CDCl3); δ1.08 (3H, d, J=6.5 Hz), 1.38 (3H, d, J=6.5 Hz), 1.74 (1H, brs), 2.33 (1H, d, J=11.5 Hz), 2.89 (1H, dd, J=11.5, 4 Hz), 3.06-3.19 (1H, m), 3.53 (1H, d, J=14.5 Hz), 3.60-3.75 (3H, m), 4.15-4.28 (1H, m), 4.70 (2H, s), 7.21 (1H, dd, J=8.5, 2 Hz), 7.25-7.35 (4H, m), 7.40 (1H, d, J=8.5 Hz), 7.53 (1H, d, J=2 Hz).


Example 137






Yield: 60%, 1H-NMR (CDCl3); δ1.71 (1H, brs), 2.38 (3H, s), 2.58 (4H, t, J=5 Hz), 3.52 (2H, s), 3.61 (4H, t, J=5 Hz), 4.67 (2H, s), 7.15-7.20 (2H, m), 7.23 (1H, dd, J=8.5, 2 Hz), 7.25-7.28 (1H, m), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Example 138






Yield: 39%, 1H-NMR (CDCl3); δ1.80 (1H, brs), 2.65 (4H, t, J=5 Hz), 3.65 (4H, t, J=5 Hz), 3.68 (2H, s), 4.70 (2H, s), 7.23 (1H, dd, J=8.2 Hz), 7.24 (1H, dd, 8.5, 2 Hz), 7.36 (1H, d, J=8 Hz), 7.42 (1H, d, J=8.5 Hz), 7.48 (1H, d, J=2 Hz), 7.55 (1H, d, J=2 Hz).


Example 139






Yield: 92%, 1H-NMR (CDCl3); δ1.66-1.73, (1H, br-s), 1.97-2.04 (2H, m), 2.33 (3H, s), 2.69 (2H, t, J=5.4 Hz), 2.78-2.81 (2H, m), 3.59 (2H, s), 3.70-3.75 (4H, m), 4.65 (2H, s), 7.16-7.17 (2H, m), 7.23 (1H, dd, J=8.7 Hz, 2.1 Hz), 7.28 (1H, s), 7.43 (1H, d, J=8.7 Hz), 7.55 (1H, d, J=2.4 Hz).


Example 140






Yield: 100%, 1H-NMR (CDCl3); δ1.70-1.88 (1H, br-s), 1.98-2.07 (2H, m), 2.75 (2H, t, J=5.4 Hz), 2.84-2.89 (2H, m), 3.72-3.84 (6H, m), 4.68 (2H, s), 7.17-7.25 (2H, m), 7.33 (1H, d, J=8.1 Hz), 7.44 (1H, d, J=8.1 Hz), 7.50 (1H, d, J=2.1 Hz), 7.55 (1H, d, J=2.4 Hz).


Example 141






Yield: 30%, 1H-NMR (CDCl3); δ1.90 (1H, brs), 2.62 (4H, t, J=5 Hz), 3.64 (4H, t, J=5 Hz), 3.74 (2H, s), 4.79 (2H, s), 6.79 (1H, d, J=3.5 Hz), 6.85 (1H, d, J=3.5 Hz), 7.23 (1H, dd, J=8.5, 2 Hz), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Example 142






Yield: 80%, 1H-NMR (CDCl3); δ1.86 (1H, s), 2.00-2.07 (2H, m), 2.71-2.74 (2H, m), 2.84-2.87 (2H, m), 3.73 (2H, t, J=6.0 Hz), 3.77-3.80 (2H, m), 3.82 (2H, s), 4.78 (2H, s), 6.76 (1H, d, J=3.3 Hz), 6.84 (1H, d, J=3.3 Hz), 7.23 (1H, dd, J=8.7, 2.4 Hz), 7.42 (1H, d, J=9.0 Hz), 7.55 (1H, d, J=2.4 Hz).


Example 143






Yield: 90%, 1H-NMR (CDCl3); δ1.81 (1H, brs), 2.36 (3H, s), 2.57 (4H, t, J=5 Hz), 3.53 (2H, s), 3.63 (4H, t, J=5 Hz), 4.67 (2H, s), 7.08 (1H, s), 7.11 (1H, s), 7.13 (1H, s), 7.23 (1H, dd, J=8.5, 2 Hz), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Example 144






Yield: q. y, 1H-NMR (CDCl3); δ1.79 (1H, t, J=4.5 Hz), 2.36 (3H, s), 2.59 (4H, t, J=5 Hz), 3.54 (2H, s), 3.68 (4H, t, J=5 Hz), 4.67 (2H, d, J=4.5 Hz), 7.09 (1H, s), 7.11 (1H, s), 7.14 (1H, s), 7.45-7.60 (2H, m), 7.84 (1H, s).


Example 145






Yield: 93%, 1H-NMR (CDCl3); δ1.70 (1H, s), 1.99-2.06 (2H, m), 2.35 (3H, s), 2.70 (2H, t, J=5.4 Hz), 2.79-2.82 (2H, m), 3.61 (2H, s), 3.71-3.77 (4H, m), 4.65 (2H, s), 7.07 (1H, s), 7.09 (1H, s), 7.13 (1H, s), 7.23 (1H, dd, J=8.7 Hz, J=2.1 Hz), 7.43 (1H, d, J=8.7 Hz), 7.55 (1H, d, J=2.1 Hz).


Example 146






Yield: q. y, 1H-NMR (CDCl3); δ1.77 (1H, brs), 1.95-2.10 (2H, m), 2.34 (3H, s), 2.68 (2H, t, J=5.5 Hz), 2.82 (2H, t, J=5.5 Hz), 3.61 (2H, s), 3.70-3.85 (4H, m), 4.65 (2H, s), 7.06 (1H, s), 7.08 (1H, s), 7.13 (1H, s), 7.45-7.60 (2H, m), 7.84 (1H, s).


Example 147






Yield: 80%, 1H-NMR (DMSO-d6): δ1.59 (1H, brs), 2.57 (4H, t, J=5 Hz), 2.88 (2H, t, J=6.5 Hz), 3.55 (2H, s), 3.63 (4H, t, J=5 Hz), 3.88 (2H, t, J=6.5 Hz), 7.20 (2H, d, J=7.5 Hz), 7.26 (1H, dd, J=8.5, 2 Hz), 7.29 (2H, d, J=7.5 Hz), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Example 148






Yield: 46%, 1H-NMR (CDCl3): δ1.14 (6H, d, J=6 Hz), 1.68 (1H, brs), 2.30 (3H, s), 2.70-2.87 (2H, m), 3.03-3.15 (2H, m), 3.82 (2H, s), 3.85-3.95 (2H, m), 4.66 (2H, s), 7.05 (1H, s), 7.11 (1H, s), 7.17 (1H, s), 7.51 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 149






Yield: 95%, 1H-NMR (CDCl3): δ1.24 (3H, d, J=6 Hz), 1.69 (1H, brs), 2.20-2.35 (1H, m), 2.36 (3H, s), 2.60-2.72 (1H, m), 2.82 (1H, dt, J=12, 3.5 Hz), 3.15-3.25 (2H, m), 3.35-3.48 (1H, m), 3.70-3.80 (1H, m), 3.85-3.95 (1H, m), 4.04 (1H, d, J=13.5 Hz), 4.67 (2H, s), 7.00-7.15 (3H, m), 7.52 (1H, dd, J=8.5, 1 Hz), 7.56 (1H, d, J=8.5 Hz), 7.83 (1H, d, J=1 Hz).


Example 150






Yield: quant. %, 1H-NMR (DMSO-d6): δ1.30 (3H, d, J=7 Hz), 2.05-2.25 (2H, m), 2.27 (3H, s), 2.65-2.75 (1H, m), 2.80-2.95 (1H, m), 3.30-3.85 (3H, m), 4.15-4.30 (1H, m), 4.43 (2H, d, J=5.5 Hz), 4.48 (1H, t, J=5 Hz), 5.21 (1H, t, J=5.5 Hz), 7.00 (2H, s), 7.06 (1H, s), 7.54 (2H, s), 8.19 (1H, s).


Example 151






Yield: 45%, 1H-NMR (CDCl3): δ1.23 (3H, d, J=6.3 Hz), 2.26 (1H, ddd, J=3.3, 9.5, 12.3 Hz), 2.36 (3H, s), 2.60-2.66 (1H, m), 2.80 (1H, dt, J=3.3, 12.0 Hz), 3.17 (2H, d, J=13.2 Hz), 3.20-3.33 (1H, m), 3.71 (1H, dt, J=2.1, 12.0 Hz), 3.87 (1H, dd, J=2.1, 12.6 Hz), 4.03 (1H, d, J=13.2 Hz), 4.67 (2H, s), 7.09 (2H, s), 7.14 (1H, s), 7.23 (1H, dd, J=2.1, 8.4 Hz), 7.42 (1H, d, J=8.4 Hz), 7.54 (1H, d, J=2.1 Hz)


Example 152






Yield: 54%, 1H-NMR (CDCl3): δ1.24 (3H, d, J=6.3 Hz), 2.23-2.31 (1H, m), 2.36 (3H, s), 2.60-2.66 (1H, m), 2.81 (1H, dt, J=3.3, 11.7 Hz), 3.18 (2H, d, J=12.9 Hz), 3.34-3.42 (1H, m), 3.71 (1H, d, J=12.9 Hz), 3.87 (1H, d, J=10.2 Hz), 4.04 (1H, d, J=13.5 Hz), 4.67 (2H, s), 7.09 (2H, s), 7.14 (1H, s), 7.23 (1H, dd, J=2.4, 8.4 Hz), 7.43 (1H, d, J=8.4 Hz), 7.55 (1H, d, J=2.4 Hz)


Example 153






Yield: 84%, 1H-NMR (CDCl3): δ1.24 (3H, d, J=6.0 Hz), 1.63-1.73 (1H, m), 2.23-2.34 (1H, m), 2.37 (3H, s), 2.59-2.72 (1H, m), 2.78-2.88 (1H, m), 3.15-3.26 (1H, m), 3.19 (1H, d, J=13.0 Hz), 3.37-3.48 (1H, m), 3.72-3.83 (1H, m), 3.86-3.97 (1H, m), 4.04 (1H, d, J=13.0 Hz), 4.67 (2H, d, J=4.5 Hz), 7.07-7.17 (3H, m), 7.48-7.59 (2H, m), 7.84 (1H, s).


Example 154
Preparation of 6-chloro[4-(3-chloromethylbenzyl)piperazine-1-yl]benzothiazole monohydrochloride






To 3-[4-[(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl]benzyl alcohol (2.35 g; 6.29 mmol) was added thionyl chloride (12 ml) at room temperature. The mixture was stirred at 60° C. for 1 hour. The reaction solution was concentrated under reduced pressure. To the obtained residue were added ice water and 10% aqueous sodium hydroxide solution to become neutral. The precipitate was collected to give 6-chloro[4-(3-chloromethylbenzyl)piperazine-1-yl]benzothiazole monohydrochloride as colorless crystal (2.50 g; 93%).



1H-NMR (DMSO-d6): δ3.20-3.30 (2H, m), 3.35-3.45 (2H, m), 3.55-3.75 (2H, m), 4.10-4.25 (2H, m), 4.35-4.40 (2H, m), 4.80 (2H, s), 7.34 (1H, dd, J=8.5, 2 Hz), 7.45-7.60 (3H, m), 7.60-7.70 (2H, m), 8.00 (1H, d, J=2 Hz), 11.45 (1H, brs).


Compounds in Examples 155 to 178 were obtained by similar methods as Example 154.


Example 155






Yield: 77%, 1H-NMR (CDCl3); δ1.99-2.06 (2H, m), 2.69 (2H, t, J=5.4 Hz), 2.80-2.83 (2H, m), 3.65 (2H, s), 3.72-3.79 (4H, m), 4.58 (2H, s), 7.21-7.31 (4H, m), 7.36 (1H, s), 7.42 (1H, d, J=8.4 Hz), 7.55 (1H, d, J=2.4 Hz).


Example 156






Yield: 77%, 1H-NMR (CDCl3); δ2.60 (4H, t, J=5 Hz), 3.59 (2H, s), 3.70 (4H, t, J=5 Hz), 4.60 (2H, s), 7.25-7.40 (4H, m), 7.50-7.60 (2H, m), 7.85 (1H, s).


Example 157






Yield: 95%, 1H-NMR (CDCl3); δ1.95-2.12 (2H, m), 2.61-2.71 (2H, m), 2.77-2.88 (2H, m), 3.66 (2H, s), 3.68-3.90 (4H, m), 4.58 (2H, s), 7.22-7.40 (4H, m), 7.48-7.60 (2H, m), 7.85 (1H, s).


Example 158






Yield: 95%, 1H-NMR (CDCl3); δ1.41 (3H, d, J=6.5 Hz), 2.25 (1H, td, J=11, 3 Hz), 2.34 (1H, dd, J=11, 3 Hz), 2.71 (1H, d, J=11 Hz), 2.92 (1H, d, J=11 Hz), 3.47 (1H, d, J=13.5 Hz), 3.49 (1H, td, J=12, 3 Hz), 3.62 (1H, d, J=13.5 Hz), 3.87 (1H, d, J=12 Hz), 4.15-4.25 (1H, m), 4.60 (2H, s), 7.22 (1H, dd, J=8.5, 2 Hz), 7.30-7.38 (3H, m), 7.38-7.42 (1H, m), 7.42 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2 Hz)


Example 159






Yield: 63%, 1H-NMR (CDCl3); δ1.23 (3H, d, J=6 Hz), 2.24-2.34 (1H, m), 2.60-2.73 (1H, m), 2.75-2.85 (1H, m), 3.13-3.23 (1H, m), 3.22 (1H, d, J=13.5 Hz), 3.34-3.44 (1H, m), 3.66-3.76 (1H, m), 3.84-3.92 (1H, m), 4.06 (1H, d, J=13.5 Hz), 4.60 (2H, s), 7.23 (1H, dd, J=8.5, 2 Hz), 7.25-7.40 (4H, m), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Example 160






Yield: 71%, 1H-NMR (CDCl3); δ1.11 (6H, d, J=6 Hz), 2.70-2.85 (2H, m), 3.06 (2H, dd, J=13, 13 Hz), 3.84 (2H, s), 3.85-3.90 (2H, m), 4.60 (2H, s), 7.20-7.45 (6H, m), 7.55 (1H, d, J=2 Hz).


Example 161






Yield: 90%, 1H-NMR (CDCl3); δ1.09 (3H, d, J=6.5 Hz), 1.39 (3H, d, J=6.5 Hz), 2.32 (1H, d, J=10.5 Hz), 2.89 (1H, dd, J=12, 4 Hz), 3.08-3.20 (1H, m), 3.52 (1H, d, J=13.5 Hz), 3.64 (1H, d, J=12 Hz), 3.70 (1H, d, J=13.5 Hz), 3.73 (1H, dd, J=12, 4 Hz), 4.15-4.30 (1H, m), 4.60 (2H, s), 7.23 (1H, dd, J=8.5, 2 Hz), 7.25-7.35 (3H, m), 7.41 (1H, d, J=8.5 Hz), 7.44 (1H, s), 7.53 (1H, d, J=2 Hz).


Example 162






Yield: 85%, 1H-NMR (CDCl3); δ2.38 (3H, s), 2.58 (4H, t, J=5 Hz), 3.52 (2H, s), 3.63 (4H, t, J=5 Hz), 4.60 (2H, s), 7.15-7.30 (4H, m), 7.44 (1H, d, J=8 Hz), 7.56 (1H, d, J=2 Hz).


Example 163






Yield: 68%, 1H-NMR (CDCl3); δ2.66 (4H, t, J=5 Hz), 3.66 (4H, t, J=5 Hz), 3.68 (2H, s), 4.58 (2H, s), 720-7.25 (2H, m), 7.37 (1H, d, J=8 Hz), 7.44 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz), 7.56 (1H, d, J=2 Hz).


Example 164






Yield: 99%, 1H-NMR (CDCl3); δ1.97-2.05 (2H, m), 2.33 (3H, s), 2.67 (2H, t, J=5.4 Hz), 2.79-2.82 (2H, m), 3.58 (2H, s), 3.72-3.77 (4H, m), 4.56 (2H, s), 7.12-7.25 (3H, m), 7.30 (1H, d, J=1.8 Hz), 7.42 (1H, d, J=8.4 Hz), 7.55 (1H, d, J=2.4 Hz).


Example 165






Yield: 81%, 1H-NMR (CDCl3); δ2.01-2.09 (2H, m), 2.75 (2H, t, J=5.1 Hz), 2.87-2.90 (2H, m), 3.74-3.83 (6H, m), 4.54 (2H, s), 7.20-7.25 (2H, m), 7.33 (1H, d, J=8.4 Hz), 7.43 (1H, d, J=9.0 Hz), 7.52 (1H, d, J=2.1 Hz), 7.55 (1H, d, J=2.1 Hz).


Example 166






Yield: 85%, 1H-NMR (CDCl3); δ2.36 (3H, s), 2.58 (4H, t, J=5 Hz), 3.53 (2H, s), 3.64 (4H, t, J=5 Hz), 4.56 (2H, s), 7.12 (1H, s), 7.13 (1H, s), 7.17 (1H, s), 7.23 (1H, dd, J=8.5, 2 Hz), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Example 167






Yield: 91%, 1H-NMR (CDCl3); δ1.98-2.06 (2H, m), 2.34 (3H, s), 2.69 (2H, t, J=5.4 Hz), 2.78-2.83 (2H, m), 3.61 (2H, s), 3.72-3.78 (4H, m), 4.55 (2H, s), 7.09-7.11 (2H, m), 7.14 (1H, s), 7.23 (1H, dd, J=8.4, 2.1 Hz), 7.43 (1H, d, J=8.7 Hz), 7.55 (1H, d, J=2.1 Hz).


Example 168






Yield: 45%, 1H-NMR (DMSO-d6): δ2.55 (4H, t, J=5 Hz), 3.57 (4H, t, J=5 Hz), 3.74 (2H, s), 4.99 (2H, s), 6.86 (1H, d, J=3.5 Hz), 7.04 (1H, d, J=3.5 Hz), 7.28 (1H, dd, J=8.5, 2 Hz), 7.42 (1H, d, J=8.5 Hz), 7.91 (1H, d, J=2 Hz).


Example 169






Yield: 45%, 1H-NMR (CDCl3); δ2.00-2.07 (2H, m), 2.71-2.74 (2H, m), 2.84-2.87 (2H, m), 3.73 (2H, t, J=6.0 Hz), 3.75-3.81 (2H, m), 3.81 (2H, s), 4.76 (2H, s), 6.73 (1H, d, J=3.3 Hz), 6.91 (1H, d, J=3.3 Hz), 7.23 (1H, dd, J=8.7, 2.4 Hz), 7.42 (1H, d, J=8.4 Hz), 7.55 (1H, d, J=2.1 Hz).


Example 170






Yield: 59%, 1H-NMR (CDCl3); δ2.37 (3H, s), 2.59 (4H, t, J=5 Hz), 3.54 (2H, s), 3.69 (4H, t, J=5 Hz), 4.57 (2H, s), 7.12 (1H, s), 7.13 (1H, s), 7.17 (1H, s), 7.50-7.60 (2H, m), 7.85 (1H, s).


Example 171






Yield: 71%, 1H-NMR (CDCl3); δ1.95-2.10 (2H, m), 2.34 (3H, s), 2.70 (2H, t, J=5.5 Hz), 2.82 (2H, t, J=5.5 Hz), 3.61 (2H, s), 3.70-3.90 (4H, m), 4.54 (2H, s), 7.05-7.14 (2H, m), 7.15 (1H, s), 7.48-7.60 (2H, m), 7.85 (1H, s).


Example 172






Yield: 77%, 1H-NMR (CDCl3); δ2.57 (4H, t, J=5 Hz), 3.07 (2H, t, J=7.5 Hz), 3.55 (2H, s), 3.63 (4H, t, J=5 Hz), 3.72 (2H, t, J=7.5 Hz), 7.19 (2H, d, J=8 Hz), 7.23 (1H, dd, J=8.5, 2 Hz), 7.29 (2H, d, J=8 Hz), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Example 173






Yield: 91%, 1H-NMR (CDCl3): δ1.12 (6H, d, J=6 Hz), 2.35 (3H, s), 2.68-2.86 (2H, m), 3.05-3.15 (2H, m), 3.81 (2H, s), 3.85-3.98 (2H, m), 4.56 (2H, s), 7.07 (1H, s), 7.14 (1H, s), 7.21 (1H, s), 7.52 (1H, d, J=8.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 174






Yield: 74%, 1H-NMR (CDCl3): δ1.24 (3H, d, J=6 Hz), 2.23-2.35 (1H, m), 2.36 (3H, s), 2.60-2.70 (1H, m), 2.80 (1H, dt, J=13, 3.5 Hz), 3.17 (1H, d, J=13.5 Hz), 3.18-3.26 (1H, m), 3.38-3.50 (1H, m), 3.72-3.80 (1H, m), 3.87-3.95 (1H, m), 4.03 (1H, d, J=13.5 Hz), 4.56 (2H, s), 7.11 (2H, s), 7.17 (1H, s), 7.53 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 175






Yield: 81%, 1H-NMR (CDCl3): δ1.43 (3H, d, J=6.5 Hz), 2.26 (1H, td, J=11.5, 3.5 Hz), 2.30-2.36 (1H, m), 2.37 (3H, s), 2.73 (1H, d, J=11.5 Hz), 2.93 (1H, d, J=11.5 Hz), 3.43 (1H, d, J=13.5 Hz), 3.54 (1H, td, J=12.5, 3.5 Hz), 3.58 (1H, d, J=13.5 Hz), 3.85-3.98 (1H, m), 4.20-4.30 (1H, m), 4.57 (2H, s), 7.12 (2H, s), 7.21 (1H, s), 7.51 (1H, dd, J=8.5, 1.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.84 (1H, d, J=1.5 Hz).


Example 176






Yield: 83%, 1H-NMR (CDCl3): δ1.23 (3H, d, J=6.0 Hz), 2.23-2.31 (1H, m), 2.36 (3H, s), 2.61-2.83 (1H, m), 2.80 (1H, dt, J=3.6, 11.7 Hz), 3.13-3.20 (2H, m), 3.35-3.43 (1H, m), 3.72 (1H, dt, J=2.7 Hz), 3.87 (1H, dd, J=1.8, 12.3 Hz), 4.03 (1H, d, J=13.2 Hz), 4.56 (2H, s), 7.11 (2H, s), 7.16 (1H, s), 7.23 (1H, dd, J=2.1, 8.7 Hz), 7.43 (1H, d, J=8.7 Hz), 7.54 (1H, d, J=2.1 Hz)


Example 177






Yield: 77%, 1H-NMR (CDCl3): δ1.23 (3H, d, J=6.0 Hz), 2.27 (1H, ddd, J=3.3, 8.7, 9.9 Hz), 2.35 (3H, s), 2.61-2.67 (1H, m), 2.80 (1H, dt, J=3.6, 12.0 Hz), 3.13-3.20 (2H, m), 3.35-3.43 (1H, m), 3.72 (1H, d, J=12.6 Hz), 3.87 (1H, dd, J=1.8, 12.6 Hz), 4.03 (1H, d, J=13.2 Hz), 4.56 (2H, s), 7.11 (2H, s), 7.16 (1H, s), 7.23 (1H, dd, J=1.8, 8.7 Hz), 7.53 (1H, d, J=8.7 Hz), 7.54 (1H, d, J=1.8 Hz)


Example 178






Yield: 60%, 1H-NMR (CDCl3): δ1.24 (3H, d, J=6.0 Hz), 2.23-2.34 (1H, m), 2.36 (3H, s), 2.60-2.72 (1H, m), 2.77-2.87 (1H, m), 3.14-3.27 (2H, m), 3.38-3.51 (1H, m), 3.72-3.82 (1H, m), 3.87-3.98 (1H, m), 4.04 (1H, d, J=13.0 Hz), 4.56 (2H, s), 7.12 (2H, s), 7.17 (1H, s), 7.48-7.59 (2H, m), 7.84 (1H, s).


Example 179
Preparation of {3-[[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl]phenyl}acetonitrile






The mixture of 6-chloro[4-(3-chloromethylbenzyl)piperazine-1-yl]benzothiazole monohydrochloride (0.50 g; 1.27 mmol) and sodium cyanide (0.19 g; 3.82 mmol) in anhydrous N,N-dimethylformamide (5 ml) were stirred at 40° C. for 1.5 hours. After cooling, water and ethyl acetate were added to the reaction solution. The organic layer was separated and washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure and the percipitate was washed with diisopropyl ether to give {3-[[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl]phenyl}acetonitrile as pale blackish brown crystal (0.35 g; 72%).



1H-NMR (CDCl3): δ2.58 (4H, t, J=5 Hz), 3.57 (2H, s), 3.67 (4H, t, J=5 Hz), 3.77 (2H, s), 7.24 (1H, dd, J=8.5, 2 Hz), 7.25-7.40 (4H, m), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Compounds in Examples 180 to 203 were obtained by similar methods as Example 179.


Example 180






Yield: 95%, 1H-NMR (CDCl3); δ1.98-2.06 (2H, m), 2.69 (2H, t, J=5.4 Hz), 2.79-2.83 (2H, m), 3.65 (2H, s) 3.72-3.80 (6H, m), 7.21-7.25 (2H, m), 7.29-7.33 (3H, m), 7.43 (1H, d, J=8.7 Hz), 7.55 (1H, d, J=2.4 Hz).


Example 181






Yield: 99%, 1H-NMR (CDCl3); δ2.59 (4H, t, J=5 Hz), 3.58 (2H, s), 3.69 (4H, t, J=5 Hz), 3.77 (2H, s), 7.20-7.40 (4H, m), 7.50-7.60 (2H, m), 7.85 (1H, d, J=0.5 Hz).


Example 182






Yield: 74%, 1H-NMR (CDCl3); δ1.98-2.10 (2H, m), 2.64-2.74 (2H, m), 2.77-2.88 (2H, m), 3.65 (2H, s), 3.68-3.90 (4H, m), 3.74 (2H, s), 7.18-7.38 (4H, m), 7.48-7.59 (2H, m), 7.84 (1H, s).


Example 183






Yield: 68%, 1H-NMR (CDCl3); δ1.41 (3H, d, J=6.5 Hz), 2.26 (1H, td, J=11, 2.5 Hz), 2.35 (1H, dd, J=11, 4 Hz), 2.71 (1H, d, J=11 Hz), 2.89 (1H, d, J=11 Hz), 3.47 (1H, d, J=13 Hz), 3.50 (1H, td, J=13, 3 Hz), 3.61 (1H, d, J=13 Hz), 3.77 (2H, s), 3.87 (1H, d, J=13 Hz), 4.15-4.25 (1H, m), 7.23 (1H, dd, J=8.5, 2 Hz), 7.25-7.30 (1H, m), 7.30-7.40 (3H, m), 7.42 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Example 184






Yield: 86%, 1H-NMR (CDCl3); δ1.23 (3H, d, J=6.5 Hz), 2.23-2.35 (1H, m), 2.58-2.72 (1H, m), 2.72-2.85 (1H, m), 3.10-3.20 (1H, m), 3.22 (1H, d, J=13.5 Hz), 3.33-3.45 (1H, m), 3.60-3.75 (1H, m), 3.76 (2H, s), 3.83-3.93 (1H, m), 4.06 (1H, d, J=13.5 Hz), 7.23 (1H, dd, J=8.5, 2 Hz), 7.25-7.35 (4H, m), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Example 185






Yield: 59%, 1H-NMR (CDCl3); δ1.10 (6H, d, J=6 Hz), 2.70-2.85 (2H, m), 3.05 (2H, dd, J=13, 13 Hz), 3.76 (2H, s), 3.83 (2H, s), 3.88 (2H, dd, J=13, 2 Hz), 7.18 (1H, d, J=7 Hz), 7.25 (1H, dd, J=8.5, 2 Hz), 7.30-7.40 (3H, m), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Example 186






Yield: 97%, 1H-NMR (CDCl3); δ1.09 (3H, d, J=6.5 Hz), 1.39 (3H, d, J=6.5 Hz), 2.31 (1H, d, J=11.5 Hz), 2.90 (1H, dd, J=11.5, 4 Hz), 3.08-3.20 (1H, m), 3.53 (1H, t, J=14 Hz), 3.64 (1H, d, J=12.5 Hz), 3.70 (1H, d, J=14 Hz), 3.72 (1H, dd, J=12.5, 4 Hz), 3.76 (2H, s), 4.18-4.30 (1H, m), 7.21 (1H, dd, J=8.5, 2 Hz), 7.21-7.25 (1H, m), 7.30-7.40 (3H, m), 7.41 (1H, d, J=8.5 Hz), 7.53 (1H, d, J=2 Hz).


Example 187






Yield: 35%, 1H-NMR (CDCl3); δ2.37 (3H, s), 2.58 (4H, t, J=5 Hz), 3.52 (2H, s), 3.63 (4H, t, J=5 Hz), 3.73 (2H, s), 7.10-7.30 (4H, m), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Example 188






Yield: 69%, 1H-NMR (CDCl3); δ2.65 (4H, t, J=5 Hz), 3.66 (4H, t, J=5 Hz), 3.68 (2H, s), 3.76 (2H, s), 7.19 (1H, dd, J=8, 2 Hz), 7.24 (1H, dd, 8.5, 2 Hz), 7.38 (1H, d, J=8 Hz), 7.44 (1H, d, J=8.5 Hz), 7.51 (1H, d, J=2 Hz), 7.56 (1H, d, J=2 Hz).


Example 189






Yield: 78%, 1H-NMR (CDCl3); δ1.99-2.05 (2H, m), 2.32 (3H, s), 2.67 (2H, t, J=5.4 Hz), 2.79-2.83 (2H, m), 3.58 (2H, s), 3.70 (2H, s), 3.72-3.78 (4H, m), 7.13-7.14 (2H, m), 7.21-7.26 (2H, m), 7.42 (1H, d, J=8.4 Hz), 7.55 (1H, d, J=2.1 Hz).


Example 190






Yield: 99%, 1H-NMR (CDCl3); δ2.03-2.07 (2H, m), 2.75 (2H, t, J=5.4 Hz), 2.87-2.90 (2H, m), 3.70 (2H, s), 3.75 (2H, s), 3.75 (2H, t, J=6.0 Hz), 3.82 (2H, t, J=5.1 Hz), 7.16 (1H, dd, J=8.1, 2.1 Hz), 7.23 (1H, dd, J=8.4 Hz, 2.1 Hz), 7.35 (1H, d, J=8.4 Hz), 7.42 (1H, d, J=8.4 Hz), 7.49 (1H, d, J=2.4 Hz), 7.56 (1H, d, J=2.1 Hz).


Example 191






Yield: 78%, 1H-NMR (CDCl3); δ2.36 (3H, s), 2.57 (4H, t, J=5 Hz), 3.51 (2H, s), 3.64 (4H, t, J=5 Hz), 3.72 (2H, s), 7.06 (1H, s), 7.10 (1H, s), 7.11 (1H, s), 7.23 (1H, dd, J=8.5, 2 Hz), 7.42 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Example 192






Yield: q. y, 1H-NMR (CDCl3); δ1.99-2.06 (2H, m), 2.35 (3H, s), 2.67 (2H, t, J=5.4 Hz), 2.78-2.82 (2H, m), 3.60 (2H, s), 3.70-3.78 (6H, m), 7.04 (1H, s), 7.09 (2H, s), 7.23 (1H, dd, J=8.7, 2.1 Hz), 7.43 (1H, d, J=8.7 Hz), 7.55 (1H, d, J=2.1 Hz).


Example 193






Yield: 68%, 1H-NMR (CDCl3); δ2.50-2.60 (4H, m), 3.50-3.60 (4H, m), 3.72 (2H, s), 4.24 (2H, s), 6.88 (1H, d, J=3 Hz), 6.91 (1H, d, J=3 Hz), 7.28 (1H, dd, J=8.5, 1.5 Hz), 7.42 (1H, d, J=8.5 Hz), 7.91 (1H, d, J=1.5 Hz).


Example 194






Yield: 32%, 1H-NMR (CDCl3); δ1.99-2.07 (2H, m), 2.70-2.74 (2H, m), 2.83-2.87 (2H, m), 3.73 (2H, t, J=6.0 Hz), 3.77-3.80 (2H, m), 3.80 (2H, s), 3.86 (2H, s), 6.76 (1H, d, J=3.3 Hz), 6.88 (1H, td, J=3.3, 0.9 Hz), 7.23 (1H, dd, J=8.7, 2.1 Hz), 7.42 (1H, d, J=8.4 Hz), 7.55 (1H, d, J=2.4 Hz).


Example 195






Yield: 93%, 1H-NMR (CDCl3); δ2.27 (3H, s), 2.58 (4H, t, J=5 Hz), 3.53 (2H, s), 3.69 (4H, t, J=5 Hz), 3.72 (2H, s), 7.07 (1H, s), 7.11 (1H, s), 7.12 (1H, s), 7.52 (1H, d, J=8.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.85 (1H, s).


Example 196






Yield: 86%, 1H-NMR (CDCl3); δ1.95-2.10 (2H, m), 2.34 (3H, s), 2.69 (2H, t, J=5.5 Hz), 2.82 (2H, t, J=5.5 Hz), 3.61 (2H, s), 3.69 (2H, s), 3.70-3.90 (4H, m), 7.04 (1H, s), 7.08 (1H, s), 7.09 (1H, s), 7.51 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.85 (1H, s).


Example 197






Yield: 85%, 1H-NMR (DMSO-d6): δ2.45-2.55 (4H, m), 2.81 (2H, t, J=5 Hz), 2.87 (2H, t, J=5 Hz), 3.52 (2H, s), 3.56 (4H, t, J=5.5 Hz), 7.20-7.35 (5H, m), 7.42 (1H, d, J=8.5 Hz), 7.91 (1H, d, J=2 Hz).


Example 198






Yield: 84%, 1H-NMR (CDCl3): δ1.12 (6H, d, J=6 Hz), 2.36 (3H, s), 2.75-2.87 (2H, m), 3.10 (1H, d, J=13 Hz), 3.13 (1H, d, J=13 Hz), 3.71 (2H, s), 3.79 (2H, s), 3.92 (2H, dd, J=13, 2 Hz), 7.00 (1H, s), 7.14 (1H, s), 7.16 (1H, s), 7.52 (1H, dd, J=8.5, 1 Hz), 7.57 (1H, d, J=8.5 Hz), 7.84 (1H, d, J=1 Hz).


Example 199






Yield: 86%, 1H-NMR (CDCl3): δ1.23 (3H, d, J=6 Hz), 2.20-2.35 (1H, m), 2.36 (3H, s), 2.61-2.73 (1H, m), 2.80 (1H, dt, J=12, 3.5 Hz), 3.15-3.28 (2H, m), 3.40-3.50 (1H, m), 3.71 (2H, s), 3.71-3.81 (1H, m), 3.87-3.97 (1H, m), 4.02 (1H, d, J=13.5 Hz), 7.05 (1H, s), 7.11 (2H, s), 7.50 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.84 (1H, s)


Example 200






Yield: 79%, 1H-NMR (CDCl3): δ1.43 (3H, d, J=6.5 Hz), 2.26 (1H, td, J=11.5, 3.5 Hz), 2.30-2.33 (1H, m), 2.34 (3H, s), 2.72 (1H, d, J=11 Hz), 2.91 (1H, d, J=11.5 Hz), 3.45 (1H, d, J=13.5 Hz), 3.54 (1H, td, J=13, 3.5 Hz), 3.58 (1H, d, J=13.5 Hz), 3.72 (2H, s), 3.92 (1H, d, J=13 Hz), 4.20-4.30 (1H, m), 7.06 (1H, s), 7.13 (1H, s), 7.15 (1H, s), 7.51 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 201






Yield: 90%, 1H-NMR (CDCl3): δ1.22 (3H, d, J=6.3 Hz), 2.23-2.32 (1H, m), 2.36 (3H, s), 2.59-2.69 (1H, m), 2.78 (1H, dt, J=3.6, 8.1 Hz), 3.17 (2H, dt, J=3.6, 13.5 Hz), 3.35-3.44 (1H, m), 3.70-3.75 (1H, m), 3.71 (2H, s), 3.85-3.90 (1H, m), 4.02 (1H, s), 7.05 (1H, s), 7.11 (2H, s), 7.23 (1H, dd, J=2.1, 8.7 Hz), 7.43 (1H, d, J=8.7 Hz), 7.55 (1H, d, J=2.1 Hz)


Example 202






Yield: 98%, 1H-NMR (CDCl3): δ1.22 (3H, d, J=6.3 Hz), 2.23-2.32 (1H, m), 2.36 (3H, s), 2.62-2.66 (1H, m), 2.78 (1H, dt, J=3.9, 11.7 Hz), 3.17 (2H, dt, J=3.9, 13.5 Hz), 3.35-3.44 (1H, m), 3.71 (2H, s), 3.70-3.74 (1H, m), 3.87 (1H, dd, J=2.1, 12.6 Hz), 4.02 (1H, d, J=13.5 Hz), 7.05 (1H, s), 7.11 (2H, s), 7.23 (1H, dd, J=2.1, 8.4 Hz), 7.43 (1H, d, J=8.4 Hz), 7.55 (1H, d, J=2.1 Hz)


Example 203






Yield: 85%, 1H-NMR (CDCl3): δ1.24 (3H, d, J=6.5 Hz), 2.23-2.34 (1H, m), 2.37 (3H, s), 2.60-2.73 (1H, m), 2.80 (1H, dt, J=12.0, 3.5 Hz), 3.13-3.27 (2H, m), 3.39-3.51 (1H, m), 3.70-3.83 (3H, m), 3.87-3.97 (1H, m), 4.03 (1H, d, J=13.5 Hz), 7.06 (1H, s), 7.11 (2H, s), 7.48-7.59 (2H, m), 7.84 (1H, s).


Example 204
Preparation of 2-{3-[4-(6-chlorobenzothiazole-2-yl)piperazine-1-ylmethyl]benzyl}diethyl malonate






To a suspension of sodium hydride (0.15 g; 60%, 3.81 mmol) in anhydrous THF suspension was added dropwise diethyl malonate (0.58 ml; 3.81 mmol) under ice-cooling. The mixture was stirred at room temperature for 30 minutes. To the reaction solution was added 6-chloro[4-(3-chloromethylbenzyl)piperazine-1-yl]benzothiazole monohydrochloride (0.50 g; 1.27 mmol). The mixture was stirred at the same temperature for 14.5 hours and at 50° C. for 38 hours. Water and ethyl acetate were added to the reaction solution and extracted. The organic layer was washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure. The residue was purified by column chromatograph on silica gel (hexane:ethyl acetate=3:1) to give 2-{3-[4-(6-chlorobenzothiazole-2-yl)piperazine-1-ylmethyl]benzyl}diethyl malonate as colorless oil (0.38 g; 58%).



1H-NMR (DMSO-d6): δ1.10 (6H, t, J=7 Hz), 2.49 (4H, t, J=5 Hz), 3.08 (2H, d, J=8 Hz), 3.50 (2H, s), 3.56 (4H, t, J=5 Hz), 3.81 (1H, t, J=8 Hz), 4.06 (4H, q, J=7 Hz), 7.10-7.20 (3H, m), 7.24 (1H, d, J=7.5 Hz), 7.28 (1H, dd, J=8.5, 2 Hz), 7.42 (1H, d, J=8.5 Hz), 7.91 (1H, d, J=2 Hz).


Compounds in Examples 205 and 206 were obtained by similar methods as Example 204.


Example 205






Yield: 46%, 1H-NMR (CDCl3); δ1.26 (6H, t, J=7 Hz), 2.59 (4H, t, J=5 Hz), 3.38 (2H, d, J=7.5 Hz), 3.60-3.68 (5H, m), 3.69 (2H, s), 4.24 (4H, q, J=7 Hz), 6.68 (1H, d, J=3 Hz), 6.71 (1H, d, J=3 Hz), 7.25 (1H, dd, J=9, 2 Hz), 7.43 (1H, d, J=9 Hz), 7.55 (1H, d, J=2 Hz).


Example 206






Yield: 5%, 1H-NMR (CDCl3); δ1.21-1.32 (6H, m), 2.00-2.05 (2H, m), 2.70 (2H, t, J=5.4 Hz), 2.81-2.84 (2H, m), 3.36-3.38 (2H, m), 3.62-3.82 (7H, m), 4.14-4.24 (4H, m), 6.65-6.68 (2H, m), 7.22 (1H, dd, J=9.0, 1.8 Hz), 7.42 (1H, d, J=8.4 Hz), 7.54 (1H, d, J=1.8 Hz).


Reference Example 195
Preparation of 6-chloro-2-[4-(2-hydroxyethyl)piperidine-1-yl]benzothiazole






A mixture of 2,6-dichlorobenzothiazole (3.00 g; 14.7 mmol), 4-piperidine ethanol (2.09 g; 16.2 mmol), potassium carbonate (2.33 g; 16.2 mmol) and anhydrous N,N-dimethylformamide (15 ml) was stirred at room temperature for 16 hours. Water and ethyl acetate were added to the reaction solution. The organic layer was separated, washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure. The precipitate was washed with diisopropyl ether to give 6-chloro-2-[4-(2-hydroxyethyl)piperidine-1-yl]benzothiazole as green crystal (2.92 g; 67%).



1H-NMR (CDCl3): δ1.26-1.44 (3H, m), 1.57 (2H, q, J=6.5 Hz), 1.68-1.91 (3H, m), 3.06-3.19 (2H, m), 3.74 (2H, q, J=6.5 Hz), 4.07-4.17 (2H, m), 7.22 (1H, dd, J=8.5, 2.0 Hz), 7.42 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2.0 Hz).


Compounds in Reference Examples 196 to 211 were obtained by similar methods as Reference Example 195.


Reference Example 196






Yield: 64%, 1H-NMR (CDCl3); δ1.60-1.75 (3H, m), 1.95-2.18 (2H, m), 3.34-3.48 (2H, m), 3.87-4.10 (3H, m), 7.23 (1H, dd, J=8.5, 2 Hz), 7.43 (1H, d, J=8.5 Hz), 7.53 (1H, d, J=2 Hz).


Reference Example 197






Yield: 100%, 1H-NMR (DMSO-d6): δ1.15-1.25 (2H, m), 1.60-1.75 (1H, m), 1.75-1.85 (2H, m), 3.05-3.20 (2H, m), 3.25-3.30 (2H, m), 3.95-4.10 (2H, m), 4.56 (1H, brs), 7.27 (1H, dd, J=8.5, 2 Hz), 7.40 (1H, d, J=8.5 Hz), 7.88 (1H, d, J=2 Hz).


Reference Example 198






Yield: 95%, 1H-NMR (CDCl3); δ1.65 (1H, s), 2.60-2.67 (6H, m), 3.63-3.69 (6H, m), 7.23 (1H, d, J=8.5, 2.0 Hz), 7.44 (1H, d, J=8.5 Hz), 7.57 (1H, d, J=2.0 Hz).


Reference Example 199






Yield: 99%, 1H-NMR (CDCl3); δ2.00-2.07 (2H, m), 2.69 (2H, t, J=5.1 Hz), 2.76 (2H, t, J=5.4 Hz), 2.89-2.93 (2H, m), 2.96 (1H, s), 3.60 (2H, t, J=5.4 Hz), 3.73 (2H, t, J=6.0 Hz), 3.80-3.83 (2H, m), 7.24 (1H, dd, J=7.8, 2.1 Hz), 7.42 (1H, d, J=8.7 Hz), 7.55 (1H, d, J=2.1 Hz).


Reference Example 200






Yield: 48%, 1H-NMR (CDCl3); δ1.28-1.46 (2H, m), 1.58 (2H, q, J=6.5 Hz), 1.72-1.94 (3H, m), 3.11-3.24 (2H, m), 3.76 (2H, t, J=6.5 Hz), 4.11-4.22 (2H, m), 7.48-7.57 (2H, m), 7.83 (1H, s).


Reference Example 201






Yield: 70%, 1H-NMR (DMSO-d6): δ2.49 (2H, t, J=6 Hz), 2.57 (4H, t, J=5 Hz), 3.55 (2H, t, J=6 Hz), 3.62 (4H, t, J=5 Hz), 4.51 (1H, brs), 7.57 (2H, s), 8.25 (1H, s).


Reference Example 202






Yield: 85%, 1H-NMR (DMSO-d6): δ1.83-1.90 (2H, m), 2.55 (2H, t, J=5.5 Hz), 2.67 (2H, t, J=5 Hz), 2.87 (2H, t, J=5 Hz), 3.47 (2H, q, J=5.5 Hz), 3.60-3.80 (4H, m), 4.39 (1H, t, J=5.5 Hz), 7.55 (1H, s), 7.95 (1H, s), 8.21 (1H, s).


Reference Example 203






Yield: 63%, 1H-NMR (CDCl3); δ1.23-1.44 (3H, m), 1.53-1.63 (2H, m), 1.68-1.90 (3H, m), 3.08-3.20 (2H, m), 3.75 (2H, q, J=6.0 Hz), 4.08-4.18 (2H, m), 7.02 (1H, dd, J=8.5, 2.0 Hz), 7.46 (1H, d, J=8.5 Hz), 7.49 (1H, d, J=2.0 Hz).


Reference Example 204






Yield: 36%, 1H-NMR (CDCl3); δ1.25-1.45 (3H, m), 1.57 (2H, q, J=6.5 Hz), 1.70-1.91 (3H, m), 3.08-3.23 (2H, m), 3.75 (2H, t, J=6.5 Hz), 4.08-4.21 (2H, m), 7.04 (1H, dd, J=8.0, 1.0 Hz), 7.21 (1H, t, J=8.0 Hz), 7.39 (1H, dd, J=8.0, 1.0 Hz).


Reference Example 205






Yield: 52%, 1H-NMR (CDCl3); δ1.26 (1H, t, J=6.5 Hz), 1.27-1.44 (2H, m), 1.57 (2H, q, J=6.5 Hz), 1.68-1.91 (3H, m), 3.06-3.19 (2H, m), 3.75 (2H, q, J=6.5 Hz), 4.05-4.19 (2H, m), 7.35-7.40 (2H, m), 7.68 (1H, s).


Reference Example 206






Yield: 31%, 1H-NMR (CDCl3); δ1.22 (1H, t, J=5.0 Hz), 1.27-1.45 (2H, m), 1.57 (2H, q, J=5.0 Hz), 1.65-1.90 (3H, m), 2.38 (3H, s), 3.03-3.19 (2H, m), 3.75 (2H, q, J=5.0 Hz), 4.06-4.17 (2H, m), 7.08 (1H, d, J=8.0 Hz), 7.39 (1H, s), 7.42 (1H, d, J=8.0 Hz).


Reference Example 207






Yield: 9%, 1H-NMR (CDCl3); δ1.23-1.45 (3H, m), 1.52-1.64 (2H, m), 1.67-1.94 (3H, m), 3.40-3.22 (2H, m), 3.68-3.83 (2H, m), 4.03-4.17 (2H, m), 7.00 (1H, td, J=8.5, 2.5 Hz), 7.29 (1H, dd, J=8.5, 2.5 Hz), 7.40 (1H, dd, J=8.5, 4.0 Hz).


Reference Example 208






Yield: 48%, 1H-NMR (DMSO-d6): δ1.12-1.29 (2H, m), 1.40 (2H, q, J=6.5 Hz), 1.57-1.81 (3H, m), 2.95-3.10 (2H, m), 3.47 (2H, q, J=6.5 Hz), 3.84-3.97 (2H, m), 4.40 (1H, t, J=6.5 Hz), 7.20 (1H, t, J=7.5 Hz), 7.35 (2H, t, J=7.5 Hz), 7.44 (2H, d, J=7.5 Hz), 7.57 (1H, s).


Reference Example 209






Yield: 88%, 1H-NMR (CDCl3): δ1.14-1.32 (2H, m), 1.40 (2H, q, J=6.5 Hz), 1.54-1.83 (3H, m), 2.95-3.08 (2H, m), 3.47 (2H, q, J=6.5 Hz), 3.88-4.00 (2H, m), 4.40 (1H, t, J=6.5 Hz), 7.22 (1H, s), 7.27 (1H, t, J=7.5 Hz), 7.38 (2H, t, J=7.5 Hz), 7.87 (2H, d, J=7.5 Hz).


Reference Example 210






Yield: 71%, 1H-NMR (DMSO-d6): δ1.82-1.93 (2H, m), 2.55 (2H, t, J=6.0 Hz), 2.62-2.70 (2H, m), 2.78-2.86 (2H, m), 3.47 (2H, q, J=6.0 Hz), 3.59 (2H, t, J=6.0 Hz), 3.61-3.68 (2H, m), 4.38 (1H, t, J=6.0 Hz), 7.18 (1H, t, J=7.5 Hz), 7.34 (2H, t, J=7.5 Hz), 7.45 (2H, d, J=7.5 Hz), 7.57 (1H, s).


Reference Example 211






Yield: 93%, 1H-NMR (DMSO-d6): δ1.80-2.01 (2H, m), 2.57 (2H, t, J=6.0 Hz), 2.64-2.77 (2H, m), 2.82-2.96 (2H, m), 3.42-3.53 (2H, m), 3.45-3.94 (4H, br), 4.34-4.46 (1H, m), 7.45 (1H, d, J=7.0 Hz), 8.23 (1H, d, J=12.5 Hz).


Reference Example 212
Preparation of 6-chloro-2-[4-(2-chloroethyl)piperidine-1-yl]benzothiazole






To 6-chloro-2-[4-(2-hydroxyethyl)piperidine-1-yl]benzothiazole (1.20 g; 4.03 mmol) was added thionyl chloride (10 ml). The mixture was stirred at 60° C. for 1 hour. The reaction solution was poured into ice water. 5N aqueous sodium hydroxide was added thereto to neutralize and the precipitate was collected. The precipitate was washed with diisopropyl ether to give 6-chloro-2-[4-(2-chloroethyl)piperidine-1-yl]benzothiazole as colorless crystal (0.98 g; 77%).



1H-NMR (CDCl3): δ 1.25-1.44 (2H, m), 1.70-1.94 (5H, m), 3.08-3.22 (2H, m), 3.62 (2H, t, J=6.5 Hz), 4.07-4.20 (2H, m), 7.23 (1H, dd, J=8.5, 2.0 Hz), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2.0).


Compounds in Reference Examples 213 to 225 were obtained by similar methods as Reference Example 212.


Reference Example 213






Yield: q. y, 1H-NMR (DMSO-d6): δ1.20-1.42 (2H, m), 1.80-2.00 (3H, m), 3.10-3.25 (2H, m), 3.60 (2H, d, J=6.5 Hz), 4.00-4.10 (2H, m), 7.28 (1H, dd, J=8.5, 2 Hz), 7.41 (1H, d, J=8.5 Hz), 7.90 (1H, d, J=2 Hz).


Reference Example 214






Yield: 95%, 1H-NMR (CDCl3); δ2.63-2.72 (4H, m), 2.80 (2H, t, J=7.0 Hz), 3.58-3.73 (6H, m), 7.23 (1H, dd, J=8.5, 2.0 Hz), 7.44 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=2.0 Hz).


Reference Example 215






Yield: 58%, 1H-NMR (CDCl3); δ1.98-2.06 (2H, m), 2.78 (2H, t, J=5.4 Hz), 2.90-2.96 (4H, m), 3.56 (2H, t, J=7.2 Hz), 3.72 (2H, t, J=6.0 Hz), 3.78-3.81 (2H, m), 7.23 (1H, dd, J=8.4, 2.1 Hz), 7.42 (1H, d, J=8.4 Hz), 7.55 (1H, d, J=2.1 Hz).


Reference Example 216






Yield: 68%, 1H-NMR (CDCl3); δ1.25-1.43 (2H, m), 1.70-1.94 (5H, m), 3.08-3.22 (2H, m), 3.62 (2H, t, J=6.5 Hz), 4.08-4.22 (2H, m), 7.03 (1H, dd, J=8.5, 2.0 Hz), 7.46 (1H, d, J=8.5 Hz), 7.52 (1H, d, J=2.0 Hz).


Reference Example 217






Yield: 90%, 1H-NMR (CDCl3); δ1.26-1.44 (2H, m), 1.71-1.93 (5H, m), 3.08-3.23 (2H, m), 3.62 (2H, t, J=6.5 Hz), 4.10-4.22 (2H, m), 7.04 (1H, d, J=8.0 Hz), 7.22 (1H, t, J=8.0 Hz), 7.40 (1H, d, J=8.0 Hz).


Reference Example 218






Yield: 95%, 1H-NMR (CDCl3); δ1.25-1.43 (2H, m), 1.71-1.92 (5H, m), 3.07-3.23 (2H, m), 3.61 (2H, t, J=6.5 Hz), 4.06-4.21 (2H, m), 7.35-7.43 (2H, m), 7.69 (1H, s).


Reference Example 219






Yield: 65%, 1H-NMR (CDCl3); δ1.22-1.41 (2H, m), 1.68-1.90 (5H, m), 2.38 (3H, s), 3.02-3.18 (2H, m), 3.59 (2H, t, J=6.5 Hz), 4.05-4.18 (2H, m), 7.06-7.12 (1H, m), 7.36-7.39 (1H, m), 7.43 (1H, d, J=8.0 Hz).


Reference Example 220






Yield: 91%, 1H-NMR (CDCl3); δ1.27-1.45 (2H, m), 1.72-1.95 (5H, m), 3.12-3.27 (2H, m), 3.62 (2H, t, J=6.5 Hz), 4.12-4.26 (2H, m), 7.49-7.59 (2H, m), 7.84 (1H, s).


Reference Example 221






Yield: 42%, 1H-NMR (CDCl3); δ2.68 (4H, t, J=5 Hz), 2.81 (2H, t, J=7 Hz), 3.63 (2H, t, J=7 Hz), 3.71 (4H, t, J=5 Hz), 7.53 (1H, d, J=8.5 Hz), 7.58 (1H, d, J=8.5 Hz), 7.86 (1H, s).


Reference Example 222






Yield: 23%, 1H-NMR (CDCl3); δ1.94-2.07 (2H, m), 2.70-2.80 (2H, m), 2.83-2.99 (4H, m), 3.50-3.58 (2H, m), 3.64-3.88 (4H, m), 7.48-7.60 (2H, m), 7.84 (1H, s).


Reference Example 223






Yield: 89%, 1H-NMR (CDCl3); δ1.27-1.44 (2H, m), 1.72-1.88 (5H, m), 2.99-3.13 (2H, m), 3.62 (2H, t, J=6.5 Hz), 3.99-4.10 (2H, m), 7.17-7.24 (1H, m), 7.30-7.37 (2H, m), 7.38-7.45 (3H, m).


Reference Example 224






Yield: 35%, 1H-NMR (DMSO-d6): δ1.81-1.94 (2H, m), 2.66-2.76 (2H, m), 2.77-2.93 (4H, m), 3.55-3.72 (6H, m), 7.18 (1H, t, J=7.5 Hz), 7.34 (2H, t, J=7.5 Hz), 7.44 (2H, d, J=7.5 Hz), 7.57 (1H, s).


Reference Example 225






Yield: quant. %, 1H-NMR (CDCl3): δ1.95-2.10 (2H, m), 2.73-2.84 (2H, m), 2.85-3.01 (4H, m), 3.56 (2H, t, J=7.0 Hz), 3.66-3.89 (4H, m), 7.27 (1H, d, J=11.5 Hz), 7.75 (1H, d, J=7.0 Hz).


Reference Example 226
Preparation of 2-chloro-1-[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]ethane-1-on






To a mixture of 4-(6-chlorobenzothiazole-2-yl)piperazine dihydrochloride (0.50 g; 1.53 mmol), triethylamine (0.32 ml; 2.25 mmol) and anhydrous THF (10 ml) was added dropwise chloroacetylchloride (0.18 ml; 2.25 mmol) under ice-cooling. The mixture was stirred at room temperature for 24 hours. Water and ethyl acetate were added to the reaction solution and extracted. The organic layer was washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure. The precipitate was washed with hexane to give 2-chloro-1-[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]ethane-1-on as blackish brown crystal (0.15 g; 30%).



1H-NMR (CDCl3): δ3.61-3.81 (8H, m), 4.12 (2H, s), 7.28 (1H, dd, J=8.5, 2.0 Hz), 7.47 (1H, d, J=8.5 Hz), 7.60 (1H, d, J=2.0 Hz).


Reference Example 227
Preparation of [(6-chlorobenzothiazole-2-yl)piperidine-4-yl]methane sulfonate






To a mixture of 1-(6-chlorobenzothiazole-2-yl)piperidine-4-ol (1.43 g; 5.32 mmol), triethylamine (0.78 ml; 5.59 mmol) and anhydrous THF (30 ml) was added dropwise methanesulfonyl chloride (0.43 ml; 5.59 mmol) under ice-cooling. The mixture was stirred at room temperature for 30 minutes. The reaction solution was condensed under reduced pressure. Water was added to the residue, and the precipitate was collected to give [(6-chlorobenzothiazole-1-yl)piperidine-4-yl]methanesulfonate as pale blackish brown crystal (1.66 g; 90%).



1H-NMR (CDCl3): δ1.97-2.20 (4H, m), 3.08 (3H, s), 3.57-3.68 (2H, m), 3.80-3.91 (2H, m), 4.97-5.08 (1H, m), 7.25 (1H, dd, J=8.5, 2.0 Hz), 7.44 (1H, d, J=8.5 Hz), 7.57 (1H, d, J=2.0 Hz).


Example 207
3-{2-[1-(6-chlorobenzothiazole-2-yl)piperidine-4-yl]ethoxy}ethyl benzoate






A mixture of 6-chloro-2-[4-(2-chloroethyl)piperidine-1-yl]benzothiazole (0.50 g; 1.59 mmol), cesium carbonate (0.78 g; 2.39 mmol), 3-hydroxy ethyl benzoate (0.40 g; 2.39 mmol) and anhydrous N,N-dimethylformamide (5 ml) was stirred at 60° C. for 9 hours. The reaction solution was returned to room temperature. Water and ethyl acetate was added thereto and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure. The residue was purified by column chromatograph on silica gel (methylene chloride) to give 3-{2-[1-(6-chlorobenzothiazole-2-yl)piperidine-4-yl]ethoxy}ethyl benzoate as colorless crystal (0.43 g; 62%).



1H-NMR (CDCl3): δ1.30-1.51 (5H, m), 1.74-1.97 (5H, m), 3.09-3.22 (2H, m), 4.04-4.18 (4H, m), 4.38 (2H, q, J=7.0 Hz), 7.09 (1H, dd, J=8.0, 1.5 Hz), 7.23 (1H, dd, J=8.5, 2.0 Hz), 7.35 (1H, t, J=8.0 Hz), 7.42 (1H, d, J=8.5 Hz), 7.52-7.58 (2H, m), 7.65 (1H, dd, J=8.0, 1.5 Hz).


Compounds in Examples 208 to 253 were obtained by similar methods as Example 207.


Example 208






Yield: 39%, 1H-NMR (CDCl3); δ1.40 (3H, t, J=7.0 Hz), 1.92-2.16 (4H, m), 3.60-3.72 (2H, m), 3.80-3.92 (2H, m), 4.38 (2H, q, J=7.0 Hz), 4.65-4.74 (1H, m), 7.13 (1H, m), 7.24 (1H, dd, J=8.5, 2.0 Hz), 7.37 (1H, t, J=8.0 Hz), 7.44 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=2.0 Hz), 7.58-7.63 (1H, m), 7.67 (1H, m).


Example 209






Yield: 16%, 1H-NMR (CDCl3); δ1.26 (3H, t, J=7.0 Hz), 1.90-2.12 (4H, m), 3.56-3.70 (4H, m), 3.78-3.90 (2H, m), 4.16 (2H, q, J=7.0 Hz), 4.61 (1H, m), 6.80-6.93 (3H, m), 7.20-7.28 (2H, m), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2.0 Hz).


Example 210






Yield: 39%, 1H-NMR (CDCl3); δ1.34 (3H, t, J=7 Hz), 1.45-1.65 (2H, m), 1.95-2.10 (2H, m), 2.10-2.25 (1H, m), 3.10-3.30 (2H, m), 3.92 (2H, d, J=6 Hz), 4.15-4.25 (2H, m), 4.32 (2H, q, J=7 Hz), 6.93 (1H, d, J=7.5 Hz), 6.98 (1H, td, J=7.5, 1 Hz), 7.24 (1H, dd, J=8.5, 2 Hz), 7.43 (1H, d, J=8.5 Hz), 7.46 (1H, td, J=7.5, 1 Hz), 7.55 (1H, d, J=2 Hz), 7.80 (1H, dd, J=7.5, 1 Hz).


Example 211






Yield: 39%, 1H-NMR (CDCl3); δ1.40 (3H, t, J=7 Hz), 1.45-1.60 (2H, m), 1.95-2.05 (2H, m), 2.05-2.20 (1H, m), 3.10-3.25 (2H, m), 3.90 (2H, d, J=6 Hz), 4.15-4.25 (2H, m), 4.37 (2H, q, J=7 Hz), 7.09 (1H, dd, J=8, 1.5 Hz), 7.23 (1H, dd, J=8.5, 2 Hz), 7.34 (1H, t, J=8 Hz), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=1.5 Hz), 7.56 (1H, d, J=2 Hz), 7.64 (1H, dd, J=8, 1.5 Hz)


Example 212






Yield: 52%, 1H-NMR (CDCl3); δ1.38 (3H, t, J=7 Hz), 1.45-1.60 (2H, m), 1.90-2.05 (2H, m), 2.05-2.20 (1H, m), 3.10-3.25 (2H, m), 3.90 (2H, d, J=6 Hz), 4.10-4.25 (2H, m), 4.35 (2H, q, J=7 Hz), 6.89 (2H, d, J=9 Hz), 7.24 (1H, dd, J=8.5, 2 Hz), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz), 7.99 (2H, d, J=9 Hz).


Example 213






Yield: 63%, 1H-NMR (DMSO-d6): δ1.25-1.45 (2H, m), 1.70-1.85 (1H, m), 1.85-2.00 (2H, m), 3.03 (2H, d, J=7 Hz), 3.08-3.24 (2H, m), 3.86 (3H, s), 3.95-4.10 (2H, m), 7.27 (1H, dd, J=8.5, 2 Hz), 7.40 (1H, d, J=8.5 Hz), 7.48 (1H, t, J=8 Hz), 7.64 (1H, d, J=8 Hz), 7.75 (1H, d, J=8 Hz), 7.84 (1H, s), 7.88 (1H, d, J=2 Hz).


Example 214






Yield: 79%, 1H-NMR (CDCl3); δ1.30-1.50 (2H, m), 1.75-2.00 (1H, m), 1.95-2.05 (2H, m), 2.89 (2H, d, J=7 Hz), 3.05-3.18 (2H, m), 3.60 (2H, s), 3.70 (3H, s), 4.05-4.20 (2H, m), 7.20-7.30 (5H, m), 7.42 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2 Hz).


Example 215






Yield: 86%, 1H-NMR (CDCl3); δ1.25-1.50 (5H, m), 1.77-2.00 (5H, m), 3.06-3.23 (2H, m), 4.05-4.20 (4H, m), 4.35 (2H, q, J=7.0 Hz), 6.93-7.04 (2H, m), 7.22 (1H, dd, J=8.5, 2.0 Hz), 7.37-7.49 (2H, m), 7.54 (1H, d, J=2.0 Hz), 7.78 (1H, dd, J=8.0, 1.5 Hz).


Example 216






Yield: 65%, 1H-NMR (CDCl3); δ1.34-1.53 (5H, m), 1.76-1.98 (5H, m), 3.09-3.24 (2H, m), 4.06-4.23 (4H, m), 4.35 (2H, q, J=7.0 Hz), 6.91 (2H, d, J=8.5 Hz), 7.23 (1H, dd, J=8.5, 2.0 Hz), 7.42 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2.0 Hz), 8.00 (2H, d, J=8.5 Hz).


Example 217






Yield: 72%, 1H-NMR (CDCl3); δ1.40 (3H, t, J=7.0 Hz), 1.33-1.52 (2H, m), 1.79-1.98 (5H, m), 2.27 (3H, s), 3.08-3.21 (2H, m), 4.07-4.18 (4H, m), 4.37 (2H, q, J=7.0 Hz), 7.19 (1H, dd, J=7.5, 1.5 Hz), 7.23 (1H, dd, J=8.5, 2.0 Hz), 7.42 (1H, d, J=8.5 Hz), 7.47 (1H, d, J=1.5 Hz), 7.55 (1H, d, J=2.0 Hz), 7.57 (1H, dd, J=7.5, 1.5 Hz).


Example 218






Yield: 46%, 1H-NMR (CDCl3); δ1.24 (3H, t, J=7.0 Hz), 1.23-1.44 (2H, m), 1.67-1.92 (5H, m), 3.02-3.16 (2H, m), 3.57 (2H, s), 3.98 (2H, t, J=6.0 Hz), 4.02-4.15 (2H, m), 4.14 (2H, q, J=7.0 Hz), 6.75-6.90 (3H, m), 7.16-7.26 (2H, m), 7.41 (1H, d, J=8.5 Hz), 7.51 (1H, d, J=2.0 Hz).


Example 219






Yield: 17%, 1H-NMR (CDCl3); δ1.23-1.44 (2H, m), 1.67-1.90 (5H, m), 3.02-3.16 (2H, m), 3.55 (2H, s), 3.67 (3H, s), 3.98 (2H, t, J=6.0 Hz), 4.02-4.14 (2H, m), 6.84 (2H, d, J=8.5 Hz), 7.18 (2H, d, J=8.5 Hz), 7.20 (1H, dd, J=8.5, 2.0 Hz), 7.40 (1H, d, J=8.5 Hz), 7.51 (1H, d, J=2.0).


Example 220






Yield: 58%, 1H-NMR (CDCl3); δ1.23 (3H, t, J=7.0 Hz), 1.33-1.50 (2H, m), 1.74-1.96 (5H, m), 2.60 (2H, t, J=8.0 Hz), 2.95 (2H, t, J=8.0 Hz), 3.08-3.22 (2H, m), 4.02-4.19 (6H, m), 6.83 (1H, d, J=7.5 Hz), 6.88 (1H, td, J=7.5, 1.0 Hz), 7.14-7.20 (2H, m), 7.23 (1H, dd, J=8.5, 2.0 Hz), 7.42 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2.0 Hz).


Example 221






Yield: 71%, 1H-NMR (CDCl3); δ1.24 (3H, t, J=7.0 Hz), 1.31-1.49 (2H, m), 1.73-1.95 (5H, m), 2.62 (2H, t, J=8.0 Hz), 2.93 (2H, t, J=8.0 Hz), 3.08-3.21 (2H, m), 4.02 (2H, t, J=6.0 Hz), 4.07-4.20 (2H, m), 4.13 (2H, q, J=7.0 Hz), 6.71-6.84 (3H, m), 7.16-7.25 (2H, m), 7.42 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2.0 Hz).


Example 222






Yield: 58%, 1H-NMR (CDCl3); δ1.30-1.47 (2H, m), 1.72-1.95 (5H, m), 2.60 (2H, t, J=8.0 Hz), 2.90 (2H, t, J=8.0 Hz), 3.08-3.20 (2H, m), 3.67 (3H, s), 4.01 (2H, t, J=6.0 Hz), 4.06-4.18 (2H, m), 6.82 (2H, d, J=8.5 Hz), 7.12 (2H, d, J=8.5 Hz), 7.23 (1H, dd, J=8.5, 2.0 Hz), 7.42 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2.0 Hz).


Example 223






Yield: 58%, 1H-NMR (CDCl3); δ1.24-1.43 (2H, m), 1.61-1.92 (5H, m), 2.97-3.20 (4H, m), 3.93 (3H, s), 4.06-4.18 (2H, m), 7.23 (1H, dd, J=8.5, 2.0 Hz), 7.36 (1H, t, J=7.5 Hz), 7.41 (1H, d, J=8.5 Hz), 7.49 (1H, dt, J=7.5, 1.5 Hz), 7.54 (1H, d, J=2.0 Hz), 7.84 (1H, dt, J=7.5, 1.5 Hz), 7.98 (1H, t, J=1.5 Hz).


Example 224






Yield: 45%, 1H-NMR (DMSO-d6): δ1.12-1.30 (2H, m), 1.50-1.61 (2H, m), 1.65-1.86 (3H, m), 2.96-3.21 (4H, m), 3.61 (3H, s), 3.67 (2H, s), 3.94-4.07 (2H, m), 7.06 (1H, d, J=7.0 Hz), 7.18-7.32 (4H, m), 7.39 (1H, d, J=8.5 Hz), 7.88 (1H, d, J=2.0 Hz).


Example 225






Yield: 50%, 1H-NMR (CDCl3): δ1.26 (3H, t, J=7.2 Hz), 1.39-1.46 (2H, m), 1.73-1.80 (1H, m), 1.89 (3H, d, J=12.3 Hz), 2.31 (3H, s), 3.54 (3H, s), 4.01 (2H, t, J=6.0 Hz), 4.05-4.15 (2H, m), 4.15 (2H, q, J=7.2 Hz), 4.10-4.12 (2H, m), 6.58-6.67 (2H, m), 6.69 (1H, m), 7.22 (1H, dd, J=8.7, 2.1 Hz), 7.42 (1H, d, J=8.7 Hz), 7.54 (1H, d, J=2.1 Hz).


Example 226






Yield: 53%, 1H-NMR (CDCl3); δ1.26 (3H, t, J=7.0 Hz), 1.31-1.51 (2H, m), 1.76-1.98 (5H, m), 3.07-3.23 (2H, m), 3.57 (2H, s), 4.04-4.20 (6H, m), 6.81 (1H, dd, J=7.5, 1.5 Hz), 6.87 (1H, d, J=1.5 Hz), 7.19-7.34 (2H, m), 7.42 (1H, d, J=8.5 Hz), 7.53 (1H, d, J=2.0 Hz).


Example 227






Yield: 93%, 1H-NMR (CDCl3); δ1.26 (3H, t, J=7 Hz), 1.30-1.50 (1H, m), 1.75-2.00 (4H, m), 3.05-3.23 (2H, m), 3.55 (2H, s), 4.05-4.15 (6H, m), 4.18 (2H, q, J=7 Hz), 6.75-6.85 (1H, m), 6.91 (1H, dd, J=8, 2 Hz), 6.92 (1H, dd, J=11, 2 Hz), 7.22 (1H, dd, J=8.5, 2 Hz), 7.42 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2 Hz).


Example 228






Yield: 67%, 1H-NMR (CDCl3); δ1.39 (3H, t, J=7.0 Hz), 2.77 (4H, t, J=5.0 Hz), 2.93 (2H, t, J=5.5 Hz), 3.65 (4H, t, J=5.0 Hz), 4.21 (2H, t, J=5.5 Hz), 4.35 (2H, q, J=7.0 Hz), 6.98 (1H, d, J=7.5 Hz), 7.00 (1H, t, J=7.5 Hz), 7.24 (1H, dd, J=8.5, 2.0 Hz), 7.44 (1H, d, J=8.5 Hz), 7.46 (1H, t, J=7.5 Hz), 7.56 (1H, d, J=2.0 Hz), 7.79 (1H, dd, J=7.5, 2.0 Hz).


Example 229






Yield: 76%, 1H-NMR (CDCl3); δ1.40 (3H, t, J=7.0 Hz), 2.73 (4H, t, J=5.0 Hz), 2.90 (2H, t, J=5.5 Hz), 3.67 (4H, t, J=5.0 Hz), 4.19 (2H, t, J=5.5 Hz), 4.38 (2H, q, J=7.0 Hz), 7.11 (1H, dd, J=8.0, 2.5 Hz), 7.24 (1H, dd, J=8.5, 2.0 Hz), 7.35 (1H, t, J=8.0 Hz), 7.44 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=2.0 Hz), 7.58 (1H, s), 7.66 (1H, dd, J=8.0, 2.5 Hz).


Example 230






Yield: 82%, 1H-NMR (CDCl3); δ1.38 (3H, t, J=7.0 Hz), 2.73 (4H, t, J=5.0 Hz), 2.90 (2H, t, J=5.5 Hz), 3.66 (4H, t, J=5.0 Hz), 4.19 (2H, t, J=5.5 Hz), 4.35 (2H, q, J=7.0 Hz), 6.93 (2H, d, J=9.0 Hz), 7.24 (1H, dd, J=8.5, 2.0 Hz), 7.43 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=2.0 Hz), 8.00 (2H, d, J=9.0 Hz).


Example 231






Yield: 18%, 1H-NMR (CDCl3); δ1.27-1.48 (2H, m), 1.64-1.95 (5H, m), 3.05-3.19 (2H, m), 3.84 (3H, s), 4.06-4.19 (4H, m), 6.22 (1H, d, J=4.0 Hz), 7.22 (1H, dd, J=8.5, 2.0 Hz), 7.42 (1H, d, J=8.5 Hz), 7.51-7.27 (2H, m).


Example 232






Yield: 46%, 1H-NMR (CDCl3); δ1.26 (3H, t, J=7.0 Hz), 2.72 (4H, t, J=5.0 Hz), 2.87 (2H, t, J=5.5 Hz), 3.58 (2H, s), 3.66 (4H, t, J=5.0 Hz), 4.14 (2H, t, J=5.5 Hz), 4.15 (2H, q, J=7.0 Hz), 6.79-6.91 (3H, m), 7.23 (1H, d, J=8.0 Hz), 7.24 (1H, dd, J=8.5, 2.0 Hz), 7.44 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=2.0 Hz).


Example 233






Yield: 81%, 1H-NMR (CDCl3); δ1.32-1.51 (5H, m), 1.74-1.99 (5H, m), 3.11-3.27 (2H, m), 4.04-4.24 (4H, m), 4.38 (2H, q, J=7.0 Hz), 7.06-7.13 (1H, m), 7.35 (1H, t, J=8.0 Hz), 7.48-7.57 (3H, m), 7.65 (1H, d, J=8.0 Hz), 7.84 (1H, s).


Example 234






Yield: 58%, 1H-NMR (CDCl3); δ1.26 (3H, t, J=7.0 Hz), 1.31-1.50 (2H, m), 1.72-1.98 (5H, m), 3.12-3.25 (2H, m), 3.59 (2H, s), 4.04 (2H, t, J=6.0 Hz), 4.10-4.24 (4H, m), 6.77-6.91 (3H, m), 7.23 (1H, t, J=7.5 Hz), 7.48-7.59 (2H, m), 7.84 (1H, s).


Example 235






Yield: 51%, 1H-NMR (DMSO-d6): δ1.26 (3H, t, J=7 Hz), 2.20 (3H, s), 2.77 (4H, t, J=5 Hz), 2.92 (2H, t, J=5.5 Hz), 3.56 (2H, s), 3.70 (4H, t, J=5 Hz), 4.13 (2H, t, J=5.5 Hz), 4.16 (2H, q, J=7 Hz), 6.75-6.80 (2H, m), 7.08 (1H, d, J=7 Hz), 7.52 (1H, dd, J=8.5, 1.5 Hz), 7.55 (1H, d, J=8.5 Hz), 7.85 (1H, d, J=0.5 Hz).


Example 236






Yield: 49%, 1H-NMR (CDCl3); δ1.26 (3H, t, J=7.0 Hz), 1.32-1.51 (2H, m), 1.78-2.00 (5H, m), 3.12-3.27 (2H, m), 3.57 (2H, s), 4.05-4.24 (6H, m), 6.81 (1H, dd, J=8.0, 2.0 Hz), 6.87 (1H, d, J=2.0 Hz), 7.30 (1H, d, J=8.0 Hz), 7.47-7.59 (2H, m), 7.83 (1H, s).


Example 237






Yield: 39%, 1H-NMR (CDCl3); δ1.27 (3H, t, J=7.0 Hz), 1.30-1.48 (2H, m), 1.72-1.94 (5H, m), 3.08-3.21 (2H, m), 3.72 (2H, s), 3.97-4.04 (2H, m), 4.07-4.19 (2H, m), 4.19 (2H, q, J=7.0 Hz), 6.76 (1H, dd, J=8.5, 3.0 Hz), 6.84 (1H, d, J=3.0 Hz), 7.23 (1H, dd, J=8.5, 2.0 Hz), 7.27 (1H, d, J=8.5 Hz), 7.42 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2.0 Hz).


Example 238






Yield: 69%, 1H-NMR (CDCl3); δ2.00-2.08 (2H, m), 2.84 (2H, t, J=8.4 Hz), 2.96-3.02 (4H, m), 3.59 (2H, s), 3.69 (3H, s), 3.73 (2H, t, J=6.0 Hz), 3.79-3.84 (2H, m), 4.07 (2H, t, J=5.4 Hz), 6.79-6.88 (3H, m), 7.20-7.27 (2H, m), 7.43 (1H, d, J=8.4 Hz), 7.55 (1H, d, J=2.1 Hz).


Example 239






Yield: 49%, 1H-NMR (CDCl3); δ1.25 (3H, t, J=0.7 Hz), 1.98-2.08 (2H, m), 2.18 (3H, s), 2.82-2.90 (2H, m), 2.98-3.05 (4H, m), 3.55 (2H, s), 3.73 (2H, t, J=5.5 Hz), 3.75-3.85 (2H, m), 4.05-4.10 (2H, m), 4.15 (2H, q, J=7 Hz), 6.74 (1H, s), 6.76 (1H, d, J=7.5 Hz), 7.07 (1H, d, 7.5 Hz), 7.22 (1H, dd, J=8.5, 2 Hz), 7.43 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2 Hz).


Example 240






Yield: 45%, 1H-NMR (CDCl3); δ1.25 (3H, t, J=7 Hz), 1.95-2.10 (2H, m), 2.88 (2H, t, J=5.5 Hz), 3.00-3.10 (4H, m), 3.55 (2H, s), 3.73 (2H, t, J=5.5 Hz), 3.75-3.85 (2H, m), 4.10-4.15 (2H, m), 4.15 (2H, q, J=7 Hz), 6.80 (1H, dd, J=8, 2 Hz), 6.85 (1H, d, J=2 Hz), 7.22 (1H, dd, J=8.5, 2.5 Hz), 7.29 (1H, d, J=8 Hz), 7.42 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2.5 Hz).


Example 241






Yield: 74%, 1H-NMR (CDCl3); δ1.25 (3H, t, J=7.0 Hz), 1.20-2.11 (2H, m), 2.79-2.90 (2H, m), 2.93-3.06 (4H, m), 3.57 (2H, s), 3.69-3.90 (4H, m), 4.04-4.12 (2H, m), 4.15 (2H, q, J=7.0 Hz), 6.76-6.90 (3H, m), 7.22 (1H, t, J=8.0 Hz), 7.48-7.59 (2H, m), 7.84 (1H, s).


Example 242






Yield: 42%, 1H-NMR (CDCl3); δ1.25 (3H, t, J=7.0 Hz), 1.99-2.09 (2H, m), 2.86-2.94 (2H, m), 3.02-3.12 (4H, m), 3.55 (2H, s), 3.69-3.90 (4H, m), 4.10-4.20 (4H, m), 6.81 (1H, dd, J=8.0, 2.0 Hz), 6.87 (1H, d, J=2.0 Hz), 7.29 (1H, d, J=8.0 Hz), 7.48-7.59 (2H, m), 7.84 (1H, s).


Example 243






Yield: 51%, 1H-NMR (CDCl3); δ1.31-1.49 (5H, m), 1.75-1.96 (5H, m), 3.09-3.22 (2H, m), 4.05-4.19 (4H, m), 4.38 (2H, q, J=7.0 Hz), 7.02 (1H, dd, J=8.0, 2.0 Hz), 7.09 (1H, ddd, J=8.0, 2.5, 1.0 Hz), 7.35 (1H, t, J=8.0 Hz), 7.47 (1H, d, J=8.0 Hz), 7.50 (1H, d, J=2.0 Hz), 7.56 (1H, dd, J=2.5, 1.5 Hz), 7.65 (1H, dt, J=8.0, 1.5, 1.0 Hz).


Example 244






Yield: 44%, 1H-NMR (CDCl3); δ1.26 (3H, t, J=6.5 Hz), 130-1.48 (2H, m), 1.72-1.95 (5H, m), 3.08-3.21 (2H, m), 3.58 (2H, s), 4.03 (2H, t, J=6.0 Hz), 4.08-4.21 (2H, m), 4.15 (2H, q, J=6.5 Hz), 6.76-6.90 (3H, m), 7.02 (1H, dd, J=8.5, 2.0 Hz), 7.22 (1H, d, J=7.5 Hz), 7.47 (1H, d, J=8.5 Hz), 7.50 (1H, d, J=2.0 Hz).


Example 245






Yield: 57%, 1H-NMR (CDCl3); δ1.26 (3H, t, J=7.0 Hz), 1.31-1.48 (2H, m), 1.71-1.96 (5H, m), 3.09-3.22 (2H, m), 3.58 (2H, s), 4.03 (2H, t, J=6.0 Hz), 4.09-4.21 (4H, m), 6.77-6.91 (3H, m), 7.03 (1H, dd, J=8.0, 1.0 Hz), 7.17-7.28 (2H, m), 7.40 (1H, dd, J=8.0, 1.0 Hz).


Example 246






Yield: 81%, 1H-NMR (CDCl3); δ1.32-1.50 (5H, m), 1.75-1.95 (5H, m), 3.09-3.21 (2H, m), 4.05-4.18 (4H, m), 4.38 (2H, q, J=7.0 Hz), 7.06-7.12 (1H, m), 7.32-7.39 (3H, m), 7.54-7.58 (1H, m), 7.62-7.67 (1H, m), 7.67-7.69 (1H, m).


Example 247






Yield: 44%, 1H-NMR (CDCl3); δ1.26 (3H, t, J=7.0 Hz), 1.31-1.48 (2H, m), 1.73-1.96 (5H, m), 3.08-3.20 (2H, m), 3.58 (2H, s), 4.00-4.18 (4H, m), 4.16 (2H, q, J=7.0 Hz), 6.78-6.90 (3H, m), 7.20-7.28 (1H, m), 7.36 (2H, m), 7.69 (1H, m).


Example 248






Yield: 48%, 1H-NMR (CDCl3); δ1.26 (3H, t, J=7.0 Hz), 1.30-1.49 (2H, m), 1.72-1.95 (5H, m), 2.39 (3H, s), 3.06-3.19 (2H, m), 3.58 (2H, s), 3.98-4.21 (6H, m), 6.77-6.91 (3H, m), 7.06-7.12 (1H, m), 7.23 (1H, t, J=7.5 Hz), 7.37-7.47 (2H, m).


Example 249






Yield: 54%, 1H-NMR (CDCl3); δ1.25 (3H, t, J=7.0 Hz), 3.56-3.82 (10H, m), 4.14 (2H, q, J=7.0 Hz), 4.74 (2H, s), 6.83-6.96 (3H, m), 7.22-7.29 (2H, m), 7.45 (1H, d, J=8.5 Hz), 7.58 (1H, d, J=2.0 Hz).


Example 250






Yield: 49%, 1H-NMR (CDCl3); δ1.26 (3H, t, J=7.0 Hz), 1.31-1.50 (2H, m), 1.73-1.93 (5H, m), 2.99-3.12 (2H, m), 3.58 (2H, s), 3.98-4.09 (4H, m), 4.15 (2H, q, J=7.0 Hz), 6.78-6.90 (3H, m), 7.16-7.47 (7H, m).


Example 251






Yield: 54%, 1H-NMR (CDCl3); δ1.26 (3H, t, J=7.0 Hz), 1.35-1.52 (2H, m), 1.78-1.97 (5H, m), 3.01-3.14 (2H, m), 3.58 (2H, s), 3.99-4.21 (6H, m), 6.81 (1H, dd, J=8.0, 2.0 Hz), 6.87 (1H, d, J=2.0 Hz), 7.16-7.24 (1H, m), 7.27-7.37 (3H, m), 7.38-7.47 (3H, m).


Example 252






Yield: 58%, 1H-NMR (DMSO-d6): δ1.18 (3H, t, J=7.0 Hz), 1.83-1.95 (2H, m), 2.74-2.84 (2H, m), 2.89-3.01 (4H, m), 3.56-3.72 (6H, m), 4.08 (2H, q, J=7.0 Hz), 4.09-4.17 (2H, m), 6.84 (1H, dd, J=8.0, 1.5 Hz), 7.09 (1H, d, J=1.5 Hz), 7.18 (1H, t, J=7.5 Hz), 7.29-7.38 (3H, m), 7.44 (2H, d, J=7.5 Hz), 7.57 (1H, s).


Example 253






Yield: 31%, 1H-NMR (CDCl3): δ1.24 (3H, t, J=7.0 Hz), 1.95-2.08 (2H, m), 2.88 (2H, t, J=5.5 Hz), 2.98-3.12 (4H, m), 3.55 (2H, s), 3.60-3.90 (4H, m), 4.06-4.19 (4H, m), 6.79 (1H, dd, J=8.0, 1.5 Hz), 6.86 (1H, d, J=1.5 Hz), 7.25 (1H, d, J=12.0 Hz), 7.27 (1H, d, J=8.0 Hz), 7.72 (1H, d, J=7.0 Hz).


Example 254
Preparation of 3-{2-[(6-chlorobenzothiazole-2-yl)piperidine-4-yl]ethoxy}-2-methylphenyl ethyl acetate






To a mixture of 6-chloro-2-[4-(2-hydroxyethyl)piperidine-1-yl]benzothiazole (0.17 g; 0.562 mmol), [3-hydroxy-2-methyl]phenyl ethyl acetate described in Reference Example 67 of WO2004/0225 (510.11 g; 0.552 mmol), 1,1-azodicarbonyldipiperidine (0.21 g; 0.844 mmol) and anhydrous THF (6 ml) was added dropwise tributyl phosphine (0.21 ml; 0.841 mmol) under argon and ice-cooling. After stirring the reaction solution at the same temperature for 2.5 hours, water and ethyl acetate were added thereto. The organic layer was separated, washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure. The residue was purified by column chromatograph on silica gel (hexane:ethyl acetate=10:1→5:1) to give 3-{2-[(6-chlorobenzothiazole-2-yl)piperidine-4-yl]ethoxy}-2-methylphenyl ethyl acetate as colorless oil (0.16 g; 59%).



1H-NMR (CDCl3): δ1.26 (3H, t, J=7.2 Hz), 1.38-1.47 (2H, m), 1.78-1.93 (5H, m), 2.18 (3H, s), 3.14 (2H, td, J=12.6, 2.4 Hz), 3.64 (2H, s), 4.02 (2H, t, J=5.7 Hz), 4.10-4.16 (2H, m), 4.15 (2H, t, J=7.2 Hz), 6.80 (2H, q, J=7.8 Hz), 7.11 (1H, t, J=7.8 Hz), 7.23 (1H, dd, J=8.4, 1.8 Hz), 7.42 (1H, d, J=8.4 Hz), 7.54 (1H, d, J=1.8 Hz).


Compounds in Examples 255 and 256 were obtained by similar methods as Example 254.


Example 255






Yield: 39%, 1H-NMR (CDCl3); δ1.26 (3H, t, J=7.0 Hz), 1.28-1.50 (2H, m), 1.70-1.98 (5H, m), 3.04-3.21 (2H, m), 3.58 (2H, s), 3.97-4.22 (4H, m), 4.15 (2H, q, J=7.0 Hz), 6.75-6.92 (3H, m), 7.00 (1H, td, J=9.0, 3.0 Hz), 7.23 (1H, t, J=8.0 Hz), 7.29 (1H, dd, J=9.0, 3.0 Hz), 7.44 (1H, dd, J=9.0, 5.0 Hz).


Example 256






Yield: 22%, 1H-NMR (CDCl3): δ1.24 (3H, t, J=7.0 Hz), 1.26-1.50 (2H, m), 1.68-1.92 (5H, m), 2.94-3.09 (2H, m), 3.58 (2H, m), 3.94-4.13 (4H, m), 4.14 (2H, q, J=7.0 Hz), 6.72 (1H, s), 6.75-6.93 (3H, m), 7.24 (2H, m), 7.35 (2H, t, J=7.0 Hz), 7.83 (2H, d, J=7.0 Hz).


Example 257
Preparation of 3-{2-[(6-phenylbenzothiazole-2-yl)piperidine-4-yl]ethoxy}phenyl ethyl acetate






A mixture of 3-{2-[(6-bromobenzothiazole-2-yl)piperidine-4-yl]ethoxy}phenyl ethyl acetate (0.30 g; 0.596 mmol), phenylboronic acid (0.09 g; 0.775 mmol), tetrakis (triphenylphosphine) palladium (0) (0.03 g; 0.03 mmol), cesium carbonate (0.25 g; 0.775 mmol) and dioxane (3 ml) was refluxed under argon for 3 hours. The reaction solution was cooled to room temperature and condensed under reduced pressure. The residue was purified by column chromatograph on silica gel (hexane:ethyl acetate=3:1) to give 3-{2-[(6-phenylbenzothiazole-2-yl)piperidine-4-yl]ethoxy}phenyl ethyl acetate as colorless crystal (0.08 g; 26%).


1H-NMR (CDCl3): δ 1.25 (3H, t, J=7.0 Hz), 1.28-1.48 (2H, m), 1.66-1.96 (5H, m), 3.04-3.21 (2H, m), 3.57 (2H, s), 3.94-4.07 (2H, m), 4.08-4.25 (4H, m), 6.73-6.92 (3H, m), 7.17-7.34 (2H, m), 7.36-7.47 (2H, m), 7.48-7.64 (4H, m), 7.79 (1H, d, J=2.0 Hz).


Example 258
Preparation of 3-{[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl}-5-methylphenol






A mixture of acetic acid 3-{[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl}-5-methylphenyl ester (1.97 g; 4.88 mmol), 2N-aqueous sodium hydroxide (10 ml) and methanol (20 ml) was stirred at 40° C. for 1 hour. The solvent was evaporated under reduced pressure. To the residue were added water and 2N-aqueous hydrochloric acid to be neutral. Ethyl acetate was added thereto and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure. The residue was purified by column chromatograph on silica gel (ethyl acetate) to give 3-{[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl}-5-methylphenol as colorless amorphous solid (1.83 g; 100%).



1H-NMR (CDCl3): δ2.29 (3H, s), 2.57 (4H, t, J=5 Hz), 3.47 (2H, s), 3.67 (4H, t, J=5 Hz), 6.59 (1H, s), 6.67 (2H, s), 7.23 (1H, dd, J=8.5, 2 Hz), 7.45 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Compounds in Examples 259 to 286 were obtained by similar methods as Example 258.


Example 259






Yield: 85%, 1H-NMR (CDCl3); δ1.74 (1H, brs), 1.96-2.05 (2H, m), 2.26 (3H, s), 2.67 (2H, t, J=5.1 Hz), 2.75-2.79 (2H, m), 3.52 (2H, s), 3.68-3.74 (4H, m), 6.55 (1H, s), 6.61 (1H, s), 6.65 (1H, s), 7.22 (1H, dd, J=8.7, 2.1 Hz), 7.43 (1H, d, J=8.4 Hz), 7.54 (1H, d, J=2.1 Hz).


Example 260






Yield: 100%, 1H-NMR (CDCl3); δ2.29 (3H, s), 2.61 (4H, t, J=5 Hz), 3.50 (2H, s), 3.71 (4H, t, J=5 Hz), 6.60 (1H, s), 6.69 (2H, s), 7.52 (1H, d, J=7.5 Hz), 7.58 (1H, d, J=7.5 Hz), 7.85 (1H, s).


Example 261






Yield: 71%, 1H-NMR (CDCl3); δ2.00-2.10 (2H, m), 2.28 (3H, s), 2.65-2.75 (2H, m), 2.80-2.90 (2H, m), 3.57 (2H, s), 3.70-3.90 (4H, m), 6.56 (1H, s), 6.65-6.70 (2H, m), 7.45-7.60 (2H, m), 7.85 (1H, s).


Example 262






Yield: 99%, 1H-NMR (CDCl3): δ1.22 (3H, d, J=6 Hz), 1.64 (1H, brs), 2.25-2.29 (1H, m), 2.30 (3H, s), 2.60-2.70 (1H, m), 2.80-2.83 (1H, m), 3.13 (1H, d, J=13.5 Hz), 3.17-3.25 (1H, m), 3.40-3.50 (1H, m), 3.73-3.83 (1H, m), 3.85-3.95 (1H, m), 3.98 (1H, d, J=13.5 Hz), 6.57 (1H, s), 6.66 (1H, s), 6.69 (1H, s), 7.52 (1H, d, J=8.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 263






Yield: quant. %, 1H-NMR (CDCl3): δ1.11 (6H, d, J=6 Hz), 2.28 (3H, s), 2.70-2.85 (2H, m), 2.95-3.10 (2H, m), 3.70-3.90 (4H, m), 6.53 (1H, s), 6.68 (1H, s), 6.72 (1H, s), 7.23 (1H, dd, J=8.5, 2 Hz), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Example 264






Yield: quant. %, 1H-NMR (CDCl3): δ1.10 (6H, d, J=6 Hz), 2.28 (3H, s), 2.70-2.85 (2H, m), 3.00-3.15 (2H, m), 3.75 (2H, s), 3.82-3.94 (2H, m), 5.53 (1H, brs), 6.52 (1H, s), 6.69 (1H, s), 6.72 (1H, s), 7.51 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 265






Yield: quant. %, 1H-NMR (CDCl3): δ1.42 (3H, d, J=7 Hz), 2.20-2.28 (1H, m), 2.28 (3H, s), 2.30-2.45 (1H, m), 2.70-2.85 (1H, m), 2.90-3.00 (1H, m), 3.43 (1H, d, J=13.5 Hz), 3.45-3.55 (1H, m), 3.58 (1H, d, J=13.5 Hz), 3.80-3.90 (1H, m), 4.15-4.25 (1H, m), 6.60 (1H, s), 6.66 (1H, s), 6.77 (1H, s), 7.22 (1H, dd, J=8.5, 2 Hz), 7.43 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2 Hz).


Example 266






Yield: quant. %, 1H-NMR (CDCl3): δ1.01 (3H, t, J=7.5 Hz), 1.55-1.78 (2H, m), 2.29 (3H, s), 2.30-2.40 (1H, m), 2.48-2.56 (1H, m), 2.79-2.83 (1H, m), 3.18 (1H, d, J=13.5 Hz), 3.37-3.56 (2H, m), 3.65-3.77 (1H, m), 3.82 (1H, dd, J=13, 3 Hz), 3.93 (1H, d, J=13.5 Hz), 6.57 (1H, s), 6.67 (1H, s), 6.70 (1H, s), 7.52 (1H, dd, J=8.5, 1.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.84 (1H, d, J=1.5 Hz).


Example 267






Yield 99%, 1H-NMR (CDCl3): δ2.27 (3H, s), 2.27-2.35 (1H, m), 2.77 (1H, d, J=13.5 Hz), 3.02 (1H, d, J=11.5 Hz), 3.28-3.50 (3H, m), 3.75 (1H, d, J=13.5 Hz), 3.98 (1H, d, J=11 Hz), 4.10-4.18 (1H, m), 5.61 (1H, brs), 6.54 (1H, s), 6.61 (1H, s), 6.64 (1H, s), 7.30-7.43 (3H, m), 7.45-7.60 (4H, m), 7.86 (1H, s).


Example 268






Yield: 96%, 1H-NMR (CDCl3): δ1.42 (3H, d, J=6.5 Hz), 2.18 (1H, td, J=12, 3.5 Hz), 2.29 (3H, s), 2.29-2.40 (1H, m), 2.74 (1H, d, J=11.5 Hz), 2.89 (1H, d, J=11.5 Hz), 3.39 (1H, d, J=13 Hz), 3.47 (1H, d, J=13 Hz), 3.55 (1H, td, J=12.5, 3.5 Hz), 3.90 (1H, d, J=13 Hz), 4.16-4.29 (1H, m), 6.58 (1H, s), 6.69 (1H, s), 6.70 (1H, s), 7.51 (1H, dd, J=8.5, 1.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.84 (1H, d, J=1.5 Hz).


Example 269






Yield: quant. %, 1H-NMR (CDCl3): δ1.43 (3H, d, J=6.5 Hz), 2.14-2.41 (5H, m), 2.71-2.80 (1H, m), 2.86-2.92 (1H, m), 3.35-3.59 (3H, m), 3.85-3.97 (1H, m), 4.17-4.29 (1H, m), 6.58 (1H, s), 6.69 (1H, s), 6.72 (1H, s), 7.48-7.60 (2H, m), 7.84 (1H, s).


Example 270






Yield: 96%, 1H-NMR (CDCl3): δ1.00 (3H, t, J=7.5 Hz), 1.55-1.75 (2H, m), 2.29 (3H, s), 2.29-2.38 (1H, m), 2.47-2.57 (1H, m), 2.78-2.88 (1H, m), 3.17 (1H, d, J=13.5 Hz), 3.37-3.55 (2H, m), 3.65-3.85 (2H, m), 3.93 (1H, d, J=13.5 Hz), 6.57 (1H, s), 6.67 (1H, s), 6.69 (1H, s), 7.52 (1H, d, J=8.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 271






Yield: 92%, 1H-NMR (CDCl3): δ1.01 (3H, t, J=7.5 Hz), 1.57-1.79 (2H, m), 2.29 (3H, s), 2.29-2.40 (1H, m), 2.46-2.58 (1H, m), 2.77-2.89 (1H, m), 3.18 (1H, d, J=13 Hz), 3.32-3.58 (2H, m), 3.65-3.87 (2H, m), 3.93 (1H, d, J=13 Hz), 6.57 (1H, s), 6.67 (1H, s), 6.69 (1H, s), 7.52 (1H, d, J=8.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 272






Yield: 95%, 1H-NMR (CDCl3): δ0.93 (3H, t, J=7.5 Hz), 1.30-1.70 (4H, m), 2.29 (3H, s), 2.29-2.39 (1H, m), 2.55-2.65 (1H, m), 2.79-2.88 (1H, m), 3.19 (1H, d, J=13.5 Hz), 3.41 (1H, dd, J=12.5, 8 Hz), 3.48-3.58 (1H, m), 3.65-3.75 (1H, m), 3.82 (1H, dd, J=12.5, 2.5 Hz), 3.92 (1H, d, J=13.5 Hz), 6.57 (1H, s), 6.68 (1H, s), 6.70 (1H, s), 7.51 (1H, dd, J=8.5, 1.5 Hz), 7.55 (1H, d, J=8.5 Hz), 7.84 (1H, d, J=1.5 Hz).


Example 273






Yield: 98%, 1H-NMR (CDCl3): δ0.93 (3H, t, J=7.5 Hz), 1.30-1.41 (1H, m), 1.48-1.63 (3H, m), 2.29 (3H, s), 2.29-2.36 (1H, m), 2.56-2.62 (1H, m), 2.79-2.86 (1H, m), 3.19 (1H, d, J=13.5 Hz), 3.41 (1H, dd, J=7.8, 12.9 Hz), 3.50-3.57 (1H, m), 3.69-3.81 (2H, m), 3.92 (1H, d, J=13.5 Hz), 6.67 (1H, s), 6.68 (2H, s), 7.50-7.59 (2H, m), 7.84 (1H, s)


Example 274






Yield: 98%, 1H-NMR (CDCl3): δ0.91 (3H, t, J=7 Hz), 1.26-1.75 (6H, m), 2.30 (3H, s), 2.30-2.40 (1H, m), 2.52-2.63 (1H, m), 2.77-2.87 (1H, m), 3.19 (1H, d, J=13.5 Hz), 3.35-3.45 (1H, m), 3.47-3.57 (1H, m), 3.65-3.75 (1H, m), 3.81 (1H, dd, J=12.5, 2.5 Hz), 3.92 (1H, d, J=13.5 Hz), 5.49 (1H, brs), 6.57 (1H, s), 6.67 (1H, s), 6.69 (1H, s), 7.52 (1H, dd, J=8.5, 1.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.84 (1H, d, J=1.5 Hz)


Example 275






Yield: 96%, 1H-NMR (CDCl3): δ0.91 (3H, d, J=6.5 Hz), 0.95 (3H, d, J=6.5 Hz), 1.32-1.46 (1H, m), 1.47-1.59 (1H, m), 1.62-1.78 (1H, m), 2.29 (3H, s), 2.33-2.45 (1H, m), 2.62-2.74 (1H, m), 2.75-2.87 (1H, m), 3.27 (1H, d, J=13.5 Hz), 3.36 (1H, dd, J=12.5, 7.5 Hz), 3.55-3.65 (2H, m), 3.70-3.79 (1H, m), 3.86 (1H, d, J=13.5 Hz), 6.56 (1H, s), 6.69 (2H, s), 7.22 (1H, dd, J=8.5, 2 Hz), 7.43 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2 Hz).


Example 276






Yield: quant. %, 1H-NMR (CDCl3): δ0.91 (3H, d, J=6.5 Hz), 0.95 (3H, d, J=6.5 Hz), 1.30-1.59 (2H, m), 1.62-1.79 (1H, m), 2.18 (1H, s), 2.29 (3H, s), 2.30-2.45 (1H, m), 2.60-2.72 (1H, m), 2.75-2.88 (1H, m), 3.27 (1H, d, J=13.5 Hz), 3.29-3.42 (1H, m), 3.53-3.65 (2H, m), 3.74 (1H, dd, J=12.5, 3.5 Hz), 3.86 (1H, d, J=13.5 Hz), 6.56 (1H, s), 6.67 (1H, s), 6.70 (1H, s), 7.23 (1H, dd, J=8.5, 2.0 Hz), 7.43 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2.0 Hz).


Example 277






Yield: 98%, 1H-NMR (CDCl3): δ0.91 (3H, d, J=6.5 Hz), 0.95 (3H, d, J=6.5 Hz), 1.37-1.45 (1H, m), 1.46-1.60 (1H, m), 1.64-1.77 (1H, m), 2.29 (3H, s), 2.36-2.47 (1H, m), 2.64-2.75 (1H, m), 2.78-2.90 (1H, m), 3.29 (1H, d, J=13.5 Hz), 3.42 (1H, dd, J=12.5, 7.5 Hz), 3.65 (2H, t, J=5 Hz), 3.78 (1H, dd, J=13, 3 Hz), 3.86 (1H, d, J=13.5 Hz), 6.57 (1H, s), 6.70 (2H, s), 7.51 (1H, dd, J=8.5, 1.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.84 (1H, d, J=1.5 Hz).


Example 278






Yield: 99%, 1H-NMR (CDCl3): δ1.21 (3H, d, J=6 Hz), 2.22-2.28 (1H, m), 2.29 (3H, s), 2.59-2.70 (1H, m), 2.83 (1H, dt, J=12, 3.5 Hz), 3.13 (1H, d, J=13.5 Hz), 3.21 (1H, dd, J=11, 8.5 Hz), 3.39-3.50 (1H, m), 3.72-3.83 (1H, m), 3.84-3.93 (1H, m), 3.97 (1H, d, J=13.5 Hz), 6.56 (1H, s), 6.65 (1H, s), 6.70 (1H, s), 7.26 (1H, d, J=11.5 Hz), 7.73 (1H, d, J=7 Hz).


Example 279






Yield: quant. %, 1H-NMR (CDCl3): δ2.00-2.14 (2H, m), 2.22 (3H, s), 2.68-2.93 (4H, m), 3.53-3.95 (6H, m), 6.60 (2H, s), 6.72 (1H, s), 7.24 (1H, d, J=11.5 Hz), 7.72 (1H, d, J=7.0 Hz), 7.85 (1H, s).


Example 280






Yield: 89%, 1H-NMR (CDCl3): δ1.13 (6H, d, J=6.0 Hz), 2.29 (3H, s), 2.72-2.88 (2H, m), 3.01-3.19 (2H, m), 3.77 (2H, s), 3.89 (2H, d, J=12.0 Hz), 6.52 (1H, s), 6.70 (1H, s), 6.72 (1H, s), 7.27 (1H, d, J=11.5 Hz), 7.75 (1H, d, J=6.5 Hz).


Example 281






Yield: 95%, 1H-NMR (CDCl3): δ1.01 (3H, t, J=7.5 Hz), 1.48-1.80 (2H, m), 2.25-2.40 (1H, m), 2.30 (3H, s), 2.46-2.58 (1H, m), 2.78-2.89 (1H, m), 3.19 (1H, d, J=13.5 Hz), 3.32-3.57 (2H, m), 3.64-3.75 (1H, m), 3.76-3.87 (1H, m), 3.93 (1H, d, J=13.5 Hz), 6.57 (1H, s), 6.67 (1H, s), 6.70 (1H, s), 7.27 (1H, d, J=11.5 Hz), 7.74 (1H, d, J=7.0 Hz).


Example 282






Yield: quant %, 1H-NMR (CDCl3): δ2.23 (3H, s), 2.62-2.80 (4H, m), 3.52-3.73 (6H, m), 6.63 (1H, s), 6.65 (1H, s), 6.78 (1H, s), 7.20 (1H, t, J=7.5 Hz), 7.31 (2H, t, J=7.5 Hz), 7.35-7.44 (3H, m), 8.70 (1H, brs).


Example 283






Yield: 93%, 1H-NMR (CDCl3): δ1.13 (6H, d, J=6.0 Hz), 2.29 (3H, s), 2.65-2.80 (2H, m), 2.90 (2H, t, J=11.5 Hz), 3.76 (2H, s), 4.29 (2H, d, J=13.0 Hz), 6.54 (1H, s), 6.70 (1H, s), 6.75 (1H, s), 7.34-7.43 (1H, m), 7.53-7.62 (1H, m), 7.69 (1H, d, J=8.0 Hz), 7.88 (1H, d, J=8.0 Hz), 8.55 (1H, s).


Example 284






Yield: 93%, 1H-NMR (CDCl3): δ1.25 (3H, d, J=5.5 Hz), 2.21-2.34 (1H, m), 2.29 (3H, s), 2.54-2.70 (1H, m), 2.83-2.94 (1H, m), 3.07-3.22 (1H, m), 3.14 (1H, d, J=13.5 Hz), 3.30-3.45 (1H, m), 4.02 (1H, d, J=13.5 Hz), 4.06-4.17 (1H, m), 4.18-4.28 (1H, m), 6.58 (1H, s), 6.66-6.74 (2H, m), 7.34-7.43 (1H, m), 7.53-7.61 (1H, m), 7.68 (1H, dd, J=8.5, 1.0 Hz), 7.88 (1H, dd, J=8.5, 1.0 Hz), 8.55 (1H, s).


Example 285






Yield: 88%, 1H-NMR (CDCl3): δ1.16 (6H, d, J=6.0 Hz), 2.29 (3H, s), 2.65-2.83 (2H, m) 2.94 (2H, t, J=11.5 Hz), 3.77 (2H, s), 4.30 (2H, d, J=14.0 Hz), 6.52 (1H, s), 6.72 (1H, s), 6.75 (1H, s), 7.50 (1H, dd, J=9.0, 2.5 Hz), 7.60 (1H, d, J=9.0 Hz), 7.85 (1H, d, J=2.5 Hz), 8.54 (1H, s).


Example 286






Yield: 97%, 1H-NMR (CDCl3): δ1.17 (6H, d, J=6.0 Hz), 2.28 (3H, s), 2.66-2.83 (2H, m), 2.90-3.06 (2H, m), 3.79 (2H, s), 4.34 (2H, d, J=13.0 Hz), 6.55 (1H, s), 6.69 (1H, s), 6.75 (1H, s), 7.72 (2H, s), 8.14 (1H, s), 8.59 (1H, s).


Example 287
Preparation of 5-{[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl}-2-methylphenol






A mixture of 6-chloro-2-[4-(2-methoxymethoxy-3-methylbenzyl)piperazine-1-yl]benzothiazole (1.70 g; 4.067 mmol) and 4N hydrochloric acid/dioxane solution (8.5 ml) was stirred at 60° C. for 2 hours. After cooling, the reaction solution was condensed under reduced pressure. To the residue was added saturated aqueous sodium hydrogencarbonate to be alkaline and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure. The precipitate was washed with diisopropyl ether to give 5-{[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl}-2-methylphenol as colorless crystal (1.33 g; 87%).



1H-NMR (CDCl3): δ2.24 (3H, s), 2.55 (4H, t, J=5 Hz), 3.46 (2H, s), 3.63 (4H, t, J=5 Hz), 5.95 (1H, brs), 6.76 (1H, d, J=7.5 Hz), 6.81 (1H, s), 7.07 (1H, d, J=7.5 Hz), 7.23 (1H, dd, J=8, 2 Hz), 7.45 (1H, d, J=8 Hz), 7.55 (1H, d, J=2 Hz).


Compounds in Examples 288 to 292 were obtained by similar methods as Example 287.


Example 288






Yield: 100%, 1H-NMR (DMSO-d6): δ2.12 (3H, s), 3.08-3.18 (2H, m), 3.39 (2H, d, J=12.0 Hz), 3.65 (2H, t, J=12.0 Hz), 4.13-4.21 (4H, m), 6.85 (1H, d, J=8.4 Hz), 7.22 (1H, d, J=8.4 Hz), 7.28 (1H, s), 7.28 (1H, m), 7.49 (1H, d, J=8.7 Hz), 7.99 (1H, d, J=2.1 Hz).


Example 289






Yield: 80%, 1H-NMR (DMSO-d6): δ2.12 (3H, s), 2.16-2.26 (2H, m), 3.03-3.15 (2H, m), 3.49-3.76 (4H, m), 4.02 (4H, s) 6.83 (1H, d, J=8.1 Hz), 7.19 (1H, d, J=8.1 Hz), 7.25 (1H, s), 7.31 (1H, dd, J=2.4, 8.7 Hz), 7.45 (1H, d, J=9.7 Hz), 7.95 (1H, d, J=2.4 Hz).


Example 290






Yield: 77%, 1H-NMR (DMSO-d6): δ1.59 (3H, d, J=6.3 Hz), 2.24 (3H, s), 3.12 (2H, br), 3.54 (1H, br), 3.65 (2H, br), 3.89-3.96 (1H, m), 4.09 (1H, d, J=14.1 Hz), 4.21 (1H, d, J=12.9 Hz), 4.63 (1H, d, J=11.2 Hz), 6.68 (1H, s), 6.81 (1H, s), 6.88 (1H, s), 7.34 (1H, dd, J=2.1, 8.7 Hz), 7.50 (1H, d, J=8.7 Hz), 8.00 (1H, d, J=2.1 Hz), 11.6 (1H, s)


Example 291






Yield: 84%, 1H-NMR (DMSO-d6): δ1.58 (3H, d, J=6.0 Hz), 2.24 (3H, s), 3.16 (2H, br), 3.53 (1H, br), 3.64 (1H, br), 3.89-3.96 (2H, m), 4.08 (1H, d, J=12.9 Hz), 4.21 (1H, d, J=12.9 Hz), 4.63 (1H, d, J=12.0 Hz), 6.68 (1H, s), 6.81 (1H, s), 6.87 (1H, s), 7.34 (1H, dd, J=2.1, 8.7 Hz), 7.50 (1H, d, J=8.7 Hz), 8.00 (1H, d, J=2.1 Hz), 11.6 (1H, br)


Example 292






Yield: 84%, 1H-NMR (CDCl3): δ1.21 (3H, d, J=6 Hz), 2.24 (3H, s), 2.25-2.33 (1H, m), 2.59-2.70 (1H, m), 2.81 (1H, dt, J=12, 3 Hz), 3.14 (1H, d, J=13.5 Hz), 3.15-3.25 (1H, m), 3.39-3.50 (1H, m), 3.73-3.83 (1H, m), 3.84-3.94 (1H, m), 3.98 (1H, d, J=13.5 Hz), 5.18 (1H, brs), 6.79 (1H, d, J=7.5 Hz), 6.80 (1H, s), 7.07 (1H, d, J=7.5 Hz), 7.51 (1H, d, J=8.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 293
Preparation of {3-[[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl]-5-methyl}phenoxyethyl acetate






A mixture of 3-{[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl}-5-methylphenol (0.50 g; 1.34 mmol), bromoethyl acetate (0.22 ml; 2.01 mmol) and cesium carbonate (0.65 g; 2.01 mmol) in anhydrous N,N-dimethylformamide (5 ml) was stirred at 50° C. for 17 hours. Water and ethyl acetate were added to the reaction solution and extracted. The organic layer was washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure. The residue was purified by column chromatograph on silica gel (hexane:ethyl acetate=2:1) to give {3-[[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl]-5-methyl}+phenoxyethyl acetate as pale yellow oil (0.48 g; 78%).



1H-NMR (CDCl3): δ1.28 (3H, t, J=7 Hz), 2.32 (3H, s), 2.56 (4H, t, J=5 Hz), 3.49 (2H, s), 3.63 (4H, t, J=5 Hz), 4.27 (2H, q, J=7 Hz), 4.61 (2H, s), 6.64 (1H, s), 6.74 (1H, s), 6.78 (1H, s), 7.23 (1H, dd, J=8.5, 2 Hz), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Compounds in Examples 294 to 329 were obtained by similar methods as Example 293.


Example 294






Yield: 84%, 1H-NMR (CDCl3); δ1.27 (3H, t, J=7 Hz), 1.59 (6H, s), 2.29 (3H, s), 2.55 (4H, t, J=5 Hz), 3.46 (2H, s), 3.62 (4H, t, J=5 Hz), 4.26 (2H, q, J=7 Hz), 6.55 (1H, s), 6.60 (1H, s), 6.77 (1H, s), 7.23 (1H, dd, J=8.5, 2 Hz), 7.42 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Example 295






Yield: 78%, 1H-NMR (CDCl3); δ1.31 (3H, t, J=7 Hz), 2.32 (3H, s), 2.58 (4H, t, J=5 Hz), 3.50 (2H, s), 3.68 (4H, t, J=5 Hz), 4.28 (2H, q, J=7 Hz), 4.62 (2H, s), 6.65 (1H, s), 6.74 (1H, s), 6.78 (1H, s), 7.50-7.60 (2H, m), 7.85 (1H, s).


Example 296






Yield: 93%, 1H-NMR (CDCl3); δ1.30 (3H, t, J=6.9 Hz), 1.98-2.05 (2H, m), 2.30 (3H, s), 2.67 (2H, t, J=5.1 Hz), 2.77-2.81 (2H, m), 3.57 (2H, s), 3.71-3.75 (4H, m), 4.27 (2H, q, J=7.2 Hz), 4.60 (2H, s), 6.63 (1H, s), 6.73 (1H, s), 6.76 (1H, s), 7.23 (1H, dd, J=8.7, 2.4 Hz), 7.42 (1H, d, J=8.4 Hz), 7.55 (1H, d, J=2.1 Hz).


Example 297






Yield: 66%, 1H-NMR (CDCl3); δ1.29 (3H, t, J=7 Hz), 1.98-2.06 (2H, m), 2.30 (3H, s), 2.68 (2H, t, J=5.5 Hz), 2.81 (2H, t, J=5.5 Hz), 3.57 (2H, s), 3.70-3.85 (4H, m), 4.27 (2H, q, J=7 Hz), 4.60 (2H, s), 6.63 (1H, s), 6.73 (1H, s), 6.76 (1H, s), 7.48-7.58 (2H, m), 7.84 (1H, s).


Example 298






Yield: 68%, 1H-NMR (CDCl3); δ1.29 (3H, t, J=7 Hz), 2.28 (3H, s), 2.55 (4H, t, J=5 Hz), 3.50 (2H, s), 3.62 (4H, t, J=5 Hz), 4.26 (2H, q, J=7 Hz), 4.65 (2H, s), 6.74 (1H, s), 6.84 (1H, d, J=7.5 Hz), 7.10 (1H, d, J=7.5 Hz), 7.23 (1H, dd, J=8.5, 2 Hz), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Example 299






Yield: 84%, 1H-NMR (CDCl3); δ1.30 (3H, t, J=7.2 Hz), 2.30 (3H, s), 2.55 (4H, t, J=5.1 Hz), 3.46 (2H, s), 3.62 (4H, t, J=5.1 Hz), 4.27 (2H, q, J=7.2 Hz), 4.64 (2H, s), 6.66 (1H, dd, J=8.1 Hz), 7.07 (1H, d, J=8.1 Hz), 7.13 (1H, s), 7.23 (1H, dd, J=8.4, 2.1 Hz), 7.43 (1H, dd, J=8.1 Hz), 7.55 (1H, d, J=2.1 Hz)


Example 300






Yield: 90%, 1H-NMR (CDCl3); δ1.30 (3H, t, J=7.2 Hz), 1.98-2.05 (2H, m), 2.28 (3H, s), 2.67 (2H, t, J=5.1 Hz), 2.78 (2H, t, J=5.1 Hz), 3.54 (2H, s), 3.71-3.78 (4H, m), 4.27 (2H, q, J=7.2 Hz), 4.63 (2H, s), 6.64 (1H, d, J=8.1 Hz), 7.05 (1H, d, J=8.1 Hz), 7.11 (1H, s), 7.22 (1H, dd, J=8.7, 2.1 Hz), 7.42 (1H, d, J=8.7 Hz), 7.54 (1H, d, J=2.1 Hz).


Example 301






Yield: 92%, 1H-NMR (CDCl3): δ1.21 (3H, d, J=6 Hz), 1.31 (3H, t, J=7 Hz), 2.20-2.32 (1H, m), 2.33 (3H, s), 2.60-2.70 (1H, m), 2.77-2.85 (1H, m), 3.05-3.25 (2H, m), 3.35-3.50 (1H, m), 3.70-3.80 (1H, m), 3.85-3.95 (1H, m), 3.98 (1H, d, J=13.5 Hz), 4.28 (2H, q, J=7 Hz), 4.61 (2H, s), 6.63 (1H, s), 6.75 (1H, s), 6.78 (1H, s), 7.53 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 302






Yield: 74%, 1H-NMR (CDCl3): δ1.10 (6H, d, J=6 Hz), 1.30 (3H, t, J=7 Hz), 2.31 (3H, s), 2.70-2.85 (2H, m), 3.01 (1H, d, J=10.5 Hz), 3.05 (1H d, J=10.5 Hz), 3.76 (2H, s), 3.80-3.90 (2H, m), 4.27 (2H, q, J=7 Hz), 4.60 (2H, s), 6.57 (1H, s), 6.78 (1H, s), 6.83 (1H, s), 7.23 (1H, dd, J=8.5, 2 Hz), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Example 303






Yield: 93%, 1H-NMR (CDCl3): δ1.12 (6H, d, J=6 Hz), 1.30 (3H, t, J=7 Hz), 2.31 (3H, s), 2.70-2.90 (2H, m), 3.00-3.15 (2H, m), 3.77 (2H, s), 3.85-3.95 (2H, m), 4.27 (2H, q, J=7 Hz), 4.60 (2H, s), 6.57 (1H, s), 6.78 (1H, s), 6.84 (1H, s), 7.52 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 304






Yield: 95%, 1H-NMR (CDCl3): δ1.30 (3H, t, J=7 Hz), 1.41 (3H, d, J=7 Hz), 2.21 (1H, td, J=12, 3.5 Hz), 2.25-2.35 (1H, m), 2.32 (3H, s), 2.73 (1H, d, J=11 Hz), 2.90 (1H, d, J=11 Hz), 3.38 (1H, d, J=13.5 Hz), 3.48 (1H, td, J=12, 3.5 Hz), 3.52 (1H, d, J=13.5 Hz), 3.85 (1H, d, J=12 Hz), 4.15-4.25 (1H, m), 4.27 (2H, q, J=7 Hz), 4.61 (2H, s), 6.64 (1H, s), 6.76 (1H, s), 6.78 (1H, s), 7.22 (1H, dd, J=8, 2 Hz), 7.42 (1H, d, J=8 Hz), 7.54 (1H, d, J=2 Hz).


Example 305






Yield: 43%, 1H-NMR (CDCl3): δ1.21 (3H, d, J=6 Hz), 1.30 (3H, t, J=7 Hz), 2.20-2.27 (1H, m), 2.28 (3H, s), 2.60-2.70 (1H, m), 2.75-2.85 (1H, m), 3.10-3.25 (2H, m), 3.35-3.50 (1H, m), 3.68-3.78 (1H, m), 3.85-3.95 (1H, m), 4.01 (1H, d, J=13 Hz), 4.27 (2H, q, J=7 Hz), 4.65 (2H, s), 6.74 (1H, s), 6.85 (1H, d, J=7.5 Hz), 7.11 (1H, d, J=7.5 Hz), 7.53 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 306






Yield: 79%, 1H-NMR (CDCl3): δ1.22 (3H, d, J=6.5 Hz), 1.31 (3H, t, J=7 Hz), 2.23-2.35 (1H, m), 2.60-2.73 (1H, m), 2.75-2.90 (1H, m), 3.15-3.25 (2H, m), 3.40-3.50 (1H, m), 3.70-3.82 (1H, m), 3.85-3.95 (1H, m), 4.03 (1H, d, J=13.5 Hz), 4.28 (2H, q, J=7 Hz), 4.63 (2H, s), 6.80 (1H, dd, J=8, 1.5 Hz), 6.93-7.02 (2H, m), 7.25 (1H, t, J=8 Hz), 7.53 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 307






Yield: 81%, 1H-NMR (CDCl3): δ1.02 (3H, t, J=7.5 Hz), 1.31 (3H, t, J=7 Hz), 1.58-1.79 (2H, m), 2.31 (3H, s), 2.31-2.38 (1H, m), 2.47-2.58 (1H, m), 2.78-2.88 (1H, m), 3.23 (1H, d, J=13.5 Hz), 3.36-3.58 (2H, m), 3.64-3.75 (1H, m), 3.84 (1H, d, J=11 Hz), 3.95 (1H, d, J=13.5 Hz), 4.28 (2H, q, J=7 Hz), 4.62 (2H, s), 6.63 (1H, s), 6.77 (1H, s), 6.78 (1H, s), 7.51 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.84 (1H, s)


Example 308






Yield: 91%, 1H-NMR (CDCl3): δ1.31 (3H, t, J=7 Hz), 2.25-2.35 (4H, m), 2.82 (1H, d, J=13.5 Hz), 3.01 (1H, d, J=11.5 Hz), 3.25-3.50 (3H, m), 3.79 (1H, d, J=13.5 Hz), 4.00-4.10 (2H, m), 4.28 (2H, q, J=7 Hz), 4.60 (2H, s), 6.59 (1H, s), 6.70 (1H, s), 6.72 (1H, s), 7.30-7.45 (3H, m), 7.50-7.58 (4H, m), 7.84 (1H, s).


Example 309






Yield: 90%, 1H-NMR (CDCl3): δ1.21 (3H, d, J=6.3 Hz), 1.31 (3H, t, J=7.2 Hz), 2.22-2.31 (1H, m), 2.32 (3H, s), 2.58-2.68 (1H, m), 2.83 (1H, dt, J=3.3, 12.3 Hz), 3.12-3.19 (2H, m), 3.34-3.43 (1H, m), 3.71 (1H, d, J=12.3 Hz), 3.86 (1H, d, J=10.5 Hz), 3.99 (1H, d, J=13.5 Hz), 4.28 (2H, q, J=7.2 Hz), 4.61 (2H, s), 6.63 (1H, s), 6.75 (1H, s), 6.78 (1H, s), 7.23 (1H, d, J=2.4, 8.7 Hz), 7.43 (1H, d, J=8.7 Hz), 7.55 (1H, d, J=2.4 Hz)


Example 310






Yield: 70%, 1H-NMR (CDCl3): δ1.21 (3H, d, J=6.3 Hz), 1.30 (3H, t, J=7.2 Hz), 2.23-2.32 (1H, m), 2.32 (3H, s), 2.58-2.67 (1H, m), 2.80 (1H, d, J=3.3, 12.3 Hz), 3.12-3.19 (2H, m), 3.35-3.42 (1H, m), 3.71 (1H, dt, J=12.0 Hz), 3.86 (1H, dt, J=12.0 Hz), 3.99 (1H, d, J=13.2 Hz), 4.28 (2H, q, J=7.2 Hz), 4.61 (2H, s), 6.63 (1H, s), 6.75 (1H, s), 6.78 (1H, s), 7.23 (1H, dd, J=2.1, 8.7 Hz), 7.43 (1H, d, J=8.7 Hz), 7.54 (1H, d, J=2.1 Hz)


Example 311






Yield: 89%, 1H-NMR (CDCl3): δ1.30 (3H, t, J=7 Hz), 1.43 (3H, d, J=6.5 Hz), 2.23 (1H, td, J=12, 3.5 Hz), 2.31 (3H, s), 2.31-2.40 (1H, m), 2.73 (1H, d, J=11 Hz), 2.91 (1H, d, J=11 Hz), 3.40 (1H, d, J=13 Hz), 3.46-3.51 (1H, m), 3.53 (1H, d, J=13 Hz), 3.85-3.95 (1H, m), 4.20-4.27 (1H, m), 4.28 (2H, q, J=7 Hz), 4.62 (2H, s), 6.65 (1H, s), 6.77 (1H, s), 6.79 (1H, s), 7.52 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 312






Yield: 84%, 1H-NMR (CDCl3): δ1.31 (3H, t, J=7.0 Hz), 1.43 (3H, d, J=6.5 Hz), 2.16-2.28 (1H, m), 2.30-2.39 (1H, m), 2.33 (3H, s), 2.70-2.78 (1H, m), 2.87-2.96 (1H, m), 3.40 (1H, d, J=13.5 Hz), 3.45-3.58 (2H, m), 3.86-3.97 (1H, m), 4.18-4.30 (1H, m), 4.28 (2H, q, J=7.0 Hz), 4.62 (2H, s), 6.65 (1H, s), 6.75-6.82 (2H, m), 7.48-7.60 (2H, m), 7.84 (1H, s).


Example 313






Yield: 86%, 1H-NMR (CDCl3): δ1.02 (3H, t, J=7.5 Hz), 1.31 (3H, t, J=7 Hz), 1.57-1.78 (2H, m), 2.30-2.33 (1H, m), 2.34 (3H, s), 2.48-2.60 (1H, m), 2.78-2.90 (1H, m), 3.17 (1H, d, J=13.5 Hz), 3.37-3.58 (2H, m), 3.62-3.73 (1H, m), 3.79-3.88 (1H, m), 3.95 (1H, d, J=13.5 Hz), 4.28 (2H, q, J=7 Hz), 4.61 (2H, s), 6.63 (1H, s), 6.76 (1H, s), 6.78 (1H, s), 7.51 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=8.5 Hz), 7.83 (1H, s).


Example 314






Yield: 85%, 1H-NMR (CDCl3): δ1.02 (3H, t, J=7.5 Hz), 1.29 (3H, t, J=7 Hz), 1.58-1.78 (2H, m), 2.04 (3H, s), 2.05-2.15 (1H, m), 2.48-2.58 (1H, m), 2.79-2.89 (1H, m), 3.23 (1H, d, J=13.5 Hz), 3.42 (1H, dd, J=12.5, 8 Hz), 3.47-3.56 (1H, m), 3.63-3.72 (1H, m), 3.80-3.90 (1H, m), 3.95 (1H, d, J=13.5 Hz), 4.27 (2H, q, J=7 Hz), 4.61 (2H, s), 6.63 (1H, s), 6.77 (1H, s), 6.78 (1H, s), 7.52 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.83 (1H, s).


Example 315






Yield: 60%, 1H-NMR (CDCl3): δ0.95 (3H, t, J=7.0 Hz), 1.22-1.68 (4H, m), 1.31 (3H, t, J=7.0 Hz), 2.27-2.40 (1H, m), 2.32 (3H, s), 2.54-2.65 (1H, m), 2.76-2.89 (1H, m), 3.25 (1H, d, J=13.5 Hz), 3.41 (1H, dd, J=13.0, 7.5 Hz), 3.48-3.59 (1H, m), 3.60-3.71 (1H, m), 3.83 (1H, dd, J=12.5, 3.5 Hz), 3.93 (1H, d, J=13.5 Hz), 4.28 (2H, q, J=7.0 Hz), 4.61 (2H, s), 6.63 (1H, s), 6.76 (1H, s), 6.78 (1H, s), 7.52 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.83 (1H, s).


Example 316






Yield: 90%, 1H-NMR (CDCl3): δ0.95 (3H, t, J=7.2 Hz), 1.31 (3H, t, J=7.2 Hz), 1.33-1.62 (4H, m), 2.32 (3H, s), 2.32-2.38 (1H, m), 2.57-2.62 (1H, m), 2.79-2.86 (1H, m), 3.24 (1H, d, J=13.5 Hz), 3.41 (1H, dd, J=7.8, 12.6 Hz), 3.38-3.44 (1H, m), 3.64-3.69 (1H, m), 3.83 (1H, dd, J=3.0, 12.6 Hz), 3.93 (1H, d, J=13.5 Hz), 4.28 (2H, q, J=7.2 Hz), 4.61 (2H, s), 6.63 (1H, s), 6.77 (2H, d, J=6.3 Hz), 7.53-7.55 (2H, m), 7.83 (1H, s)


Example 317






Yield: 64%, 1H-NMR (CDCl3): δ0.93 (3H, t, J=7.0 Hz), 1.22-1.75 (6H, m), 1.31 (3H, t, J=7.0 Hz), 2.27-2.39 (1H, m), 2.32 (3H, s), 2.51-2.64 (1H, m), 2.76-2.88 (1H, m), 3.24 (1H, d, J=13.0 Hz), 3.41 (1H, dd, J=13.0, 7.5 Hz), 3.47-3.59 (1H, m), 3.61-3.72 (1H, m), 3.84 (1H, dd, J=13.0, 3.0 Hz), 3.94 (1H, d, J=13.0 Hz), 4.28 (2H, q, J=7.0 Hz), 4.61 (2H, s), 6.63 (1H, s), 6.76 (1H, s), 6.78 (1H, s), 7.51 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 318






Yield: 83%, 1H-NMR (CDCl3): δ0.91 (3H, d, J=6.5 Hz), 0.95 (3H, d, J=6.5 Hz), 1.30 (3H, t, J=7 Hz), 1.35-1.45 (1H, m), 1.46-1.58 (1H, m), 1.65-1.80 (1H, m), 2.32 (3H, s), 2.33-2.44 (1H, m), 2.62-2.73 (1H, m), 2.75-2.86 (1H, m), 3.30 (1H, d, J=13.5 Hz), 3.35 (1H, dd, J=13, 6.5 Hz), 3.58 (2H, t, J=5 Hz), 3.75 (1H, dd, J=13, 6.5 Hz), 3.87 (1H, d, J=13.5 Hz), 4.28 (2H, q, J=7 Hz), 4.61 (2H, s), 6.62 (1H, s), 6.76 (1H, s), 6.78 (1H, s), 7.23 (1H, dd, J=8.5, 2 Hz), 7.42 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2 Hz).


Example 319






Yield: 68%, 1H-NMR (CDCl3): δ0.92 (3H, d, J=6.5 Hz), 0.95 (3H, d, J=7.0 Hz), 1.20-1.44 (1H, m), 1.30 (3H, t, J=6.5 Hz), 1.45-1.80 (2H, m), 2.27-2.47 (1H, m), 2.32 (3H, s), 2.61-2.72 (1H, m), 2.75-2.88 (1H, m), 3.25-3.41 (2H, m), 3.58 (2H, t, J=5.0 Hz), 3.75 (1H, dd, J=12.5, 3.5 Hz), 3.87 (1H, d, J=13.5 Hz), 4.28 (2H, q, J=7.0 Hz), 4.61 (2H, s), 6.62 (1H, s), 6.76 (1H, s), 6.78 (1H, s), 7.23 (1H, dd, J=8.0, 2.0 Hz), 7.42 (1H, d, J=8.0 Hz), 7.54 (1H, d, J=2.0 Hz).


Example 320






Yield: 85%, 1H-NMR (CDCl3): δ0.92 (3H, d, J=6.5 Hz), 0.95 (3H, d, J=6.5 Hz), 1.31 (3H, t, J=7 Hz), 1.34-1.45 (1H, m), 1.45-1.55 (1H, m), 1.65-1.80 (1H, m), 2.32 (3H, s), 2.35-2.46 (1H, m), 2.64-2.75 (1H, m), 2.78-2.88 (1H, m), 3.32 (1H, d, J=13.5 Hz), 3.42 (1H, dd, J=13, 6.5 Hz), 3.60-3.67 (2H, m), 3.79 (1H, dd, J=13, 3.5 Hz), 3.87 (1H, d, J=13.5 Hz), 4.28 (2H, q, J=7 Hz), 4.61 (2H, s), 6.63 (1H, s), 6.77 (1H, s), 6.79 (1H, s), 7.51 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.83 (1H, s).


Example 321






Yield: 98%, 1H-NMR (CDCl3): δ1.21 (3H, d, J=6 Hz), 1.31 (3H, t, J=7 Hz), 2.20-2.32 (1H, m), 2.32 (3H, s), 2.59-2.70 (1H, m), 2.75-2.88 (1H, m), 3.16 (1H, d, J=13.5 Hz), 3.17-3.25 (1H, m), 3.48-3.50 (1H, m), 3.69-3.80 (1H, m), 3.85-3.95 (1H, m), 3.98 (1H, d, J=13.5 Hz), 4.28 (2H, q, J=7 Hz), 4.62 (2H, s), 6.63 (1H, s), 6.75 (1H, s), 6.78 (1H, s), 7.26 (1H, d, J=12 Hz), 7.74 (1H, d, J=7 Hz).


Example 322






Yield: 69%, 1H-NMR (CDCl3): δ1.30 (3H, t, J=7.0 Hz), 1.96-2.08 (2H, m), 2.30 (3H, s), 2.63-2.71 (2H, m), 2.74-2.84 (2H, m), 3.57 (2H, s), 3.60-3.89 (4H, m), 4.27 (2H, q, J=7.0 Hz), 4.60 (2H, s), 6.62 (1H, s), 6.73 (1H, s), 6.75 (1H, s), 7.27 (1H, d, J=7.0 Hz), 7.75 (1H, d, J=11.5 Hz).


Example 323






Yield: 75%, 1H-NMR (CDCl3): δ1.12 (6H, d, J=6.0 Hz), 1.30 (3H, t, J=7.0 Hz), 2.32 (3H, s), 2.72-2.86 (2H, m), 3.07 (1H, d, J=13.0 Hz), 3.11 (1H, d, J=13.0 Hz), 3.77 (2H, s), 3.89 (2H, d, J=11.0 Hz), 4.28 (2H, q, J=7.0 Hz), 4.60 (2H, s), 6.57 (1H, s), 6.78 (1H, s), 6.84 (1H, s), 7.27 (1H, d, J=11.5 Hz), 7.75 (1H, d, J=6.0 Hz).


Example 324






Yield: 79%, 1H-NMR (CDCl3): δ1.01 (3H, t, J=7.5 Hz), 1.31 (3H, t, J=7.0 Hz), 1.50-1.80 (2H, m), 2.26-2.39 (1H, m), 2.32 (3H, s), 2.47-2.58 (1H, m), 2.77-2.88 (1H, m), 3.24 (1H, d, J=13.5 Hz), 3.36-3.57 (2H, m), 3.61-3.73 (1H, m), 3.77-3.88 (1H, m), 3.94 (1H, d, J=13.5 Hz), 4.28 (2H, q, J=7.0 Hz), 4.61 (2H, s), 6.62 (1H, s), 6.73-6.82 (2H, m), 7.26 (1H, d, J=11.5 Hz), 7.74 (1H, d, J=7.0 Hz)


Example 325






Yield: 71%, 1H-NMR (CDCl3): δ1.29 (3H, t, J=7.0 Hz), 2.31 (3H, s), 2.54 (4H, t, J=5.0 Hz), 3.47 (2H, s), 3.52 (4H, t, J=5.0 Hz), 4.26 (2H, q, J=7.0 Hz), 4.60 (2H, s), 6.64 (1H, s), 6.74 (1H, s), 6.78 (1H, s), 7.18 (1H, tt, J=7.5, 1.5 Hz), 7.26-7.35 (2H, m), 7.37-7.44 (3H, m).


Example 326






Yield: 74%, 1H-NMR (CDCl3): δ1.15 (6H, d, J=7.0 Hz), 1.30 (3H, t, J=7.0 Hz), 2.32 (3H, s), 2.68-2.83 (2H, m), 2.93 (1H, d, J=13.0 Hz), 2.96 (1H, d, J=13.0 Hz), 3.78 (2H, s), 4.26-4.38 (2H, m), 4.27 (2H, q, J=7.0 Hz), 4.61 (2H, s), 6.57 (1H, s), 6.80 (1H, s), 6.86 (1H, s), 7.34-7.43 (1H, m), 7.52-7.62 (1H, m), 7.67 (1H, dd, J=8.5, 1.5 Hz), 7.87 (1H, dd, J=8.5, 1.5 Hz), 8.56 (1H, s).


Example 327






Yield: 79%, 1H-NMR (CDCl3): δ1.25 (3H, d, J=6.0 Hz), 1.31 (3H, t, J=7.0 Hz), 2.20-2.32 (1H, m), 2.33 (3H, s), 2.55-2.68 (1H, m), 2.85 (1H, dt, J=12.0, 3.5 Hz), 3.14 (1H, d, J=13.0 Hz), 3.16 (1H, d, J=13.5 Hz), 3.30-3.43 (1H, m), 4.02 (1H, d, J=13.0 Hz), 4.04-4.15 (1H, m), 4.17-4.26 (1H, m), 4.28 (2H, q, J=7.0 Hz), 4.62 (2H, s), 6.63 (1H, s), 6.77 (1H, s), 6.80 (1H, s), 7.34-7.42 (1H, m), 7.52-7.61 (1H, m), 7.67 (1H, dd, J=8.5, 1.5 Hz), 7.87 (1H, dd, J=8.5, 1.5 Hz), 8.55 (1H, s).


Example 328






Yield: 74%, 1H-NMR (CDCl3): δ1.15 (6H, d, J=6.0 Hz), 1.30 (3H, t, J=7.0 Hz), 2.32 (3H, s), 2.67-2.81 (2H, m), 2.93 (1H, d, J=13.0 Hz), 2.97 (1H, d, J=13.0 Hz), 3.78 (2H, s), 4.24-4.35 (2H, m), 4.27 (2H, q, J=7.0 Hz), 4.61 (2H, s), 6.66 (1H, s), 6.79 (1H, s), 6.86 (1H, s), 7.50 (1H, dd, J=9.5, 2.0 Hz), 7.59 (1H, d, J=9.5 Hz), 7.85 (1H, d, J=2.0 Hz), 8.54 (1H, s).


Example 329






Yield: 51%, 1H-NMR (CDCl3): δ1.15 (6H, d, J=6.0 Hz), 1.29 (3H, t, J=7.0 Hz), 2.31 (3H, s), 2.65-2.79 (2H, m), 2.95 (1H, d, J=13.0 Hz), 2.99 (1H, d, J=13.0 Hz), 3.76 (2H, s), 4.26 (2H, q, J=7.0 Hz), 4.35 (2H, d, J=12.0 Hz), 4.62 (2H, s), 6.58 (1H, s), 6.79 (1H, s), 6.86 (1H, s), 7.69 (1H, s), 7.70 (1H, s), 8.13 (1H, s), 8.59 (1H, s).


Example 330
Preparation of 4-{[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl}phenoxyethyl acetate






A mixture of acetic acid 4-{[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl}phenyl ester (0.33 g; 0.834 mmol), lithium hydroxide (0.04 g; 0.831 mmol) and THF (8 ml) was stirred at room temperature for 5 hours. The solvent was evaporated under reduced pressure. To the residue were added bromoethyl acetate (0.14 ml; 1.26 mmol), cesium carbonate (0.41 g; 1.26 mmol) and anhydrous N,N-dimethylformamide (4 ml). The mixture was stirred at room temperature for 17 hours. Water and ethyl acetate were added to the reaction solution and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure. The residue was purified by column chromatograph on silica gel (hexane:ethyl acetate=2:1) to give 4-{[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl}phenoxyethyl acetate as colorless oil (0.35 g; 93%).



1H-NMR (CDCl3): δ1.31 (3H, t, J=7.2 Hz), 2.55 (4H, t, J=5.1 Hz), 3.50 (2H, s), 3.62 (4H, t, J=5.1 Hz), 4.28 (2H, q, J=7.2 Hz), 4.66 (2H, s), 6.88 (1H, d, J=8.1 Hz), 7.22-7.26 (4H, m), 7.43 (1H, d, J=8.1 Hz), 7.55 (1H, d, J=2.1 Hz).


Example 331
Preparation of 3-chloro-5-{[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl}phenoxyethyl acetate






A mixture of 3-chloro-5-[4-(2-methoxymethoxy-3-methylbenzyl)piperazine-1-yl]benzothiazole (0.15 g; 0.346 mmol) and 4N hydrochloric acid/dioxane solution (8.5 ml) was stirred at 60° C. for 2 hours. After cooling, the reaction solution was condensed under reduced pressure. To the residue were added bromoethyl acetate (0.05 ml; 0.451 mmol), cesium carbonate (0.50 g; 1.56 mmol) and anhydrous N,N-dimethylformamide (3 ml). The mixture was stirred at room temperature for 17 hours. Water and ethyl acetate were added to the reaction solution and extracted with etyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure. The residue was purified by column chromatograph on silica gel (hexane:ethyl acetate=2:1) to give 3-chloro-5-{[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl}phenoxyethyl acetate as colorless oil (0.13 g; 77%).



1H-NMR (CDCl3): δ1.31 (3H, t, J=6.9 Hz), 2.56 (4H, t, J=5.1 Hz), 3.49 (2H, s), 3.63 (4H, t, J=5.1 Hz), 4.28 (2H, q, J=6.9 Hz), 4.61 (2H, s), 6.87 (1H, t, J=1.5 Hz), 6.84 (1H, s), 6.99 (1H, t, J=1.5 Hz), 7.24 (1H, dd, J=2.1, 8.7 Hz), 7.44 (1H, d, J=8.7 Hz), 7.55 (1H, dd, J=2.1 Hz)


Example 332

The following compound was obtained by a similar method as Example 129 with a compound in Example 217 as a raw material.







Yield: 84%, 1H-NMR (CDCl3); δ1.31-1.50 (2H, m), 1.65 (1H, s), 1.74-1.96 (5H, m), 2.21 (3H, s), 3.07-3.20 (2H, m), 4.02-4.18 (4H, m), 4.65 (2H, d, J=5.5 Hz), 6.83 (1H, d, J=7.5 Hz), 6.86 (1H, s), 7.12 (1H, d, J=7.5 Hz), 7.22 (1H, dd, J=8.5, 2.0 Hz), 7.42 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2.0 Hz).


Example 333

The following compound was obtained by a similar method as Example 154 with a compound in Example 332 as a raw material.







Yield: 79%, 1H-NMR (CDCl3); δ1.33-1.52 (2H, m), 1.78-1.98 (5H, m), 2.21 (3H, s), 3.08-3.21 (2H, m), 4.03-4.17 (4H, m), 4.50 (2H, s), 6.82-6.90 (2H, m), 7.11 (1H, d, J=7.5 Hz), 7.22 (1H, dd, J=8.5, 2.0 Hz), 7.42 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2.0 Hz).


Example 334

The following compound was obtained by a similar method as Example 179 with a compound in Example 333 as a raw material.







Yield: 96%, 1H-NMR (CDCl3); δ1.34-1.52 (2H, m), 1.77-1.97 (5H, m), 2.21 (3H, s), 3.08-3.22 (2H, m), 3.72 (2H, s), 4.01-4.19 (4H, m), 6.75-6.81 (2H, m), 7.13 (1H, d, J=7.5 Hz), 7.23 (1H, dd, J=8.5, 2.0 Hz), 7.42 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2.0 Hz).


Example 335
Preparation of 3-{2-[1-(6-chlorobenzothiazole-2-yl)piperidine-4-yl]ethoxy}benzoic acid






A mixture of Ethyl 3-{2-[1-(6-chlorobenzothiazole-2-yl)piperidine-4-yl]ethoxy}benzoate (0.30 g; 6.671 mmol), 2N-aqueous sodium hydroxide (1.5 ml) and methanol (3 ml) was stirred at 60° C. for 1 hour. The reaction solution was condensed under reduced pressure. To the residue were added water and 2N aqueous hydrochloric acid to be neutral. The precipitate was collected and washed with water and diisopropyl ether to give 3-{2-[1-(6-chlorobenzothiazole-2-yl)piperidine-4-yl]ethoxy}benzoic acid as colorless crystal (0.26 g; 93%).



1H-NMR (DMSO-d6): δ1.20-1.39 (2H, m), 1.66-1.93 (5H, m), 3.10-3.26 (2H, m), 3.94-4.16 (4H, m), 7.20 (1H, dd, J=8.5, 2.5 Hz), 7.27 (1H, d, J=8.5, 2.0 Hz), 7.36-7.47 (3H, m), 7.52 (1H, d, J=7.5 Hz), 7.89 (1H, d, J=2.0 Hz).


Compounds in Examples 336 to 489 were obtained by similar methods as Example 335.


Example 336






Yield: 18%, 1H-NMR (DMSO-d6): δ1.68-1.84 (2H, m), 2.00-2.15 (2H, m), 3.50-3.64 (2H, m), 3.78-3.92 (2H, m), 4.68-4.81 (1H, m), 7.12-7.18 (1H, m), 7.26-7.39 (2H, m), 7.43 (1H, d, J=8.5 Hz), 7.48-7.55 (2H, m), 7.91 (1H, d, J=2.0 Hz).


Example 337






Yield: 27%, 1H-NMR (DMSO-d6): δ1.66-1.83 (2H, m), 2.00-2.15 (2H, m), 3.48-3.64 (4H, m), 3.78-3.93 (2H, m), 4.62-4.75 (1H, m), 6.80-6.98 (3H, m), 7.19-7.28 (1H, m), 7.29 (1H, dd, J=8.5, 2.5 Hz), 7.44 (1H, d, J=8.5 Hz), 7.90 (1H, d, J=2.5 Hz), 12.29 (1H, s).


Example 338






Yield: 84%, 1H-NMR (DMSO-d6): δ1.35-1.55 (2H, m), 1.85-2.00 (2H, m), 2.00-2.20 (1H, m), 3.10-3.30 (2H, m), 3.94 (2H, d, J=6 Hz), 4.00-4.15 (2H, m), 6.98 (1H, t, J=7.5 Hz), 7.10 (1H, d, J=7.5 Hz), 7.27 (1H, dd, J=8.5, 2 Hz), 7.41 (1H, d, J=8.5 Hz), 7.47 (1H, t, J=7.5 Hz), 7.61 (1H, d, J=7.5 Hz), 7.89 (1H, d, J=2 Hz), 12.50 (1H, brs).


Example 339






Yield: 84%, 1H-NMR (DMSO-d6): δ1.30-1.50 (2H, m), 1.80-1.95 (2H, m), 2.00-2.15 (1H, m), 3.15-3.30 (2H, m), 3.93 (2H, d, J=6 Hz), 4.00-4.15 (2H, m), 7.20 (1H, dd, J=8, 2.5 Hz), 7.27 (1H, dd, J=8.5, 2 Hz), 7.35-7.45 (3H, m), 7.52 (1H, d, J=8 Hz), 7.88 (1H, d, J=2 Hz), 13.0 (1H, brs).


Example 340






Yield: 59%, 1H-NMR (DMSO-d6): δ1.30-1.50 (2H, m), 1.85-1.95 (2H, m), 2.00-2.20 (1H, m), 3.00-3.20 (2H, m), 3.96 (2H, d, J=6.5 Hz), 4.04-4.14 (2H, m), 7.00 (2H, d, J=8 Hz), 7.28 (1H, dd, J=8.5, 1.5 Hz), 7.41 (1H, d, J=8.5 Hz), 7.87 (2H, d, J=8 Hz), 7.89 (1H, d, J=1.5 Hz).


Example 341






Yield: 88%, 1H-NMR (DMSO-d6): δ1.20-1.45 (2H, m), 1.70-1.90 (1H, m), 1.90-2.05 (2H, m), 3.02 (2H, d, J=7 Hz), 3.10-3.25 (2H, m), 3.95-4.10 (2H, m), 7.70 (1H, dd, J=8.5, 2 Hz), 7.40 (1H, d, J=8.5 Hz), 7.44 (1H, t, J=7.5 Hz), 7.59 (1H, d, J=7.5 Hz), 7.73 (1H, d, J=7.5 Hz), 7.83 (1H, s), 7.88 (1H, d, J=2 Hz), 13.40 (1H, brs).


Example 342






Yield: 32%, 1H-NMR (CDCl3); δ1.30-1.48 (2H, m), 1.70-1.90 (1H, m), 1.85-2.05 (2H, m), 2.88 (2H, d, J=7 Hz), 3.02-3.15 (2H, m), 3.63 (2H, s), 4.05-4.18 (2H, m), 7.05-7.15 (1H, m), 7.24 (1H, dd, J=8.5, 2 Hz), 7.25-7.30 (3H, m), 7.42 (1H, d, J=8.5 Hz), 7.53 (1H, d, J=2 Hz).


Example 343






Yield: 88%, 1H-NMR (DMSO-d6): δ1.20-1.38 (2H, m), 1.71 (2H, q, J=6.0 Hz), 1.78-1.94 (3H, m), 3.09-3.23 (2H, m), 3.95-4.07 (2H, m), 4.10 (2H, t, J=6.0 Hz), 6.99 (1H, td, J=7.5, 1.5 Hz), 7.14 (1H, d, J=7.5 Hz), 7.27 (1H, dd, J=8.5, 2.0 Hz), 7.40 (1H, d, J=8.5 Hz), 7.48 (1H, td, J=1.5, 7.5 Hz), 7.60 (1H, dd, J=7.5, 1.5 Hz), 7.88 (1H, d, J=2.0 Hz), 12.55 (1H, br).


Example 344






Yield: 82%, 1H-NMR (DMSO-d6): δ1.20-1.39 (2H, m), 1.68-1.92 (5H, m), 3.10-3.26 (2H, m), 3.08-4.08 (2H, m), 4.12 (2H, t, J=6.0 Hz), 7.03 (2H, d, J=9.0 Hz), 7.27 (1H, dd, J=8.5, 2.0 Hz), 7.40 (1H, d, J=8.5 Hz), 7.88 (1H, d, J=2.0 Hz), 7.88 (2H, d, J=9.0 Hz), 12.62 (1H, br).


Example 345






Yield: 75%, 1H-NMR (DMSO-d6): δ1.22-1.40 (2H, m), 1.70-1.92 (5H, m), 2.21 (3H, s), 3.12-3.24 (2H, m), 3.96-4.08 (2H, m), 4.09 (2H, t, J=6.0 Hz), 7.25 (1H, d, J=8.0 Hz), 7.27 (1H, dd, J=8.5, 2.0 Hz), 7.40 (1H, d, J=8.5 Hz), 7.43 (2H, m), 7.88 (1H, d, J=2.0 Hz).


Example 346






Yield: 78%, 1H-NMR (DMSO-d6): δ1.18-1.38 (2H, m), 1.64-1.91 (5H, m), 3.11-3.24 (2H, m), 3.52 (2H, s), 3.96-4.07 (4H, m), 6.78-6.87 (3H, m), 7.21 (1H, t, J=7.5 Hz), 7.27 (1H, dd, J=8.5, 2.0 Hz), 7.40 (1H, d, J=8.5 Hz), 7.88 (1H, d, J=2.0 Hz), 12.31 (1H, brs).


Example 347






Yield: 84%, 1H-NMR (DMSO-d6): δ1.19-1.39 (2H, m), 1.64-1.92 (5H, m), 3.09-3.28 (2H, m), 3.47 (2H, s), 3.95-4.10 (4H, m), 6.80 (2H, d, J=8.5 Hz), 7.15 (2H, d, J=8.5 Hz), 7.27 (1H, dd, J=8.5, 2.0 Hz), 7.40 (1H, d, J=8.5 Hz), 7.88 (1H, d, J=2.0 Hz).


Example 348






Yield: 35%, 1H-NMR (CDCl3); δ1.18-1.37 (2H, m), 1.68-1.91 (5H, m), 2.77 (2H, t, J=7.5 Hz), 3.09-3.43 (4H, m), 3.94-4.06 (4H, m), 6.71-6.83 (3H, m), 7.16 (1H, t, J=8.0 Hz), 7.27 (1H, dd, J=8.5, 2.0 Hz), 7.40 (1H, d, J=8.5 Hz), 7.88 (1H, d, J=2.0 Hz).


Example 349






Yield: 27%, 1H-NMR (DMSO-d6): δ1.18-1.42 (2H, m), 1.68-1.94 (5H, m), 2.47 (2H, t, J=7.5 Hz), 2.80 (2H, t, J=7.5 Hz), 3.10-3.23 (2H, m), 3.96-4.10 (4H, m), 6.84 (1H, t, J=7.5 Hz), 6.96 (1H, d, J=7.5 Hz), 7.12-7.21 (2H, m), 7.27 (1H, dd, J=8.5, 2.0 Hz), 7.40 (1H, d, J=8.5 Hz), 7.88 (1H, d, J=2.0 Hz), 12.09 (1H, s).


Example 350






Yield: 27%, 1H-NMR (DMSO-d6): δ1.14-1.31 (2H, m), 1.50-1.61 (2H, m), 1.64-1.86 (3H, m), 2.96-3.22 (4H, m), 3.93-4.03 (2H, m), 7.23-7.36 (3H, m), 7.39 (1H, d, J=8.5 Hz), 7.67 (1H, d, J=7.0 Hz), 7.81 (1H, s), 7.88 (1H, d, J=2.0 Hz).


Example 351






Yield: 72%, 1H-NMR (DMSO-d6): δ1.12-1.32 (2H, m), 1.50-1.63 (2H, m), 1.64-1.87 (3H, m), 2.95-3.06 (2H, m), 3.07-3.22 (2H, m), 3.55 (2H, s), 3.92-4.08 (2H, m), 4.05 (1H, d, J=2.0 Hz), 7.17-7.31 (4H, m), 7.39 (1H, d, J=8.5 Hz), 7.87 (1H, d, J=7.5 Hz), 12.36 (1H, brs).


Example 352






Yield: 65%, 1H-NMR (CDCl3); δ1.33 (2H, m), 1.73-1.90 (5H, m), 2.31 (3H, s), 3.14 (2H, t, J=12.6 Hz), 3.58 (2H, s), 4.01 (2H, t, J=5.7 Hz), 4.11 (2H, d, J=14.1 Hz), 6.65 (2H, s), 6.70 (1H, s), 7.23 (1H, dd, J=8.4, 2.1 Hz), 7.43 (1H, d, J=8.4 Hz), 7.54 (1H, d, J=2.1 Hz)


Example 353






Yield: 90%, 1H-NMR (DMSO-d6): δ1.23-1.36 (2H, m), 1.72-1.87 (5H, m), 2.07 (3H, s), 3.15-3.23 (2H, m), 3.56 (2H, s), 4.01 (4H, t, J=5.7 Hz), 6.77 (1H, d, J=8.1 Hz), 6.87 (1H, d, J=8.1 Hz), 7.07 (1H, t, J=8.1 Hz), 7.28 (1H, dd, J=8.7, 2.1 Hz), 7.40 (1H, d, J=8.7 Hz), 7.89 (1H, d, J=2.1 Hz).


Example 354






Yield: 65%, 1H-NMR (DMSO-d6): δ1.20-1.35 (1H, m), 1.65-1.90 (6H, m), 3.10-3.25 (2H, m), 3.54 (2H, s), 3.95-4.15 (4H, m), 6.75-6.85 (1H, m), 7.10 (1H, dd, J=8, 3.5 Hz), 7.14 (1H, d, J=8 Hz), 7.24 (1H, dd, J=8.5, 2 Hz), 7.40 (1H, d, J=8.5 Hz), 7.88 (1H, d, J=2 Hz), 12.34 (1H, brs).


Example 355






Yield: 36%, 1H-NMR (DMSO-d6): δ1.20-1.39 (2H, m), 1.66-1.93 (5H, m), 3.08-3.23 (2H, m), 3.40 (2H, s), 3.94-4.13 (4H, m), 6.76-6.84 (1H, m), 7.06 (1H, s), 7.23-7.32 (2H, m), 7.36-7.43 (1H, m), 7.87 (1H, d, J=2.0 Hz).


Example 356






Yield: 59%, 1H-NMR (DMSO-d6): δ1.17-1.37 (2H, m), 1.62-1.91 (5H, m), 3.09-3.25 (2H, m), 3.34 (2H, s), 3.92-4.07 (4H, m), 6.75 (1H, dd, J=8.5, 3.0 Hz), 6.92 (1H, d, J=3.0 Hz), 7.21 (1H, d, J=8.5 Hz), 7.27 (1H, dd, J=8.5, 2.0 Hz), 7.40 (1H, d, J=8.5 Hz), 7.88 (1H, d, J=2.0 Hz).


Example 357






Yield: 63%, 1H-NMR (DMSO-d6): δ2.69 (4H, t, J=4.5 Hz), 2.80 (2H, t, J=5.5 Hz), 3.56 (4H, t, J=4.5 Hz), 4.22 (2H, t, J=5.5 Hz), 7.01 (1H, t, J=7.5 Hz), 7.16 (1H, d, J=7.5 Hz), 7.29 (1H, dd, J=8.5, 2.0 Hz), 7.43 (1H, d, J=8.5 Hz), 7.48 (1H, t, J=7.5 Hz), 7.61 (1H, d, J=7.5 Hz), 7.91 (1H, d, J=2.0 Hz).


Example 358






Yield: 31%, 1H-NMR (DMSO-d6): δ2.65 (4H, t, J=5.0 Hz), 2.80 (2H, t, J=5.5 Hz), 3.57 (4H, t, J=5.0 Hz), 4.15 (2H, t, J=5.5 Hz), 7.10 (1H, d, J=8.0 Hz), 7.27-7.36 (2H, m), 7.41-7.52 (3H, m), 7.91 (1H, d, J=2.2 Hz).


Example 359






Yield: 50%, 1H-NMR (DMSO-d6): δ2.64 (4H, t, J=5.0 Hz), 2.80 (2H, t, J=5.5 Hz), 3.57 (4H, t, J=5.0 Hz), 4.20 (2H, t, J=5.5 Hz), 7.03 (2H, d, J=9 Hz), 7.29 (1H, dd, J=8.5, 2.0 Hz), 7.42 (1H, d, J=8.5 Hz), 7.87 (2H, d, J=9.0 Hz), 7.91 (1H, d, J=2.0 Hz).


Example 360






Yield: 29%, 1H-NMR (DMSO-d6): δ1.18-1.36 (2H, m), 1.68-1.88 (5H, m), 3.00-3.25 (2H, m), 3.94-4.07 (2H, m), 4.20 (2H, t, J=6.0 Hz), 6.41 (1H, d, J=4.0 Hz), 7.27 (1H, dd, J=8.5, 2.0 Hz), 7.40 (1H, d, J=8.5 Hz), 7.44 (1H, d, J=4.0 Hz), 7.88 (1H, d, J=2.0 Hz).


Example 361






Yield: 64%, 1H-NMR (DMSO-d6): δ2.13 (3H, s), 2.68 (4H, t, J=5 Hz), 2.82 (2H, t, J=5.5 Hz), 3.47 (2H, s), 3.63 (4H, t, J=5 Hz), 4.10 (2H, t, J=5.5 Hz), 6.72 (1H, d, J=8 Hz), 6.86 (1H, s), 7.05 (1H, d, J=7.5 Hz), 7.57 (2H, s), 8.25 (1H, s), 12.50 (1H, brs).


Example 362






Yield: 25%, 1H-NMR (DMSO-d6): δ1.88-1.94 (2H, m), 2.73-2.75 (2H, m), 2.87 (2H, t, J=5.1 Hz), 2.92-2.95 (2H, m), 3.25 (2H, s), 3.67-3.72 (4H, m), 4.01 (2H, t, J=5.7 Hz), 6.68-6.82 (3H, m), 7.10 (1H, t, J=7.5 Hz), 7.26 (1H, dd, J=8.7, 2.1 Hz), 7.40 (1H, d, J=8.7 Hz), 7.88 (1H, d, J=2.1 Hz).


Example 363






Yield: 68%, 1H-NMR (DMSO-d6): δ1.85-1.95 (2H, m), 2.09 (3H, s), 2.75-2.82 (2H, m), 2.92 (2H, t, J=5.5 Hz), 2.95-3.02 (2H, m), 3.49 (2H, s), 3.60-3.75 (4H, m), 4.03 (2H, t, J=5.5 Hz), 6.71 (1H, d, J=7.5 Hz), 6.83 (1H, s), 7.03 (1H, d, J=7.5 Hz), 7.26 (1H, dd, J=8.5, 2 Hz), 7.39 (1H, d, J=8.5 Hz), 7.87 (1H, d, J=2 Hz), 12.37 (1H, brs).


Example 364






Yield: 67%, 1H-NMR (DMSO-d6): δ1.85-1.95 (2H, m), 2.75-2.85 (2H, m), 2.93 (2H, t, J=5.5 Hz), 2.95-3.05 (2H, m), 3.55 (2H, s), 3.60-3.80 (4H, m), 4.12 (2H, t, J=5.5 Hz), 6.83 (1H, dd, J=8, 1.5 Hz), 7.07 (1H, d, J=1.5 Hz), 7.25 (1H, dd, J=8.5, 2 Hz), 7.33 (1H, d, J=8 Hz), 7.39 (1H, d, J=8.5 Hz), 7.87 (1H, d, J=2 Hz), 12.37 (1H, brs).


Example 365






Yield: 45%, 1H-NMR (DMSO-d6): δ1.20-1.39 (2H, m), 1.65-1.94 (5H, m), 3.17-3.32 (2H, m), 3.99-4.12 (4H, m), 6.92-6.99 (1H, m), 7.23 (1H, t, J=7.5 Hz), 7.40-7.48 (2H, m), 7.51-7.59 (2H, m), 8.21 (1H, s).


Example 366






Yield: 48%, 1H-NMR (DMSO-d6): δ1.18-1.38 (2H, m), 1.63-1.94 (5H, m), 3.13-3.30 (2H, m), 3.32 (2H, s), 3.93-4.13 (4H, m), 6.70-6.85 (3H, m), 7.13 (1H, t, J=8.0 Hz), 7.49-7.60 (2H, m), 8.21 (1H, s).


Example 367






Yield: 82%, 1H-NMR (DMSO-d6): δ1.17-1.42 (2H, m), 1.68-1.96 (5H, m), 3.13-3.30 (2H, m), 3.43 (2H, s), 3.95-4.19 (4H, m), 6.81 (1H, d, J=7.5 Hz), 7.07 (1H, s), 7.28 (1H, d, J=7.5 Hz), 7.49-7.61 (2H, m), 8.21 (1H, s).


Example 368






Yield: 77%, 1H-NMR (DMSO-d6): δ1.85-2.00 (2H, m), 2.68-2.81 (2H, m), 2.82-3.03 (4H, m), 3.51 (2H, s), 3.60-3.89 (4H, m), 3.97-4.09 (2H, m), 6.75-6.90 (3H, m), 7.19 (1H, t, J=8.0 Hz), 7.50-7.60 (2H, m), 8.22 (1H, s), 12.26 (1H, br).


Example 369






Yield: 78%, 1H-NMR (DMSO-d6): δ1.84-1.98 (2H, m), 2.74-2.85 (2H, m), 2.86-3.07 (4H, m), 3.56 (2H, s), 3.60-3.85 (4H, m), 4.06-4.18 (2H, m), 6.83 (1H, dd, J=8.0, 2.0 Hz), 7.07 (1H, d, J=2.0 Hz), 7.33 (1H, d, J=8.0 Hz), 7.51-7.57 (2H, m), 8.22 (1H, s), 12.35 (1H, br).


Example 370






Yield: 68%, 1H-NMR (CDCl3); δ1.19-1.39 (2H, m), 1.64-1.92 (5H, m), 3.12-3.27 (2H, m), 3.96-4.08 (4H, m), 6.80-6.87 (1H, m), 7.06 (1H, dd, J=8.0, 2.0 Hz), 7.15 (1H, t, J=8.0 Hz), 7.38-7.47 (3H, m), 7.76 (1H, d, J=8.0 Hz).


Example 371






Yield: 87%, 1H-NMR (DMSO-d6): δ1.19-1.40 (2H, m), 1.63-1.92 (5H, m), 3.10-3.27 (2H, m), 3.51 (2H, s), 3.94-4.10 (4H, m), 6.77-6.86 (3H, m), 7.07 (1H, dd, J=8.5, 2.0 Hz), 7.20 (1H, t, J=7.5 Hz), 7.44 (1H, d, J=2.0 Hz), 7.76 (1H, d, J=8.5 Hz), 12.33 (1H, br).


Example 372






Yield: 36%, 1H-NMR (DMSO-d6): δ1.20-1.39 (2H, m), 1.63-1.93 (5H, m), 3.12-3.28 (2H, m), 3.53 (2H, s), 3.95-4.12 (4H, m), 6.78-6.88 (3H, m), 7.13 (1H, dd, J=8.0, 1.0 Hz), 7.20 (1H, t, J=7.5 Hz), 7.31 (1H, d, J=8.0 Hz), 7.39 (1H, dd, J=8.0, 1.0 Hz), 12.31 (1H, s).


Example 373






Yield: 89%, 1H-NMR (DMSO-d6): δ1.19-1.39 (2H, m), 1.65-1.93 (5H, m), 3.10-3.25 (2H, m), 3.96-4.09 (4H, m), 6.87-6.94 (1H, m), 7.20 (1H, t, J=8.0 Hz), 7.31-7.48 (4H, m), 8.00 (1H, d, J=2.0 Hz).


Example 374






Yield: 58%, 1H-NMR (DMSO-d6): δ1.18-1.37 (2H, m), 1.63-1.91 (5H, m), 3.10-3.26 (4H, m), 3.92-4.07 (4H, m), 6.63-6.84 (3H, m), 7.08 (1H, t, J=8.0 Hz), 7.31-7.42 (2H, m), 7.99 (1H, d, J=2.0 Hz).


Example 375






Yield: 46%, 1H-NMR (DMSO-d6): δ1.18-1.36 (2H, m), 1.61-1.90 (5H, m), 2.32 (3H, s), 3.04-3.19 (2H, m), 3.39 (2H, s), 3.91-4.07 (4H, m), 6.72-6.86 (3H, m), 7.06 (1H, d, J=8.5 Hz), 7.16 (1H, t, J=8.0 Hz), 7.31 (1H, d, J=8.5 Hz), 7.53 (1H, s).


Example 376






Yield: 83%, 1H-NMR (DMSO-d6): δ1.18-1.39 (2H, m), 1.63-1.92 (5H, m), 3.07-3.24 (2H, m), 3.52 (2H, s), 3.93-4.09 (4H, m), 6.77-6.78 (3H, m), 7.10 (1H, td, J=9.0, 2.5 Hz), 7.21 (1H, t, J=8.0 Hz), 7.41 (1H, dd, J=9.0, 4.5 Hz), 7.69 (1H, dd, J=9.0, 2.5 Hz), 12.34 (1H, br).


Example 377






Yield: 51%, 1H-NMR (DMSO-d6): δ1.18-1.35 (2H, m), 1.63-1.93 (5H, m), 3.09-3.26 (2H, m), 3.52 (2H, s), 3.95-4.13 (4H, m), 6.77-6.90 (3H, m), 7.20 (1H, t, J=8.0 Hz), 7.31 (1H, t, J=8.0 Hz), 7.43 (2H, t, J=8.0 Hz), 7.48 (1H, d, J=8.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.66 (2H, d, J=8.0 Hz), 8.07 (1H, s), 12.31 (1H, br).


Example 378






Yield: 77%, 1H-NMR (DMSO-d6): δ1.19-1.40 (2H, m), 1.64-1.91 (5H, m), 2.98-3.14 (2H, m), 3.53 (2H, s), 3.86-4.10 (4H, m), 6.78-6.90 (3H, m), 7.16-7.26 (2H, m), 7.31-7.34 (2H, m), 7.44-7.50 (2H, m), 7.58 (1H, s), 12.30 (1H, s).


Example 379






Yield: 76%, 1H-NMR (DMSO-d6): δ1.22-1.41 (2H, m), 1.68-1.90 (5H, m), 2.97-3.13 (2H, m), 3.56 (2H, s), 3.86-3.99 (2H, m), 4.06-4.16 (2H, m), 6.84 (1H, dd, J=8.0, 1.5 Hz), 7.09 (1H, d, J=1.5 Hz), 7.20 (1H, t, J=7.5 Hz), 7.31-7.41 (3H, m), 7.43-7.51 (2H, m), 7.58 (1H, s).


Example 380






Yield: 69%, 1H-NMR (DMSO-d6): δ1.83-1.95 (2H, m), 2.73-2.83 (2H, m), 2.87-3.00 (4H, m), 3.52-3.71 (6H, m), 4.12 (2H, m), 6.83 (1H, d, J=7.0 Hz), 7.08 (1H, s), 7.18 (1H, t, J=7.5 Hz), 7.28-7.38 (3H, m), 7.40-7.47 (2H, m), 7.56 (1H, s).


Example 381






Yield: 79%, 1H-NMR (DMSO-d6): δ1.20-1.41 (2H, m), 1.65-1.93 (5H, m), 3.05 (2H, m), 3.53 (2H, s), 3.90-4.10 (4H, m), 6.76-6.87 (3H, m), 7.16-7.32 (3H, m), 7.38 (2H, t, J=7.5 Hz), 7.85 (2H, d, J=7.5 Hz), 12.29 (1H, s).


Example 382






Yield: 54%, 1H-NMR (CDCl3): 1.88-2.03 (2H, m), 2.73-3.04 (6H, m), 3.30 (2H, s), 3.47-3.84 (4H, m), 3.86-4.02 (2H, m), 6.59 (1H, d, J=8.0 Hz), 6.68 (1H, s), 7.07 (1H, d, J=8.0 Hz), 7.20 (1H, d, J=11.5 Hz), 7.68 (1H, d, J=7.0 Hz).


Example 383






Yield 12%, 1H-NMR (DMSO-d6): δ2.25 (3H, s), 2.45-2.55 (4H, m), 3.44 (2H, s), 3.50-3.60 (4H, m), 4.47 (2H, s), 6.59 (1H, s), 6.65 (1H, s), 7.00 (1H, s), 7.28 (1H, dd, J=8.5, 2 Hz), 7.42 (1H, d, J=8.5 Hz), 7.90 (1H, d, J=2 Hz).


Example 384






Yield 68%, 1H-NMR (CDCl3); δ1.60 (6H, s), 2.23 (3H, s), 2.65 (4H, t, J=5 Hz), 3.57 (2H, s), 3.62 (4H, t, J=5 Hz), 6.19 (1H, brs), 6.70-6.88 (3H, m), 7.24 (1H, dd, J=8.5, 2 Hz), 7.42 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2 Hz).


Example 385






Yield 64%, 1H-NMR (DMSO-d6): δ2.24 (3H, s), 2.51 (4H, t, J=5.5 Hz), 3.43 (2H, s), 3.62 (4H, t, J=5.5 Hz), 4.10 (2H, s), 6.53 (1H, s), 6.61 (1H, s), 6.64 (1H, s), 7.57 (2H, s), 8.24 (1H, s).


Example 386






Yield 96%, 1H-NMR (DMSO-d6): δ1.89-1.97 (2H, m), 2.23 (3H, s), 2.60 (2H, t, J=4.2 Hz), 2.74-2.77 (2H, m), 3.55 (2H, s), 3.68-3.70 (4H, m), 4.56 (2H, s), 6.58 (1H, s), 6.65 (1H, s), 6.70 (1H, s), 7.26 (1H, dd, J=9.0, 2.1 Hz), 7.39 (1H, d, J=8.7 Hz), 7.86 (1H, d, J=2.4 Hz).


Example 387






Yield 98%, 1H-NMR (DMSO-d6): δ1.85-2.00 (2H, m), 2.20 (3H, s), 2.55-2.65 (2H, m), 2.70-2.83 (2H, m), 3.52 (2H, s), 3.55-3.85 (4H, m), 4.14 (2H, s), 6.52 (1H, s), 6.58-6.65 (2H, m), 7.55 (2H, s), 8.22 (1H, s).


Example 388






Yield 59%, 1H-NMR (CD3OD): δ2.29 (3H, s), 2.60 (4H, t, J=5.0 Hz), 3.46-3.57 (6H, m), 4.36 (2H, s), 6.69 (1H, s), 6.75 (2H, s), 7.21 (1H, t, J=7.5 Hz), 7.33 (2H, t, J=7.5 Hz), 7.41 (1H, s), 7.45 (2H, d, J=7.5 Hz).


Example 389






Yield 67%, 1H-NMR (CD3OD): δ1.98-2.12 (2H, m), 2.27 (3H, s), 2.70-2.81 (2H, m), 2.84-2.94 (2H, m), 3.65 (2H, s), 3.67-3.93 (4H, m), 4.39 (2H, s), 6.67 (1H, s), 6.73 (1H, s), 6.74 (1H, s), 7.27 (1H, d, J=12.0 Hz), 7.96 (1H, d, J=7.0 Hz).


Example 390






Yield 97%, 1H-NMR (DMSO-d6): δ1.15 (3H, d, J=6 Hz), 2.18-2.33 (1H, m), 2.58-2.70 (1H, m), 2.70-2.83 (1H, m), 3.15-3.30 (2H, m), 3.35-3.50 (1H, m), 3.65-3.80 (1H, m), 3.83 (1H, d, J=11 Hz), 3.93 (1H, d, J=14 Hz), 4.65 (2H, s), 6.78 (1H, d, J=8 Hz), 6.90-6.95 (2H, m), 7.24 (1H, t, J=8 Hz), 7.56 (2H, s), 8.24 (1H, s), 13.0 (1H, brs).


Example 391






Yield 86%, 1H-NMR (DMSO-d6): δ1.13 (3H, d, J=6 Hz), 2.17 (3H, s), 2.20-2.30 (1H, m), 2.55-2.65 (1H, m), 2.68-2.80 (1H, m), 3.15-3.50 (3H, m), 3.65-3.75 (1H, m), 3.82 (1H, d, J=9 Hz), 3.88 (1H, d, J=13.5 Hz), 4.68 (2H, s), 6.80 (1H, s), 6.83 (1H, d, J=7.5 Hz), 7.09 (1H, d, J=7.5 Hz), 7.56 (2H, s), 8.23 (1H, s), 12.30 (1H, brs).


Example 392






Yield 86%, 1H-NMR (DMSO-d6): δ1.14 (3H, d, J=6 Hz), 2.20-2.25 (1H, m), 2.26 (3H, s), 2.55-2.65 (1H, m), 2.70-2.80 (1H, m), 3.10-3.50 (3H, m), 3.70-3.82 (3H, m), 4.63 (2H, s), 6.61 (1H, s), 6.70 (1H, s), 6.75 (1H, s), 7.55-7.59 (2H, m), 8.24 (1H, s), 12.9 (1H, brs).


Example 393






Yield 73%, 1H-NMR (DMSO-d6): δ1.03 (6H, d, J=6 Hz), 2.25 (3H, s), 2.60-2.80 (2H, m), 2.95-3.10 (2H, m), 3.71 (2H, s), 3.80-3.85 (2H, m), 4.61 (2H, s), 6.55 (1H, s), 6.76 (2H, s), 7.28 (1H, dd, J=8.5, 2 Hz), 7.42 (1H, d, J=8.5 Hz), 7.90 (1H, d, J=2 Hz), 12.95 (1H, s).


Example 394






Yield 82%, 1H-NMR (DMSO-d6): δ1.04 (6H, d, J=6 Hz), 2.25 (3H, s), 2.70-2.80 (2H, m), 2.95-3.15 (2H, m), 3.71 (2H, s), 3.80-3.95 (2H, m), 4.61 (2H, s), 6.55 (1H, s), 6.76 (2H, s), 7.57 (2H, s), 8.24 (1H, s), 12.94 (1H, brs).


Example 395






Yield 72%, 1H-NMR (DMSO-d6): δ1.31 (3H, d, J=6.5 Hz), 2.02-2.24 (2H, m), 2.25 (3H, s), 2.70 (1H, d, J=11 Hz), 2.88 (1H, d, J=12 Hz), 3.20-3.35 (1H, m), 3.37 (1H, d, J=13.5 Hz), 3.51 (1H, d, J=13.5 Hz), 3.77 (1H, d, J=13 Hz), 4.10-4.25 (1H, m), 4.60 (2H, s), 6.61 (1H, s), 6.70 (1H, s), 6.73 (1H, s), 7.26 (1H, dd, J=8.5, 2 Hz), 7.40 (1H, d, J=8.5 Hz), 7.88 (1H, d, J=2 Hz), 13.00 (1H, brs).


Example 396






Yield 76%, 1H-NMR (DMSO-d6): δ1.34 (3H, d, J=6.5 Hz), 2.06-2.30 (5H, m), 2.73 (1H, d, J=10.5 Hz), 2.90 (1H, d, J=10.5 Hz), 3.30-3.56 (3H, m), 3.84 (1H, d, J=11.5 Hz), 4.19-4.32 (1H, m), 4.38 (2H, s), 6.58 (1H, s), 6.67 (1H, s), 6.70 (1H, s), 7.56 (2H, s), 8.24 (1H, s).


Example 397






Yield 82%, 1H-NMR (CDCl3): δ0.97 (3H, t, J=7.5 Hz), 1.62-1.85 (2H, m), 2.28 (3H, s), 2.80-3.00 (3H, m), 3.55 (1H, d, J=13 Hz), 3.65-3.77 (1H, m), 3.77-3.90 (3H, m), 4.23 (1H, d, J=13 Hz), 4.65 (2H, s), 6.63 (1H, s), 6.80 (1H, s), 7.01 (1H, s), 7.53 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 398






Yield 92%, 1H-NMR (CDCl3): δ2.27 (3H, s), 2.27-2.40 (1H, m), 2.90 (1H, d, J=13.5 Hz), 3.06 (1H, d, J=11.5 Hz), 3.32-3.55 (3H, m), 3.80 (1H, d, J=13.5 Hz), 3.95-4.10 (2H, m), 5.30 (2H, s), 6.63 (1H, s), 6.66 (1H, s), 6.72 (1H, s), 7.30-7.45 (3H, m), 7.45-7.60 (4H, m), 7.82 (1H, s).


Example 399






Yield 81%, 1H-NMR (CDCl3): δ1.32 (3H, d, J=6.6 Hz), 2.26 (3H, s), 2.76 (1H, s), 2.93-3.02 (2H, m), 3.37 (1H, d, J=12.9 Hz), 3.49-3.56 (1H, m), 3.70 (2H s), 3.87 (1H, d, J=10.8 Hz), 4.25 (1H, d, J=12.9 Hz), 4.63 (2H, s), 6.62 (1H, s), 6.77 (1H, s), 6.99 (1H, s), 7.24 (1H, dd, J=2.1, 8.7 Hz), 7.42 (1H, d, J=8.7 Hz), 7.54 (1H, d, J=2.1 Hz)


Example 400






Yield 80%, 1H-NMR (CDCl3): δ1.33 (3H, d, J=6.0 Hz), 2.27 (3H, s), 2.76 (1H, br), 2.93-3.02 (2H, m), 3.38 (1H, d, J=12.6 Hz), 3.49-3.56 (1H, m), 3.71 (2H, s), 3.87 (1H, d, J=11.1 Hz), 4.25 (1H, d, J=12.6 Hz), 4.63 (2H, s), 6.62 (1H, s), 6.77 (1H, s), 6.99 (1H, s), 7.24 (1H, dd, J=1.8, 8.7 Hz), 7.42 (1H, d, J=8.7 Hz), 7.54 (1H, d, J=1.8 Hz)


Example 401






Yield 88%, 1H-NMR (CDCl3): δ1.41 (3H, d, J=6.5 Hz), 2.29 (3H, s), 2.35 (1H, td, J=12, 3.5 Hz), 2.48 (1H, dd, J=12, 4 Hz), 2.91 (1H, d, J=12 Hz), 3.26 (1H, d, J=11.5 Hz), 3.52 (1H, d, J=13 Hz), 3.54-3.65 (1H, m), 3.80 (1H, d, J=13 Hz), 3.89 (1H, d, J=13 Hz), 4.25-4.36 (1H, m), 4.62 (2H, s), 6.69 (1H, s), 6.75 (1H, s), 6.86 (1H, s), 7.52 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=8.5 Hz), 7.83 (1H, s).


Example 402






Yield 94%, 1H-NMR (CDCl3): δ0.96 (3H, t, J=7 Hz), 1.60-1.86 (2H, m), 2.29 (3H, s), 2.75-2.86 (1H, m), 2.87-3.00 (1H, m), 3.00-3.10 (1H, m), 3.51 (1H, d, J=13 Hz), 3.65-3.80 (1H, m), 3.80-3.93 (3H, m), 4.28 (1H, d, J=13 Hz), 4.63 (1H, d, J=16.5 Hz), 4.71 (1H, d, J=16.5 Hz) 6.63 (1H, s), 6.81 (1H, s), 7.02 (1H, s), 7.53 (1H, d, J=8.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 403






Yield 86%, 1H-NMR (CDCl3): δ0.96 (3H, t, J=7.5 Hz), 1.62-1.86 (2H, m), 2.28 (3H, s), 2.76-2.88 (1H, m), 2.89-3.00 (1H, m), 3.01-3.13 (1H, m), 3.52 (1H, d, J=13 Hz), 3.65-3.93 (4H, m), 4.30 (1H, d, J=13 Hz), 4.63 (1H, d, J=16.5 Hz), 4.72 (1H, d, J=16.5 Hz), 6.63 (1H, s), 6.82 (1H, s), 7.03 (1H, s), 7.49-7.60 (2H, m), 7.84 (1H, s).


Example 404






Yield 68%, 1H-NMR (DMSO-d6): δ0.89 (3H, t, J=7.0 Hz), 1.22-1.69 (4H, m), 2.22-2.37 (1H, m), 2.24 (3H, s), 2.49-2.62 (1H, m), 2.68-2.82 (1H, m), 3.28 (1H, d, J=13.5 Hz), 3.38-3.68 (3H, m), 3.69-3.80 (1H, m), 3.83 (1H, d, J=13.5 Hz), 4.28 (2H, s), 6.53 (1H, s), 6.64 (1H, s), 6.67 (1H, s), 7.53 (1H, d, J=8.5 Hz), 7.57 (1H, d, J=8.5 Hz), 8.22 (1H, s).


Example 405






Yield 87%, 1H-NMR (CDCl3): δ0.90 (3H, t, J=7.2 Hz), 1.19-1.28 (1H, m), 1.45-1.52 (1H, m), 1.65 (2H, br), 2.78 (3H, s), 2.93 (2H, br), 3.05 (1H, br), 3.52 (1H, d, J=12.6 Hz), 3.67-3.74 (1H, m), 3.81-3.91 (3H, m), 4.30 (1H, d), 4.66 (2H, q, J=11.1 Hz), 6.62 (1H, s), 6.81 (1H, s), 7.03 (1H, s), 7.52-7.61 (2H, m), 7.84 (1H, s)


Example 406






Yield 82%, 1H-NMR (DMSO-d6): δ0.88 (3H, t, J=6.5 Hz), 1.18-1.70 (6H, m), 2.23 (3H, s), 2.24-2.37 (1H, m), 2.48-2.60 (1H, m), 2.67-2.80 (1H, m), 3.27 (1H, d, J=13.5 Hz), 3.36-3.82 (4H, m), 3.83 (1H, d, J=13.5 Hz), 4.31 (2H, s), 6.54 (1H, s), 6.65 (1H, s), 6.67 (1H, s), 7.53 (1H, d, J=9.0 Hz), 7.56 (1H, d, J=9.0 Hz), 8.22 (1H, s).


Example 407






Yield 70%, 1H-NMR (DMSO-d6): δ0.88 (6H, t, J=6.5 Hz), 1.21-1.35 (1H, m), 1.45-1.58 (1H, m), 1.58-1.73 (1H, m), 2.23 (3H, s), 2.32-2.43 (1H, m), 2.59-2.80 (2H, m), 3.35 (1H, d, J=13.5 Hz), 3.37-3.45 (1H, m), 3.45-3.60 (2H, m), 3.60-3.71 (1H, m), 3.77 (1H, d, J=13.5 Hz), 4.19 (2H, s), 6.51 (1H, s), 6.63 (1H, s), 6.66 (1H, s), 7.27 (1H, dd, J=8.5, 2 Hz), 7.40 (1H, d, J=8.5 Hz), 7.88 (1H, d, J=2 Hz).


Example 408






Yield 77%, 1H-NMR (DMSO-d6): δ0.87 (3H, d, J=6.5 Hz), 0.89 (3H, d, J=6.5 Hz), 1.21-1.36 (1H, m), 1.43-1.57 (1H, m), 1.58-1.73 (1H, m), 2.23 (3H, s), 2.30-2.43 (1H, m), 2.60-2.79 (2H, m), 3.34 (1H, d, J=13.5 Hz), 3.35-3.72 (4H, m), 3.77 (1H, d, J=13.5 Hz), 4.25 (2H, s), 6.53 (1H, s), 6.64 (1H, s), 6.70 (1H, s), 7.27 (1H, dd, J=8.5, 2.0 Hz), 7.40 (1H, d, J=8.5 Hz), 7.88 (1H, d, J=2.0 Hz).


Example 409






Yield 76%, 1H-NMR (CDCl3): δ0.77 (3H, d, J=6.5 Hz), 0.92 (3H, d, J=6.5 Hz), 1.40-1.75 (3H, m), 2.25 (3H, s), 2.80-3.05 (3H, m), 3.46 (1H, d, J=13 Hz), 3.60-3.95 (4H, m), 4.22 (1H, d, J=13 Hz), 4.56 (1H, d, J=16 Hz), 4.65 (1H, d, J=16 Hz), 6.63 (1H, s), 6.77 (1H, s), 7.01 (1H, s), 7.52 (1H, d, J=8.5 Hz), 7.59 (1H, d, J=8.5 Hz), 7.83 (1H, s).


Example 410






Yield 79%, 1H-NMR (CDCl3): δ1.33 (3H, d, J=6.5 Hz), 2.28 (3H, s), 2.70-2.83 (1H, m), 2.92-3.08 (2H, m), 3.38 (1H, d, J=13 Hz), 3.54-3.65 (1H, m), 3.70-3.82 (2H, m), 3.87-3.97 (1H, m), 4.25 (1H, d, J=13 Hz), 4.60 (1H, d, J=16.5 Hz), 4.67 (1H, d, J=16.5 Hz), 6.64 (1H, s), 6.78 (1H, s), 6.99 (1H, s), 7.26 (1H, d, J=11.5 Hz), 7.74 (1H, d, J=7 Hz).


Example 411






Yield 93%, 1H-NMR (CDCl3): δ0.92 (3H, t, J=7.0 Hz), 1.42-1.74 (2H, m), 2.13 (3H, s), 2.27-2.57 (2H, m), 2.62-2.82 (1H, m), 3.08-3.24 (1H, m), 3.35-3.77 (4H, m), 3.80-3.97 (1H, m), 4.37 (2H, s), 6.58 (1H, s), 6.63 (1H, s), 6.74 (1H, s), 7.20 (1H, d, J=11.5 Hz), 7.66 (1H, d, J=7.0 Hz).


Example 412






Yield 80%, 1H-NMR (CDCl3): δ1.18 (6H, d, J=6.0 Hz), 2.25 (3H, s), 2.78-2.94 (2H, m), 3.13-3.29 (2H, m), 3.78-3.94 (4H, m), 4.54 (2H, s), 6.61 (1H, s), 6.74 (1H, s), 6.80 (1H, s), 7.24 (1H, d, J=11.5 Hz), 7.72 (1H, d, J=7.0 Hz).


Example 413






Yield 82%, 1H-NMR (DMSO-d6): δ3.52 (2H, s), 3.57 (8H, s), 4.65 (2H, s), 6.87 (2H, s), 6.98 (1H, s), 7.29 (1H, d, J=8.7, 2.4 Hz), 7.42 (1H, dd, J=8.7 Hz), 7.91 (1H, d, J=2.4 Hz)


Example 414






Yield 83%, 1H-NMR (DMSO-d6): δ2.40-2.55 (4H, m), 3.46 (2H, s), 3.53-3.56 (4H, m), 4.55 (2H, s), 6.85 (2H, d, J=8.4 Hz), 7.22 (2H, d, J=8.4 Hz), 7.28 (1H, dd, J=8.4, 2.4 Hz), 7.42 (1H, d, J=8.4 Hz), 7.90 (1H, d, J=2.4 Hz).


Example 415






Yield 51%, 1H-NMR (DMSO-d6): δ2.16 (3H, s), 2.40-2.55 (4H, m), 3.47 (2H, s), 3.50-3.60 (4H, m), 4.67 (2H, s), 6.75-6.85 (2H, m), 7.08 (1H, d, J=7.5 Hz), 7.27 (1H, dd, J=8.5, 1 Hz), 7.41 (1H, d, J=8 Hz), 7.88 (1H, d, J=2 Hz), 12.9 (1H, brs).


Example 416






Yield 92%, 1H-NMR (DMSO-d6): δ2.19 (3H, s), 2.50-2.55 (4H, m), 3.52 (4H, s), 3.55-3.58 (4H, m), 6.76 (1H, d, J=8.4 Hz), 7.07 (1H, d, J=8.4 Hz), 7.11 (1H, s), 7.28 (1H, dd, 8.7, 1.5 Hz), 7.42 (1H, d, J=8.7 Hz), 7.90 (1H, d, J=1.5 Hz).


Example 417






Yield 91%, 1H-NMR (DMSO-d6): δ1.90 (2H, m), 2.14 (3H, s), 2.58 (2H, m), 2.73 (2H, m), 3.50 (2H, s), 3.65-3.70 (4H, m), 4.49 (2H, s), 6.68 (1H, d, J=8.4 Hz), 7.01 (1H, d, J=8.4 Hz), 705 (1H, s), 7.26 (1H, dd, J=8.7, 2.1 Hz), 7.40 (1H, d, J=8.7 Hz), 7.88 (1H, d, J=2.1 Hz).


Example 418






Yield 28%, 1H-NMR (CDCl3): δ1.33 (6H, d, J=6.0 Hz), 2.27 (3H, s), 2.87-3.04 (2H, m), 3.12-3.29 (2H, m), 4.02 (2H, s), 4.30 (2H, d, J=13.0 Hz), 4.59 (2H, s), 6.70 (2H, s), 6.83 (1H, s), 7.35-7.44 (1H, m), 7.52-7.61 (1H, m), 7.65 (1H, d, J=7.0 Hz), 7.86 (1H, d, J=7.0 Hz), 8.51 (1H, s).


Example 419






Yield 37%, 1H-NMR (CDCl3): δ1.37 (3H, d, J=6.5 Hz), 2.26 (3H, s), 2.84-3.23 (3H, m), 3.45 (1H, d, J=13.0 Hz), 3.71-4.14 (4H, m), 4.34 (1H, d, J=13.0 Hz), 4.62 (1H, d, J=16.0 Hz), 4.69 (1H, d, J=16.0 Hz), 6.60 (1H, s), 6.81 (1H, s), 7.12 (1H, s), 7.37-7.47 (1H, m), 7.53-7.63 (1H, m), 7.67 (1H, d, J=8.0 Hz), 7.89 (1H, d, J=8.0 Hz), 8.52 (1H, s).


Example 420






Yield 55%, 1H-NMR (CDCl3): δ1.24 (6H, d, J=6.0 Hz), 2.20 (3H, s), 2.77-2.92 (2H, m), 3.03-3.18 (2H, m), 3.89 (2H, s), 4.23 (2H, d, J=11.5 Hz), 4.48 (2H, s), 6.61 (1H, s), 6.69 (1H, s), 6.78 (1H, s), 7.46 (1H, dd, J=9.0, 2.0 Hz), 7.54 (1H, d, J=9.0 Hz), 7.81 (1H, d, J=2.0 Hz), 8.47 (1H, s).


Example 421






Yield 60%, 1H-NMR (CDCl3): δ1.32 (6H, d, J=6.0 Hz), 2.27 (3H, s), 2.85-3.00 (2H, m), 3.16-3.30 (2H, m), 3.98 (2H, s), 4.29-4.41 (2H, m), 4.60 (2H, s), 6.67 (1H, s), 6.73 (1H, s), 6.83 (1H, s), 7.65-7.75 (2H, m), 8.12 (1H, s), 8.57 (1H, s).


Example 422






Yield 46%, 1H-NMR (DMSO-d6): δ3.53 (2H, s), 3.54-3.74 (8H, m), 4.87 (2H, s), 6.79-6.90 (3H, m), 7.22 (1H, t, J=7.5 Hz), 7.32 (1H, dd, J=8.5, 2.0 Hz), 7.46 (1H, d, J=8.5 Hz), 7.94 (1H, d, J=2.0 Hz), 12.31 (1H, br).


Example 423






Yield 21%, 1H-NMR (DMSO-d6): δ2.45-2.55 (4H, m), 3.33 (2H, s), 3.55-3.60 (4H, m), 6.50-6.60 (1H, m), 7.15-7.20 (1H, m), 7.29 (1H, dd, J=8.5, 2 Hz), 7.43 (1H, d, J=8.5 Hz), 7.92 (1H, d, J=2.5 Hz).


Example 424






Yield 76%, 1H-NMR (DMSO-d6): δ2.58 (4H, s), 3.35 (2H, s), 3.59 (2H, s), 3.81 (2H, s), 7.06 (1H, d, J=3.6 Hz), 7.29 (1H, dd, J=8.7, 2.1 Hz), 7.43 (1H, d, J=8.4 Hz), 7.60 (1H, d, J=3.3 Hz), 7.91 (1H, d, J=2.1 Hz), 12.99 (1H, brs).


Example 425






Yield 76%, 1H-NMR (DMSO-d6): δ1.25 (2H, m), 3.30 (2H, m), 3.62 (2H, m), 4.20 (2H, m), 4.45 (2H, brs), 7.33 (1H, dd, J=8.4, 1.8 Hz), 7.49 (1H, d, J=8.7 Hz), 7.69-7.71 (2H, m), 7.98 (1H, d, J=1.8 Hz), 8.02 (2H, d, J=8.1 Hz).


Example 426






Yield 81%, 1H-NMR (DMSO-d6): δ2.45-2.50 (4H, m), 3.45-3.60 (8H, m), 7.15-7.35 (5H, m), 7.42 (1H, d, J=8.5 Hz), 7.91 (1H, d, J=2 Hz), 12.31 (1H, brs).


Example 427






Yield 94%, 1H-NMR (DMS-d6): δ2.50-2.55 (4H, m), 3.52 (4H, s), 3.57 (4H, s), 7.17 (1H, s), 7.24 (2H, s), 7.29 (1H, dd, J=2.1, 8.4 Hz), 7.42 (1H, d, J=8.4 Hz), 7.91 (1H, d, J=2.1 Hz)


Example 428






Yield 86%, 1H-NMR (DMS-d6): δ1.92 (2H, s), 2.61 (2H, s), 2.77 (2H, s), 3.53 (2H, s), 3.61 (2H, s), 3.60-3.65 (4H, m), 7.15 (1H, s), 7.21 (1H, s), 7.22 (1H, s), 7.26 (1H, dd, J=8.4, 2.1 Hz), 7.40 (1H, d, J=8.4 Hz), 7.88 (1H, d, J=2.1 Hz).


Example 429






Yield 18%, 1H-NMR (DMSO-d6): δ1.85-2.00 (2H, m), 2.57-2.68 (2H, m), 2.74-2.85 (2H, m), 3.52 (2H, s), 3.61 (2H, s), 3.62-3.85 (4H, m), 7.09-7.31 (4H, m), 7.52-7.58 (2H, m), 8.22 (1H, s).


Example 430






Yield 95%, 1H-NMR (DMSO-d6): δ1.05 (6H, d, J=6.5 Hz), 2.65-2.80 (2H, m), 3.04-3.15 (2H, m), 3.55 (2H, s), 3.79 (2H, s), 3.83-3.95 (2H, m), 7.05-7.15 (1H, m), 7.20-7.30 (3H, m), 7.57 (2H, s), 8.24 (1H, s), 12.27 (1H, brs).


Example 431






Yield 61%, 1H-NMR (CDCl3): δ1.08 (6H, d, J=6.5 Hz), 2.74-2.86 (2H, m), 3.08 (1H, d, J=13 Hz), 3.12 (1H, d, J=13 Hz), 3.62 (2H, s), 3.78 (2H, s), 3.86-3.95 (2H, m), 7.16-7.18 (2H, m), 7.34 (1H, s), 7.52 (1H, d, J=8.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 432






Yield 87%, 1H-NMR (DMSO-d6): δ1.01 (3H, d, J=6.5 Hz), 1.33 (3H, d, J=6.5 Hz), 2.25-2.35 (1H, m), 2.75-2.85 (1H, m), 3.08-3.20 (1H, m), 3.49 (1H, d, J=14 Hz), 3.56 (2H, s), 3.63-3.75 (3H, m), 4.23-4.35 (1H, m), 7.10-7.20 (1H, m), 7.20-7.35 (3H, m), 7.50-7.60 (2H, m), 8.21 (1H, s), 12.23 (1H, brs).


Example 433






Yield 87%, 1H-NMR (DMSO-d6): δ1.33 (3H, d, J=6.5 Hz), 2.10-2.30 (2H, m), 2.72 (1H, d, J=11.5 Hz), 2.94 (1H, d, J=12 Hz), 3.35-3.50 (2H, m), 3.57 (2H, s), 3.60 (1H, d, J=13.5 Hz), 3.75-3.90 (1H, m), 4.20-4.30 (1H, m), 7.15-7.32 (4H, m), 7.56 (2H, s), 8.22 (1H, s), 12.28 (1H, brs).


Example 434






Yield 82%, 1H-NMR (DMSO-d6): δ1.16 (3H, d, J=6 Hz), 2.15-2.35 (1H, m), 2.55-2.68 (1H, m), 2.70-2.80 (1H, m), 3.15-3.30 (2H, m), 3.35-3.50 (1H, m), 3.56 (2H, s), 3.70-3.80 (1H, m), 3.80-3.90 (1H, m), 3.97 (1H, d, J=13.5 Hz), 7.10-7.35 (4H, m), 7.56 (2H, s), 8.23 (1H, s), 12.29 (1H, brs).


Example 435






Yield 98%, 1H-NMR (CDCl3): δ1.00 (3H, t, J=7.5 Hz), 1.59-1.69 (1H, m), 1.73-1.80 (1H, m), 2.37-2.45 (1H, m), 2.54-2.59 (1H, m), 2.80-2.86 (1H, m), 3.34-3.54 (3H, m), 3.59-3.63 (1H, m), 3.63 (2H, s), 3.79 (1H, dd, J=2.7, 13.2 Hz), 4.04 (1H, d, J=13.2 Hz), 7.20-7.29 (5H, m), 7.42 (1H, d, J=8.7 Hz), 7.53 (1H, d, J=2.1 Hz)


Example 436






Yield 96%, 1H-NMR (CDCl3): δ0.92 (6H, dd, J=6.3, 16.2 Hz), 1.38-1.47 (1H, m), 1.51-1.59 (1H, m), 1.64-1.75 (1H, m), 2.43-2.51 (1H, m), 2.71-2.76 (1H, m), 2.79-2.87 (1H, m), 3.40 (2H, dt, J=3.0, 13.2 Hz), 3.57-3.64 (2H, m), 3.63 (2H, s), 3.76 (1H, dd, J=3.0, 12.9 Hz), 3.99 (1H, d, J=13.2 Hz), 7.21-7.31 (5H, m), 7.43 (1H, d, J=8.4 Hz), 7.53 (1H, d, J=2.4 Hz)


Example 437






Yield 89%, 1H-NMR (CDCl3): δ1.25 (3H, d, J=6.0 Hz), 2.30-2.38 (1H, m), 2.68-2.74 (1H, m), 2.83 (1H, dt, J=3.9, 12.0 Hz), 3.18-3.28 (2H, m), 3.39-3.49 (1H, m), 3.63 (2H, s), 3.63-3.70 (1H, m), 3.86 (1H, dd, J=2.4, 12.0 Hz), 4.10 (1H, d, J=13.2 Hz), 7.19-7.30 (5H, m), 7.43 (1H, d, J=8.4 Hz), 7.53 (1H, d, J=2.4 Hz)


Example 438






Yield 91%, 1H-NMR (CDCl3): δ1.30 (3H, d, J=6.0 Hz), 2.40 (1H, t, J=9.6 Hz), 2.78 (1H, br), 2.88 (1H, br), 3.33 (2H, d, J=12.6 Hz), 3.48-3.54 (1H, m), 3.64 (2H, s), 3.72 (1H, d, J=13.2 Hz), 3.89 (1H, d, J=10.2 Hz), 4.16 (1H, d, J=13.2 Hz), 7.22-7.33 (5H, m), 7.43 (1H, d, J=8.7 Hz), 7.54 (1H, d, J=2.1 Hz)


Example 439






Yield 96%, 1H-NMR (CDCl3): δ1.26 (3H, d, J=6 Hz), 2.25-2.40 (4H, m), 2.65-2.75 (1H, m), 2.80-2.90 (1H, m), 3.20 (1H, d, J=13 Hz), 3.25-3.30 (1H, m), 3.45-3.53 (1H, m), 3.61 (2H, s), 3.68-3.80 (1H, m), 3.84-3.95 (1H, m), 4.07 (1H, d, J=13 Hz), 7.03 (2H, s), 7.10 (1H, s), 7.51 (1H, d, J=8.5 Hz), 7.53 (1H, d, J=8.5 Hz), 7.83 (1H, s)


Example 440






Yield 67%, 1H-NMR (DMSO-d6): δ1.31 (3H, d, J=6.5 Hz), 2.03-2.25 (2H, m), 2.70 (1H, d, J=11.5 Hz), 2.91 (1H, d, J=12 Hz), 3.35-3.43 (2H, m), 3.56 (2H, s), 3.56-3.65 (1H, m), 3.79 (1H, d, J=11 Hz), 4.15-4.25 (1H, m), 7.15 (1H, d, J=7 Hz), 7.20-7.33 (4H, m), 7.41 (1H, d, J=8.5 Hz), 7.89 (1H, d, J=1.5 Hz), 12.30 (1H, brs).


Example 441






Yield 86%, 1H-NMR (CDCl3): δ1.37 (3H, d, J=7.0 Hz), 2.23 (1H, td, J=11.0, 3.5 Hz), 2.31 (1H, dd, J=11.0, 3.5 Hz), 2.71 (1H, d, J=11.0 Hz), 2.91 (1H, d, J=11.0 Hz), 3.44 (1H, d, J=13.5 Hz), 3.47 (1H, td, J=12.5, 3.5 Hz), 3.60 (1H, d, J=11.0 Hz), 3.64 (2H, s), 3.83 (1H, d, J=12.5 Hz), 4.09-4.21 (1H, m), 7.14-7.33 (5H, m), 7.42 (1H, d, J=8.5 Hz), 7.53 (1H, d, J=2.0 Hz).


Example 442






Yield 94%, 1H-NMR (CDCl3): δ1.37 (3H, d, J=6.5 Hz), 2.23 (1H, td, J=11.5, 3.5 Hz), 2.25-2.30 (1H, m), 2.32 (3H, s), 2.71 (1H, d, J=11.5 Hz), 2.91 (1H, d, J=11 Hz), 3.39 (1H, d, J=13.5 Hz), 3.45-3.54 (1H, m), 3.55 (1H, d, J=13.5 Hz), 3.60 (2H, s), 3.83 (1H, d, J=11.5 Hz), 4.10-4.20 (1H, m), 7.01 (1H, s), 7.06 (1H, s), 7.09 (1H, s), 7.23 (1H, dd, J=8.5, 2 Hz), 7.42 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2 Hz).


Example 443






Yield 82%, 1H-NMR (CDCl3): δ1.37 (3H, d, J=6.5 Hz), 2.13-2.36 (5H, m), 2.70 (1H, d, J=11.5 Hz), 2.89 (1H, d, J=11.5 Hz), 3.32-3.62 (5H, m), 3.76-3.87 (1H, m), 4.07-4.22 (1H, m), 6.99 (1H, s), 7.05 (1H, s), 7.07 (1H, s), 7.22 (1H, dd, J=8.5, 2.0 Hz), 7.42 (1H, d, J=8.5 Hz), 7.53 (1H, d, J=2.0 Hz).


Example 444






Yield 87%, 1H-NMR (DMSO-d6): δ1.33 (3H, d, J=6.5 Hz), 2.10-2.30 (2H, m), 2.72 (1H, d, J=11.5 Hz), 2.93 (1H, d, J=11.5 Hz), 3.30-3.50 (2H, m), 3.56 (2H, s), 3.59 (1H, d, J=13.5 Hz), 3.86 (1H, d, J=12.5 Hz), 4.20-4.30 (1H, m), 7.10-7.35 (4H, m), 7.56 (2H, s), 8.24 (1H, s), 12.43 (1H, brs).


Example 445






Yield 96%, 1H-NMR (CDCl3): δ1.34 (3H, d, J=6.5 Hz), 2.14 (1H, td, J=11.5, 3.5 Hz), 2.25 (1H, dd, J=11.5, 3.5 Hz), 2.66 (1H, d, J=11.5 Hz), 2.83 (1H, d, J=11.5 Hz), 3.37 (1H, d, J=13.5 Hz), 3.38-3.55 (4H, m), 3.82 (1H, d, J=11.5 Hz), 4.08-4.22 (1H, m), 7.10 (1H, s), 7.14-7.23 (3H, m), 7.45-7.56 (2H, m), 7.81 (1H, s).


Example 446






Yield 98%, 1H-NMR (CDCl3): δ1.39 (3H, d, J=6.5 Hz), 2.23 (1H, td, J=12, 3.5 Hz), 2.25-2.31 (1H, m), 2.32 (3H, s), 2.73 (1H, d, J=11.5 Hz), 2.92 (1H, d, J=12 Hz), 3.41 (1H, d, J=13 Hz), 3.45-3.55 (1H, m), 3.56 (1H, d, J=13 Hz), 3.59 (2H, s), 3.88 (1H, d, J=12 Hz), 4.17-4.28 (1H, m), 7.01 (1H, s), 7.06 (1H, s), 7.09 (1H, s), 7.51 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=8.5 Hz), 7.83 (1H, s).


Example 447






Yield 72%, 1H-NMR (CDCl3): δ1.39 (3H, d, J=6.5 Hz), 2.13-2.34 (5H, m), 2.71 (1H, d, J=11.5 Hz), 2.90 (1H, d, J=11.5 Hz), 3.39 (1H, d, J=13.0 Hz), 3.43-3.60 (4H, m), 3.87 (1H, d, J=12.5 Hz), 4.13-4.26 (1H, m), 6.99 (1H, s), 7.05 (2H, s), 7.46-7.58 (2H, m), 7.83 (1H, s).


Example 448






Yield 90%, 1H-NMR (CDCl3): δ1.40 (3H, d, J=6.5 Hz), 2.26 (1H, td, J=12, 3.5 Hz), 2.35 (1H, dd, J=11.5, 3.5 Hz), 2.72 (1H, d, J=11.5 Hz), 2.91 (1H, d, J=12 Hz), 3.43 (1H, d, J=13.5 Hz), 3.52 (1H, td, J=12.5, 3.5 Hz), 3.57 (1H, d, J=13.5 Hz), 3.64 (2H, s), 3.85-3.95 (1H, m), 4.19-4.30 (1H, m), 7.18 (1H, s), 7.21 (1H, s), 7.29 (1H, s), 7.51 (1H, d, J=8.5 Hz), 7.57 (1H, d, J=8.5 Hz), 7.84 (1H, s).


Example 449






Yield 68%, 1H-NMR (CDCl3): δ0.85 (3H, t, J=7.5 Hz), 1.82-1.99 (2H, m), 2.17-2.29 (2H, m), 2.78-2.92 (2H, m), 3.37-3.51 (1H, m), 3.42 (1H, d, J=13.0 Hz), 3.59 (1H, d, J=13.0 Hz), 3.65 (2H, s), 3.76-3.87 (1H, m), 3.93-4.04 (1H, m), 7.16-7.34 (5H, m), 7.39 (1H, d, J=8.5 Hz), 7.52 (1H, d, J=2.0 Hz).


Example 450






Yield 95%, 1H-NMR (DMSO-d6): δ0.79 (3H, t, J=7.5 Hz), 1.72-1.95 (2H, m), 2.07-2.20 (2H, m), 2.81 (1H, d, J=11 Hz), 2.89 (1H, d, J=11 Hz), 3.25-3.39 (2H, m), 3.40 (1H, d, J=13.5 Hz), 3.55 (2H, s), 3.59 (1H, d, J=13.5 Hz), 3.80-3.95 (1H, m), 7.13-7.34 (5H, m), 7.38 (1H, d, J=8.5 Hz), 7.87 (1H, d, J=2 Hz), 12.45 (1H, brs).


Example 451






Yield 96%, 1H-NMR (CDCl3): δ0.86 (3H, t, J=7.5 Hz), 1.80-2.00 (2H, m), 2.16-2.29 (2H, m), 2.33 (3H, s), 2.79-2.94 (2H, m), 3.38 (1H, d, J=13.5 Hz), 3.50 (1H, td, J=12.5, 3.5 Hz), 3.57 (1H, d, J=13.5 Hz), 3.61 (2H, s), 3.75-3.87 (1H, m), 3.93-4.03 (1H, m), 7.02 (1H, s), 7.06 (1H, s), 7.08 (1H, s), 7.21 (1H, dd, J=8.5, 2 Hz), 7.39 (1H, d, J=8.5 Hz), 7.52 (1H, d, J=2 Hz).


Example 452






Yield 77%, 1H-NMR (DMSO-d6): δ0.80 (3H, t, J=7.5 Hz), 1.67-1.97 (2H, m), 2.03-2.19 (2H, m), 2.28 (3H, s), 2.81 (1H, d, J=11.5 Hz), 2.89 (1H, d, J=11.0 Hz), 3.27-3.44 (2H, m), 3.48 (2H, s), 3.55 (1H, d, J=13.5 Hz), 3.81-3.95 (2H, m), 6.96 (1H, s), 7.02 (2H, s), 7.26 (1H, dd, J=8.5, 2.0 Hz), 7.38 (1H, d, J=8.5 Hz), 7.87 (1H, d, J=2.0 Hz).


Example 453






Yield 96%, 1H-NMR (DMSO-d6): δ0.80 (3H, t, J=7.5 Hz), 1.76-1.96 (2H, m), 2.09-2.20 (2H, m), 2.82 (1H, d, J=11.5 Hz), 2.89 (1H, d, J=11.5 Hz), 3.30-3.42 (2H, m), 3.43 (1H, d, J=13.5 Hz), 3.56 (2H, s), 3.60 (1H, d, J=13.5 Hz), 3.88-4.00 (1H, m), 7.12-7.32 (4H, m), 7.51 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=8.5 Hz), 8.21 (1H, s), 12.3 (1H, brs).


Example 454






Yield 89%, 1H-NMR (CDCl3): δ0.87 (3H, t, J=7.5 Hz), 1.85-2.00 (2H, m), 2.23 (2H, td, J=12.5, 3.5 Hz), 2.34 (3H, s), 2.81-2.96 (2H, m), 3.38 (1H, d, J=13.5 Hz), 3.49 (1H, td, J=12.5, 3.5 Hz), 3.58 (1H, d, J=13.5 Hz), 3.62 (2H, s), 3.80-3.95 (1H, m), 3.97-4.10 (1H, m), 7.02 (1H, s), 7.06 (1H, s), 7.08 (1H, s), 7.46-7.50 (2H, m), 7.81 (1H, s).


Example 455






Yield 89%, 1H-NMR (CDCl3): δ0.88 (3H, t, J=7.5 Hz), 1.93 (2H, quant, J=7.5 Hz), 2.19-2.32 (2H, m), 2.78-2.93 (2H, m), 3.40 (1H, d, J=13.5 Hz), 3.49 (1H, td, J=12.5, 3.5 Hz), 3.57 (1H, d, J=13.5 Hz), 3.64 (2H, s), 3.84-3.95 (1H, m), 3.96-4.10 (1H, m), 7.16 (1H, s), 7.22 (1H, s), 7.28 (1H, s), 7.45-7.57 (2H, m), 7.82 (1H, s).


Example 456






Yield 93%, 1H-NMR (CDCl3): δ0.86 (3H, t, J=7.5 Hz), 1.92 (2H, quant, J=7.5 Hz), 2.15-2.31 (2H, m), 2.80-2.96 (2H, m), 3.42 (1H, d, J=13 Hz), 3.48 (1H, td, J=12.5, 3 Hz), 3.61 (1H, d, J=13 Hz), 3.66 (2H, s), 3.80-3.95 (1H, m), 3.96-4.10 (1H, m), 7.15-7.33 (4H, m), 7.49 (1H, d, J=8.5 Hz), 7.50 (1H, d, J=8.5 Hz) 7.81 (1H, s).


Example 457






Yield 96%, 1H-NMR (CDCl3): δ0.87 (3H, t, J=7.5 Hz), 1.85-2.00 (2H, m), 2.15-2.28 (2H, m), 2.34 (3H, s), 2.80-2.95 (2H, m), 3.39 (1H, d, J=13 Hz), 3.51 (1H, td, J=13, 3.5 Hz), 3.58 (1H, d, J=13 Hz), 3.62 (2H, s), 3.80-3.95 (1H, m), 3.96-4.10 (1H, m), 7.02 (1H, s), 7.06 (1H, s), 7.08 (1H, s), 7.50 (1H, d, J=8.5 Hz), 7.53 (1H, d, J=8.5 Hz) 7.81 (1H, s).


Example 458






Yield 98%, 1H-NMR (CDCl3): δ0.87 (3H, t, J=7.5 Hz), 1.11-1.28 (2H, m), 1.68-1.88 (2H, m), 2.20-2.18 (2H, m), 2.64-2.79 (2H, m), 3.23-3.48 (5H, m), 3.74-3.96 (2H, m), 6.98-7.23 (5H, m), 7.35 (1H, d, J=8.5 Hz), 7.49 (1H, d, J=2.0 Hz).


Example 459






Yield 98%, 1H-NMR (CDCl3): δ0.91 (3H, t, J=7.2 Hz), 1.19-1.29 (2H, m), 1.77-1.94 (2H, m), 2.18-2.28 (2H, m), 2.81 (1H, d, J=11.1 Hz), 2.89 (1H, d, J=11.1 Hz), 3.40-3.47 (2H, m), 3.61 (1H, d, J=13.2 Hz), 3.66 (2H, s), 3.90 (1H, s), 3.99 (1H, d, J=12.0 Hz), 7.20-7.31 (5H, m), 7.39 (1H, d, J=8.7 Hz), 7.52 (1H, d, J=2.1 Hz)


Example 460






Yield 69%, 1H-NMR (CDCl3): δ0.92 (3H, t, J=7.0 Hz), 1.16-1.34 (2H, m), 1.68-2.00 (2H, m), 2.12-2.27 (2H, m), 2.32 (3H, s), 2.79 (1H, d, J=11.5 Hz), 2.86 (1H, d, J=11.5 Hz), 3.35 (1H, d, J=13.5 Hz), 3.39-3.62 (2H, m), 3.58 (2H, s), 3.82-4.03 (2H, m), 6.99 (1H, s), 7.03 (1H, s), 7.06 (1H, s), 7.21 (1H, dd, J=8.5, 2.0 Hz), 7.39 (1H, d, J=8.5 Hz), 7.52 (1H, d, J=2.0 Hz).


Example 461






Yield 91%, 1H-NMR (CDCl3): δ0.92 (3H, t, J=7.2 Hz), 1.20-1.30 (2H, m), 1.75-1.84 (1H, m), 1.87-1.97 (1H, m), 2.18-2.28 (2H, m), 2.34 (3H, s), 2.86 (2H, dd, J=11.1 Hz), 3.37 (1H, d, J=13.2 Hz), 3.48 (1H, dt, J=3.3, 12.6 Hz), 3.61 (1H, d, J=12.1 Hz), 3.62 (2H, s), 3.90 (1H, s), 3.99 (1H, d, J=11.1 Hz), 7.02 (1H, s), 7.07 (2H, s), 7.22 (1H, dd, J=2.1, 8.7 Hz), 7.40 (1H, d, J=8.7 Hz), 7.52 (1H, d, J=2.1 Hz)


Example 462






Yield 70%, 1H-NMR (CDCl3): δ0.92 (3H, t, J=7.0 Hz), 1.18-1.35 (2H, m), 1.75-1.98 (2H, m), 2.15-2.29 (2H, m), 2.81 (1H, d, J=11.5 Hz), 2.88 (1H, d, J=11.5 Hz), 3.41 (1H, d, J=13.0 Hz), 3.48 (1H, td, J=12.5, 3.0 Hz), 3.58 (1H, d, J=13.0 Hz), 3.62 (2H, s), 3.89-4.09 (2H, m), 7.14-7.32 (4H, m), 7.49 (1H, d, J=8.5 Hz), 7.53 (1H, d, J=8.5 Hz), 7.81 (1H, s).


Example 463






Yield 81%, 1H-NMR (CDCl3): δ0.92 (3H, t, J=7.2 Hz), 1.21-1.31 (2H, m), 1.80-1.94 (2H, m), 2.20-2.29 (2H, m), 2.82 (1H, d, J=11.4 Hz), 2.91 (1H, d, J=11.1 Hz), 3.43 (1H, d, J=13.2 Hz), 3.50 (1H, dt, J=3.0, 12.6 Hz), 3.61 (1H, d, J=13.2 Hz), 3.67 (2H, s), 3.99 (1H, d, J=14.1 Hz), 4.06 (1H, s), 7.20-7.34 (4H, m), 7.52 (2H, s), 7.82 (1H, s)


Example 464






Yield 81%, 1H-NMR (CDCl3): δ0.86 (3H, t, J=7.5 Hz), 1.14-1.38 (4H, m), 1.74-1.99 (2H, m), 2.16-2.30 (2H, m), 2.81 (1H, d, J=11.5 Hz), 2.89 (1H, d, J=11.5 Hz), 3.42 (1H, d, J=13 Hz), 3.46 (1H, td, J=13.5, 3.5 Hz), 3.60 (1H, d, J=13 Hz), 3.66 (2H, s), 3.80-3.93 (1H, m), 3.95-4.06 (1H, m), 7.15-7.35 (5H, m), 7.40 (1H, d, J=8.5 Hz), 7.52 (1H, d, J=2.5 Hz).


Example 465






Yield 91%, 1H-NMR (CDCl3): δ0.86 (3H, t, J=7.5 Hz), 1.13-1.40 (4H, m), 1.74-2.00 (2H, m), 2.16-2.30 (2H, m), 2.82 (1H, d, J=12 Hz), 2.88 (1H, d, J=11.5 Hz), 3.41 (1H, d, J=13.5 Hz), 3.41-3.51 (1H, m), 3.60 (1H, d, J=13.5 Hz), 3.66 (2H, s), 3.80-3.92 (1H, m), 3.94-4.05 (1H, m), 7.16-7.34 (5H, m), 7.39 (1H, d, J=8.5 Hz), 7.52 (1H, d, J=2 Hz).


Example 466






Yield 81%, 1H-NMR (CDCl3): δ0.87 (3H, t, J=7.5 Hz), 1.17-1.39 (4H, m), 1.75-2.03 (2H, m), 2.17-2.30 (2H, m), 2.34 (3H, s), 2.83 (1H, d, J=11.5 Hz), 2.91 (1H, d, J=10.5 Hz), 3.38 (1H, d, J=13.5 Hz), 3.44-3.55 (1H, m), 3.58 (1H, d, J=13.5 Hz), 3.62 (2H, s), 3.85-3.97 (1H, m), 4.00-4.10 (1H, m), 7.02 (1H, s), 7.06 (1H, s), 7.07 (1H, s), 7.51 (2H, s), 7.82 (1H, s).


Example 467






Yield 53%, 1H-NMR (DMSO-d6): δ0.87 (3H, d, J=6.5 Hz), 0.89 (3H, d, J=6.5 Hz), 2.02-2.25 (2H, m), 2.29 (3H, s), 2.45-3.05 (4H, m), 3.10 (1H, d, J=13.0 Hz), 3.35-3.58 (2H, m), 3.53 (2H, s), 4.01-4.22 (1H, m), 6.96 (1H, s), 7.00 (1H, s), 7.03 (1H, s), 7.49 (2H, s), 7.78 (1H, s).


Example 468






Yield 70%, 1H-NMR (DMSO-d6): δ0.85 (6H, t, J=7.5 Hz), 2.00 (1H, d, J=11.5 Hz), 2.14 (1H, t, J=11.5 Hz), 2.28 (3H, s), 2.50-2.57 (1H, m), 2.93 (2H, t, J=11.5 Hz), 3.32 (1H, d, J=13.5 Hz), 3.32-3.48 (1H, m), 3.49 (2H, s), 3.57 (1H, d, J=13.5 Hz), 3.58-3.65 (1H, m), 3.95-4.10 (1H, m), 6.97 (1H, s), 7.02 (2H, s), 7.49 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=8.5 Hz), 8.18 (1H, s), 12.4 (1H, brs).


Example 469






Yield 67%, 1H-NMR (DMSO-d6): δ0.88 (3H, d, J=6.5 Hz), 0.90 (3H, d, J=6.5 Hz), 1.32-1.58 (2H, m), 1.80-1.96 (1H, m), 2.05-2.23 (2H, m), 2.75 (1H, d, J=10.5 Hz), 2.89 (1H, d, J=11.5 Hz), 3.30-3.53 (2H, m), 3.48 (2H, s), 3.59 (1H, d, J=13.5 Hz), 3.80-4.08 (2H, m), 7.10-7.30 (5H, m), 7.38 (1H, d, J=8.5 Hz), 7.87 (1H, d, J=2.0 Hz).


Example 470






Yield 88%, 1H-NMR (CDCl3): δ0.90 (6H, dd, J=6, 2 Hz), 1.30-1.59 (2H, m), 1.80-1.95 (1H, m), 2.08-2.24 (2H, m), 2.75 (1H, d, J=11.5 Hz), 2.91 (1H, d, J=11.5 Hz), 3.20-3.37 (1H, m), 3.38 (1H, d, J=13.5 Hz), 3.55 (2H, s), 3.62 (1H, d, J=13.5 Hz), 3.80-3.96 (1H, m), 3.97-4.10 (1H, m), 7.10-7.32 (5H, m), 7.38 (1H, d, J=8.5 Hz), 7.89 (1H, d, J=2 Hz), 12.43 (1H, brs).


Example 471






Yield 62%, 1H-NMR (CDCl3): δ0.91 (3H, d, J=6.5 Hz), 0.93 (3H, d, J=6.5 Hz), 1.34-1.64 (2H, m), 1.85-2.00 (1H, m), 2.11-2.38 (2H, m), 2.31 (3H, s), 2.77 (1H, d, J=11.0 Hz), 2.86 (1H, d, J=10.5 Hz), 3.32 (1H, d, J=13.0 Hz), 3.38-3.64 (2H, m), 3.56 (2H, s), 3.83-4.07 (2H, m), 6.98 (1H, s), 7.01 (1H, s), 7.05 (1H, s), 7.21 (1H, dd, J=8.5, 2.0 Hz), 7.39 (1H, d, J=8.5 Hz), 7.52 (1H, d, J=2.0 Hz).


Example 472






Yield 92%, 1H-NMR (CDCl3): δ0.90 (6H, t, J=6 Hz), 1.42-1.53 (2H, m), 1.93-2.01 (1H, m), 2.02-2.12 (2H, m), 2.29 (3H, s), 2.75 (1H, d, J=11.5 Hz), 2.91 (1H, d, J=11.5 Hz), 3.31 (1H, d, J=13.5 Hz), 3.32-3.50 (1H, m), 3.51 (2H, s), 3.61 (1H, d, J=13.5 Hz), 3.87-4.04 (2H, m), 6.97 (1H, s), 7.02 (1H, s), 7.04 (1H, s), 7.27 (1H, dd, J=8.5, 2 Hz), 7.38 (1H, d, J=8.5 Hz), 7.89 (1H, d, J=2 Hz), 12.28 (1H, brs).


Example 473






Yield 99%, 1H-NMR (CDCl3): δ0.90 (3H, d, J=6.0 Hz), 0.92 (3H, d, J=6.0 Hz), 1.34-1.64 (2H, m), 1.84-1.98 (1H, m), 2.07-2.30 (2H, m), 2.26 (3H, s), 2.74 (1H, d, J=11.0 Hz), 2.82 (1H, d, J=10.5 Hz), 3.28 (1H, d, J=13.5 Hz), 3.35-3.54 (4H, m), 3.87-4.07 (2H, m), 6.91 (1H, s), 6.93 (1H, s), 7.02 (1H, s), 7.50 (2H, s), 7.81 (1H, s).


Example 474






Yield 98%, 1H-NMR (CDCl3): δ0.93 (6H, dd, J=3.6, 6.3 Hz), 1.42-1.50 (1H, m), 1.55-1.64 (1H, m), 1.90-1.99 (1H, m), 2.23 (2H, td, J=3.6, 11.4 Hz), 2.34 (3H, s), 2.81 (1H, d, J=11.4 Hz), 2.92 (1H, d, J=10.2 Hz), 3.37 (1H, d, J=13.2 Hz), 3.52 (1H, td, J=3.3, 12.9 Hz), 3.62 (1H, d, J=13.2 Hz), 3.62 (2H, s), 4.04 (2H, br), 7.02 (1H, s), 7.07 (2H, s), 7.52 (2H, s), 7.82 (1H, s)


Example 475






Yield 62%, 1H-NMR (CDCl3): δ1.23 (3H, d, J=6.5 Hz), 1.38 (3H, d, J=6.5 Hz), 2.11-2.26 (1H, m), 2.65-2.89 (2H, m), 2.98-3.15 (1H, m), 3.35-3.52 (1H, m), 3.67 (2H, s), 3.68-3.82 (1H, m), 4.03-4.22 (2H, m), 7.17-7.36 (4H, m), 7.48-7.60 (2H, m), 7.83 (1H, s).


Example 476






Yield 80%, 1H-NMR (DMSO-d6): δ2.43-2.58 (4H, m), 3.54 (2H, s), 3.57 (2H, s), 3.58-3.70 (4H, m), 7.13-7.34 (4H, m), 7.47 (1H, d, J=12.5 Hz), 8.27 (1H, d, J=7.5 Hz), 12.28 (1H, s).


Example 477






Yield 92%, 1H-NMR (CDCl3): δ2.28 (3H, s), 2.50-2.62 (4H, m), 3.47 (2H, s), 3.52 (2H, s), 3.58-3.68 (4H, m), 6.97 (2H, s), 7.04 (1H, s), 7.25 (1H, d, J=11.5 Hz), 7.73 (1H, d, J=7.0 Hz).


Example 478






Yield 59%, 1H-NMR (CD3OD): δ2.06-2.18 (2H, m), 2.31 (3H, s), 2.87-2.97 (2H, m), 2.99-3.08 (2H, m), 3.52 (2H, s), 3.70-3.98 (4H, m), 3.82 (2H, s), 7.07 (2H, s), 7.11 (1H, s), 7.29 (1H, d, J=12.0 Hz), 7.98 (1H, d, J=7.0 Hz).


Example 479






Yield 85%, 1H-NMR (DMSO-d6): δ1.15 (3H, d, J=6 Hz), 2.16-2.27 (1H, m), 2.28 (3H, s), 2.55-2.68 (1H, m), 2.69-2.80 (1H, m), 3.17 (1H, d, J=13.5 Hz), 3.18-3.26 (1H, m), 3.35-3.48 (1H, m), 3.49 (2H, s), 3.65-3.79 (1H, m), 3.80-3.90 (1H, m), 3.92 (1H, d, J=13.5 Hz), 6.96 (1H, s), 7.00 (1H, s), 7.01 (1H, s), 7.45 (1H, d, J=12 Hz), 8.25 (1H, d, J=8 Hz), 12.40 (1H, brs).


Example 480






Yield 67%, 1H-NMR (CDCl3): δ1.39 (3H, d, J=7.0 Hz), 2.14-2.35 (2H, m), 2.32 (3H, s), 2.72 (1H, d, J=11.0 Hz), 2.91 (1H, d, J=11.0 Hz), 3.40 (1H, d, J=14.0 Hz), 3.43-3.62 (2H, m), 3.58 (2H, s), 3.86 (1H, d, J=12.5 Hz), 4.12-4.28 (1H, m), 6.99 (1H, s), 7.02-7.10 (2H, m), 7.25 (1H, d, J=11.5 Hz), 7.73 (1H, d, J=7.0 Hz).


Example 481






Yield 78%, 1H-NMR (CDCl3): δ1.38 (3H, d, J=7.0 Hz), 2.12-2.35 (2H, m), 2.30 (3H, s), 2.70 (1H, d, J=11.5 Hz), 2.88 (1H, d, J=11.5 Hz), 3.32-3.60 (5H, m), 3.84 (1H, d, J=11.5 Hz), 4.10-4.25 (1H, m), 6.97 (1H, s), 7.04 (2H, s), 7.24 (1H, d, J=12.0 Hz), 7.73 (1H, d, J=7.0 Hz).


Example 482






Yield 82%, 1H-NMR (DMSO-d6): δ2.45-2.60 (4H, m), 3.48-3.63 (8H, m), 7.06 (1H, td, J=7.5, 1.0 Hz), 7.13-7.33 (5H, m), 7.45 (1H, d, J=7.5 Hz), 7.76 (1H, d, J=7.5 Hz), 12.32 (1H, brs).


Example 483






Yield 60%, 1H-NMR (CDCl3): δ0.85 (3H, t, J=7.5 Hz), 1.80-2.00 (2H, m), 2.12-2.26 (2H, m), 2.31 (3H, s), 2.77-2.91 (2H, m), 3.36 (1H, d, J=13.5 Hz), 3.36-3.62 (2H, m), 3.57 (2H, s), 3.75-3.87 (1H, m), 3.88-4.02 (1H, m), 6.98 (1H, s), 7.04 (2H, s), 7.24 (1H, d, J=10.5 Hz), 7.51 (1H, d, J=7.0 Hz).


Example 484






Yield 67%, 1H-NMR (CDCl3): δ2.75 (4H, t, J=5.0 Hz), 3.68 (4H, s), 3.85 (4H, t, J=5.0 Hz), 7.13-7.21 (1H, m), 7.22-7.34 (2H, m), 7.37-7.46 (2H, m), 7.54-7.64 (1H, m), 7.69 (1H, dd, J=8.0, 51.0 Hz), 7.89 (1H, dd, J=8.0, 1.0 Hz), 8.56 (1H, s).


Example 485






Yield 57%, 1H-NMR (CDCl3): δ2.82 (4H, t, J=4.5 Hz), 3.66 (2H, s), 3.74 (2H, s), 3.83 (4H, t, J=4.5 Hz), 6.93 (1H, d, J=9.0 Hz), 7.07-7.15 (1H, m), 7.20-7.31 (3H, m), 7.47 (1H, s), 7.54 (1H, td, J=8.0, 1.5 Hz), 7.60 (1H, d, J=8.0), 7.70 (1H, d, J=8.0 Hz), 7.89 (1H, d, J=9.0 Hz).


Example 486






Yield 42%, 1H-NMR (CDCl3): δ2.65-2.77 (4H, m), 3.64 (4H, s), 3.76-3.88 (4H, m), 7.13-7.32 (3H, m), 7.38 (1H, s), 7.50 (1H, dd, J=9.0, 2.0 Hz), 7.59 (1H, d, J=9.0 Hz), 7.86 (1H, d, J=2.0 Hz), 8.53 (1H, s).


Example 487






Yield 81%, 1H-NMR (CDCl3): δ2.60-2.74 (4H, m), 2.63 (3H, s), 3.35-3.49 (4H, m), 3.52 (2H, s), 3.54 (2H, s), 7.05-7.23 (3H, m), 7.29 (1H, s), 7.69 (1H, d, J=9.0 Hz), 7.80 (1H, d, J=9.0 Hz), 8.14 (1H, s).


Example 488






Yield 79%, 1H-NMR (CDCl3): δ1.35 (3H, d, J=6.5 Hz), 2.12-2.35 (5H, m), 2.79 (1H, d, J=11.5 Hz), 2.99 (1H, d, J=11.5 Hz), 3.27-3.43 (2H, m), 3.50-3.62 (3H, m), 4.35 (1H, d, J=12.5 Hz), 4.59-4.72 (1H, m), 6.98 (1H, s), 7.05 (1H, s), 7.08 (1H, s), 7.70 (2H, s), 8.13 (1H, s), 8.56 (1H, s).


Example 489






Yield 76%, 1H-NMR (CD3OD): δ2.69-2.78 (4H, m), 3.52-3.60 (4H, m), 3.61 (2H, s), 3.71 (2H, s), 7.18-7.39 (7H, m), 7.42-7.50 (3H, m).


Example 490
3-[[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl]phenyl acetic acid






A mixture of {3-[[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl]phenyl}acetonitrile (0.35 g; 0.914 mmol), concentrated sulfuric acid (2 ml) and water (2 ml) was stirred at 80° C. for 2 hours. After air cooling, 5N-aqueous sodium hydroxide was added thereto to be alkaline. Ethyl acetate was added thereto and back-extracted. The water layer became neutral with 2N-aqueous hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure to give 3-[[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl]phenyl acetic acid as colorless amorphous solid (0.08 g; 22%).



1H-NMR (DMSO-d6): δ2.45-2.50 (4H, m), 3.53 (2H, s), 3.53-3.65 (6H, m), 7.10-7.35 (5H, m), 7.42 (1H, d, J=8.5 Hz), 7.91 (1H, d, J=2 Hz), 12.28 (1H, brs).


Compounds in Examples 491 to 512 were obtained by similar methods as Example 490.


Example 491






Yield: 43%, 1H-NMR (DMSO-d6): δ1.90-1.96 (2H, m), 2.61 (2H, t, J=4.8 Hz), 2.77-2.80 (2H, m), 3.57-3.62 (4H, m), 3.62-3.71 (4H, m), 7.12-7.16 (2H, m), 7.21-7.28 (3H, m), 7.40 (1H, d, J=8.5 Hz), 7.88 (1H, d, J=2.4 Hz).


Example 492






Yield: 78%, 1H-NMR (DMSO-d6): δ2.52 (4H, t, J=5 Hz), 3.54 (2H, s), 3.57 (2H, s), 3.63 (4H, t, J=5 Hz), 7.10-7.35 (4H, m), 7.57 (2H, s), 8.24 (1H, s), 12.31 (1H, s).


Example 493






Yield: 18%, 1H-NMR (DMSO-d6): δ1.85-2.00 (2H, m), 2.57-2.68 (2H, m), 2.74-2.85 (2H, m), 3.52 (2H, s), 3.61 (2H, s), 3.62-3.85 (4H, m), 7.09-7.31 (4H, m), 7.52-7.58 (2H, m), 8.22 (2H, s).


Example 494






Yield: 79%, 1H-NMR (DMSO-d6): δ1.31 (3H, d, J=6.5 Hz), 2.15 (1H, td, J=12, 3.5 Hz), 2.22 (1H, dd, J=11.5, 3.5 Hz), 2.70 (1H, d, J=11.5 Hz), 2.91 (1H, d, J=12 Hz), 3.41 (1H, td, J=12, 3.5 Hz), 3.44 (1H, d, J=13.5 Hz), 3.56 (2H, s), 3.59 (1H, d, J=13.5 Hz), 3.80 (1H, d, J=12 Hz), 4.10-4.30 (1H, m), 7.10-7.35 (5H, m), 7.41 (1H, d, J=8.5 Hz), 7.90 (1H, d, J=2 Hz), 12.40 (1H, brs).


Example 495






Yield: 69%, 1H-NMR (DMSO-d6): δ1.05-1.25 (3H, m), 2.15-2.30 (1H, s), 2.50-2.65 (1H, m), 2.65-2.80 (1H, m), 3.05-3.40 (3H, m), 3.57 (2H, s), 3.60-3.70 (1H, m), 3.70-3.85 (1H, m), 3.90-4.00 (1H, m), 7.05-7.35 (5H, m), 7.41 (1H, d, J=8.5 Hz), 7.90 (1H, s), 12.29 (1H, s).


Example 496






Yield: 92%, 1H-NMR (DMSO-d6): δ1.04 (6H, d, J=6 Hz), 2.60-2.80 (2H, m), 2.95-3.10 (2H, m), 3.53 (2H, s), 3.77 (2H, s), 3.77-3.87 (2H, m), 7.00-7.10 (1H, m), 7.20-7.30 (4H, m), 7.42 (1H, d, J=8.5 Hz), 7.90 (1H, d, J=2 Hz), 12.5 (1H, brs).


Example 497






Yield: 76%, 1H-NMR (DMSO-d6): δ1.00 (3H, d, J=6 Hz), 1.30 (3H, d, J=6 Hz), 2.30 (1H, d, J=9.5 Hz), 2.70-2.85 (1H, m), 3.05-3.15 (1H, m), 3.40-3.45 (1H, m), 3.49 (2H, s), 3.62 (2H, s), 3.63-3.70 (1H, m), 4.10-4.30 (1H, m), 7.05-7.10 (1H, m), 7.20-7.35 (4H, m), 7.38 (1H, d, J=9 Hz), 7.87 (1H, d, J=2 Hz).


Example 498






Yield: 42%, 1H-NMR (DMSO-d6): 2.31 (3H, s), 2.50 (4H, t, J=5 Hz), 3.47 (2H, s), 3.52 (2H, s), 3.55 (4H, t, J=5 Hz), 7.00-7.18 (3H, m), 7.28 (1H, dd, J=8.5, 2 Hz), 7.42 (1H, d, J=8.5 Hz), 7.91 (1H, d, J=2 Hz), 12.25 (1H, brs).


Example 499






Yield: 39%, 1H-NMR (DMSO-d6): δ2.58 (4H, t, J=5 Hz), 3.58 (4H, t, J=5 Hz), 3.61 (2H, s), 3.62 (2H, s), 7.19 (1H, dd, J=8, 2 Hz), 7.29 (1H, dd, J=8.5, 1.5 Hz), 7.39 (1H, d, J=8.5 Hz), 7.42 (1H, d, J=8 Hz), 7.43 (1H, d, J=1.5 Hz), 7.91 (1H, d, J=2 Hz), 12.41 (1H, brs).


Example 500






Yield: 68%, 1H-NMR (CDCl3); δ2.32 (3H, s), 2.67 (4H, t, J=5 Hz), 3.59 (2H, s), 3.61 (2H, s), 3.67 (4H, t, J=5 Hz), 6.99 (1H, s), 7.04 (1H, s), 7.14 (1H, s), 7.24 (1H, dd, J=8.5, 2 Hz), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Example 501






Yield: 73%, 1H-NMR (DMSO-d6): δ1.88-1.94 (2H, m), 2.25 (3H, s), 2.60 (2H, t, J=4.5 Hz), 2.74-2.78 (2H, m), 3.48 (2H, s), 3.56 (2H, s), 3.66-3.73 (4H, m), 6.94-6.98 (3H, m), 7.26 (1H, dd, J=8.7, 2.1 Hz), 7.40 (1H, d, J=8.4 Hz), 7.88 (1H, d, J=2.1 Hz).


Example 502






Yield: 67%, 1H-NMR (CDCl3); δ2.71 (4H, t, J=5 Hz), 3.67 (4H, t, J=5 Hz), 3.78 (2H, s), 3.81 (2H, s), 6.78 (2H, s), 7.24 (1H, dd, J=8.5, 2 Hz), 7.43 (1H, d, J=8.5 Hz), 7.56 (1H, d, J=2 Hz).


Example 503






Yield: 46%, 1H-NMR (CDCl3); δ2.16-2.20 (2H, m), 2.91-2.95 (2H, m), 3.03-3.06 (2H, m), 3.68 (2H, t, J=6.0 Hz), 3.79 (2H, s), 3.90-3.91 (2H, m), 3.97 (2H, s), 6.75 (1H, d, J=3.6 Hz), 6.77 (1H, d, J=3.3 Hz), 7.24 (1H, dd, J=9.0, 2.4 Hz), 7.43 (1H, d, J=9.0 Hz), 7.55 (1H, d, J=2.1 Hz).


Example 504






Yield: 2%, 1H-NMR (DMSO-d6): δ2.40-2.50 (4H, m), 2.53 (2H, t, J=7.5 Hz), 2.81 (2H, t, J=7.5 Hz), 3.50 (2H, s), 3.55 (4H, t, J=5 Hz), 7.19 (2H, d, J=8 Hz), 7.23 (2H, d, J=8 Hz), 7.29 (1H, dd, J=8.5, 2 Hz), 7.41 (1H, d, J=8.5 Hz), 7.90 (1H, d, J=2 Hz), 12.05 (1H, brs).


Example 505






Yield: 70%, 1H-NMR (DMSO-d6): δ2.28 (3H, s), 2.45-2.55 (4H, m), 3.49 (2H, s), 3.51 (2H, s), 3.60-3.65 (4H, m), 6.97 (1H, s), 7.02 (2H, s), 7.57 (2H, s), 8.25 (1H, s), 12.4 (1H, brs).


Example 506






Yield: 55%, 1H-NMR (DMSO-d6): δ1.85-2.00 (2H, m), 2.25 (3H, s), 2.55-2.70 (2H, m), 2.70-2.85 (2H, m), 3.49 (2H, s), 3.57 (2H, s), 3.60-3.85 (4H, m), 6.94 (1H, s), 6.99 (2H, s), 7.55 (2H, s), 8.22 (1H, s), 12.4 (1H, brs).


Example 507






Yield 99%, 1H-NMR (CDCl3): δ1.24 (3H, d, J=6.0 Hz), 2.26-2.33 (1H, m), 2.33 (3H, s), 2.64-2.71 (1H, m), 2.82 (1H, dt, J=3.6, 12.0 Hz), 3.19 (2H, d, J=12.9 Hz), 3.38-3.45 (1H, m), 3.61 (2H, s), 3.70 (1H, dt, J=3.6, 12.9 Hz), 3.86 (1H, dd, J=2.1, 11.7 Hz), 4.05 (1H, d, J=12.9 Hz), 7.03 (2H, d, J=4.5 Hz), 7.09 (1H, s), 7.23 (1H, dd, J=2.1, 8.7 Hz), 7.43 (1H, d, J=8.7 Hz), 7.54 (1H, d, J=2.1 Hz)


Example 508






Yield 93%, 1H-NMR (CDCl3): δ1.24 (3H, d, J=6.3 Hz), 2.27-2.37 (1H, m), 2.33 (3H, s), 2.56-2.71 (1H, m), 2.83 (1H, dt, J=3.3, 12.0 Hz), 3.19 (2H, d, J=13.2 Hz), 3.38-3.47 (1H, m), 3.60 (2H, s), 3.70 (1H, dt, J=4.8, 12.6 Hz), 3.86 (1H, dd, J=2.7, 12.6 Hz), 4.06 (1H, d, J=13.2 Hz), 7.03 (2H, s), 7.09 (1H, s), 7.23 (1H, dd, J=2.1, 8.7 Hz), 7.43 (1H, d, J=8.7 Hz), 7.54 (1H, d, J=2.1 Hz)


Example 509






Yield 95%, 1H-NMR (DMSO-d6): δ1.04 (6H, d, J=6 Hz), 2.26 (3H, s), 2.60-2.80 (2H, m), 3.07 (1H, d, J=13 Hz), 3.09 (1H, d, J=13 Hz), 3.48 (2H, s), 3.73 (2H, s), 3.80-3.90 (2H, m), 6.88 (1H, s), 7.05 (2H, s), 7.55 (2H, s), 8.22 (1H, s), 12.21 (1H, brs).


Example 510






Yield 82%, 1H-NMR (DMSO-d6): δ1.15 (3H, d, J=6.5 Hz), 2.18-2.25 (1H, m), 2.28 (3H, s), 2.55-2.68 (1H, m), 2.68-2.80 (1H, m), 3.15-3.48 (3H, m), 3.50 (2H, s), 3.70-3.76 (1H, m), 3.80-3.90 (1H, m), 3.93 (1H, d, J=13.5 Hz), 6.96 (1H, s), 7.02 (2H, s), 7.56 (2H, s), 8.23 (1H, s), 12.43 (1H, brs).


Example 511






Yield 64%, 1H-NMR (CDCl3): δ1.23 (3H, d, J=6.5 Hz), 2.22-2.40 (4H, m), 2.60-2.74 (1H, m), 2.76-2.89 (1H, m), 3.10-3.31 (2H, m), 3.38-3.52 (1H, m), 3.59 (2H, s), 3.67-3.80 (1H, m), 3.84-3.96 (1H, m), 4.04 (1H, d, J=13.0 Hz), 6.97-7.12 (3H, m), 7.47-7.60 (2H, m), 7.83 (1H, s).


Example 512






Yield 93%, 1H-NMR (DMSO-d6): δ1.33 (3H, d, J=6.5 Hz), 2.05-2.28 (2H, m), 2.29 (3H, s), 2.72 (1H, d, J=11 Hz), 2.93 (1H, d, J=11 Hz), 3.25-3.50 (2H, m), 3.51 (2H, s), 3.51-3.60 (1H, m), 3.86 (1H, d, J=11 Hz), 4.20-4.35 (1H, m), 6.97 (1H, s), 7.05 (2H, s), 7.56 (2H, s), 8.24 (1H, s), 12.43 (1H, brs).


Example 513
Preparation of 3-{3-[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl}phenylpropionic acid






To 2-{3-[4-(6-chlorobenzothiazole-2-yl)piperazine-1-ylmethyl]benzyl}diethyl malonate (0.38 g; 0.736 mmol) was added 6N-aqueous hydrochloric acid. The mixture was refluxed for 2 hours. After cooling, saturated aqueous sodium hydrogencarbonate was added thereto to become neutral. Ethyl acetate was added thereto and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulphate, and evaporated under reduced pressure. The residue was washed with diisopropyl ether to give 3-{3-[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl}phenylpropionic acid as colorless crystal (0.08 g; 22%).



1H-NMR (DMSO-d6): δ2.50-2.52 (4H, m), 2.53 (2H, t, J=7.5 Hz), 2.82 (2H, t, J=7.5 Hz), 3.51 (2H, s), 3.57 (4H, t, J=5 Hz), 7.10-7.20 (3H, m), 7.24 (1H, d, J=7.5 Hz), 7.28 (1H, dd, J=8.5, 2 Hz), 7.42 (1H, d, J=8.5 Hz), 7.91 (1H, d, J=2 Hz), 12.15 (1H, brs).


A compound in Example 514 was obtained by a similar method as Example 513.


Example 514






Yield: 55%, 1H-NMR (CDCl3): δ2.63 (4H, t, J=5 Hz), 2.72 (2H, t, J=7.5 Hz), 3.13 (2H, t, J=7.5 Hz), 3.64 (4H, t, J=5 Hz), 3.72 (2H, s), 6.68 (1H, d, J=3.5 Hz), 6.73 (1H, d, J=3.5 Hz), 7.24 (1H, dd, J=8.5, 2 Hz), 7.43 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2 Hz).


Example 515
Preparation of 3-{3-[4-(6-chlorobenzothiazole-2-yl)piperazine-1-yl]methyl}phenoxyacetic acid

The following compound was obtained by a similar method as Reference Example 155.







Yield: 55%, 1H-NMR (DMSO-d6): δ2.50-2.55 (4H, m), 3.51 (2H, s), 3.55-3.65 (4H, m), 4.61 (2H, s), 6.75-7.00 (3H, m), 7.20-7.35 (2H, m), 7.42 (1H, d, J=8 Hz), 7.90 (1H, d, J=2 Hz).


Example 516
Preparation of 3-{2-[1-(6-chlorobenzothiazole-2-yl)piperidine-4-yl]ethoxy}-4-methylphenyl acetic acid






A mixture of [3-{2-[1-(6-chlorobenzothiazole-2-yl)piperidine-4-yl]ethoxy}-4-methylphenyl]acetonitrile (1.14 g; 2.68 mmol), sodium hydroxide (0.54 g; 13.5 mmol), water (1.6 ml) and ethanol (21 ml) was stirred at 80° C. for 6 hours. The reaction solution was concentrated under reduced pressure and became pH=7 with 2N-aqueous hydrochloric acid. The precipitate was collected to give 3-{2-[1-(6-chlorobenzothiazole-2-yl)piperidine-4-yl]ethoxy}-4-methylphenyl acetic acid as colorless crystal (0.63 g; 53%).



1H-NMR (DMSO-d6): δ1.20-1.38 (2H, m), 1.67-1.91 (5H, m), 2.09 (3H, s), 3.10-3.25 (4H, m), 3.93-4.06 (4H, m), 6.54 (1H, d, J=7.5 Hz), 6.82 (1H, s), 6.92 (1H, d, J=7.5 Hz), 7.27 (1H, dd, J=8.5, 2.0 Hz), 7.40 (1H, d, J=8.5 Hz), 7.88 (1H, d, J=2.0 Hz).


The present invention includes the following compounds synthesized by similar methods.


Example 517






m/z=461 (M+H)+


Example 518






m/z=431 (M+H)+


Example 519






m/z=447 (M+H)+


Example 520






m/z=435 (M+H)+


Example 521






Rf=0.49 (AcOEt)


Example 522






1H NMR (DMSO-d6): d 12.9 (br, 1H), 7.86 (s, 1H), 7.39 (d, 1H, J=6.3 Hz), 7.25 (d, 1H, J=6.3 Hz), 6.88 (s, 1H), 6.87 (d, 1H, J=6.0 Hz), 6.77 (d, 1H, J=6.0 Hz), 4.01 (m, 2H), 3.72 (s, 3H), 3.67 (br, 4H), 3.46 (s, 2H), 2.94 (s, 2H), 2.87 (t, 2H, J=4.2 Hz), 2.75 (br, 2H), 1.90 (s, 2H).


Example 523






m/z=461 (M+H)+


Example 524






m/z=475 (M+H)+


Example 525






m/z=505 (M+H)+


Example 526






m/z=493 (M+H)+


Example 527






MS (ESI) m/e calcd. for C24H25ClFN2O3S2 (MH)+ 507.1, found 507


Example 528






MS (ESI) m/e calcd. for C24H26ClN2O2S2 (MH)+ 473.1, found 473


Example 529






MS (ESI) m/e calcd. for C23H23Cl2N2O2S2 (MH)+ 493.1, found 493


Example 530






MS (ESI) m/e calcd. for C25H26ClN2O3S2 (MH+) 501.1, found 501.4


Example 531






MS (ESI) m/e calcd. for C25H26ClN2O2S3 (MH+) 517.1, found 517.4


Example 532






MS (ESI) m/e calcd. for C24H25 ClN3O2S2 (MH+) 486.1, found 486.4


Example 533






m/z=489 (M+H)+


Example 534






m/z=445 (M+H)+


Example 535






MS (ESI) m/e calcd. for C24H29 ClN3O3S (MH+) 474.2, found 474.4


Example 536






MS (ESI) m/e calcd. for C26H29ClN3O3S (MH)+ 498.2, found 498


Example 537






m/z=460 (M+H)+


Example 538






m/z=461 (M+H)+


Example 539






MS (ESI) m/e calcd. for C25H26ClN2O4S (MH+) 485.1, found 485.2


Example 540






MS (ESI) m/e calcd. for C24H28ClN2O3S (MH+) 459.2, found 459.4


Example 541






m/z=479 (M+H)+


Example 542






m/z=493 (M+H)+


Example 543






MS (ESI) m/z 438 [M+H]+


Example 544






MS (ESI) m/z 438 [M+H]+


Example 545






m/z=446 (M+H)+


Example 546






m/z=466 (M+H)+


Example 547






m/z=482 (M+H)+


Example 548






m/z=430 (M+H)+


Example 549






m/z=444 (M+H)+


Example 550






m/z=494 (M+H)+


Example 551






m/z=474 (M+H)+


Example 552






m/z=402 (M+H)+


Example 553






m/z=431 (M+H)+


Example 554






m/z=451 (M+H)+


Example 555






m/z=462 (M+H)+


Example 556






m/z=478 (M+H)+


Example 557






m/z=478 (M+H)+


Reference Example 228
Preparation of 1-(5-bromothiazole-2-yl)-3,5-dimethyl piperazine






A mixture of 2,5-dibromothiazole (29.5 g), 2,6-dimethyl piperazine (13.8 g), potassium carbonate (20.1 g) and dimethylformamide (150 mL) was stirred at 60° C. for 6 hours. To the reaction solution was added water and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over sodium sulphate. The solvent was evaporated under reduced pressure to give the title compound (21.5 g). Yield: 64%.



1H-NMR (CDCl3) δ: 1.14 (6H, d, J=6.3 Hz), 2.05 (1H, br), 2.59-2.63 (2H, m), 2.98-3.02 (2H, m), 3.70-3.74 (2H, m), 7.06 (1H, s).


Reference Example 229
Preparation of [4-(5-bromothiazole-2-yl)-2,6-dimethyl piperazine-1-yl]acetic acid methyl ester






A mixture of 1-(5-bromothiazole-2-yl)-3,5-dimethyl piperazine (21.5 g), bromo acetic acid methyl ester (8.8 mL), potassium carbonate (12.9 g) and dimethylformamide (150 mL) was stirred at 60° C. for 2.5 hours. To the reaction solution was added water and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure. The residue was purified by column chromatograph on silica gel to give the title compound (20.1 g). Yield: 74%.



1H-NMR (CDCl3) δ: 1.17 (6H, d, J=6.0 Hz), 2.80-2.84 (2H, m), 3.13-3.16 (2H, m), 3.65 (2H, s), 3.65-3.68 (2H, m), 3.73 (3H, s), 7.08 (1H, s).


Reference Example 230
Preparation of 2-[4-(5-bromothiazole-2-yl)-2,6-dimethyl piperazine-1-yl]ethanol






To a solution of [4-(5-bromothiazole-2-yl)-2,6-dimethyl piperazine-1-yl]acetic acid methyl ester (20.1 g) in tetrahydrofuran (300 mL) was added dropwise diisobutyl aluminium hydride (1M toluene solution, 200 mL) at −78° C. The mixture was stirred at −78° C. for 3.5 hours. To the reaction solution were added aqueous ammonium chloride solution (150 mL) and diethyl ether (45 mL). The insoluble material was filtrated. The filtrate was extracted diethyl ether. The organic layer was washed with water and brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure. The residue was purified by column chromatograph on silica gel to give the title compound (13.2 g). Yield: 71%.



1H-NMR (CDCl3) δ: 1.17 (6H, d, J=5.8 Hz), 2.44 (1H, br), 2.84 (6H, dd, J=16.9, 11.1 Hz), 3.60-3.64 (4H, m), 7.06 (1H, s).


Reference Example 231
Preparation of [3-[2-[4-(5-bromothiazole-2-yl)-2,6-dimethyl piperazine-1-yl]ethoxy]-4-methylphenyl]acetic acid methyl ester






To a mixture of 2-[4-(5-bromothiazole-2-yl)-2,6-dimethyl piperazine-1-yl]ethanol (9.87 g), triethylamine (8.6 mL) and methylene chloride (100 mL) was added dropwise methanesulfonyl chloride (2.9 mL) at 0° C. After stirring at 0° C. for 0.5 hour, to the reaction solution was added water and extracted with chloroform. The organic layer was washed with water and brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure. The obtained residue was dissolved in acetonitrile (100 mL). (3-hydroxy-4-methylphenyl)acetic acid methyl ester (5.0 g) and cesium carbonate (12.0 g) were added thereto and stirred at 60° C. for 1 hour. The reaction solution was diluted with ethyl acetate and the insoluble material was filtrated. The filtrate was evaporated under reduced pressure. The residue was purified by column chromatograph on silica gel to give the title compound (8.49 g). Yield: 57%.



1H-NMR (CDCl3) δ: 1.27 (6H, d, J=6.6 Hz), 2.20 (3H, s), 2.87-2.91 (4H, m), 3.25-3.27 (2H, m), 3.60 (2H, s), 3.68 (2H, brm), 3.71 (3H, s), 4.03-4.05 (2H, m), 6.75 (1H, d, J=1.4 Hz), 6.79 (1H, dd, J=7.7, 1.4 Hz), 7.07 (1H, s), 7.10 (1H, d, J=7.7 Hz).


Reference Example 232
Preparation of [3-[2-[4-(5-bromothiazole-2-yl)-2,6-dimethyl piperazine-1-yl]ethoxy]-4-methylphenyl]acetic acid






A mixture of [3-[2-[4-(5-bromothiazole-2-yl)-2,6-dimethyl piperazine-1-yl]ethoxy]-4-methylphenyl]acetic acid methyl ester (8.49 g), 2N aqueous sodium hydroxide solution (22 mL), methanol (50 mL) and tetrahydrofuran (50 mL) was stirred at room temperature for 1.5 hours. To the reaction solution were added water and brine. The mixture was washed with ethyl acetate. The water layer was neutralized with 2N hydrochloric acid and extracted with chloroform. The organic layer was washed with water and brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure and the residue was washed with diisopropyl ether to give the title compound (5.81 g).


Yield: 71%.



1H-NMR (DMSO-d6) δ: 1.16 (6H, d, J=5.5 Hz), 2.13 (3H, s), 2.71-2.83 (4H, m), 3.12-3.14 (2H, m), 3.52 (2H, s), 3.65-3.68 (2H, m), 3.99-4.01 (2H, m), 6.74 (1H, d, J=7.4 Hz), 6.87 (1H, s), 7.07 (1H, d, J=7.4 Hz), 8.34 (1H, s).


Example 558
Preparation of [3-[2-[4-[5-(2,5-difluorophenyl)thiazole-2-yl]-2,6-dimethyl piperazine-1-yl]ethoxy]-4-methylphenyl]acetic acid






A mixture of [3-[2-[4-(5-bromothiazole-2-yl)-2,6-dimethyl piperazine-1-yl]ethoxy]-4-methylphenyl]acetic acid (400 mg), 2,5-difluorophenyl boronic acid (270 mg), tetrakis(triphenylphosphine) palladium (100 mg), 1M sodium carbonate (4.3 mL) and dimethylformamide (8 mL) was reacted with a microwave reaction device at 180° C. for 5 minutes. To the reaction solution was added water and extracted with chloroform. The organic layer was washed with water and brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure. The residue was purified by column chromatograph on silica gel to give the title compound (369 mg). Yield: 87%.


MS (ESI) m/z 502 [M+H]


The following compounds were obtained by similar methods as above.


Example 559






MS (ESI) m/z 508 [M+]


Example 560






MS (ESI) m/z 508 [M+]


Example 561






MS (ESI) m/z 515, 517 [M+H]+


Example 562






MS (ESI) m/z 501, 503 [M+H]+


Example 563






MS (ESI) m/z 579, 581 [+H]+


Example 564






MS (ESI) m/z 529, 531 [M+H]+


Example 565






1H-NMR (DMSO-d6) δ: 1.11 (6H, d, J=5.1 Hz), 2.60-2.70 (2H, m), 3.00-3.05 (2H, m), 3.55 (2H, s), 3.96-4.05 (2H, m), 4.32-4.45 (2H, m), 6.80-6.96 (3H, m), 8.44 (2H, s).


Example 566






1H-NMR (DMSO-d6) δ: 1.17 (6H, d, J=4.9 Hz), 2.64-2.74 (4H, m), 3.09-3.18 (2H, m), 3.55 (2H, s), 4.03-4.10 (2H, m), 4.48-4.60 (2H, m), 6.83 (1H, dd, J=8.0, 0.8 Hz), 7.09 (1H, d, J=1.1 Hz), 7.33 (1H, d, J=8.0 Hz), 7.47-7.83 (3H, m), 8.71 (2H, s).


Example 567






1H-NMR (DMSO-d6) δ: 1.17 (6H, d, J=4.4 Hz), 2.64-2.76 (4H, m), 3.10-3.18 (2H, m), 3.56 (2H, s), 4.04-4.11 (2H, m), 4.49-4.60 (2H, m), 6.83 (1H, d, J=8.0 Hz), 7.07-7.59 (5H, m), 8.59 (2H, s).


Example 568






1H-NMR (CDCl3) δ: 1.31 (6H, d, J=5.8 Hz), 2.40 (3H, s), 2.90-3.08 (4H, m), 3.35-3.42 (2H, m), 3.54 (2H, s), 4.08-4.16 (2H, m), 4.52-4.67 (2H, m), 6.79-7.34 (7H, m), 8.52 (2H, s).


Example 569






1H-NMR (Acetone) δ: 8.62 (2.0H, s), 7.61-7.59 (2.0H, m), 7.45 (2.0H, dd, J=7.55, 7.55 Hz), 7.37-7.28 (2.0H, m), 7.14 (1.0H, d, J=1.89 Hz), 6.89 (1.0H, dd, J=8.10, 1.89 Hz), 4.64 (2.0H, d, J=11.81 Hz), 4.16 (2.0H, dd, J=6.11, 6.11 Hz), 3.59 (2.0H, s), 3.24 (2.0H, dd, J=6.11, 6.11 Hz), 2.93-2.64 (4.0H, m), 1.25 (6.0H, d, J=6.04 Hz).


Example 570






MS (ESI) m/z 508 [M+H]+


Example 571






1H-NMR (DMSO-d6)) d: 7.81 (1H, s), 7.67 (1H, s), 7.32-7.29 (2H, m), 7.07 (1H, s), 6.81 (1H, d, J=8.8 Hz), 6.75 (1H, s), 4.06-4.03 (2H, m), 3.67 (2H, d, J=10.8 Hz), 3.52 (2H, s), 3.12-3.09 (2H, m), 2.82-2.69 (4H, m), 1.13 (6H, d, J=5.7 Hz).


Example 572






MS (ESI) m/z 525 [M+H]+


Example 573






1H-NMR (DMSO-d6) δ: 7.79 (1.0H, s), 7.70-7.64 (4.0H, m), 7.03 (1.0H, d, J=7.56 Hz), 6.85 (1.0H, s), 6.71 (1.0H, d, J=7.56 Hz), 3.99 (2.0H, dd, J=5.49, 5.49 Hz), 3.79 (2.0H, d, J=9.06 Hz), 3.47 (2.0H, s), 3.15-3.11 (2.0H, m), 2.89-2.78 (4.0H, m), 2.11 (3.0H, s), 1.17 (6.0H, d, J=5.22 Hz).


Example 574






1H-NMR (DMSO-d6) δ: 7.83-7.70 (3.0H, m), 7.63-7.50 (2.0H, m), 7.03 (1.0H, d, J=7.69 Hz), 6.85 (1.0H, s), 6.70 (1.0H, d, J=7.69 Hz), 4.02-3.96 (2.0H, m), 3.79 (2.0H, d, J=9.06 Hz), 3.47 (2.0H, s), 3.17-3.10 (2.0H, m), 2.91-2.76 (4.0H, m), 2.12 (3.0H, s), 1.26-1.11 (6.0H, d, J=6.0 Hz).


Example 575






1H-NMR (DMSO-d6) δ: 7.58 (1.0H, s), 7.46 (2.0H, d, J=7.42 Hz), 7.35 (2.0H, dd, J=7.42, 7.42 Hz), 7.21 (1.0H, dd, J=7.42, 7.42 Hz), 7.03 (1.0H, d, J=7.80 Hz), 6.85 (1.0H, s), 6.70 (1.0H, d, J=7.80 Hz), 4.01-3.97 (2.0H, m), 3.76 (2.0H, d, J=10.99 Hz), 3.45 (2.0H, s), 3.14-3.11 (2.0H, m), 2.89-2.74 (4.0H, m), 2.11 (3.0H, s), 1.17 (6.0H, d, J=5.49 Hz).


Example 576






1H-NMR (CDCl3) δ 1.17 (6H, m), 2.12 (3H, s), 2.82 (4H, m), 2.13 (2H, br), 3.30 (3H, d, J=2.1 Hz), 3.49 (2H, s), 3.77 (2H, d, J=10.2 Hz), 3.99 (2H, br), 4.41 (2H, s), 6.71 (1H, brd), 6.85 (1H, brd), 7.04 (1H, brd), 7.15 (1H, brd), 7.30-7.41 (3H, m), 7.60 (1H, d, 1.8 Hz)


Example 577






1H-NMR (DMSO-d6) δ 1.16 (6H, d, J=6.0 Hz), 1.33 (3H, t, J=6.9 Hz), 2.12 (3H, s), 2.74-2.90 (4H, m), 3.13 (2H, t, J=5.1 Hz), 3.49 (2H, s), 3.76 (2H, d, J=10.5 Hz), 3.97-4.08 (4H, m), 6.72 (1H, d, J=7.8 Hz), 6.78 (1H, dd, J=8.4 Hz, 2.4 Hz), 6.85 (1H, s), 6.98-7.06 (3H, m), 7.24 (1H, t, J=8.1 Hz), 7.61 (1H, s)


Example 578






1H-NMR (DMSO-d6) δ 1.16 (6H, d, J=5.7 Hz), 2.12 (3H, s), 2.72-2.91 (4H, m), 2.91 (6H, s), 3.12 (2H, brs), 3.49 (2H, s), 3.76 (2H, d, J=10.5 Hz), 3.99 (2H, brs), 6.57-6.61 (1H, m), 6.70-6.77 (3H, m), 6.85 (1H, s), 7.05 (1H, d, J=7.5 Hz), 7.15 (1H, t, J=7.8 Hz), 7.54 (1H, s)


Example 579






1H-NMR (Acetone) δ: 8.62 (2.0H, s), 7.61-7.59 (2.0H, m), 7.45 (2.0H, dd, J=7.55, 7.55 Hz), 7.37-7.28 (2.0H, m), 7.14 (1.0H, d, J=1.89 Hz), 6.89 (1.0H, dd, J=8.10, 1.89 Hz), 4.64 (2.0H, d, J=11.81 Hz), 4.16 (2.0H, dd, J=6.11, 6.11 Hz), 3.59 (2.0H, s), 3.24 (2.0H, dd, J=6.11, 6.11 Hz), 2.93-2.64 (4.0H, m), 1.25 (6.0H, d, J=6.04 Hz).


Example 580






1H-NMR (DMSO-d6) δ: 8.69 (2.0H, s), 7.63 (2.0H, d, J=7.42 Hz), 7.45 (2.0H, dd, J=7.42, 7.42 Hz), 7.35 (1.0H, d, J=7.42 Hz), 6.62 (3.0H, s), 4.53 (2.0H, d, J=8.79 Hz), 3.96 (2.0H, dd, J=6.48, 6.48 Hz), 3.45 (2.0H, s), 3.03 (2.0H, dd, J=6.48, 6.48 Hz), 2.67 (4.0H, d, J=7.97 Hz), 2.23 (3.0H, s), 1.14 (6.0H, d, J=4.94 Hz).


Example 581






1H-NMR (DMSO-d6) δ: 8.65 (2.0H, s), 7.32 (1.0H, d, J=8.23 Hz), 7.23 (1.0H, dd, J=8.10, 8.10 Hz), 7.09 (1.0H, d, J=1.65 Hz), 6.87-6.81 (3.0H, m), 6.72-6.67 (1.0H, m), 4.52 (2.0H, d, J=9.61 Hz), 4.07 (2.0H, dd, J=5.40, 5.40 Hz), 3.55 (2.0H, s), 3.13 (2.0H, dd, J=5.40, 5.40 Hz), 2.93 (6.0H, s), 2.73-2.62 (4.0H, m), 1.18 (6.0H, d, J=6.04 Hz).


Reference Example 233
Preparation of 3,5-dimethyl carbonyl piperazine-1-carboxylic acid t-butyl ester






To a mixture of 2,6-dimethyl piperazine (10.0 g) in methylene chloride (200 mL) was added di-t-butyldicarbonate (19.1 g) under ice-cooling. After stirring at room temperature for 17 hours, to the reaction solution was added water and extracted with methylene chloride. The organic layer was washed with brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure to give the title compound (18.7 g). Yield: 100%.


1H-NMR (CDCl3) δ 1.15 (6H, d, J=6.3), 1.32 (2H, m), 1.49 (9H, s), 2.43 (1H, m), 2.85 (2H, m), 3.99 (1H, m).


Reference Example 234
Preparation of 4-methoxycarbonyl methyl-3,5-dimethyl piperazine-1-carboxylic acid t-butyl ester






A mixture of 3,5-dimethyl carbonyl piperazine-1-carboxylic acid t-butyl ester (18.7 g), potassium carbonate (14.5 g), bromo acetic acid methyl ester (14.7 g), DMF (90 mL) was stirred at 60° C. for 3 hours. To the reaction solution was added water and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure to give the title compound. This compound was provided to the next reaction without further purification.


Reference Example 235
Preparation of 4-(2-hydroxyethyl)-3,5-dimethyl piperazine-1-carboxylic acid t-butyl ester






3,5-Dimethyl carbonyl piperazine-1-carboxylic acid t-butyl ester derived from the above reaction was dissolved in THF (300 mL) and lithium aluminium hydride (3.31 g) was added thereto under ice-cooling. After stirring at 0° C. for 1 hour, water and 2N aqueous sodium hydroxide solution was sequentially added. After filtration of the insoluble material, the filtrate was concentrated under reduced pressure to give the title compound (20.3 g). Yield: 90%.


Reference Example 236
Preparation of 4-[2-(5-carbonylmethyl-2-chlorophenoxy)ethyl]-3,5-dimethyl piperazine-1-1-carboxylic acid t-butyl ester






A mixture of 4-(2-hydroxyethyl)-3,5-dimethyl piperazine-1-carboxylic acid t-butyl ester (3.0 g), triethylamine (1.76 g), mesyl chloride (1.60 g) and methylene chloride (60 mL) was stirred at under ice-cooling for 1.5 hours. To the reaction solution was added water and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure. The obtained residue was dissolved in acetonitrile (60 mL), and (4-chloro-3-hydroxyphenyl)acetic acid methyl ester (2.33 g) and cesium carbonate (4.54 g) were added thereto. The mixture was stirred at 60° C. for 5 hours. After filtration of the insoluble material, the filtrate was concentrated and the obtained residue was purified by column chromatograph on silica gel to give the title compound (3.58 g). Yield: 70%.


1H-NMR (DMSO-d6) δ: 1.09 (6H, d, J=6.0), 1.40 (9H, s), 2.40-2.50 (2H, m), 2.52-2.61 (2H, m), 3.08-3.12 (2H, m), 3.64 (3H, s), 3.71 (2H, 2), 3.77 (2H, m), 4.02-4.09 (2H, m), 6.87 (1H, d, J=8.0), 7.13 (1H, s), 7.37 (1H, d, J=8.0)


Reference Example 237
Preparation of [4-chloro-3-[2-(2,6-dimethylpiperazine-1-yl)ethoxy]phenyl]acetic acid methyl ester






A solution of 4-[2-(5-carbonyl methyl-2-chlorophenoxy)ethyl]-3,5-dimethyl piperazine-1-1-carboxylic acid t-butyl ester (400 mg) in 4N hydrochloric acid-dioxane (4 mL) was stirred at room temperature for 2 hours. To the reaction solution were added water and ethyl acetate. The mixture was neutralized with sodium carbonate. The mixture was extracted with ethyl acetate and the organic layer was washed with brine. The solvent was evaporated under reduced pressure to give the title compound (291 mg). Yield: 94%.


1H-NMR (DMSO-d6) δ: 1.02 (3H, d, J=6.3), 2.22-2.29 (2H, m), 2.50-2.54 (2H, m), 2.72-2.76 (2H, m), 3.03-3.07 (2H, m), 4.03-4.07 (2H, m), 6.87 (1H, d, J=8.2), 7.13 (1H, s), 7.37 (1H, d, J=8.2)


Example 582
Preparation of [4-chloro-3-[2-(2,6-dimethyl-4-phenyl carbamoyl piperazine-1-yl)ethoxy]phenyl]acetic acid methyl ester






A mixture of [4-chloro-3-[2-(2,6-dimethyl piperazine-1-yl)ethoxy]phenyl]acetic acid methyl ester (50 mg), phenylisocyanate (19 mg), potassium carbonate (41 mg) and methylene chloride (2 mL) was stirred at room temperature for 3 hours. After filtration of the insoluble material, the filtrate was concentrated under reduced pressure. The residue was purified by column chromatograph on silica gel to give the title compound (52 m). Yield: 77%.


1H-NMR (DMSO-d6) δ: 1.15 (6H, d, J=5.8), 2.11 (2H, brm), 2.57 (2H, brm), 2.67 (2H, brm), 3.13 (2H, brm), 3.64 (3H, s), 3.71 (2H, s), 4.04-4.09 (2H, m), 6.86-6.97 (2H, m), 7.14 (1H, s), 7.22-7.25 (2H, m), 7.36-7.47 (3H, m), 8.48 (1H, s).


Example 583
Preparation of [4-chloro-3-[2-(2,6-dimethyl-4-phenyl carbamoyl piperazine-1-yl)ethoxy]phenyl]acetic acid






A mixture of [4-chloro-3-[2-(2,6-dimethyl-4-phenyl carbamoyl piperazine-1-yl)ethoxy]phenyl]acetic acid methyl ester (50 mg), 2N sodium hydroxide (0.1 mL) and tetrahydrofuran (1 mL) was stirred at room temperature for 4 hours. After neutralizing with 2N hydrochloric acid, the mixture was extracted with ethyl acetate. The organic layer was washed with brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure. The residue was purified by column chromatograph on silica gel to give the title compound (18 mg). Yield: 37%.


1H-NMR (DMSO-d6) δ: 1.12 (6H, d, J=5.8 Hz), 2.42-2.70 (4H, m), 3.06-3.16 (2H, m), 3.56 (2H, s), 3.93-4.11 (4H, m), 6.81-7.47 (6H, m), 8.46 (1H, s).


The following compound was obtained by a similar method as above.


Example 584






1H-NMR (DMSO-d6) δ: 1.10-1.29 (2H, m), 1.70-1.83 (4H, m), 2.73-2.87 (2H, m), 3.59 (2H, s), 4.07-4.20 (4H, m), 6.83-7.51 (6H, m), 8.46 (1H, s).


Reference Example 238
Preparation of 2-(2,6-dimethyl piperazine-1-yl)-6-trifluoromethyl benzothiazole






To a solution of cis-2,6-dimethyl piperazine (247 mg) in tetrahydrofuran (5 mL) was added n-BuLi (2.67 M hexane solution, 1.62 mL) at −78° C. The mixture was stirred at room temperature for 30 minutes, and trimethyl silyl chloride (0.27 mL) was added thereto. After stirring for 40 minutes, a solution of 2-chloro-6-trifluoromethyl benzothiazole (500 mg) in tetrahydrofuran (2 mL) was added thereto and the mixture was stirred for 2 hours. To the reaction solution was added water and extracted with ethyl acetate. The organic layer was washed with water and dried over sodium carbonate. The residue was purified by column chromatograph on silica gel to give the title compound (367 mg). Yield: 54%.



1H-NMR (CDCl3) δ: 1.47 (6H, d, J=6.87 Hz), 2.13 (2H, s), 2.91-3.10 (4H, m), 4.14-4.23 (2H, m), 7.51-7.59 (2H, m), 7.85 (1H, s).


Reference Example 239
Preparation of 2-[3,5-dimethyl-4-(6-trifluoromethylbenzothiazole-2-yl)piperazine-1-yl]ethanol






A mixture of 2-(2,6-dimethyl piperazine-1-yl)-6-trifluoromethyl benzothiazole (360 mg), (2-bromoethoxy)-t-butyldimethyl silane (257 uL), potassium carbonate (157 mg) and dimethylformamide (2 mL) was stirred at 60° C. for 20 hours. To the reaction solution was added water and extracted with ethyl acetate. The organic layer was washed with water and dried over sodium carbonate. After evaporating the solvent, the residue was purified by column chromatograph on silica gel to give the title compound (265 mg). Yield: 65%.



1H-NMR (CDCl3) δ: 1.53 (6H, d, J=6.59 Hz), 2.54-2.57 (2H, br m), 2.67-2.70 (2H, br m), 2.80-2.90 (2H, br m), 3.74-3.77 (2H, br m), 4.29-4.32 (2H, br m), 7.52-7.61 (2H, m), 7.87 (1H, s).


Example 585
Preparation of [4-chloro-3-[2-[3,5-dimethyl-4-(6-trifluoromethyl benzothiazole-2-yl)piperazine-1-yl]ethoxy]phenyl]acetic acid methyl ester






To a solution of 2-[3,5-dimethyl-4-(6-trifluoromethylbenzothiazole-2-yl)piperazine-1-yl]ethanol (138 mg) in methylene chloride (3 mL) were added methanesulfonyl chloride (45 μL) and triethylamine (107 μL). The mixture was stirred at room temperature for 1 hour. To the reaction solution was added water and extracted with chloroform. The organic layer was washed with water and brine, and dried over sodium sulphate. The solvent was evaporated under reduced pressure. To the obtained residue were added dimethylformamide (2 mL), cesium carbonate (248 mg) and (4-chloro-3-hydroxyphenyl)acetic acid methyl ester (92 mg). The mixture was stirred at 60° C. for 2 hours. To the reaction solution was added 2N hydrochloric acid to neutralize and extracted with ethyl acetate. The organic layer was washed with water and dried over magnesium sulphate. The residue was purified by column chromatograph on silica gel to give the title compound (178 mg). Yield: 89%.


Example 586
Preparation of [4-chloro-3-[2-[3,5-dimethyl-4-(6-trifluoromethyl benzothiazole-2-yl)piperazine-1-yl]ethoxy]phenyl]acetic acid






A mixture of [4-chloro-3-[2-[3,5-dimethyl-4-(6-trifluoromethyl benzothiazole-2-yl)piperazine-1-yl]ethoxy]phenyl]acetic acid methyl ester (178 mg), 2N aqueous sodium hydroxide (0.66 mL), tetrahydrofuran (2 mL) and methanol (2 mL) was stirred at room temperature for 2 hours. The mixture was neutralized with 2N hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with water and dried over sodium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (83 mg). Yield: 48%.


MS (ESI) m/z 528 [M+H]+


The following compound was obtained by a similar method as above.


Example 587






MS (ESI) m/z 508 [M+H]+


Example 588
Preparation of [3-[3,5-dimethyl-4-(6-trifluoromethyl benzothiazole-2-yl)piperazine-1-ylmethyl]phenyl]acetic acid methyl ester






A mixture of 2-(2,6-dimethyl piperazine-1-yl)-6-trifluoromethyl benzothiazole (163 mg), (3-bromomethylphenyl)acetic acid methyl ester (126 mg), potassium carbonate (75 mg) and dimethylformamide (4 mL) was stirred at room temperature for 18 hours. To the reaction solution was added water and extracted with ethyl acetate. The organic layer was washed with water and dried over sodium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (171 mg). Yield: 65%.


Example 589
Preparation of [3-[3,5-dimethyl-4-(6-trifluoromethyl benzothiazole-2-yl)piperazine-1-ylmethyl]phenyl]acetic acid






A mixture of [3-[3,5-dimethyl-4-(6-trifluoromethyl benzothiazole-2-yl)piperazine-1-ylmethyl]phenyl]acetic acid methyl ester (171 mg), 2N sodium hydroxide (1 mL) and methanol (2 mL) was stirred at room temperature for 1 hour. The mixture was neutralized with 2N hydrochloric acid and extracted with ethyl acetate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (82 mg). Yield: 52%.


MS (ESI) m/z 464 [M+H]+


The following compounds were obtained by similar methods as above.


Example 590






MS (ESI) m/z 494 [M+H]+


Example 591






MS (ESI) m/z 475 [M+H]+


Example 592






MS (ESI) m/z 478 [M+H]+


Reference Example 240
Preparation of 4-methoxycarboxylmethylene piperidine-1-carboxylic acid t-butyl ester






To a suspension of sodium hydride (4.02 g) in tetrahydrofuran (300 mL) was added phosphonoacetic acid trimethyl at 0° C. After stirring at 0° C. for 1 hours, a solution of 1-Boc-4-piperidone (20 g) in tetrahydrofuran (150 mL) was added thereto. After stirring at 50° C. for 1.5 hours, to the reaction solution was added water and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over sodium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (27.0 g). Yield: 100%.



1H-NMR (CDCl3) δ: 1.47 (9H, s), 2.27-2.29 (2H, m), 2.93-2.94 (2H, m), 3.47-3.51 (4H, m), 3.70 (3H, s), 5.72 (1H, s).


Reference Example 241
Preparation of [1-(6-chlorobenzothiazole-2-yl)piperidine-4-ylidene]acetic acid methyl ester






A solution of 4-carboxylmethylene piperidine-1-carboxylic acid t-butyl ester (8.00 g) in 4N hydrochloric acid/dioxane (80 mL) was stirred at room temperature for 1 hour. The solvent was evaporated under reduced pressure and the residue was dissolved in dimethylformamide (60 mL). Potassium carbonate (8.65 g) and 2,6-dichlorobenzothiazole (6.39 g) were added thereto at 0° C. After stirring at 50° C. for 1 hour and at 60° C. for 3 hours, water was added thereto and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over sodium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (9.48 g). Yield: 94%.



1H-NMR (CDCl3) δ: 2.47-2.49 (2H, m), 3.14-3.19 (2H, m), 3.72 (3H, s), 3.70-3.77 (4H, m), 5.81 (1H, s), 7.25 (1H, dd, J=8.5, 2.2 Hz), 7.46 (1H, d, J=8.8 Hz), 7.57 (1H, d, J=2.2 Hz).


Reference Example 242
Preparation of [1-(6-chlorobenzothiazole-2-yl)-4-ethyl piperidine-4-yl]acetic acid methyl ester






Copper iodide (1.77 g) was suspended in tetrahydrofuran (18 mL), and ethyl magnesium bromide (1.0 M tetrahydrofuran solution, 18.6 mL) was added thereto at −30° C. After stirring at −25° C. for 0.5 hour, the reaction solution was cooled to −78° C. To the mixture was added dropwise a solution of [1-(6-chlorobenzothiazole-2-yl)piperidine-4-ylidene]acetic acid methyl ester (1.00 g) in tetrahydrofuran (10 mL), and then added trimethylsilyl trifluoromethansulfonate (1.12 mL). After stirring at −78° C. for 2 hours, aqueous sodium hydrogencarbonate solution was added thereto. After filtration of the insoluble material, the filtrate was extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (979 mg). Yield: 90%.



1H-NMR (CDCl3) δ: 0.93 (3H, t, J=7.6 Hz), 1.67-1.75 (6H, m), 2.42 (2H, s), 3.57-3.68 (4H, m), 3.70 (3H, s), 7.26 (1H, dd, J=8.5, 2.2 Hz), 7.47 (1H, d, J=8.5 Hz), 7.58 (1H, d, J=2.2 Hz).


Reference Example 243
Preparation of 2-[1-(6-chlorobenzothiazole-2-yl)-4-ethyl piperidine-4-yl]ethanol






Lithium aluminium hydride (202 mg) was suspended in tetrahydrofuran (10 mL). A solution of [1-(6-chlorobenzothiazole-2-yl)-4-ethyl piperidine-4-yl]acetic acid methyl ester (940 mg) in tetrahydrofuran (10 mL) was added thereto at 0° C. After stirring at 0° C. for 1 hour, to the reaction solution were sequentially added water (0.2 mL), 10% sodium hydroxide (0.2 mL) and water (0.6 mL). The insoluble material was filtrated and the filtrate was extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over sodium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (790 mg). Yield: 91%.



1H-NMR (CDCl3) δ: 0.87 (3H, t, J=7.5 Hz), 1.44 (2H, q, J=7.5 Hz), 1.58-1.60 (4H, m), 1.68 (2H, t, J=7.5 Hz), 1.81 (1H, br), 3.60-3.62 (4H, m), 3.71-3.74 (2H, m), 7.23 (1H, dd, J=8.8, 2.2 Hz), 7.44 (1H, d, J=8.8 Hz), 7.55 (1H, d, J=2.2 Hz).


Reference Example 244
Preparation of 6-chloro-2-[4-(2-chloroethyl)-4-ethyl piperidine-1-yl]benzothiazole






A mixture of 2-[1-(6-chlorobenzothiazole-2-yl)-4-ethyl piperidine-4-yl]ethanol (764 mg) and thionyl chloride (4 mL) were stirred at 60° C. for 1.5 hours. To the reaction solution was added ice and extracted with ethyl acetate. The organic layer was washed with sodium hydrogencarbonate and brine and dried over sodium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (739 mg). Yield: 92%.



1H-NMR (CDCl3) δ: 0.91 (3H, t, J=7.6 Hz), 1.47 (2H, q, J=7.6 Hz), 1.60-1.63 (4H, m), 1.92-1.94 (2H, m), 3.53-3.56 (2H, m), 3.62-3.65 (4H, m), 7.26 (1H, dd, J=8.5, 2.2 Hz), 7.47 (1H, d, J=8.5 Hz), 7.58 (1H, d, J=2.2 Hz).


Example 593
Preparation of [4-Chloro-3-[2-[1-(6-chlorobenzothiazole-2-yl)-4-ethyl piperidine-4-yl]ethoxy]phenyl]acetic acid methyl ester






A mixture of 6-chloro-2-[4-(2-chloroethyl)-4-ethyl piperidine-1-yl]benzothiazole (150 mg), (4-chloro-3-hydroxyphenyl)acetic acid methyl ester (176 mg), cesium carbonate (285 mg) and dimethylformamide (2 mL) was stirred at 75° C. for 24 hours. To the reaction solution was added water and extracted with ethyl acetate. The organic layer was washed with brine, and dried over sodium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (174 mg). Yield: 79%.



1H-NMR (CDCl3) δ: 0.94 (3H, t, J=7.6 Hz), 1.52-1.78 (8H, m), 3.59 (2H, s), 3.60-3.63 (2H, m), 3.68-3.70 (2H, m), 3.72 (3H, s), 4.09-4.18 (2H, m), 6.80-6.88 (2H, m), 6.98-6.98 (1H, m), 7.27-7.32 (1H, m), 7.48 (1H, d, J=8.5 Hz), 7.57 (1H, d, J=1.9 Hz).


Example 594
Preparation of [4-Chloro-3-[2-[1-(6-chlorobenzothiazole-2-yl)-4-ethyl piperidine-4-yl]ethoxy]phenyl]acetic acid






A mixture of [4-Chloro-3-[2-[1-(6-chlorobenzothiazole-2-yl)-4-ethyl piperidine-4-yl]ethoxy]phenyl]acetic acid methyl ester (152 mg), 2N aqueous sodium hydroxide (0.45 mL), tetrahydrofuran (1 mL) and methanol (1 mL) was stirred at room temperature for 2 hours. The reaction solution was neutralized with 2N hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over sodium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (53 mg). Yield: 36%.


MS (ESI) m/z 493 [M+H]+


The following compounds were obtained by similar methods as above.


Example 595






MS (ESI) m/z 479 [M+H]+


Example 596






MS (ESI) m/z 459 [M+H]+


Example 597






MS (ESI) m/z 507 [M+H]+


Example 598






MS (ESI) m/z 547 [M+H]+


Example 599






MS (ESI) m/z 564 [M+H]+


Example 600






1H-NMR (Acetone-d6) δ: 8.65 (1H, s), 7.60-7.63 (2H, m), 7.48 (2H, t, J=7.55 Hz), 7.36 (1H, t, J=7.55 Hz), 7.20-7.25 (1H, m), 6.97 (1H, s), 6.84-6.87 (2H, m), 4.19-4.27 (2H, m), 4.14 (2H, t, J=7.42 Hz), 3.65-3.72 (2H, m), 3.62 (2H, s), 2.05-2.10 (2H, m), 1.57-1.79 (7H, m), 0.96-1.00 (6H, m).


Example 601






1H-NMR (Acetone-d6) δ: 8.65 (1H, s), 7.62-7.65 (2H, m), 7.48 (2H, t, J=7.55 Hz), 7.36 (1H, t, J=7.55 Hz), 6.76 (1H, s), 6.72 (2H, s), 4.19-4.27 (2H, m), 4.14 (2H, t, J=7.42 Hz), 3.65-3.72 (2H, m), 3.62 (2H, s), 2.25 (3H, s), 2.05-2.10 (2H, m), 1.57-1.79 (7H, m), 0.96-1.00 (6H, m).


Example 602






1H-NMR (Acetone) δ: 8.65 (1H, s), 7.62-7.65 (2H, m), 7.48 (2H, t, J=7.55 Hz), 7.36 (1H, t, J=7.55 Hz), 6.76 (1H, s), 6.72 (2H, s), 4.19-4.27 (2H, m), 4.14 (2H, t, J=7.42 Hz), 3.65-3.72 (2H, m), 3.62 (2H, s), 2.05-2.10 (2H, m), 1.57-1.79 (7H, m), 0.96-1.00 (6H, m).


Example 603






MS (ESI) m/z 547 [M+H]+


Example 604






1H-NMR (CDCl3) δ: 0.87-1.98 (15H, m), 3.44-3.78 (6H, m), 4.03 (3H, t, J=7.1 Hz), 6.78-7.45 (7H, m), 7.54 (1H, d, J=1.9 Hz).


Example 605






1H-NMR (CDCl3) δ: 0.83-1.99 (15H, m), 2.30 (3H, s), 3.47-3.79 (6H, m), 4.02 (2H, t, J=7.1 Hz), 6.62 (2H, s), 6.69 (1H, s), 7.22-7.26 (1H, m), 7.46 (1H, d, J=9.1 Hz), 7.54 (1H, d, J=2.2 Hz).


Example 606






1H-NMR (CDCl3) δ: 7.42 (1.0H, s), 7.29-7.24 (1.0H, m), 7.17 (1.0H, ddd, J=7.97, 1.30, 1.30 Hz), 7.10 (1.0H, ddd, J=9.89, 2.13, 2.13 Hz), 6.93-6.85 (2.0H, m), 6.80 (1.0H, dd, J=1.92, 1.92 Hz), 6.72 (1.0H, dd, J=1.79, 1.79 Hz), 4.03 (2.0H, dd, J=7.14, 7.14 Hz), 3.67-3.57 (4.0H, m), 3.47-3.39 (2.0H, m), 1.93 (2.0H, dd, J=7.14, 7.14 Hz), 1.82-1.77 (2.0H, m), 1.67-1.54 (4.0H, m), 1.50-1.42 (1.0H, m), 0.98-0.90 (6.0H, m).


Example 607






1H-NMR (CDCl3) δ: 7.42 (1.0H, s), 7.30 (1.0H, dd, J=5.63, 2.06 Hz), 7.17 (1.0H, d, J=8.79 Hz), 7.12-7.07 (1.0H, m), 6.92-6.85 (1.0H, m), 6.69 (1.0H, s), 6.63 (2.0H, d, J=4.67 Hz), 4.04 (2.0H, dd, J=7.00, 7.00 Hz), 3.68-3.57 (4.0H, m), 3.47-3.39 (2.0H, m), 2.31 (3.0H, s), 1.95-1.54 (8.0H, m), 1.49-1.42 (1.0H, m), 0.97-0.90 (6.0H, m).


Example 608






1H-NMR (Acetone) δ: 7.60 (1.0H, d, J=1.65 Hz), 7.42-7.33 (1.0H, m), 7.30-7.18 (3.0H, m), 6.99-6.92 (2.0H, m), 6.89-6.83 (2.0H, m), 4.15-4.09 (2.0H, m), 3.72-3.47 (6.0H, m), 1.85-1.56 (6.0H, m), 1.31-1.27 (3.0H, m), 0.99-0.92 (6.0H, m).


Example 609






1H-NMR (DMSO-d6) δ 1.25 (2H, br), 1.46-1.64 (10H, m), 1.94 (2H, t, J=6.9 Hz), 2.12 (1H, m), 3.43-3.52 (2H, m), 3.56 (2H, s), 3.70-3.80 (2H, br), 4.02 (3H, 2H, J=6.9 Hz), 6.83 (1H, s), 6.90 (1H, s), 6.96 (1H, s), 7.25-7.29 (1H, m), 7.40 (1H, d, J=8.7 Hz), 7.89 (1H, d, J=2.4 Hz)


Reference Example 245
Preparation of 1-(6-chlorobenzothiazole-2-yl)pyrrolidine-3-ylamine






A mixture of 2,6-dichlorobenzothiazole (2.00 g), 2-(trifluoroacetamide)pyrrolidine hydrochloride (2.14 g), potassium carbonate (4.06 g) and dimethylformamide (15 mL) was stirred at 60° C. for 2 hours. To the reaction solution was added water and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure and the residue was washed with n-hexane. The obtained purified product was dissolved in tetrahydrofuran (20 mL) and methanol (10 mL). 2N sodium hydroxide was added thereto and the mixture was stirred for 2.5 hours. The solvent was evaporated under reduced pressure. Water was added thereto and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over sodium sulphate. The solvent was evaporated under reduced pressure to give the title compound (2.49 g). Yield: 100%.


1H-NMR (DMSO-d6) δ: 1.72-1.80 (2H, m), 3.45-3.63 (5H, m), 7.26 (1H, dd, H=2.0, 8.0), 7.41 (1H, d, J=8.5), 7.88 (1H, d, J=2.0)


Reference Example 246
Preparation of N-[1(6-chlorobenzothiazole-2-yl)pyrrolidine-3-yl]-2-nitro benzenesulfonamide






A mixture of 1-(6-chlorobenzothiazole-2-yl)pyrrolidine-3-ylamine (2.49 g), 2-nitrobenzenesulphonyl chloride (2.40 g), triethylamine (3.02 mL) and dimethylformamide (15 mL) was stirred at 60° C. for 3 hours. To the reaction solution was added water and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over sodium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (2.01 g). Yield: 47



1H-NMR (DMSO-d6) δ: 1.99-2.03 (1H, m), 2.19-2.23 (1H, m), 3.55-3.63 (4H, m), 4.07-4.09 (1H, m), 7.30 (1H, dd, J=8.5, 2.2 Hz), 7.45 (1H, d, J=8.8 Hz), 7.90-7.94 (3H, m), 8.01-8.10 (2H, m).


Reference Example 247
Preparation of [3-[[[1-(6-chlorobenzothiazole-2-yl)pyrrolidine-3-yl]-(2-nitrobenzensulphonyl)amino]methyl]phenyl]acetic acid methyl ester






N-[1(6-chlorobenzothiazole-2-yl)pyrrolidine-3-yl]-2-nitrobenzenesulfonamide (500 mg) was dissolved in dimethylformamide (5 mL). Sodium hydride (60%, oil, 50 mg) was added thereto and the mixture was stirred at room temperature for 1 hour. (3-bromomethylphenyl)acetic acid methyl ester (305 mg) was added thereto and the mixture was stirred for 16 hours. To the reaction solution was added water and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (412 mg). Yield: 60%.



1H-NMR (CDCl3) δ: 2.11-2.19 (1H, m), 2.34-2.37 (1H, m), 3.53-3.59 (6H, m), 3.69 (3H, s), 3.78-3.81 (1H, m), 4.53-4.63 (2H, m), 7.07-7.19 (4H, m), 7.25-7.32 (1H, m), 7.50-7.58 (3H, m), 7.65-7.67 (2H, m), 7.85 (1H, d, J=7.7 Hz).


Example 610
Preparation of [3-[[1-(6-chlorobenzothiazole-2-yl)pyrrolidine-3-ylamino]methyl]phenyl]acetic acid methyl ester






A mixture of [3-[[[1-(6-chlorobenzothiazole-2-yl)pyrrolidine-3-yl]-(2-nitrobenzensulphonyl)amino]methyl]phenyl]acetic acid methyl ester (412 mg), mercaptoacetic acid (95 mL), 1,8-diazabicyclo [5,4,0]-7-undecene (4 mL) and dimethylformamide (4 mL) was stirred at room temperature for 1 hour. To the reaction solution was added water and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over sodium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (204 mg). Yield: 71%.



1H-NMR (CDCl3) δ: 2.11-2.14 (1H, m), 2.27-2.32 (1H, m), 3.49-3.59 (2H, m), 3.63 (2H, s), 3.70 (3H, s), 3.74-3.82 (2H, m), 3.89 (2H, s), 7.23 (2H, dd, J=8.5, 2.2 Hz), 7.31-7.33 (3H, m), 7.45 (1H, d, J=8.5 Hz), 7.46 (1H, s), 7.54 (1H, d, J=2.2 Hz), 8.02 (1H, brs).


Example 611
Preparation of [3-[[butyl[1-(6-chlorobenzothiazole-2-yl)pyrrolidine-3-yl]amino]methyl]phenyl]acetic acid methyl ester






A mixture of [3-[[1-(6-chlorobenzothiazole-2-yl)pyrrolidine-3-ylamino]methyl]phenyl]acetic acid methyl ester (68 mg), 1-iodobutane (37 μL), potassium carbonate (45 mg) and dimethylformamide (1 mL) was stirred at 80° C. for 3.5 hours. To the reaction solution was added water and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over sodium sulphate. The residue was purified by column chromatograph on silica gel to give the title compound (28 mg). Yield: 36%.



1H-NMR (CDCl3) δ: 0.90 (3H, t, J=7.3 Hz), 1.24-1.36 (2H, m), 1.47-1.50 (2H, m), 2.54-2.56 (2H, m), 3.51-3.71 (14H, m), 7.21-7.29 (5H, m), 7.50 (1H, d, J=8.8 Hz), 7.58 (1H, d, J=2.2 Hz).


Example 612
Preparation of [3-[[butyl[1-(6-chlorobenzothiazole-2-yl)pyrrolidine-3-yl]amino]methyl]phenyl]acetic acid






A mixture of [3-[[butyl[1-(6-chlorobenzothiazole-2-yl)pyrrolidine-3-yl]amino]methyl]phenyl]acetic acid methyl ester (28 mg), 2N sodium hydroxide (0.15 mL), tetrahydrofuran (1 mL) and methanol (0.5 mL) was stirred at room temperature for 1 hour. The mixture was neutralized with 2N hydrochloric acid and concentrated under reduced pressure. The solution was extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over sodium sulphate to give the title compound (19 mg). Yield: 68%.


MS (ESI) m/z 458 [M+H]+


The following compounds were obtained by similar methods as above.


Example 613






MS (ESI) m/z 430 [M+H]+


Example 614






MS (ESI) m/z 416 [M+H]+


Example 615






MS (ESI) m/z 480 [M+H]+


Example 616






MS (ESI) m/z 402 [M+H]+


Reference Example 248
Preparation of [1-(6-chlorobenzothiazole-2-yl)piperidine-4-yl]carbamic acid tert-butyl ester






A mixture of 4-Boc-amino piperidine (3.23 g), 2,6-dichlorobenzothiazole (3.29 g), potassium carbonate (6.68 g) and dimethylformamide (20 mL) was stirred at 60° C. for 16 hours. Water was added to the reaction solution. The precipitate was collected and the obtained title compound was provided to the next reaction without purification.


Reference Example 249
Synthesis of 1-(6-chlorobenzothiazole-2-yl)piperidine-4-ylamine






[1-(6-chlorobenzothiazole-2-yl)piperidine-4-yl]carbamic acid tert-butyl ester obtained from the above reaction was dissolved in chloroform. 4N solution of hydrochloric acid/dioxane was added thereto and the mixture was stirred at room temperature for 16 hours. The solvent was concentrated under reduced pressure. Water was added thereto and washed with ethyl acetate. The water layer was neutralized with 2N sodium hydroxide and extracted with ethyl acetate. The organic layer was washed with magnesium sulphate and the solvent was evaporated under reduced pressure to give the title compound (3.31 g). Yield: 77%.



1H-NMR (DMSO-d6) δ: 1.24-1.33 (4H, m), 3.20-3.30 (3H, m), 3.90-3.95 (2H, m), 7.27 (1H, dd, J=8.5, 2.2 Hz), 7.40 (1H, d, J=8.8 Hz), 7.88 (1H, d, J=2.2 Hz).


Example 617
Preparation of [3-[[1-(6-chlorobenzothiazole-2-yl)piperidine-4-ylamino]methyl]phenyl]acetic acid methyl ester






A mixture of 1-(6-chlorobenzothiazole-2-yl)piperidine-4-ylamine (500 mg), (3-bromomethylphenyl)acetic acid methyl ester (454 mg), potassium carbonate (284 mg) and dimethylformamide (6 mL) was stirred at room temperature for 1 hour. To the reaction solution was added water and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over sodium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (434 mg). Yield: 55%.


Example 618
Preparation of [3-[[[1-(6-chlorobenzothiazole-2-yl)piperidine-4-yl]ethylamino]methyl]phenyl]acetic acid methyl ester






A mixture of [3-[[1-(6-chlorobenzothiazole-2-yl)piperidine-4-ylamino]methyl]phenyl]acetic acid methyl ester (110 mg), methyl iodide (800 mg), potassium carbonate (71 mg) and dimethylformamide (2 mL) was stirred at 80° C. for 5 hours. To the reaction solution was added water and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over sodium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (65 mg). Yield: 56%.



1H-NMR (CDCl3) δ: 1.03-1.07 (3H, br m), 1.63-1.66 (2H, br m), 1.89-1.92 (2H, br m), 2.58-2.62 (1H, br m), 2.91 (2H, s), 2.98 (2H, s), 3.09-3.13 (2H, m), 3.64-3.67 (2H, br m), 3.71 (3H, s), 4.20-4.23 (2H, br m), 7.25-7.28 (5H, m), 7.44 (1H, d, J=8.5 Hz), 7.57 (1H, d, J=10.0 Hz).


Example 619
Preparation of [3-[[[1-(6-chlorobenzothiazole-2-yl)piperidine-4-yl]ethylamino]methyl]phenyl]acetic acid






A mixture of [3-[[[1-(6-chlorobenzothiazole-2-yl)piperidine-4-yl]ethylamino]methyl]phenyl]acetic acid methyl ester (65 mg), 2N sodium hydroxide (0.36 mL), tetrahydrofuran (1 mL) and methanol (1 mL) was stirred at room temperature for 1 hour. The solution was neutralized with 2N hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over sodium sulphate. The solvent was evaporated under reduced pressure and the obtained residue was washed with the mixed solvent of ethyl acetate and n-hexane to give the title compound (19 mg). Yield: 30%.


MS (ESI) m/z 444 [M+H]+


The following compounds were obtained by similar methods as above.


Example 620






MS (ESI) m/z 472 [M+H]+


Example 621






MS (ESI) m/z 472 [M+H]+


Example 622






MS (ESI) m/z 494 [M+H]+


Reference Example 250
Preparation of [1-(6-chlorobenzothiazole-2-yl)piperidine-4-yl]isopropylamine






A mixture of 1-(6-chlorobenzothiazole-2-yl)piperidine-4-ylamine (335 mg), acetone (92 ul), acetic acid (0.1 mL) and methanol (3 mL) was stirred at room temperature for 5 minutes. To the reaction solution was added triacetoxy sodium boron hydride (332 mg). The mixture was stirred at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure. Aqueous sodium hydrogencarbonate was added thereto and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over sodium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (160 mg). Yield: 41%.



1H-NMR (CDCl3) δ: 1.11 (6H, d, J=6.3 Hz), 1.48-1.51 (2H, m), 2.01-2.05 (2H, m), 2.84-2.91 (1H, m), 3.00-3.08 (1H, m), 3.14-3.24 (2H, m), 4.08-4.16 (2H, m), 7.23 (1H, dd, J=8.5, 2.2 Hz), 7.42 (1H, d, J=8.5 Hz), 7.55 (1H, d, J=2.2 Hz).


Example 623
Preparation of [3-[[[1-(6-chlorobenzothiazole-2-yl)piperidine-4-yl]isopropylamino]methyl]phenyl]acetic acid methyl ester






A mixture of [1-(6-chlorobenzothiazole-2-yl)piperidine-4-yl]isopropylamine (159 mg), (3-bromomethylphenyl)acetic acid methyl ester (138 mg), potassium carbonate (107 mg) and dimethylformamide (2 mL) was stirred at 80° C. for 8 hours. To the reaction solution was added water and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (90 mg). Yield: 37%.


Example 624
Preparation of [3-[[[1-(6-chlorobenzothiazole-2-yl)piperidine-4-yl]isopropylamino]methyl]phenyl]acetic acid






A mixture of [3-[[[1-(6-chlorobenzothiazole-2-yl)piperidine-4-yl]isopropylamino]methyl]phenyl]acetic acid methyl ester (90 mg), 2N sodium hydroxide (0.5 mL), tetrahydrofuran (2 mL) and methanol (1 mL) was stirred at room temperature for 1 hour. After neutralizing with 2N hydrochloric acid, the reaction solution was concentrated under reduced pressure and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (28 mg).


Yield: 32%.


MS (ESI) m/z 458 [M+H]+


Example 625
Preparation of [3-[2-[1-(6-chlorobenzothiazole-2-yl)pyrrolidine-3-ylamino]ethoxy]phenyl]acetic acid methyl ester






A mixture of 1-(6-chlorobenzothiazole-2-yl)pyrrolidine-3-ylamine (190 mg), [3-(2-bromoethoxy)phenyl]acetic acid methyl ester (205 mg) and potassium carbonate (114 mg) was stirred at 80° C. for 2 hours. To the reaction solution, was added water and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over sodium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (174 mg). Yield: 52%.



1H-NMR (CDCl3) δ: 2.01-2.06 (1H, m), 2.31-2.36 (1H, m), 3.09 (2H, t, J=4.9 Hz), 3.48-3.50 (1H, m), 3.62 (2H, s), 3.64-3.80 (4H, m), 3.72 (3H, s), 4.12 (2H, t, J=4.9 Hz), 6.83-6.91 (3H, m), 7.24-7.28 (3H, m), 7.50 (1H, d, J=8.5 Hz), 7.59 (1H, d, J=1.9 Hz).


Example 626
Preparation of [3-[2-[[1-(6-chlorobenzothiazole-2-yl)pyrrolidine-3-yl]ethylamino]ethoxy]phenyl]acetic acid methyl ester






A mixture of [3-[2-[1-(6-chlorobenzothiazole-2-yl)pyrrolidine-3-ylamino]ethoxy]phenyl]acetic acid methyl ester (174 mg), ethyl iodide (68 uL), potassium carbonate (81 mg) and dimethylformamide (2 mL) was stirred at 80° C. for 6.5 hours. To the reaction solution was added water and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over sodium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (101 mg). Yield: 55%.



1H-NMR (CDCl3) δ: 1.14 (3H, t, J=6.7 Hz), 2.08-2.11 (1H, m), 2.29-2.32 (1H, m), 2.79-2.81 (2H, m), 2.98-3.03 (2H, m), 3.46-3.86 (5H, m), 3.62 (2H, s), 3.71 (3H, s), 4.05-4.08 (2H, m), 6.82-6.90 (3H, m), 7.23-7.29 (2H, m), 7.50 (1H, d, J=8.8 Hz), 7.59 (1H, d, J=1.9 Hz).


Example 627
Preparation of [3-[2-[[1-(6-chlorobenzothiazole-2-yl)pyrrolidine-3-yl]ethylamino]ethoxy]phenyl]acetic acid






A mixture of [3-[2-[[1-(6-chlorobenzothiazole-2-yl)pyrrolidine-3-yl]ethylamino]ethoxy]phenyl]acetic acid methyl ester (101 mg), 2N aqueous sodium hydroxide (0.535 mL), tetrahydrofuran (1 mL) and methanol (0.5 mL) was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over sodium sulphate. The solvent was evaporated under reduced pressure and the residue was washed with ethyl acetate/n-hexane to give the title compound (13 mg). Yield: 14%.


MS (ESI) m/z 459 [M+H]+


The following compounds were obtained by similar methods as above.


Example 628






MS (ESI) m/z 487 [M+H]+


Example 629






MS (ESI) m/z 473 [M+H]+


Example 630






MS (ESI) m/z 516 [M+H]+


Example 631






MS (ESI) m/z 548 [M+H]+


Example 632






MS (ESI) m/z 528 [M+H]+


Example 633






MS (ESI) m/z 508 [M+H]+


Reference Example 251
Preparation of (1-benzyl-4-pyrrolidine-1-ylpiperidine-4-yl)acetic acid methyl ester






A mixture of 1-benzyl-4-piperidone (3 mL), pyrrolidine (6.95 mL) and toluene (30 mL) was refluxed for 1 hour. The solvent was evaporated under reduced pressure. To the residue was added acetic acid (0.96 mL). The mixture was stirred at room temperature for 5 minutes. To the reaction solution were added zinc (1.37 g) and bromo acetic acid methyl ester (2.17 mL). The mixture was stirred at room temperature for 2 hours. To the reaction solution was added aqueous sodium carbonate solution (20 mL) and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over sodium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (2.77 g). Yield: 52%.



1H-NMR (CDCl3) δ: 1.71-1.73 (4H, m), 1.81-1.84 (4H, m), 2.45-2.56 (10H, m), 3.55-3.58 (2H, m), 3.69 (3H, s), 7.26-7.36 (5H, m).


Reference Example 252
Preparation of 2-(1-benzyl-4-pyrrolidine-1-ylpiperidine-4-yl)ethanol






Lithium aluminium hydride (324 mg) was suspended in tetrahydrofuran (25 mL). A solution of (1-benzyl-4-pyrrolidine-1-ylpiperidine-4-yl)acetic acid methyl ester (2.70 g) in tetrahydrofuran (25 mL) was added thereto at 0° C. After stirring at 0° C. for 1 hour, to the reaction solution were sequentially added with water (0.35 mL), 10% aqueous sodium hydroxide (0.35 mL) and water (1.05 mL). The insoluble material was filtrated and the filtrate was extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over sodium sulphate. The solvent was evaporated under reduced pressure to give the title compound. The obtained objective substance was provided to the next reaction without further purification.



1H-NMR (CDCl3) δ: 1.74-1.76 (6H, m), 1.89-1.94 (4H, m), 2.06-2.17 (2H, m), 2.80-2.83 (6H, m), 3.54 (3H, s), 3.85-3.87 (2H, m), 7.33 (5H, t, J=3.6 Hz).


Reference Example 253
Preparation of 2-[1-(6-chlorobenzothiazole-2-yl)-4-pyrrolidine-1-ylpiperidine-4-yl]ethanol






2-(1-Benzyl-4-pyrrolidine-1-ylpiperidine-4-yl) ethanol obtained above was dissolved in methanol (60 mL). Pd/C (600 mg) was added thereto and the mixture was stirred under a hydrogen atmosphere for 19 hours. The insoluble material was filtrated and the filtrate was concentrated under reduced pressure. To the obtained residue were added dimethylformamide (30 mL), potassium carbonate (1.24 g) and 2,6-dichlorobenzothiazole (1.83 g). The mixture was stirred at 60° C. for 21 hours. To the reaction solution was added water and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over sodium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (2.58 g).


Yield: 83%.



1H-NMR (CDCl3) δ: 1.83-1.86 (4H, m), 2.00-2.01 (6H, m), 2.91-2.98 (4H, m), 3.29-3.38 (2H, m), 3.92-4.05 (4H, m), 7.26 (1H, d, J=2.2 Hz), 7.45 (1H, t, J=7.8 Hz), 7.59 (1H, d, J=2.2 Hz).


Example 634
Preparation of [3-chloro-5-[2-[1-(6-chlorobenzothiazole-2-yl)-4-pyrrolidine-1-ylpiperidine-4-yl]ethanol]phenyl]acetic acid methyl ester






A mixture of 2-[1-(6-chlorobenzothiazole-2-yl)-4-pyrrolidine-1-ylpiperidine-4-yl]ethanol (1.60 g), tri-n-butylphosphine (1.15 mL), 1,1′-(azodicarbonyl)dipiperidine (1.16 g) and tetrahydrofuran (25 mL) was stirred at room temperature for 1 hour. The insoluble material was filtrated. To the filtrate was added aqueous sodium hydrogencarbonate solution and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over sodium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (874 mg).


Yield: 36%.



1H-NMR (CDCl3) δ: 1.77-1.81 (6H, m), 1.94-2.03 (4H, m), 2.69-2.72 (4H, m), 3.53-3.77 (4H, m), 3.56 (2H, s), 3.72 (3H, s), 4.01 (2H, m), 6.75-6.84 (3H, m), 7.25 (1H, dd, J=8.7, 2.1 Hz), 7.44 (1H, d, J=8.8 Hz), 7.57 (1H, d, J=2.2 Hz).


Example 635
Preparation of [3-chloro-5-[2-[1-(6-chlorobenzothiazole-2-yl)-4-pyrrolidine-1-ylpiperidine-4-yl]ethanol]phenyl]acetic acid






A mixture of [3-chloro-5-[2-[1-(6-chlorobenzothiazole-2-yl)-4-pyrrolidine-1-ylpiperidine-4-yl]ethanol]phenyl]acetic acid methyl ester (851 mg), 2N sodium hydroxide (2.33 mL), tetrahydrofuran (5 mL) and methanol (5 mL) was stirred at room temperature for 0.5 hour. The mixture was neutralized with 2N hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure and the residue was washed with hexane to give the title compound (725 mg). Yield: 88%.


MS (ESI) m/z 534 [M+H]+


The following compounds were obtained by similar methods as above.


Example 636






MS (ESI) m/z 568 [M+H]+


Example 637






MS (ESI) m/z 534 [M+H]+


Example 638






MS (ESI) m/z 568 [M+H]+


Example 639






MS (ESI) m/z 520 [M+H]+


Example 640






MS (ESI) m/z 548 [M+H]+


Example 641






MS (ESI) m/z 582 [M+H]+


Example 642






MS (ESI) m/z 582 [M+H]+


Example 643






MS (ESI) m/z 514 [M+H]+


Example 644






MS (ESI) m/z 514 [M+H]+


Example 645






MS (ESI) m/z 584 [M+H]+


Example 646






MS (ESI) m/z 584 [M+H]+


Example 647






MS (ESI) m/z 550 [M+H]+


Example 648






MS (ESI) m/z 612 [M+H]+


Example 649






MS (ESI) m/z 612 [M+H]+


Example 650






MS (ESI) m/z 612 [M+H]+


Example 651






MS (ESI) m/z 612 [M+H]+


Example 652






MS (ESI) m/z 578 [M+H]+


Example 653






MS (ESI) m/z 578 [M+H]+


Example 654







1H-NMR (CDCl3) δ: 1.08 (6H, t, J=7.1 Hz), 1.65-1.77 (2H, m), 1.92-2.05 (4H, m), 2.65 (4H, q, J=7.1 Hz), 3.54-3.77 (6H, m), 4.01 (2H, t, J=6.6 Hz), 6.70 (1H, s), 6.78 (1H, s), 6.87 (1H, s), 7.22 (1H, dd, J=8.5, 2.2 Hz), 7.43 (1H, d, J=8.5 Hz), 7.54 (1H, d, J=2.2 Hz).


Example 655






1H-NMR (CDCl3) δ: 1.07 (6H, t, J=7.0 Hz), 1.70-2.10 (6H, m), 2.66 (4H, q, J=7.0 Hz), 3.56-3.79 (6H, m), 4.05-4.13 (2H, m), 6.76-6.85 (2H, m), 7.19-7.30 (2H, m), 7.42 (1H, d, J=8.5 Hz), 7.53 (1H, d, J=1.6 Hz).


Example 656






1H-NMR (CDCl3) δ: 1.08 (3H, t, J=6.9 Hz), 1.64-2.03 (6H, m), 2.26 (3H, s), 2.53 (2H, q, J=6.9 Hz), 3.52-3.68 (6H, m), 3.96-4.03 (2H, m), 6.68-6.88 (3H, m), 7.22 (1H, dd, J=8.5, 2.2 Hz), 7.43 (1H, d, J=8.8 Hz), 7.54 (1H, d, J=2.2 Hz).


Example 657






1H-NMR (CDCl3) δ: 1.05 (3H, t, J=7.1 Hz), 1.64-2.03 (6H, m), 2.23 (3H, s), 2.44-2.56 (2H, m), 3.45-3.68 (6H, m), 3.98-4.08 (2H, m), 6.68-6.85 (2H, m), 7.18-7.25 (2H, m), 7.41 (1H, d, J=8.8 Hz), 7.52 (1H, d, J=1.4 Hz).







1H-NMR (CDCl3) δ: 1.08 (3H, t, J=7.1 Hz), 1.64-2.06 (6H, m), 2.26 (3H, s), 2.52 (2H, q, J=7.1 Hz), 3.56 (2H, s), 3.60-3.80 (4H, m), 4.00 (2H, t, J=6.7 Hz), 6.68-6.89 (3H, m), 7.49-7.58 (2H, m), 7.83 (1H, s).


Example 659






1H-NMR (CDCl3) δ: 1.07 (3H, t, J=6.9 Hz), 1.70-2.07 (6H, m), 2.25 (3H, s), 2.52 (2H, q, J=6.9 Hz), 3.53 (2H, s), 3.59-3.76 (5H, m), 4.03-4.10 (2H, m), 6.74-6.84 (2H, m), 7.23-7.28 (1H, m), 7.47-7.57 (2H, m), 7.82 (1H, s).


Example 660






1H-NMR (CDCl3) δ: 7.54 (1.0H, d, J=1.92 Hz), 7.42 (1.0H, d, J=8.79 Hz), 7.31-7.29 (1.0H, m), 7.24-7.21 (1.0H, m), 6.85-6.79 (2.0H, m), 4.09 (2.0H, dd, J=7.14, 7.14 Hz), 3.78-3.58 (6.0H, m), 2.79-2.73 (4.0H, br m), 2.10-1.52 (14.0H, m).


Example 661






1H-NMR (CDCl3) δ: 7.54 (1.0H, d, J=2.20 Hz), 7.43 (1.0H, d, J=8.24 Hz), 7.25-7.20 (1.0H, m), 6.87 (1.0H, s), 6.78 (1.0H, s), 6.70 (1.0H, s), 3.99 (2.0H, dd, J=7.00, 7.00 Hz), 3.77-3.56 (6.0H, m), 2.76-2.72 (4.0H, m), 2.13-1.91 (10.0H, m), 1.73-1.56 (4.0H, m).


Example 662






1H-NMR (CDCl3) δ: 7.53 (1.0H, d, J=1.92 Hz), 7.41 (1.0H, d, J=8.79 Hz), 7.26-7.20 (2.0H, m), 6.86 (1.0H, s), 6.76 (1.0H, d, J=8.52 Hz), 4.17-4.10 (2.0H, m), 3.92-3.84 (1.0H, m), 3.81-3.40 (4.0H, m), 3.33-3.24 (2.0H, m), 2.97-2.89 (1.0H, m), 2.76-2.66 (1.0H, m), 2.19-1.61 (8.0H, m), 1.54-1.42 (2.0H, m), 1.04 (3.0H, d, J=6.30 Hz).


Example 663






MS (ESI) m/z 548 [M+H]+


Example 664






MS (ESI) m/z 525 [M+H]+


Example 665






1H-NMR (CDCl3) δ: 7.83 (1.0H, d, J=1.24 Hz), 7.55 (1.0H, d, J=8.51 Hz), 7.50 (1.0H, dd, J=8.78, 1.24 Hz), 7.30 (1.0H, d, J=8.10 Hz), 6.85 (1.0H, d, J=1.78 Hz), 6.80 (1.0H, dd, J=8.10, 1.78 Hz), 4.15-4.10 (2.0H, m), 3.79-3.61 (6.0H, m), 3.47 (2.0H, t, J=6.45 Hz), 3.36 (3.0H, s), 2.71 (4.0H, t, J=6.45 Hz), 2.07-1.98 (4.0H, m), 1.82-1.71 (2.0H, m).


Example 666






1H-NMR (CDCl3) δ: 7.83 (1.0H, d, J=0.89 Hz), 7.56 (1.0H, d, J=8.85 Hz), 7.51 (1.0H, dd, J=8.85, 0.89 Hz), 6.88-6.87 (1.0H, m), 6.79 (1.0H, dd, J=1.92, 0.96 Hz), 6.71-6.69 (1.0H, m), 4.02 (2.0H, t, J=6.31 Hz), 3.79-3.63 (4.0H, m), 3.57 (2.0H, s), 3.46 (2.0H, t, J=6.24 Hz), 3.35 (3.0H, s), 2.68 (3.0H, t, J=6.24 Hz), 2.31 (3.0H, s), 2.07-1.91 (4.0H, m), 1.77-1.64 (2.0H, m).


Reference Example 254
Preparation of 2-(4-pyrrolidine-1-ylpiperidine-4-yl)ethanol






A mixture of 2-(1-benzyl-4-pyrrolidine-1-ylpiperidine-4-yl)ethanol (9.28 g), 10% Pd/C (1.86 g) and methanol (100 mL) was stirred under hydrogen (4 atm) for 3 days. The insoluble material was filtrated and the filtrate was concentrated to give the title compound (6.30 g).


Yield: 99%.



1H-NMR (DMSO-d6) δ: 1.76-1.79 (6H, m), 1.88-1.91 (4H, m), 2.77-2.80 (4H, m), 3.02-3.05 (2H, br m), 3.15-3.18 (2H, br m), 3.53-3.55 (2H, br m).


Reference Example 255
Preparation of 2-[1-(5-bromothiazole-2-yl)-4-pyrrolidine-1-ylpiperidine-4-yl]ethanol






A mixture of 2-(4-pyrrolidine-1-ylpiperidine-4-yl)ethanol (4.11 g), 2,5-dibromothiazole (5.03 g), potassium carbonate (3.43 g) and dimethylformamide (75 mL) was stirred at 60° C. for 16 hours. To the reaction solution was added water and extracted with ethyl acetate. The organic layer was washed with water and brine, and washed with magnesium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (3.88 g). Yield: 52%.


Example 667
Preparation of [3-[2-[1-(5-bromothiazole-2-yl)-4-pyrrolidine-1-ylpiperidine-4-yl]ethoxy]-5-chlorophenyl]acetic acid methyl ester






A mixture of 2-[1-(5-bromothiazole-2-yl)-4-pyrrolidine-1-ylpiperidine-4-yl]ethanol (1.30 g), (3-chloro-5-hydroxy phenyl)acetic acid (796 mg), tri-n-butylphosphine (0.99 mL), 1,1′-(azodicarbonyl)dipiperidine (1.00 g) and tetrahydrofuran (20 mL) was stirred at room temperature for 4 hours. To the reaction solution was added water and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (1.45 g). Yield: 74%.



1H-NMR (CDCl3) δ: 1.71-1.85 (8H, m), 2.09-2.10 (2H, m), 2.69-2.71 (4H, br m), 3.48-3.53 (4H, m), 3.61 (2H, s), 3.71 (3H, s), 4.12-4.16 (2H, m), 6.83 (2H, dd, J=8.0, 2.2 Hz), 7.07 (1H, d, J=2.2 Hz), 7.31 (1H, d, J=8.0 Hz).


Example 668
Preparation of [3-[2-[1-(5-bromothiazole-2-yl)-4-pyrrolidine-1-ylpiperidine-4-yl]ethoxy]-5-chlorophenyl]acetic acid






A mixture of [3-[2-[1-(5-bromothiazole-2-yl)-4-pyrrolidine-1-ylpiperidine-4-yl]ethoxy]-5-chlorophenyl]acetic acid methyl ester (1.45 g), 2N sodium hydroxide (3.3 mL), tetrahydrofuran (15 mL) and methanol (15 mL) was stirred at room temperature for 3 hours. To the reaction solution was added water and washed with chloroform. The water layer was neutralized with 2N hydrochloric acid and extracted with chloroform. The organic layer was washed with water and brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (916 mg). Yield: 65%.



1H-NMR (DMSO-d6) δ: 1.75-1.89 (10H, m), 2.64-2.67 (4H, m), 3.33-3.36 (2H, m), 3.34 (2H, s) 3.51-3.55 (2H, m), 4.11-4.14 (2H, m), 6.85 (1H, dd, J=7.8, 2.1 Hz), 7.10 (1H, d, J=2.1 Hz), 7.19 (1H, s), 7.34 (1H, d, J=7.8 Hz).


Example 669
Preparation of [3-chloro-5-[2-[1-[5-(3-fluorophenyl)thiazole-2-yl]-4-pyrrolidine-1-ylpiperidine-4-yl]ethoxy]phenyl]acetic acid






A mixture of [3-[2-[1-(5-bromothiazole-2-yl)-4-pyrrolidine-1-ylpiperidine-4-yl]ethoxy]-5-chlorophenyl]acetic acid (60 mg), 3-fluorophenyl boronic acid (32 mg), tetrakis (triphenylphosphine) palladium (13 mg), 1M sodium carbonate (0.55 mL) and dimethylformamide (1 mL) was reacted with a microwave reaction device at 180° C. for 5 minutes. The insoluble material was filtrated. To the filtrate was added formic acid. The solvent was evaporated under reduced pressure and the residue was purified by high performance liquid chromatography to give the title compound (14.4 mg). Yield: 24%.


1H-NMR (DMSO-d6)) δ: 8.18 (1H, s), 7.69 (1H, s), 7.39-7.26 (3H, m), 7.01 (1H, m), 6.90 (1H, d, J=10.8 Hz), 6.82 (1H, s), 4.53 (2H, m), 3.58-3.54 (4H, m), 2.64 (2H, s), 1.94-1.69 (8H, m)


The following compounds were obtained by similar methods as above.


Example 670






MS (ESI) m/z 584[M+]


Example 671






MS (ESI) m/z 586 [M+]


Example 672






MS (ESI) m/z 569[M+]


Example 673






MS (ESI) m/z 584 [M+]


Example 674






MS (ESI) m/z 586 [M+]


Example 675






MS (ESI) m/z 569 [M+]


Example 676






MS (ESI) m/z 546 [M+H]+


Example 677







1H-NMR (DMSO-d6)) d: 8.18 (1H, s), 7.69 (1H, s), 7.39-7.26 (3H, m), 7.01 (1H, m), 6.90 (1H, d, J=10.8 Hz), 6.82 (1H, s), 4.53 (2H, m), 3.58-3.54 (4H, m), 2.64 (2H, s), 1.94-1.69 (8H, m).


Example 678






MS (ESI) m/z 540 [M+H]+


Reference Example 256






1H-NMR (CDCl3) δ 2.93-3.18 (4H, m), 3.29 (1H, td, J=12.0, 3.2 Hz), 3.35-3.42 (1H, m), 3.39 (3H, s), 3.48 (1H, dd, J=9.2, 3.6 Hz), 3.91 (1H, d, J=12.0 Hz), 3.99 (1H, d, J=12.0 Hz), 7.24 (1H, dd, J=8.8, 2.4 Hz), 7.44 (1H, d, J=8.8 Hz), 7.56 (1H, d, J=2.4 Hz).


Reference Example 257






1H-NMR (CDCl3) δ 1.22 (3H, t, J=7.2 Hz), 2.92-3.02 (2H, m), 3.04-3.11 (1H, m), 3.12-3.17 (1H, m), 3.26 (1H, td, J=12.0, 3.2 Hz), 3.39 (1H, dd, J=9.2, 7.2 Hz), 3.48-3.59 (3H, m), 3.91 (1H, brd, J=12.0 Hz), 3.98 (1H, brd, J=12.0 Hz), 7.24 (1H, dd, J=8.8, 2.0 Hz), 7.44 (1H, d, J=8.8 Hz), 7.56 (1H, d, J=2.0 Hz).


Example 679






TLC Rf 0.13 (MeOH—CHCl3, 1:10)


Example 680






mp 109-112


Example 681






mp 92-98


Example 682






TLC Rf 0.15 (MeOH—CHCl3, 1:10)


Example 683






TLC Rf 0.23 (MeOH—CHCl3, 1:10)


Example 684






Rf 0.12 (MeOH—CHCl3, 1:10)


Example 685






Rf 0.24 (MeOH—CHCl3, 1:10)


Example 686






MS (ESI) m/z 480 [M+H]+


Example 687






MS (ESI) m/z 480 [M+H]+


Example 688






MS (ESI) m/z 479 [M+H]+


Example 689






MS (ESI) m/z 514, 516 [M+H]+


Example 690






MS (ESI) m/z 514, 516 [M+H]+


Example 691






MS (ESI) m/z 494 [M+H]+


Example 692






MS (ESI) m/z 494 [M+H]+


Example 693






MS (ESI) m/z 528, 530 [M+H]+


Example 694






MS (ESI) m/z 528, 530 [M+H]+


Example 695






MS (ESI) m/z 508 [M+H]+


Example 696






MS (ESI) m/z 508 [M+H]+


Example 697






MS (ESI) m/z 480 [M+H]+


Example 698






1H-NMR (300 MHz, CDCl3): 1.46 (3H, d, J=6.9 Hz), 2.53-2.60 (1H, m), 2.73-2.77 (1H, m), 3.06 (2H, s), 3.16-3.20 (1H, m), 3.27-3.31 (1H, m), 3.55-3.60 (1H, m), 3.60 (2H, s), 3.89-3.94 (1H, m), 4.29 (3H, m), 6.84 (1H, d, J=8.1 Hz), 6.87 (1H, s), 7.25 (1H, dd, J=8.7 Hz, 2.1 Hz), 7.31 (1H, d, J=8.1 Hz), 7.44 (1H, d, J=8.7 Hz), 7.56 (1H, d, J=2.1 Hz)


Example 699






MS (ESI) m/z 494 [M+H]+


Example 700






MS (ESI) m/z 528 [M+H]+


Example 701






MS (ESI) m/z 508 [M+H]+


Example 702






MS (ESI) m/z 528 [M+H]+


Example 703






MS (ESI) m/z 474, 476, 478 [M+H]+


Example 704






1H-NMR (DMSO-d6) δ: 1.18 (6H, d, J=4.7 Hz), 2.80-2.95 (4H, m), 3.10-3.19 (2H, m), 3.55 (2H, s), 3.85 (2H, d, J=9.9 Hz), 4.03-4.11 (2H, m), 6.83 (1H, d, J=8.2 Hz), 7.02-7.11 (2H, m), 7.22-7.48 (3H, m), 7.75 (1H, d, J=8.0 Hz).


Example 705






1H-NMR (DMSO-d6) δ: 1.16 (6H, d, J=5.8 Hz), 2.61-2.85 (5H, m), 3.07-3.16 (3H, m), 3.55 (2H, s), 3.89-4.11 (5H, m), 6.79-7.36 (8H, m).


Example 706






1H-NMR (DMSO-d6) δ: 1.22 (6H, d, J=6.0 Hz), 2.58-2.84 (4H, m), 3.09-3.19 (2H, m), 3.52 (2H, s), 4.06-4.14 (2H, m), 4.34-4.46 (2H, m), 6.84 (1H, d, J=8.2 Hz), 7.09-7.74 (7H, m), 8.03 (1H, d, J=9.1 Hz).


Example 707






1H-NMR (Acetone) δ: 8.38-8.35 (1.0H, m), 7.71 (1.0H, dd, J=9.34, 2.20 Hz), 7.31 (1.0H, dd, J=7.97, 1.65 Hz), 7.13 (1.0H, d, J=1.92 Hz), 6.97-6.87 (2.0H, m), 4.33 (2.0H, d, J=12.64 Hz), 4.17 (2.0H, dd, J=5.91, 5.91 Hz), 3.61 (2.0H, s), 3.25-3.23 (2.0H, m), 2.83-2.67 (4.0H, m), 1.24 (6.0H, d, J=6.00 Hz).


Example 708






1H-NMR (DMSO-d6) δ: 8.66 (1.0H, d, J=4.94 Hz), 7.31 (1.0H, d, J=8.10 Hz), 7.08 (1.0H, s), 6.99 (1.0H, d, J=4.94 Hz), 6.82 (1.0H, d, J=8.10 Hz), 4.45 (2.0H, d, J=8.24 Hz), 4.08-3.99 (3.0H, m), 3.53 (2.0H, s), 3.13 (2.0H, dd, J=5.63, 5.63 Hz), 2.76-2.65 (4.0H, m), 1.16 (6.0H, d, J=6.32 Hz).


Example 709






1H-NMR (Acetone) δ: 8.14 (1.0H, d, J=2.54 Hz), 7.60 (1.0H, dd, J=9.13, 2.54 Hz), 7.40 (1.0H, s), 7.34 (1.0H, d, J=7.69 Hz), 7.25 (1.0H, dd, J=7.69, 7.69 Hz), 7.15 (1.0H, d, J=7.69 Hz), 6.81 (1.0H, d, J=9.13 Hz), 4.13 (2.0H, d, J=11.54 Hz), 3.81 (2.0H, s), 3.62 (2.0H, s), 2.76-2.62 (4.0H, m), 1.07 (6.0H, d, J=5.77 Hz).


Example 710






1H-NMR (DMSO-d6) δ: 1.14 (6H, d, J=5.1 Hz), 2.60-2.76 (2H, m), 3.00-3.10 (2H, m), 3.55 (2H, s), 3.97-4.06 (2H, m), 4.46-4.60 (2H, m), 6.80-6.96 (3H, m), 7.30-7.67 (3H, m), 8.69 (2H, s).


Example 711






1H-NMR (DMSO-d6) δ: 7.18-7.18 (1.0H, m), 7.04 (1.0H, d, J=7.28 Hz), 6.84 (1.0H, s), 6.71 (1.0H, d, J=7.28 Hz), 3.98 (2.0H, dd, J=5.10, 5.10 Hz), 3.64 (2.0H, d, J=10.99 Hz), 3.48 (2.0H, s), 3.10 (2.0H, dd, J=5.10, 5.10 Hz), 2.84-2.69 (4.0H, m), 2.11 (3.0H, s), 1.14 (6.0H, d, J=5.77 Hz).


Example 712






1H-NMR (Acetone) δ: 8.12 (1.0H, d, J=2.68 Hz), 7.59 (1.0H, dd, J=9.13, 2.68 Hz), 7.32 (1.0H, d, J=8.11 Hz), 7.13 (1.0H, d, J=1.92 Hz), 6.90 (1.0H, dd, J=8.11, 1.92 Hz), 6.80 (1.0H, d, J=9.13 Hz), 4.18-4.13 (4.0H, m), 3.63 (2.0H, s), 3.22 (2.0H, dd, J=6.04, 6.04 Hz), 2.85-2.78 (2.0H, m), 2.62-2.53 (2.0H, m), 1.23 (6.0H, d, J=6.04 Hz).


Example 713






1H-NMR (Acetone) δ: 8.34 (2.0H, s), 7.30 (1.0H, d, J=8.04 Hz), 7.13 (1.0H, d, J=1.65 Hz), 6.90 (1.0H, dd, J=8.04, 1.65 Hz), 4.49 (2.0H, d, J=12.36 Hz), 4.15 (2.0H, dd, J=5.91, 5.91 Hz), 3.60 (2.0H, s), 3.23 (2.0H, dd, J=6.04, 6.04 Hz), 2.82-2.60 (4.0H, m), 1.22 (6.0H, d, J=6.04 Hz).


Example 714






1H-NMR (DMSO-d6) δ: 8.44 (2.0H, s), 6.61 (3.0H, s), 4.43-4.33 (2.0H, m), 3.95 (2.0H, dd, J=6.59, 6.59 Hz), 3.43 (2.0H, s), 3.03 (2.0H, dd, J=6.00, 6.00 Hz), 2.63 (4.0H, d, J=6.90 Hz), 2.23 (3.0H, s), 1.12 (6.0H, d, J=5.22 Hz).


Example 715






1H-NMR (DMSO-d6) δ: 1.23-1.41 (2H, m), 1.70-1.92 (5H, m), 3.09-3.23 (2H, m), 3.57 (2H, s), 3.98-4.15 (4H, m), 6.81-7.46 (6H, m), 7.74 (1H, d, J=8.0 Hz).


Example 716






1H-NMR (Acetone) δ: 8.37 (1.0H, s), 7.71 (1.0H, dd, J=9.06, 2.47 Hz), 7.33 (1.0H, d, J=7.97 Hz), 7.12 (1.0H, d, J=1.65 Hz), 6.93-6.89 (2.0H, m), 4.55-4.50 (2.0H, m), 4.19 (2.0H, dd, J=6.32, 6.32 Hz), 3.62 (2.0H, s), 2.96-2.92 (3.0H, m), 1.96-1.79 (4.0H, m), 1.37-1.24 (2.0H, m).


Example 717






1H-NMR (DMSO-d6) δ: 8.65 (1.0H, d, J=4.67 Hz), 7.33 (1.0H, d, J=8.11 Hz), 7.08 (1.0H, s), 6.95 (1.0H, d, J=4.67 Hz), 6.83 (1.0H, d, J=8.11 Hz), 4.64 (2.0H, d, J=12.42 Hz), 4.10 (2.0H, dd, J=6.59, 6.59 Hz), 3.55 (2.0H, s), 3.40-3.25 (1.0H, m), 2.96 (2.0H, dd, J=12.42, 12.42 Hz), 1.91-1.72 (4.0H, m), 1.24-1.15 (2.0H, m).


Example 718






1H-NMR (DMSO-d6) δ: 1.13-1.36 (2H, m), 1.67-1.87 (5H, m), 2.86-3.00 (2H, m), 3.56 (2H, s), 4.05-4.16 (5H, m), 6.80-7.36 (7H, m).


Example 719






1H-NMR (300 MHz, CDCl3): 1.40 (6H, m), 3.27-3.44 (6H, m), 3.93-3.98 (2H, m), 4.14 (2H, m), 4.53 (2H, s), 6.47-6.55 (3H, m), 7.13-7.26 (2H, m), 7.43 (1H, d, J=8.1 Hz), 7.55 (1H, s).


Example 720






1H-NMR (300 MHz, CDCl3): 1.98-2.17 (5H, m), 3.21-3.29 (2H, m), 3.84 (2H, d, J=6.0 Hz), 4.23 (2H, m), 4.65 (2H, s), 6.49-6.56 (3H, m), 7.20 (1H, t, J=8.1 Hz), 7.26-7.29 (2H, m), 7.55 (1H, d, J=2.1 Hz)


Example 721






1H-NMR (300 MHz, CDCl3): 1.28 (6H, m), 2.64 (2H, t, J=7.5 Hz), 2.91 (2H, t, J=7.5 Hz), 2.99 (4H, m), 3.24 (2H, m), 3.87-3.91 (2H, m), 4.05 (2H, m), 6.70-6.73 (2H, m), 6.80 (1H, d, J=7.5 Hz), 7.19 (1H, t, J=7.5 Hz), 7.22-7.25 (1H, m), 7.43 (1H, d, J=8.4 Hz), 7.54 (1H, d, J=2.1 Hz).


Example 722






1H-NMR (300 MHz, CDCl3): 1.27 (6H, m), 2.99 (4H, m), 3.23 (2H, m), 3.89-3.93 (2H, m), 4.09 (2H, m), 6.43 (1H, d, J=15.9 Hz), 6.92 (1H, dd, J=8.1 Hz, 2.1 Hz), 7.04 (1H, s), 7.14 (1H, d, J=8.1 Hz), 7.24 (1H, dd, J=8.7 Hz, 2.1 Hz), 7.31 (1H, t, J=8.1 Hz), 7.44 (1H, d, J=8.7 Hz), 7.56 (1H, d, J=2.1 Hz), 7.71 (1H, d, J=15.9 Hz).


Example 723






1H-NMR (300 MHz, CDCl3): 1.35 (6H, m), 2.53 (4H, m), 3.15 (2H, m), 3.71 (3H, s), 3.90-3.94 (2H, m), 4.14 (2H, m), 6.81 (1H, dd, J=8.7 Hz, 2.1 Hz), 7.01-7.02 (2H, m), 7.14 (1H, d, J=8.7 Hz), 7.24 (1H, dd, J=8.7 Hz), 7.44 (1H, d, J=8.7 Hz), 7.54 (1H, d, J=2.1 Hz).


Example 724






TLC Rf 0.13 (MeOH—CHCl3, 1:10)


Example 725






TLC Rf 0.20 (MeOH—CHCl3, 1:10)


Example 726






TLC Rf 0.30 (MeOH—CHCl3, 1:10)


Example 727






TLC Rf 0.31 (MeOH—CHCl3, 1:10)


Example 728






TLC Rf 0.23 (MeOH—CHCl3, 1:5)


Example 729






MS (ESI) m/z 495 [M+H]+


Example 730






MS (ESI) m/z 564 [M+H]+


Example 731






MS (ESI) m/z 564 [M+H]+


Example 732






MS (ESI) m/z 602 [M+H]+


Example 733






MS (ESI) m/z 585 [M+H]+


Example 734






MS (ESI) m/z 600 [M+H]+


Example 735






MS (ESI) m/z 534 [M+H]+


Example 736






MS (ESI) m/z 539 [M+H]+


Example 737






MS (ESI) m/z 555 [M+H]+


Example 738






MS (ESI) m/z 544 [M+H]+


Example 739






MS (ESI) m/z 537 [M+H]+


Example 740






MS (ESI) m/z 527 [M+H]+


Example 741






MS (ESI) m/z 560 [M+H]+


Example 742






MS (ESI) m/z 542 [M+H]+


Example 743






MS (ESI) m/z 532 [M+H]+


Example 744






MS (ESI) m/z 528 [M+H]+


Example 745






MS (ESI) m/z 578 [M+H]+


Example 746






MS (ESI) m/z 584 [M+H]+


Example 747






MS (ESI) m/z 512 [M+H]+


Example 748






MS (ESI) m/z 512 [M+H]+


Example 749






MS (ESI) m/z 569 [M+H]+


Example 750






MS (ESI) m/z 569 [M+H]+


Example 751






TLC: (SiO2) CHCl3-MeOH (10:1) Rf=0.1


Example 752






1H-NMR (DMSO-d6) δ: 7.56 (1.0H, d, J=1.92 Hz), 7.26 (1.0H, d, J=8.51 Hz), 7.19 (1.0H, dd, J=8.51, 4.25 Hz), 7.04 (1.0H, d, J=7.41 Hz), 6.86 (1.0H, s), 6.71 (1.0H, d, J=7.41 Hz), 4.06-4.03 (2.0H, m), 3.84-3.80 (2.0H, m), 3.65-3.48 (2.0H, m), 2.68 (4.0H, br s), 2.10 (2.0H, s), 2.03-1.67 (6.0H, m), 1.06 (3.0H, d, J=6.04 Hz).


Example 753






1H-NMR (CDCl3) δ: 7.84-7.82 (1.0H, m), 7.64-7.49 (2.0H, m), 6.93-6.76 (3.0H, m), 4.22-4.11 (1.0H, m), 3.99-3.37 (9.0H, m), 3.31 (3.0H, s), 3.09-2.95 (1.0H, m), 2.89-2.64 (3.0H, m), 2.31-1.12 (8.0H, m).


Example 754






1H-NMR (CDCl3) δ: 7.86-7.82 (1.0H, m), 7.59-7.48 (2.0H, m), 6.89-6.85 (1.0H, m), 6.80-6.77 (1.0H, m), 6.73-6.69 (1.0H, m), 4.05 (2.0H, dd, J=6.59, 6.59 Hz), 3.95-3.87 (1.0H, m), 3.79-3.60 (4.0H, m), 3.56 (2.0H, s), 3.31 (3.0H, s), 3.01 (1.0H, dd, J=7.68, 5.49 Hz), 2.83-2.69 (3.0H, m), 2.07-1.68 (8.0H, m).


Example 755






1H-NMR (CDCl3) δ: 7.83 (1.0H, s), 7.58-7.48 (2.0H, m), 7.07 (1.0H, d, J=7.41 Hz), 6.79-6.70 (2.0H, m), 4.04 (2.0H, dd, J=6.59, 6.59 Hz), 3.83-3.56 (6.0H, m), 3.47 (2.0H, dd, J=6.59, 6.59 Hz), 3.36 (3.0H, s), 2.70 (2.0H, dd, J=6.59, 6.59 Hz), 2.33 (3.0H, s), 2.17 (3.0H, s), 2.06-1.95 (4.0H, m), 1.84-1.70 (2.0H, m).


Example 756






1H-NMR (CDCl3) δ: 7.83 (1.0H, br s), 7.57-7.48 (2.0H, m), 6.68 (1.0H, s), 6.62-6.58 (2.0H, m), 4.00 (2.0H, dd, J=6.59, 6.59 Hz), 3.82-3.61 (4.0H, m), 3.55 (2.0H, s), 3.47 (2.0H, dd, J=6.31, 6.31 Hz), 3.35 (3.0H, s), 2.68 (2.0H, dd, J=6.31, 6.31 Hz), 2.31 (3.0H, s), 2.29 (3.0H, s), 2.04-1.91 (4.0H, m), 1.80-1.66 (2.0H, m).


Example 757






1H-NMR (CDCl3) δ: 7.31 (1.0H, d, J=8.23 Hz), 7.08 (1.0H, s), 6.93-6.87 (1.0H, m), 6.83 (1.0H, dd, J=8.23, 1.65 Hz), 4.30-4.07 (2.0H, m), 3.89-3.66 (4.0H, m), 3.65-3.55 (4.0H, m), 3.53-3.34 (4.0H, m), 2.87-2.52 (4.0H, m), 2.32-1.62 (6.0H, m).


Example 758






1H-NMR (CDCl3) δ: 7.55-7.44 (2.0H, m), 7.31 (1.0H, d, J=8.23 Hz), 7.19-7.13 (1.0H, m), 6.93-6.80 (2.0H, m), 4.32-4.08 (2.0H, m), 3.91-3.57 (10.0H, m), 2.91-2.51 (4.0H, m), 2.33-1.61 (6.0H, m).


Example 759






1H-NMR (DMSO-d6) δ: 8.22 (1.0H, s), 7.59-7.52 (2.0H, m), 7.13 (1.0H, dd, J=8.51, 8.51 Hz), 6.54-6.49 (1.0H, m), 6.46-6.41 (3.0H, m), 4.57-4.47 (2.0H, m), 4.00 (2.0H, dd, J=7.14, 7.14 Hz), 3.82-3.67 (2.0H, m), 3.63-3.44 (6.0H, m), 2.60-2.53 (4.0H, m), 2.01 (2.0H, d, J=12.90 Hz), 1.90 (2.0H, dd, J=7.14, 7.14 Hz), 1.77-1.63 (2.0H, m).


Example 760






1H-NMR (DMSO-d6) δ: 7.55 (1.0H, d, J=2.20 Hz), 7.30 (1.0H, d, J=8.23 Hz), 7.24 (1.0H, d, J=8.23 Hz), 7.20-7.14 (1.0H, m), 7.07 (1.0H, s), 6.82 (1.0H, d, J=9.61 Hz), 4.12-4.00 (2.0H, m), 3.83-3.71 (2.0H, m), 3.63-3.51 (8.0H, m), 2.58-2.53 (4.0H, m), 2.03-1.89 (4.0H, m), 1.77-1.65 (2.0H, m).


Example 761






1H-NMR (DMSO-d6) δ: 12.36 (1.0H, br s), 7.59 (1.0H, s), 7.46 (2.0H, d, J=7.41 Hz), 7.38-7.31 (3.0H, m), 7.20 (1.0H, dd, J=7.41, 7.41 Hz), 7.10 (1.0H, d, J=1.65 Hz), 6.83 (1.0H, dd, J=7.41, 1.65 Hz), 4.11 (2.0H, dd, J=6.59, 6.59 Hz), 3.63-3.53 (8.0H, m), 3.47-3.39 (2.0H, m), 2.60-2.53 (4.0H, m), 2.05-1.90 (4.0H, m), 1.80-1.66 (2.0H, m).


Example 762






1H-NMR (DMSO-d6) δ: 7.70 (1.0H, s), 7.42-7.30 (3.0H, m), 7.25 (1.0H, d, J=8.23 Hz), 7.10 (1.0H, d, J=1.92 Hz), 7.06-6.97 (1.0H, m), 6.83 (1.0H, dd, J=8.23, 1.92 Hz), 4.11 (2.0H, dd, J=6.59, 6.59 Hz), 3.63-3.54 (8.0H, m), 3.47-3.40 (2.0H, m), 2.60-2.53 (4.0H, m), 2.06-1.90 (4.0H, m), 1.80-1.66 (2.0H, m).


Example 763






1H-NMR (CDCl3) δ: 8.29 (2.0H, s), 7.31 (1.0H, d, J=8.23 Hz), 6.91 (1.0H, s), 6.85-6.82 (1.0H, m), 4.31-4.16 (2.0H, m), 4.00-3.70 (6.0H, m), 3.69-3.60 (4.0H, m), 2.98-2.69 (4.0H, m), 2.29-1.60 (6.0H, m).


Example 764






1H-NMR (DMSO-d6) δ: 8.23 (1.0H, d, J=7.41 Hz), 7.44 (1.0H, d, J=12.35 Hz), 7.31 (1.0H, d, J=8.23 Hz), 7.08 (1.0H, d, J=2.20 Hz), 6.82 (1.0H, dd, J=8.23, 2.20 Hz), 4.10 (2.0H, dd, J=7.14, 7.14 Hz), 3.65-3.50 (6.0H, m), 3.49-3.12 (4.0H, m), 2.60-2.53 (4.0H, m), 2.10-1.89 (4.0H, m), 1.82-1.68 (2.0H, m).


Example 765






1H-NMR (DMSO-d6) δ: 7.86 (1.0H, d, J=8.51 Hz), 7.76 (1.0H, d, J=8.51 Hz), 7.31 (1.0H, d, J=7.96 Hz), 7.08 (1.0H, d, J=1.92 Hz), 6.83 (1.0H, dd, J=7.96, 1.92 Hz), 4.10 (2.0H, dd, J=6.86, 6.86 Hz), 3.67-3.52 (6.0H, m), 3.44-3.22 (4.0H, m), 2.62-2.54 (4.0H, m), 2.10-1.92 (4.0H, m), 1.83-1.68 (2.0H, m).


Example 766






1H-NMR (DMSO-d6) δ: 7.83 (1.0H, s), 7.71-7.67 (1.0H, m), 7.33-7.31 (2.0H, m), 7.09 (1.0H, s), 6.83 (1.0H, d, J=7.96 Hz), 6.78 (1.0H, s), 4.10 (2.0H, dd, J=6.86, 6.86 Hz), 3.63-3.46 (6.0H, m), 3.45-3.24 (4.0H, m), 2.61-2.52 (4.0H, m), 2.03-1.89 (4.0H, m), 1.78-1.65 (2.0H, m), 1.04 (2.7H, d, J=6.04 Hz).


Example 767






1H-NMR (DMSO-d6) δ: 12.37 (1.0H, br s), 8.61 (2.0H, s), 8.10 (1.0H, s), 7.75-7.72 (1.0H, m), 7.32 (1.0H, d, J=8.23 Hz), 7.08 (1.0H, s), 6.93 (1.0H, s), 6.82 (1.0H, d, J=8.23 Hz), 4.16-3.96 (4.0H, m), 3.64-3.47 (8.0H, m), 2.62-2.53 (4.0H, m), 2.00-1.86 (4.0H, m), 1.67-1.52 (2.0H, m).


Example 768






1H-NMR (DMSO-d6) δ: 12.40 (1.0H, br s), 8.69 (2.0H, s), 7.63 (2.0H, d, J=7.72 Hz), 7.43 (2.0H, dd, J=7.72, 7.72 Hz), 7.34-7.31 (2.0H, m), 7.08 (1.0H, d, J=1.85 Hz), 6.82 (1.0H, dd, J=8.23, 1.85 Hz), 4.20-4.06 (4.0H, m), 3.63-3.52 (8.0H, m), 2.62-2.54 (4.0H, m), 2.02-1.87 (4.0H, m), 1.68-1.54 (2.0H, m).


Example 769






1H-NMR (DMSO-d6) δ: 8.73 (2.0H, s), 7.57-7.42 (3.0H, m), 7.31 (1.0H, d, J=8.23 Hz), 7.19-7.07 (2.0H, m), 6.82 (1.0H, d, J=8.23 Hz), 4.20-4.06 (4.0H, m), 3.63-3.51 (8.0H, m), 2.63-2.55 (4.0H, m), 2.01-1.87 (4.0H, m), 1.67-1.54 (2.0H, m).


Example 770






1H-NMR (DMSO-d6) δ: 8.21 (1.0H, s), 7.58-7.51 (2.0H, m), 7.12 (1.0H, dd, J=8.56, 8.56 Hz), 6.54-6.40 (2.0H, m), 4.56-4.41 (1.0H, m), 4.08-3.97 (3.0H, m), 3.84-3.69 (2.0H, m), 3.59-3.46 (2.0H, m), 2.71-2.60 (4.0H, m), 2.00-1.81 (4.0H, m), 1.79-1.65 (6.0H, m).


Example 771






1H-NMR (CDCl3) δ: 7.85 (1.0H, s), 7.62-7.49 (2.0H, m), 7.31-7.20 (1.0H, m), 6.94-6.76 (3.0H, m), 4.14-3.95 (2.0H, m), 3.84-3.58 (8.0H, m), 2.72-2.55 (4.0H, m), 2.12-1.90 (4.0H, m), 1.88-1.69 (2.0H, m).


Reference Example 258
Preparation of piperidine-4-carbonitrile trifluoroacetate






4-Cyanopiperidine-1-carboxylic acid t-butyl ester (5.35 g) was added to trifluoroacetic acid (20 mL) and the mixture was stirred at room temperature for 10 minutes. Trifluoroacetic acid was evaporated under reduced pressure to give the title compound as colorless crystal (5.62 g). Yield: 99%.



1H-NMR (DMSO-d6) δ: 1.83-1.96 (2H, m), 2.08-2.14 (2H, m), 3.00-3.08 (2H, m), 3.14-3.26 (2H, m), 3.41 (1H, br s).


Reference Example 259
Preparation of 1-(6-trifluoromethylbenzothiazole-2-yl)piperidine-4-carbonitrile






2-Chloro-6-trifluorobenzothiazole (5.84 g), piperidine-4-carbonitrile trifluoroacetate (5.62 g), potassium carbonate (10.39 g) and dimethyl sulfoxide (50 mL) were stirred at 60° C. for 6 hours. To the reaction solution was added water and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure and the residue was washed with isopropylether to give the title compound as colorless crystal (6.84 g). Yield: 89%.



1H-NMR (CDCl3) δ: 1.99-2.17 (4H, m), 2.97-3.05 (1H, m), 3.68-3.76 (2H, m), 3.87-3.95 (2H, m), 7.55-7.63 (2H, m), 7.89-7.90 (1H, m).


Reference Example 260
Preparation of 4-[2-(t-butyldimethylsilyloxy)ethyl]-1-(6-trifluoromethyl benzothiazole-2-yl)piperidine-4-carbonitrile






To a solution of 1-(6-trifluoromethyl benzothiazole-2-yl)piperidine-4-carbonitrile (1.00 g) in tetrahydrofuran (10 mL) was added lithium bis(trimethylsilyl)amide (3.21 mL) at −15° C. To the reaction solution was added (2-bromoethoxy)-t-butyldimethyl silane (689 μL). The mixture was stirred at 0° C. for 3 hours. To the reaction solution was added brine and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure and the obtained residue was purified by column chromatograph on silica gel to give the title compound (1.23 g). Yield: 82%.



1H-NMR (CDCl3) δ: 0.10 (6H, s), 0.93 (9H, s), 1.71-1.81 (2H, m), 1.88 (2H, t, J=6.0 Hz), 2.17-2.21 (2H, m), 3.49-3.59 (2H, m), 3.94 (2H, t, J=6.0 Hz), 4.11-4.23 (2H, m), 7.55-7.62 (2H, m), 7.89-7.89 (1H, m).


Reference Example 261
Preparation of 4-(2-hydroxyethyl)-1-(6-trifluoromethyl benzothiazole-2-yl)piperidine-4-carbonitrile






To 4-[2-(t-butyldimethyl silyloxy)ethyl]-1-(6-trifluoromethyl benzothiazole-2-yl)piperidine-4-carbonitrile (510 mg) was added tetramethylammonium fluoride (1 M tetrahydrofuran solution, 1.63 mL). The mixture was stirred at 0° C. for 0.5 hour. To the reaction solution was added aqueous citric acid solution and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over sodium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (366 mg). Yield: 95%.



1H-NMR (Acetone) δ: 1.82-1.99 (4H, m), 2.20-2.25 (2H, m), 3.44-3.54 (2H, m), 3.89 (2H, t, J=5.9 Hz), 4.25-4.29 (2H, m), 7.62-7.63 (2H, m), 8.13-8.16 (1H, br m).


Example 772
Preparation of [3-chloro-5-[2-[4-cyano-1-(6-trifluoromethyl benzothiazole-2-yl)piperidine-4-yl]ethoxy]phenyl]acetic acid






The above compound was synthesized from 4-(2-hydroxyethyl)-1-(6-trifluoromethyl benzothiazole-2-yl)piperidine-4-carbonitrile according to the methods of Example 585 and 586.


MS (ESI) m/z 524 [M+H]+


The following compound was obtained by a similar method as above.


Example 773






MS (ESI) m/z 524 [M+H]+


Reference Example 262
Preparation of 4-[2-(t-butyldimethyl silanyloxy)ethyl]-1-(6-trifluoromethyl benzothiazole-2-yl)piperidine-4-carboxaldehyde






To a solution of 4-[2-(t-butyldimethyl silyloxy)ethyl]-1-(6-trifluoromethyl benzothiazole-2-yl)piperidine-4-carbonitrile (600 mg) in 1,2-dimethoxyethane (12 mL) was added diisobutylaluminum hydride (1.0 M toluene solution, 6.39 mL) at 0° C. The mixture was stirred for 4 hours. To the reaction solution was added aqueous citric acid solution and extracted with ethyl acetate. The organic layer was sequentially washed with aqueous citric acid solution, water and brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (526 mg). Yield: 87%.



1H-NMR (CDCl3) δ: 0.05 (6H, s), 0.90 (9H, s), 1.64-1.74 (2H, m), 1.85 (2H, t, J=5.8 Hz), 2.13-2.19 (2H, m), 3.40-3.50 (2H, m), 3.68 (2H, t, J=5.8 Hz), 3.93-4.00 (2H, m), 7.52-7.59 (2H, m), 7.85-7.88 (1H, br m), 9.57-9.60 (1H, br m).


Reference Example 263
Preparation of N-[4-(2-hydroxyethyl)-1-(6-trifluoromethyl benzothiazole-2-yl)piperidine-4-yl]formimido ethyl ester






To a solution of 4-[2-(t-butyldimethyl silanyloxy)ethyl]-1-(6-trifluoromethyl benzothiazole-2-yl)piperidine-4-carboxaldehyde (500 mg) in tetrahydrofuran (20 mL) was added ethoxy aminehydrochloride (124 mg). The mixture was stirred at 60° C. for 4 hours. The solvent was evaporated under reduced pressure. To the residue was added tetrabuthyl ammonium fluoride (1M tetrahydrofuran solution, 1.59 mL). The mixture was stirred at 0° C. for 0.5 hour, at room temperature for 1 hour and at 40° C. for 2 hours. To the reaction solution was added aqueous citric acid solution and extracted with ethyl acetate. The organic layer was washed with brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (394 mg). Yield: 93%.



1H-NMR (CDCl3) δ: 1.28 (3H, t, J=7.0 Hz), 1.68-1.77 (2H, m), 1.80 (2H, t, J=6.7 Hz), 2.03-2.10 (2H, m), 3.47-3.56 (2H, m), 3.74-3.80 (2H, m), 3.92-3.99 (2H, m), 4.13 (2H, q, J=7.0 Hz), 7.33-7.36 (1H, br m), 7.52-7.59 (2H, m), 7.84-7.88 (1H, br m).


Example 774
Preparation of [3-chloro-5-[2-[4-ethoxy methyleneamino-1-(6-trifluoromethyl benzothiazole-2-yl)piperidine-4-yl]ethoxy]phenyl]acetic acid






The above compound was synthesized from N-[4-(2-hydroxyethyl)-1-(6-trifluoromethylbenzothiazole-2-yl)piperidine-4-yl]formimido ethyl ester according to the methods of Example 585 and 586.


MS (ESI) m/z 570 [M+H]+


The following compounds were obtained by similar methods as above.


Example 775






MS (ESI) m/z 570 [M+H]+


Example 776






MS (FABMS) m/z 582 [M+H]+


Example 777






TLC_Rf=0.61 (MeOH:CHCl3=1:15)


Example 778






TLC_Rf=0.63 (MeOH:CHCl3=1:15)


Example 779






MS (ESI) m/z 547 [M+H]+


Example 780






MS (ESI) m/z 521 [M+H]+


Example 781






MS (ESI) m/z 507 [M+H]+


Example 782






MS (ESI) m/z 521 [M+H]+


Example 783






MS (ESI) m/z 521 [M+H]+


Example 784






MS (ESI) m/z 555 [M+H]+


Example 785






MS (ESI) m/z 508 [M+H]+


Example 786






MS (ESI) m/z 493 [M+H]+


Example 787






MS (ESI) m/z 479 [M+H]+


Example 788






1H-NMR (DMSO-d6) δ: 7.88 (1.0H, d, J=8.51 Hz), 7.78 (1.0H, d, J=8.51 Hz), 7.05 (2.0H, d, J=5.21 Hz), 7.00 (1.0H, s), 4.22-3.91 (1.0H, m), 3.65-3.36 (4.0H, m), 2.97 (1.0H, d, J=11.53 Hz), 2.83 (1.0H, d, J=11.53 Hz), 2.31 (3.0H, s), 2.21-2.16 (3.0H, m), 2.02-1.93 (1.0H, m), 1.83-1.78 (1.0H, m), 1.38-1.16 (4.0H, m), 0.86 (3.0H, t, J=7.27 Hz).


Example 789






1H-NMR (DMSO-d6) δ: 7.88 (1.0H, d, J=8.23 Hz), 7.78 (1.0H, d, J=8.23 Hz), 7.34-7.18 (4.0H, m), 4.06 (1.0H, br s), 3.61-3.41 (5.0H, m), 2.96 (1.0H, d, J=11.80 Hz), 2.84 (1.0H, d, J=11.80 Hz), 2.19-2.17 (2.0H, m), 1.92-1.84 (2.0H, m), 1.32-1.21 (4.0H, m), 0.86 (3.0H, t, J=7.27 Hz).


Example 790






1H-NMR (DMSO-d6) δ: 12.32 (1.0H, br s), 8.26 (1.0H, d, J=7.41 Hz), 7.46 (1.0H, d, J=12.08 Hz), 7.05 (2.0H, d, J=5.76 Hz), 7.00 (1.0H, s), 4.07-4.04 (1.0H, m), 3.58-3.40 (5.0H, m), 2.95 (1.0H, d, J=12.08 Hz), 2.82 (1.0H, d, J=12.08 Hz), 2.31 (3.0H, s), 2.22-2.11 (2.0H, m), 2.02-1.92 (1.0H, m), 1.78-1.74 (1.0H, m), 1.30-1.22 (4.0H, m), 0.86 (3.0H, t, J=7.27 Hz).


Example 791







1H-NMR (300 MHz, DMSO-d6): δ 0.83 (3H, t, J=7.2 Hz), 1.13-1.20 (2H, m), 1.27-1.34 (2H, m), 1.71-1.94 (2H, m), 2.09-2.19 (2H, m), 2.28 (3H, s), 2.78-2.94 (2H, m), 3.32-3.61 (5H, m), 3.99 (2H, m), 6.97-7.02 (3H, m), 7.50-7.57 (2H, m), 8.22 (1H, s)


Example 792







1H-NMR (300 MHz, DMSO-d6): δ 0.83 (3H, t, J=7.2 Hz), 1.13-1.20 (2H, m), 1.27-1.36 (2H, m), 1.72-1.94 (2H, m), 2.12-2.15 (2H, m), 2.78-2.92 (2H, m), 3.37-3.61 (5H, m), 3.99 (2H, m), 7.16-7.29 (4H, m), 7.50-7.57 (2H, m), 8.21 (1H, s)


Example 793







1H-NMR (300 MHz, DMSO-d6): δ 0.81 (3H, t, J=7.2 Hz), 1.07-1.17 (2H, m), 1.25-1.32 (2H, m), 1.68-1.77 (2H, m), 2.09-2.18 (2H, m), 2.26 (3H, s), 2.75-2.93 (2H, m), 3.26-3.42 (3H, m), 3.48 (2H, s), 3.57 (1H, d, J=13.5 Hz), 3.97 (1H, m), 6.95-7.02 (3H, m), 7.41 (1H, d, J=12.3 Hz), 8.22 (1H, d, J=6.6 Hz), 12.24 (1H, br)


Example 794







1H-NMR (300 MHz, DMSO-d6): δ 0.81 (3H, t, J=7.2 Hz), 1.13-1.31 (4H, m), 1.75-1.95 (2H, m), 2.10-2.13 (2H, m), 2.76-2.90 (1H, m), 3.21-4.37 (8H, m), 7.15-7.59 (5H, m), 8.21-8.30 (1H, m), 12.34 (1H, br)


Example 795







1H-NMR (300 MHz, CDCl3): δ 0.88 (3H, t, J=7.2 Hz), 1.21-1.39 (4H, m), 1.94 (2H, m), 2.27 (2H, m), 2.36 (3H, s), 2.91 (2H, m), 3.45 (3H, m), 3.64 (2H, s). 4.11 (2H, m), 7.06-7.11 (3H, m), 7.58 (1H, d, J=8.4 Hz), 7.71 (1H, d, J=8.4 Hz)


Example 796






1H-NMR (DMSO-d6) δ: 8.24 (1H, s), 7.58-7.55 (2H, m), 7.06 (2H, s), 7.00 (1H, s), 4.09-3.95 (2H, m), 3.64-3.32 (2H, m), 3.53 (2H, s), 2.94 (1H, d, J=11.2 Hz), 2.82 (1H, d, J=11.4 Hz), 2.31 (3H, s), 2.19-2.14 (2H, m), 1.98-1.89 (1H, m), 1.80-1.71 (1H, m), 1.27-1.19 (2H, m), 0.92 (3H, t, J=7.3 Hz).


Example 797







1H-NMR (300 MHz, CDCl3): δ 0.87 (3H, t, J=7.2 Hz), 1.20-1.38 (4H, m), 1.92 (2H, m), 2.27 (2H, m), 2.89 (2H, m), 3.50 (3H, m), 3.67 (2H, s). 4.11 (2H, m), 7.31 (4H, m), 7.57 (1H, d, J=8.4 Hz), 7.70 (1H, d, J=8.4 Hz)


Example 798






1H-NMR (DMSO-d6) δ: 7.55 (1H, d, J=2.0 Hz), 7.26-7.17 (2H, m), 7.04 (1H, s), 7.02 (1H, s), 6.97 (1H, s), 4.13 (1H, s), 3.95 (1H, d, J=12.3 Hz), 3.50 (2H, s), 3.48 (2H, dd, J=58.3, 14.7 Hz), 2.90 (1H, d, J=12.1 Hz), 2.76 (1H, d, J=12.1 Hz), 2.28 (3H, s), 2.15-2.09 (2H, m), 1.92-1.83 (1H, m), 1.79-1.70 (1H, m), 1.31-1.26 (2H, m), 1.16-1.10 (2H, m), 0.83 (3H, t, J=7.3 Hz).


Example 799






1H-NMR (DMSO-d6) δ: 7.88 (1H, s), 7.45 (1H, d, J=8.8 Hz), 7.24 (1H, d, J=9.1 Hz), 7.03 (1H, s), 7.01 (1H, s), 6.97 (1H, s), 3.99-3.90 (2H, m), 3.50 (2H, s), 3.49 (2H, dd, J=58.4, 12.7 Hz), 2.91 (1H, d, J=11.5 Hz), 2.79 (1H, d, J=11.5 Hz), 2.28 (3H, s), 2.15-2.09 (2H, m), 1.97-1.91 (1H, m), 1.73-1.67 (1H, m), 1.32-1.26 (2H, m), 1.19-1.13 (2H, m), 0.84 (3H, t, J=7.1 Hz).


Example 800






1H-NMR (DMSO-d6) δ: 8.40 (1H, s), 7.77 (1H, dd, J=9.3, 2.6 Hz), 7.05 (2H, d, J=6.2 Hz), 6.99 (1H, s), 6.88 (1H, d, J=9.1 Hz), 4.41 (1H, s), 4.25 (1H, d, J=10.0 Hz), 3.63-3.29 (2H, m), 3.51 (2H, s), 3.14 (1H, t, J=11.3 Hz), 2.93 (1H, d, J=10.2 Hz), 2.81 (1H, d, J=11.8 Hz), 2.30 (3H, s), 2.11-1.88 (3H, m), 1.53-1.48 (1H, m), 1.32-1.23 (2H, m), 1.16-1.06 (2H, m), 0.84 (3H, t, J=7.3 Hz).


Example 801






1H-NMR (DMSO-d6) δ: 8.37 (1H, s), 7.74 (1H, dd, J=9.1, 2.5 Hz), 7.03 (2H, d, J=6.6 Hz), 6.97 (1H, s), 6.85 (1H, d, J=9.3 Hz), 4.38 (1H, s), 4.22 (1H, d, J=11.6 Hz), 3.50 (2H, s), 3.44 (2H, dd, J=87.8, 13.2 Hz), 3.12 (1H, t, J=11.3 Hz), 2.91 (1H, d, J=11.0 Hz), 2.79 (1H, d, J=11.3 Hz), 2.28 (3H, s), 1.51-1.45 (1H, m), 1.28-1.21 (2H, m), 1.13-1.06 (2H, m), 0.81 (3H, t, J=7.3 Hz).


Example 802






1H-NMR (DMSO-d6) δ: 7.87 (1H, d, J=8.6 Hz), 7.78 (1H, d, J=8.6 Hz), 7.05 (2H, s), 7.00 (1H, s), 4.13-4.02 (2H, m), 3.63-3.34 (2H, m), 3.51 (2H, s), 2.96 (1H, d, J=11.4 Hz), 2.83 (1H, d, J=11.9 Hz), 2.31 (3H, s), 2.21-2.15 (2H, m), 1.95-1.87 (1H, m), 1.84-1.76 (1H, m), 1.27-1.18 (2H, m), 0.92 (3H, t, J=7.3 Hz).


Example 803






1H-NMR (CDCl3) δ: 7.71 (1.0H, d, J=8.23 Hz), 7.58 (1.0H, d, J=8.23 Hz), 7.17-7.00 (3.0H, m), 4.22-4.01 (2.0H, m), 3.67-3.29 (5.0H, m), 3.07-2.72 (2.0H, m), 2.38-2.19 (5.0H, m), 2.03-1.90 (1.0H, m), 1.75-1.56 (2.0H, m), 1.55-1.40 (1.0H, m), 1.02-0.88 (6.0H, m).


Example 804






1H-NMR (CDCl3) δ: 7.70 (1.0H, d, J=8.51 Hz), 7.57 (1.0H, d, J=8.51 Hz), 7.37-7.20 (4.0H, m), 4.22-4.03 (2.0H, m), 3.74-3.38 (5.0H, m), 3.13-2.74 (2.0H, m), 2.43-2.18 (2.0H, m), 2.00-1.85 (1.0H, m), 1.80-1.58 (1.0H, m), 1.50-1.41 (1.0H, m), 0.98-0.89 (6.0H, m).


Example 805






1H-NMR (DMSO-d6) δ: 8.25 (1.0H, d, J=7.41 Hz), 7.42 (1.0H, d, J=12.90 Hz), 7.05-6.95 (3.0H, m), 4.17-3.88 (2.0H, m), 3.59 (2.0H, d, J=14.00 Hz), 3.49 (2.0H, s), 3.45-3.19 (2.0H, m), 2.93 (1.0H, d, J=11.53 Hz), 2.76 (1.0H, d, J=11.53 Hz), 2.28 (3.0H, s), 2.23-2.07 (2.0H, m), 1.98-1.87 (1.0H, m), 1.59-1.34 (1.6H, m), 0.93-0.87 (6.0H, m).


Example 806






1H-NMR (DMSO-d6) δ: 8.24 (1.0H, d, J=7.41 Hz), 7.42 (1.0H, d, J=12.62 Hz), 7.32-7.13 (4.0H, m), 4.24-3.82 (2.0H, m), 3.63 (1.0H, d, J=13.72 Hz), 3.56 (2.0H, s), 3.53-3.36 (3.0H, m), 2.93 (1.0H, d, J=11.53 Hz), 2.77 (1.0H, d, J=11.53 Hz), 2.23-2.11 (2.0H, m), 1.95-1.80 (1.0H, m), 1.64-1.50 (1.0H, m), 1.48-1.32 (1.0H, m), 0.94-0.86 (6.0H, m).


Example 807






1H-NMR (CDCl3) δ: 7.29-7.19 (3.0H, m), 7.17-7.02 (3.0H, m), 4.43-4.25 (1.0H, m), 4.16-4.01 (1.0H, m), 3.67-3.35 (4.0H, m), 3.11-2.69 (2.0H, m), 2.41-2.16 (5.0H, m), 1.85-1.70 (2.0H, m), 1.53-1.39 (1.0H, m), 0.98-0.86 (6.0H, m).


Example 808






1H-NMR (CDCl3) δ: 7.40-7.19 (6.0H, m), 7.14 (1.0H, dd, J=8.51, 1.92 Hz), 4.49-4.24 (1.0H, m), 4.22-4.01 (1.0H, m), 3.71-3.39 (4.0H, m), 2.99-2.71 (2.0H, m), 2.53-1.69 (4.0H, m), 1.55-1.39 (1.0H, m), 0.96-0.89 (6.0H, m).


Example 809






TLC_Rf=0.55 (MeOH:CHCl3=1:10)


Reference Example 264
(S)-4-(6-trifluoromethyl benzothiazole-2-yl)piperazine-1,3-dicarboxylic acid-1-t-butyl ester-3-methyl ester






2-Chloro-6-trifluoromethyl benzothiazole (2.79 g), (S)-4-N-Boc-piperazine carboxylic acid methyl ester (3.10 g), potassium carbonate (1.95 g) and dimethylformamide (20 mL) were stirred at 55° C. for 16 hours and at 90° C. for 7 hours. To the reaction solution was added water and extracted with ethyl acetate. The organic layer was washed with brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (1.40 g).


Yield: 27%.


1H-NMR (CDCl3) δ: 1.47 (9H, s), 2.97-3.18 (1H, m), 3.20-3.38 (1H, m), 3.58-3.81 (2H, m), 3.76 (3H, s), 4.09-4.37 (1H, m), 4.61-4.77 (1H, m), 5.06 (1H, brs), 7.55 (1H, d, J=8.4, 1.2 Hz), 7.61 (1H, d, J=8.4 Hz), 7.90 (1H, d, J=1.2 Hz).


Reference Example 265


Preparation of (S)-3-hydroxymethyl-4-(6-trifluoromethyl benzothiazole-2-yl)piperazine-1-carboxylic acid t-butyl ester






To a solution of (S)-4-(6-trifluoromethyl benzothiazole-2-yl)piperazine-1,3-dicarboxylic acid-1-t-butyl ester-3-methyl ester (1.18 g) in tetrahydrofuran (10 mL) was added lithium borohydride (65.7 mg). The mixture was stirred for 20 hours. To the reaction solution was added aqueous ammonium chloride solution and extracted with ethyl acetate. The organic layer was washed with brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (840 mg). Yield: 76%.


1H-NMR (CDCl3) δ: 1.50 (9H, s), 3.03-3.30 (2H, m), 3.35-3.55 (1H, m), 3.68-4.00 (3H, m), 4.00-4.43 (3H, m), 7.51-7.59 (2H, m), 7.87 (1H, d, J=0.8 Hz).


Reference Example 266
Preparation of (S)-3-methoxymethyl-4-(6-trifluoromethyl benzothiazole-2-yl)piperazine-1-carboxylic acid t-butyl ester






To a solution of (S)-3-hydroxymethyl-4-(6-trifluoromethyl benzothiazole-2-yl) piperazine-1-carboxylic acid t-butyl ester (209 mg) in dimethylformamide (2 mL) were sequentially added methyl iodide (0.5 mL) and sodium hydride (62.4 mg). The mixture was stirred at room temperature for 24 hours. To the reaction solution was added ice water and extracted with ethyl acetate. The organic layer was washed with brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (167 mg).


Yield: 77%.


1H-NMR (CDCl3) δ: 1.50 (9H, s), 2.96-3.19 (2H, m), 3.34-3.45 (1H, m), 3.38 (3H, s), 3.57 (2H, d, J=6.9 Hz), 3.94-4.06 (1H, m), 4.20-4.33 (3H, m), 7.53 (1H, dd, J=8.7, 1.5 Hz), 7.58 (1H, d, J=8.7 Hz), 7.86 (1H, d, J=1.5 Hz).


Reference Example 267
Preparation of 2-((S)-2-methoxymethylpiperazine-1-yl)-6-trifluoromethyl benzothiazole






To a solution of (S)-3-methoxymethyl-4-(6-trifluoromethyl benzothiazole-2-yl)piperazine-1-carboxylic acid t-butyl ester (167 mg) in methylene chloride (1.5 mL) was added trifluoroacetic acid (0.3 mL). The mixture was stirred at room temperature for 20 hours. The reaction solution was concentrated under reduced pressure. Saturated aqueous sodium hydrogencarbonate solution was added thereto and extracted with ethyl acetate. The organic layer was washed with brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure to give the title compound (123 mg). Yield: 96%.


1H-NMR (CDCl3) δ: 2.84-2.96 (3H, m), 3.01 (1H, dd, J=12.0, 3.9 Hz), 3.06-3.16 (1H, m), 3.26 (1H, d, J=12.9 Hz), 3.39 (1H, s), 3.46 (1H, dd, J=12.0, 3.3 Hz), 3.66 (1H, dd, J=12.4, 5.1 Hz), 3.91 (1H, dd, J=12.4, 7.2 Hz), 3.90-3.96 (1H, m), 4.12-4.21 (1H, m), 7.52 (1H, dd, J=8.4, 2.1 Hz), 7.56 (1H, d, J=8.4 Hz), 7.85 (1H, d, J=2.1 Hz).


Reference Example 268
Preparation of [3-[(S)-3-methoxymethyl-4-(6-trifluoromethyl benzothiazole-2-yl)piperazine-1-ylmethyl]phenyl]ethyl acetate ester






A mixture of 2-((S)-2-methoxymethylpiperazine-1-yl)-6-trifluoromethyl benzothiazole (123 mg), (3-bromomethylphenyl)ethyl acetate ester (104 mg), potassium carbonate (259 mg) and dimethylformamide (1.5 mL) was stirred at room temperature for 2 hours. To the reaction solution was added water and extracted with ethyl acetate. The organic layer was washed with brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (169 mg). Yield: 90%.


1H-NMR (CDCl3) δ: 1.26 (3H, t, J=7.2 Hz), 2.20-2.32 (2H, m), 2.90 (1H, brd, J=10.8 Hz), 3.04 (1H, d, J=11.7 Hz), 3.36 (3H, s), 3.39-3.64 (3H, m), 3.62 (2H, s), 3.70 (1H, dd, J=9.0, 6.0 Hz), 3.83 (1H, t, J=9.0 Hz), 4.03 (1H, brd, J=12.6 Hz), 4.16 (2H, q, J=7.2 Hz), 4.13-4.24 (1H, m), 7.18-7.33 (4H, m), 7.51 (1H, dd, J=8.4, 1.8 Hz), 7.56 (1H, d, J=8.4 Hz), 7.83 (1H, d, J=1.8 Hz).


Example 810
Preparation of [3-[(S)-3-methoxymethyl-4-(6-trifluoromethyl benzothiazole-2-yl)piperazine-1-ylmethyl]phenyl]acetic acid






A mixture of [3-[(S)-3-methoxymethyl-4-(6-trifluoromethyl benzothiazole-2-yl)piperazine-1-ylmethyl]phenyl]ethyl acetate ester (167 mg), 2N aqueous sodium hydroxide solution (0.8 mL), tetrahydrofuran (1.2 mL) and methanol (1.2 mL) was stirred at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure. To the residue was added 2N hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure to give the title compound (153 mg). Yield: 97%.


TLC_Rf=0.40 (MeOH:CHCl3=1:10)


The following compounds were obtained by similar methods as above.


Example 811






TLC_Rf=0.33 (MeOH:CHCl3=1:10)


Example 812






TLC_Rf=0.52 (MeOH:CHCl3=1:15)


Example 813






TLC_Rf=0.088 (MeOH:CHCl3=1:5)


Example 814






TLC_Rf=0.17 (MeOH:CHCl3=1:15)


Example 815






TLC_Rf=0.29 (MeOH:CHCl3=1:15)


Example 816






TLC_Rf=0.23 (MeOH:CHCl3=1:15)


Example 817






TLC_Rf=0.28 (MeOH:CHCl3=1:15)


Example 818






MS (ESI); m/z 463 [M+H]+


Example 819






MS (ESI); m/z 445 [M+H]+


Example 820






MS (ESI); m/z 449 [M+H]+


Example 821






MS (ESI); m/z 431 [M+H]+


Example 822






TLC: (SiO2) AcOEt-Hexane (3:1) Rf=0.21


Example 823






TLC: (SiO2) AcOEt Rf=0.46


Example 824






TLC: (SiO2) AcOEt Rf=0.45


Example 825






TLC: (SiO2) AcOEt Rf=0.67


Example 826






TLC: (SiO2) AcOEt Rf=0.60


Example 827






TLC: (SiO2) AcOEt-Hexane (1:1) Rf=0.18


Example 828






TLC: (SiO2) AcOEt-Hexane (1:1) Rf=0.25


Example 829






TLC: (SiO2) AcOEt-Hexane (1:1) Rf=0.34


Example 830






TLC: (SiO2) AcOEt Rf=0.29


Example 831






TLC: (SiO2) AcOEt Rf=0.25


Example 832






MS (ESI) m/z 468 [M+H]+


Example 833






MS (ESI) m/z 477 [M+H]+


Example 834






MS (ESI) m/z 449 [M+H]+


Example 835






MS (ESI) m/z 463 [M+H]+


Example 836






MS (ESI) m/z 435 [M+H]+


Example 837






MS (ESI) m/z 483 [M+H]+


Example 838






MS (ESI) m/z 465 [M+H]+


Example 839






1H-NMR (DMSO-d6) δ: 8.17 (1.0H, s), 7.78 (1.0H, d, J=2.01 Hz), 7.33-7.17 (4.0H, m), 6.91 (1.0H, s), 6.83 (1.0H, d, J=2.01 Hz), 4.06-0.29 (0.0H, m), 3.67-3.32 (4.0H, m), 3.19-3.16 (1.0H, m), 2.81 (1.0H, d, J=11.58 Hz), 2.67 (1.0H, d, J=11.58 Hz), 2.28-2.24 (2.0H, m), 1.95-1.92 (1.0H, br m), 1.45-1.42 (1.0H, br m), 1.28-1.08 (4.0H, m), 0.83 (3.0H, t, J=7.22 Hz).


Example 840







1H-NMR (300 MHz, DMSO-d6): δ 0.84 (3H, t, J=7.5 Hz), 1.12-1.34 (4H, m), 1.83-1.93 (2H, m), 2.34 (3H, s), 2.99-3.14 (2H, m), 3.14-3.57 (5H, m), 4.21-4.35 (2H, m), 4.81-4.86 (1H, m), 5.05-5.06 (1H, m), 7.15-7.63 (7H, m), 8.82 (2H, s), 10.52 (2H, br), 12.41 (1H, br)


Example 841







1H-NMR (300 MHz, DMSO-d6): δ0.83 (3H, t, J=7.2 Hz), 1.12-1.32 (4H, m), 1.82-1.95 (2H, m), 3.00-3.15 (2H, m), 3.24-3.39 (3H, m), 3.62 (2H, s), 4.25-4.40 (2H, m), 4.81-4.86 (1H, m), 5.05 (1H, m), 7.18 (1H, m), 7.39-7.60 (7H, m), 8.82 (2H, s), 10.62 (2H, br), 12.45 (1H, br)


Example 842






1H-NMR (DMSO-d6) δ: 8.72 (2H, s), 7.52-7.48 (3H, m), 7.14-7.11 (1H, m), 7.03 (2H, s), 6.96 (1H, s), 4.73 (1H, s), 4.56 (1H, d, J=12.3 Hz), 3.56-3.31 (2H, m), 3.51 (2H, s), 3.19-3.15 (1H, m), 2.90 (1H, d, J=9.9 Hz), 2.79 (1H, d, J=11.0 Hz), 2.29 (3H, s), 2.03 (2H, s), 1.86-1.83 (1H, m), 1.65-1.62 (1H, m), 1.18-1.15 (2H, m), 0.88 (3H, t, J=7.1 Hz).


Example 843






1H-NMR (DMSO-d6) δ: 8.65 (2H, s), 7.23 (1H, t, J=8.2 Hz), 7.03 (2H, s), 6.96 (1H, s), 6.88 (1H, s), 6.87 (1H, d, J=7.8 Hz), 6.69 (1H, d, J=9.3 Hz), 4.72 (1H, s), 4.54 (1H, d, J=10.0 Hz), 3.59-3.32 (2H, m), 3.51 (2H, s), 3.15 (1H, t, J=10.0 Hz), 2.94 (6H, s), 2.91-2.88 (1H, m), 2.77 (1H, t, J=11.0 Hz), 2.29 (3H, s), 2.05-1.97 (2H, m), 1.89-1.81 (1H, m), 1.65-1.58 (1H, m), 1.18-1.14 (2H, m), 0.88 (3H, t, J=7.3 Hz).


Example 844






1H-NMR (DMSO-d6) δ: 8.42 (1H, d, J=2.7 Hz), 7.82 (1H, dd, J=8.9, 2.6 Hz), 7.62 (1H, d, J=1.4 Hz), 7.59 (1H, s), 7.42 (2H, t, J=7.5 Hz), 7.29 (1H, d, J=7.4 Hz), 7.04 (2H, d, J=8.8 Hz), 6.97 (1H, s), 6.81 (1H, d, J=9.1 Hz), 4.31 (1H, s), 4.14 (1H, d, J=10.9 Hz), 3.62-3.33 (2H, m), 3.50 (2H, s), 3.14-3.06 (1H, m), 2.91 (1H, d, J=10.0 Hz), 2.80 (1H, d, J=10.0 Hz), 2.29 (3H, s), 2.09 (1H, t, J=10.0 Hz), 2.01-1.92 (2H, m), 1.47-1.38 (1H, m), 1.29-1.23 (2H, m), 1.15-1.07 (2H, m), 0.82 (3H, t, J=7.1 Hz).


Example 845






1H-NMR (DMSO-d6) δ: 8.47 (1H, d, J=2.5 Hz), 7.87 (1H, dd, J=8.9, 2.7 Hz), 7.46 (3H, t, J=8.8 Hz), 7.05 (1H, s), 7.02 (1H, s), 6.97 (1H, s), 6.81 (1H, d, J=9.1 Hz), 4.32 (1H, s), 4.16 (1H, d, J=12.6 Hz), 3.63-3.28 (2H, m), 3.50 (2H, s), 3.10 (1H, t, J=12.6 Hz), 2.92 (1H, d, J=9.9 Hz), 2.80 (1H, d, J=10.9 Hz), 2.29 (3H, s), 2.09 (1H, t, J=9.4 Hz), 1.98-1.91 (2H, m), 1.44-1.39 (1H, m), 1.31-1.22 (2H, m), 1.15-1.06 (2H, m), 0.82 (3H, t, J=7.2 Hz).


Example 846






MS (ESI); m/z 445 [M+H]+


Example 847






MS (ESI) m/z 459 [M+H]+


Example 848






MS (ESI) m/z 426 [M−H]−


Example 849






MS (ESI) m/z 440 [M−H]−


Example 850






1H-NMR (DMSO-d6) δ: 1.03 (6H, d, J=6.0 Hz), 2.27 (3H, s), 2.63-2.80 (2H, m), 2.85-2.97 (2H, m), 3.49 (2H, s), 3.69-3.78 (4H, m), 6.86-7.61 (9H, m).


Example 851






TLC Rf 0.64 (hexane:AcOEt=1:1)


Example 852






TLC Rf 0.70 (hexane:AcOEt=1:1)


Example 853






TLC: (SiO2) AcOEt-Hexane (1:1) Rf=0.34


Reference Example 269
Preparation of 2-((R)-2-butylpiperazine-1-yl)-6-trifluoromethoxybenzothiazole dihydrochloride






The above compound was synthesized with 2-chloro-6-trifluoromethyl benzothiazole and piperazine-1-carboxylic acid t-butyl ester as starting materials by a similar method of Reference Example 84 or 155.



1H-NMR (DMSO-d6) δ: 0.90 (3H, t, J=7.0 Hz), 1.31-1.37 (4H, m), 1.85-1.95 (2H, m), 3.03-3.18 (1H, m), 3.25-3.39 (3H, m), 3.42-3.55 (1H, m), 4.13-4.33 (2H, m), 7.31 (1H, dd, J=8.5, 1.8 Hz), 7.54 (1H, d, J=8.5 Hz), 7.99 (1H, d, J=1.8 Hz), 9.14 (1H, br s), 9.57 (1H, br s).


Reference Example 270
Preparation of [3-[(R)-3-butyl-4-(6-trifluoromethoxybenzothiazole-2-yl)-piperazine-1-ylmethyl]-5-methylphenoxy]acetic acid methyl ester






A mixture of 2-((R)-2-butylpiperazine-1-yl)-6-trifluoromethoxybenzothiazole dihydrochloride (170 mg), (3-chloromethyl-5-methylphenoxy)acetic acid methyl ester (108 mg), potassium carbonate (270 mg), potassium iodide (65 mg) and dimethylformamide (4 mL) was stirred at room temperature for 24 hours. To the reaction solution was added water and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatograph on silica gel to give the title compound (203 mg). Yield: 94%.


TLC Rf 0.62 (AcOEt/n-hexane=1/5).
Example 854
Preparation of
[3-[(R)-3-butyl-4-(6-trifluoromethoxybenzothiazole-2-yl)-piperazine-1-ylmethyl]-5-methylphenoxy]acetic acid






A mixture of [3-[(R)-3-butyl-4-(6-trifluoromethoxybenzothiazole-2-yl)-piperazine-1-ylmethyl]-5-methylpheno xy]acetic acid methyl ester (203 mg), 2N sodium hydroxide (0.46 mL), tetrahydrofuran (2 mL) and methanol (2 mL) was stirred at room temperature for 16 hours. To the reaction solution were added water and chloroform. The mixture was neutralized with 2N hydrochloric acid. The reaction solution was extracted with chloroform. The organic layer was washed with brine, and dried over magnesium sulphate. The solvent was evaporated under reduced pressure to give the title compound (182 mg). Yield: 91%.


1H-NMR (DMSO-d6) δ: 7.90 (1.0H, d, J=1.65 Hz), 7.48 (1.0H, d, J=8.78 Hz), 7.25 (1.0H, dd, J=8.78, 1.65 Hz), 6.74 (1.0H, s), 6.67 (1.0H, s), 6.61 (1.0H, s), 4.48 (2.0H, s), 4.06-3.80 (1.0H, m), 3.72-3.20 (3.0H, m), 2.90 (1.0H, d, J=12.62 Hz), 2.81


The following compounds were obtained by similar methods as above.


Example 855






MS (ESI) m/z 508 [M+H]+


Example 856






1H-NMR (DMSO-d6) δ: 8.23 (1.0H, s), 7.58-7.54 (2.0H, m), 6.74 (1.0H, s), 6.68 (1.0H, s), 6.62 (1.0H, s), 4.48 (2.0H, s), 4.11-3.87 (1.0H, m), 3.58-3.33 (3.0H, m), 2.94 (1.0H, d, J=12.42 Hz), 2.83 (1.0H, d, J=12.42 Hz), 2.27 (3.0H, s), 2.16-2.12 (2.0H, m), 2.01-1.92 (1.0H, m), 1.80-1.76 (1.0H, m), 1.34-1.21 (4.0H, m), 0.86 (3.0H, t, J=7.22 Hz).


Example 857






1H-NMR (DMSO-d6) δ: 8.22 (1.0H, s), 7.59-7.49 (2.0H, m), 7.24 (1.0H, dd, J=7.72, 7.72 Hz), 6.95-6.87 (2.0H, m), 6.82-6.76 (1.0H, m), 4.60 (2.0H, s), 4.20-3.89 (2.0H, m), 3.57 (1.0H, d, J=13.76 Hz), 3.47-3.22 (2.0H, m), 2.96-2.70 (2.0H, m), 2.24-2.08 (2.0H, m), 1.93-1.79 (1.5H, br m), 1.70-1.56 (1.2H, br m), 1.52-1.37 (1.4H, br m), 0.92 (6.0H, d, J=6.55 Hz).


Example 858






1H-NMR (DMSO-d6) δ: 8.22 (1.0H, s), 7.59-7.49 (2.0H, m), 6.75 (1.0H, s), 6.68 (1.0H, s), 6.64-6.61 (1.0H, m), 4.61 (2.0H, s), 4.18-3.89 (2.0H, m), 3.55 (1.0H, d, J=13.26 Hz), 3.51-3.17 (2.0H, m), 2.90 (1.0H, d, J=9.90 Hz), 2.83-2.71 (1.0H, m), 2.26 (3.0H, s), 2.22-2.09 (2.3H, m), 1.96-1.84 (1.0H, m), 1.65-1.52 (1.0H, m), 1.52-1.39 (1.0H, m), 0.98-0.88 (6.0H, m).


Example 859






MS (ESI) m/z 492 [M−H]−


Example 860






MS (ESI) m/z 506 [M−H]−


Example 861






1H-NMR (300 MHz, DMSO-d6) δ 0.85 (3H, t, J=7.2 Hz), 1.16-1.36 (4H, m), 1.79-1.95 (2H, m), 2.15-2.19 (2H, m), 2.81-2.92 (2H, m), 3.34-3.60 (3H, m), 4.03 (2H, m), 4.66 (2H, s), 6.82 (1H, dd, J=7.8 Hz, 1.8 Hz), 6.91 (1H, s), 6.94 (1H, d, J=7.8 Hz), 7.26 (1H, t, J=7.8 Hz), 7.51-7.58 (2H, m), 8.22 (1H, s), 13.00 (1H, br s)


Example 862






1H-NMR (300 MHz, DMSO-d6) δ 0.84 (3H, t, J=7.2 Hz), 1.15-1.36 (4H, m), 1.73-1.97 (2H, m), 2.11-2.16 (2H, m), 2.27 (3H, s), 2.79-2.92 (2H, m), 3.33-3.57 (3H, m), 4.02 (2H, m), 4.62 (2H, s), 6.63 (1H, s), 6.69 (1H, s), 6.76 (1H, s), 7.51-7.58 (2H, m), 8.22 (1H, s), 12.98 (1H, br s)


Example 863






MS (ESI) 492[M−H]−


Example 864






MS (ESI) 506[M−H]−


Example 865







1H-NMR (300 MHz, DMSO-d6) δ 0.84 (3H, t, J=7.2 Hz), 1.15-1.35 (4H, m), 1.77-1.95 (2H, m), 2.10-2.18 (2H, m), 2.80-2.92 (2H, m), 3.25-3.59 (3H, m), 4.01 (2H, m), 4.61 (2H, s), 6.80 (1H, d, J=7.8 Hz), 6.89 (1H, s), 6.92 (1H, d, J=7.8 Hz), 7.25 (1H, t, J=7.8 Hz), 7.43 (1H, d, J=12.3 Hz), 8.23 (1H, d, J=7.5 Hz)


Example 866






1H-NMR (300 MHz, DMSO-d6) δ 0.84 (3H, t, J=7.2 Hz), 1.15-1.35 (4H, m), 1.74-1.99 (2H, m), 2.11-2.14 (2H, m), 2.26 (3H, s), 2.79-2.92 (2H, m), 3.33-3.57 (3H, m), 3.99 (2H, m), 4.61 (2H, s), 6.63 (1H, s), 6.69 (1H, s), 6.75 (1H, s), 7.43 (1H, d, J=12.3 Hz), 8.23 (1H, d, J=7.5 Hz)


Example 867






1H-NMR (DMSO-d6) δ: 8.24 (1.0H, d, J=7.72 Hz), 7.42 (1.0H, d, J=12.59 Hz), 7.24 (1.0H, dd, J=7.72, 7.72 Hz), 6.95-6.86 (2.0H, m), 6.82-6.75 (1.0H, m), 4.55 (2.0H, s), 4.11-3.86 (2.0H, m), 3.60-3.20 (3.0H, m), 2.90 (1.0H, d, J=12.25 Hz), 2.77 (1.0H, d, J=12.25 Hz), 2.25-2.06 (2.0H, m), 1.92-1.76 (1.0H, m), 1.70-1.54 (1.0H, m), 1.53-1.35 (1.0H, m), 0.95-0.88 (6.0H, m).


Example 868






1H-NMR (DMSO-d6) δ: 8.24 (1.0H, d, J=7.39 Hz), 7.42 (1.0H, d, J=12.59 Hz), 6.75 (1.0H, s), 6.68 (1.0H, s), 6.62 (1.0H, s), 4.61 (2.0H, s), 4.19-3.89 (2.0H, m), 3.59-3.21 (3.0H, m), 2.90 (1.0H, d, J=10.74 Hz), 2.83-2.71 (1.0H, m), 2.26 (3.0H, s), 2.21-2.08 (2.0H, m), 1.96-1.83 (1.0H, m), 1.65-1.52 (1.0H, m), 1.51-1.36 (1.0H, m), 0.95-0.88 (6.0H, m).


Example 869






1H-NMR (DMSO-d6) δ: 8.23 (1.0H, d, J=7.39 Hz), 7.43 (1.0H, d, J=12.42 Hz), 7.25 (1.0H, dd, J=7.72, 7.72 Hz), 6.96-6.88 (2.0H, m), 6.80 (1.0H, dd, J=8.31, 2.27 Hz), 4.64 (2.0H, s), 4.15-3.89 (2.0H, m), 3.60-3.22 (3.0H, m), 2.89 (1.0H, d, J=11.92 Hz), 2.82 (2.0H, d, J=11.92 Hz), 2.23-2.07 (2.0H, m), 1.90-1.76 (2.0H, m), 1.31-1.14 (2.0H, m), 0.90 (3.0H, t, J=7.30 Hz).


Example 870






1H-NMR (DMSO-d6) δ: 8.23 (1.0H, d, J=7.22 Hz), 7.43 (1.0H, d, J=12.42 Hz), 6.75 (1.0H, s), 6.69 (1.0H, s), 6.63 (1.0H, s), 4.62 (2.0H, s), 4.17-3.86 (2.0H, m), 3.57-3.22 (3.0H, m), 2.89 (1.0H, d, J=11.58 Hz), 2.81 (1.0H, d, J=11.58 Hz), 2.26 (3.0H, s), 2.19-2.07 (2.0H, m), 1.97-1.71 (2.0H, m), 1.31-1.15 (2.0H, m), 0.90 (3.0H, t, J=7.30 Hz).


Example 871






1H-NMR (DMSO-d6) δ: 7.87 (1.0H, d, J=8.73 Hz), 7.77 (1.0H, d, J=8.39 Hz), 6.71 (1.0H, s), 6.64 (1.0H, s), 6.57 (1.0H, s), 4.28 (2.0H, s), 3.53-3.39 (6.0H, m), 3.00-2.71 (2.0H, m), 2.30-2.26 (3.0H, m), 2.18-2.15 (2.0H, m), 1.36-1.17 (4.0H, m), 0.87 (3.0H, t, J=7.13 Hz).


Example 872






MS (ESI) 493 [M−H]−


Example 873






MS (ESI) 507 [M−H]−


Example 874






MS (ESI) m/z 493 [M−H]−


Example 875






MS (ESI) m/z 507 [M−H]−


Example 876






MS (ESI) m/z 524 [M+H]+


Example 877






1H-NMR (DMSO-d6) δ: 7.89 (1.0H, d, J=2.18 Hz), 7.45 (1.0H, d, J=8.73 Hz), 7.29-7.20 (2.0H, m), 6.95-6.88 (2.0H, m), 6.80 (1.0H, dd, J=8.73, 2.18 Hz), 4.64 (2.0H, s), 4.11-4.01 (1.0H, m), 3.97-3.85 (1.0H, m), 3.56 (1.0H, d, J=13.76 Hz), 3.44-3.29 (2.0H, m), 2.88 (1.0H, d, J=10.74 Hz), 2.78 (1.0H, d, J=10.74 Hz), 2.22-2.06 (2.0H, m), 1.90-1.76 (1.0H, m), 1.67-1.54 (1.0H, m), 1.50-1.37 (1.0H, m), 0.91 (6.0H, d, J=6.55 Hz).


Example 878






1H-NMR (DMSO-d6) δ: 7.89 (1.0H, d, J=2.18 Hz), 7.45 (1.0H, d, J=8.73 Hz), 7.23 (1.0H, dd, J=8.73, 2.18 Hz), 6.75 (1.0H, s), 6.68 (1.0H, s), 6.62 (1.0H, s), 4.61 (2.0H, s), 4.09-4.00 (1.0H, m), 3.96-3.86 (1.0H, m), 3.55 (2.0H, d, J=13.26 Hz), 3.50-3.14 (1.0H, m), 2.89 (1.0H, d, J=11.92 Hz), 2.77 (1.0H, d, J=11.92 Hz), 2.26 (3.0H, s), 2.21-2.08 (2.0H, m), 1.96-1.83 (1.0H, m), 1.62-1.36 (2.0H, m), 0.94-0.88 (6.0H, m).


Example 879






1H-NMR (300 MHz, DMSO-d6) δ0.90 (3H, t, J=7.2 Hz), 1.14-1.28 (2H, m), 1.72-1.90 (2H, m), 2.12-2.18 (2H, m), 2.79-2.89 (2H, m), 3.33-3.58 (3H, m), 3.89-4.00 (2H, m), 4.66 (2H, s), 6.80 (1H, dd, J=8.1 Hz, 1.8 Hz), 6.90-6.94 (2H, m), 7.22-7.28 (2H, m), 7.45 (1H, d, J=8.7 Hz), 7.88 (1H, s), 12.98 (1H, br s)


Example 880






1H-NMR (300 MHz, DMSO-d6) δ0.88 (3H, t, J=7.5 Hz), 1.21 (2H, m), 1.71-1.91 (2H, m), 2.10-2.13 (2H, m), 2.24 (3H, s), 2.76-2.88 (2H, m), 3.30-3.53 (3H, m), 3.87-3.98 (2H, m), 4.60 (2H, s), 6.61 (1H, s), 6.67 (1H, s), 6.73 (1H, s), 7.21 (1H, d, J=8.7 Hz), 7.43 (1H, d, J=8.7 Hz), 7.85 (1H, s), 13.02 (1H, br s)


Example 881






1H-NMR (DMSO-d6) δ: 7.54 (1H, s), 7.28-7.15 (2H, m), 6.74 (1H, s), 6.94-6.89 (2H, m), 6.80 (1H, d, J=7.8 Hz), 4.64 (2H, s), 4.13 (1H, s), 3.95 (1H, m), 3.57-3.32 (3H, m), 2.90-2.76 (2H, m), 2.19-2.11 (2H, m), 1.85-1.80 (2.0H, m), 1.28 (2H, q, J=7.2 Hz), 1.13 (2H, q, J=7.5 Hz), 0.83 (3H, t, J=7.2 Hz).


Example 892







1H-NMR (DMSO-d6) δ: 7.54 (1H, d, J=1.85 Hz), 7.20 (2H, d, J=8.4 Hz), 6.74 (1H, s), 6.68 (1H, s), 6.62 (1H, s), 4.62 (2H, s), 4.14-3.92 (2H, m), 3.52 (1H, d, J=13.8 Hz), 2.90-2.75 2H, m), 2.26 (3H, s), 2.15-2.11 (2H, m), 1.80 (2.0H, m), 1.26 (2H, t, J=7.2 Hz), 0.85 (7.0H, t, J=5.96 Hz).


Example 883






1H-NMR (DMSO-d6) δ: 7.54 (1.0H, d, J=2.18 Hz), 7.28-7.21 (2.0H, m), 7.17 (1.0H, dd, J=8.23, 2.18 Hz), 6.94-6.87 (2.0H, m), 6.79 (1.0H, dd, J=8.23, 2.18 Hz), 4.63 (2.0H, s), 4.29-4.21 (1.0H, m), 3.94 (1.0H, d, J=13.93 Hz), 3.54 (1.0H, d, J=13.93 Hz), 3.45-3.24 (2.0H, m), 2.86 (1.0H, d, J=10.74 Hz), 2.75 (1.3H, d, J=10.74 Hz), 2.30-2.05 (2.0H, m), 1.81-1.62 (2.0H, m), 1.47-1.35 (1.0H, m), 0.93-0.86 (6.0H, m).


Example 884






1H-NMR (DMSO-d6) δ: 7.54 (1.0H, d, J=1.85 Hz), 7.24 (1.0H, d, J=8.56 Hz), 7.17 (1.0H, dd, J=8.56, 1.85 Hz), 6.74 (1.0H, s), 6.68 (1.0H, s), 6.62 (1.0H, s), 4.62 (2.0H, s), 4.29-4.20 (1.0H, m), 3.94 (1.0H, d, J=12.25 Hz), 3.52 (1.0H, d, J=13.76 Hz), 3.45-3.36 (2.0H, m), 2.87 (1.0H, d, J=10.58 Hz), 2.74 (1.0H, d, J=10.58 Hz), 2.26 (3.0H, s), 2.20-2.05 (2.0H, m), 1.80-1.62 (2.0H, m), 1.49-1.34 (1.0H, m), 0.90 (7.0H, t, J=5.96 Hz).


Example 885






MS (ESI) m/z 442 [M−H]−


Example 886






MS (ESI) m/z 456[M−H]−


Example 887






MS (ESI) m/z 442[M−H]−


Example 888






MS (ESI) m/z 456[M−H]−


Example 889






1H-NMR (DMSO-d6) δ: 8.74 (2H, s), 7.55-7.45 (3H, m), 7.24 (1H, t, J=8.1 Hz), 7.14 (1H, m), 6.95-6.90 (2H, m), 6.80 (1H, dd, J=8.1, 2.4 Hz), 4.74 (1H, s), 4.64 (2H, s), 4.55 (1H, m), 3.57-3.53 (2H, m), 3.15 (1H, m), 2.89-2.79 (2H, m), 2.06-2.01 (2H, m), 1.84 (1H, m), 1.68 (1H, m), 127 (2H, q, J=7.2 Hz), 117 (2H, q, J=7.2 Hz), 0.82 (3H, t, J=7.1 Hz).


Example 890






1H-NMR (DMSO-d6) δ: 8.74 (2H, s), 7.55-7.45 (3H, m), 7.24 (1H, t, J=8.1 Hz), 6.75 (1H, s), 6.68 (1H, s), 6.62 (1H, s), 4.74 (1H, s), 4.64 (2H, s), 4.55 (1H, m), 3.57-3.53 (2H, m), 3.15 (1H, m), 2.89-2.79 (2H, m), 2.25 (3H, s), 2.06-2.01 (2H, m), 1.84 (1H, m), 1.68 (1H, m), 127 (2H, q, J=7.2 Hz), 117 (2H, q, J=7.2 Hz), 0.82 (3H, t, J=7.1 Hz).


Example 891






1H-NMR (DMSO-d6) δ: 8.73 (2.0H, s), 7.57-7.42 (3.0H, m), 7.25 (1.0H, dd, J=7.89, 7.89 Hz), 7.18-7.09 (1.0H, m), 6.96-6.87 (2.0H, m), 6.80 (1.0H, dd, J=7.89, 2.52 Hz), 4.92-4.83 (1.0H, m), 4.66-4.52 (3.0H, m), 3.53 (1.0H, d, J=13.60 Hz), 3.48-3.07 (2.0H, m), 2.86 (1.0H, d, J=11.25 Hz), 2.77 (1.0H, d, J=11.25 Hz), 2.11-1.94 (2.0H, m), 1.74-1.61 (2.0H, m), 1.46-1.34 (1.0H, m), 0.93-0.86 (6.0H, m).


Example 892






1H-NMR (DMSO-d6) δ: 8.73 (2.0H, s), 7.58-7.42 (3.0H, m), 7.18-7.09 (1.0H, m), 6.76 (1.0H, s), 6.69 (1.0H, s), 6.62 (1.0H, s), 4.91-4.81 (1.0H, m), 4.64-4.52 (3.0H, m), 3.51 (1.0H, d, J=13.60 Hz), 3.47-3.09 (2.0H, m), 2.92-2.82 (1.0H, m), 2.80-2.71 (1.0H, m), 2.26 (3.0H, s), 2.08-1.95 (2.0H, m), 1.81-1.69 (1.0H, m), 1.66-1.53 (1.0H, m), 1.49-1.35 (1.0H, m), 0.93-0.86 (6.0H, m).


Example 893






1H-NMR (DMSO-d6) δ: 8.74 (2H, s), 7.55-7.45 (3H, m), 7.25 (1H, t, J=8.0 Hz), 7.14 (1H, m), 6.94-6.90 (2H, m), 6.79 (1H, dd, J=8.1, 2.4 Hz), 4.78 (1H, s), 4.64 (2H, s), 4.59 (1H, m), 3.57-3.10 (3H, m), 2.89-2.79 (2H, m), 2.08-2.04 (2H, m), 1.77 (2H, m), 1.17 (2H, q, J=7.2 Hz), 0.87 (3H, t, J=7.1 Hz).


Example 894






1H-NMR (DMSO-d6) δ: 8.74 (2H, s), 7.55-7.45 (3H, m), 7.25 (1H, t, J=8.0 Hz), 6.75 (1H, s), 6.68 (1H, s), 6.62 (1H, s), 4.78 (1H, s), 4.64 (2H, s), 4.59 (1H, m), 3.57-3.10 (3H, m), 2.89-2.79 (2H, m), 2.26 (3H, s), 2.08-2.04 (2H, m), 1.77 (2H, m), 1.17 (2H, q, J=7.2 Hz), 0.87 (3H, t, J=7.1 Hz).


Example 895






1H-NMR (300 MHz, DMSO-d6) δ0.83 (3H, t, J=7.2 Hz), 1.13-1.33 (4H, m), 1.62-1.91 (2H, m), 1.98-2.04 (2H, m), 2.79-2.90 (2H, m), 3.12-3.56 (3H, m), 4.52-4.57 (3H, m), 4.74 (1H, m), 6.77 (1H, d, J=7.8 Hz), 6.88 (1H, s), 6.91 (1H, d, J=7.8 Hz), 7.11-7.16 (1H, m), 7.23 (1H, t, J=7.8 Hz), 7.43-7.55 (3H, m), 8.73 (2H, s)


Example 896






1H-NMR (300 MHz, DMSO-d6) δ0.83 (3H, t, J=7.2 Hz), 1.06-1.33 (4H, m), 1.61-1.91 (2H, m), 1.98-2.05 (2H, m), 2.26 (3H, s), 2.78-2.90 (2H, m), 3.11-3.55 (3H, m), 4.55 (1H, d, =12.3 Hz), 4.61 (2H, s), 4.72 (1H, m), 6.62 (1H, s), 6.69 (1H, s), 6.76 (1H, s), 7.14 (1H, m), 7.45-7.55 (3H, m), 8.73 (2H, s), 12.94 (1H, br s)


Example 897






TLC: (SiO2) AcOEt Rf=0.29


Example 898






1H-NMR (DMSO-d6) δ: 8.42 (2.0H, s), 7.24 (1.0H, dd, J=7.72, 7.72 Hz), 6.94-6.86 (2.0H, m), 6.79 (1.0H, dd, J=8.56, 1.85 Hz), 4.76-4.67 (1.0H, m), 4.64 (2.0H, s), 4.40 (1.0H, d, J=12.93 Hz), 3.51 (1.0H, d, J=13.60 Hz), 3.42-3.21 (1.0H, m), 3.18-3.05 (1.0H, m), 2.83 (1.0H, d, J=11.25 Hz), 2.74 (1.0H, d, J=11.25 Hz), 2.09-1.90 (2.0H, m), 1.72-1.52 (2.0H, m), 1.41-1.30 (1.0H, m), 0.89-0.83 (6.0H, m).


Example 899






1H-NMR (DMSO-d6) δ: 8.42 (2.0H, s), 6.74 (1.0H, s), 6.67 (1.0H, s), 6.61 (1.0H, s), 4.76-4.66 (1.0H, br m), 4.60 (2.0H, s), 4.40 (1.0H, d, J=13.26 Hz), 3.49 (1.0H, d, J=13.93 Hz), 3.45-3.20 (1.0H, m), 3.18-3.05 (1.0H, m), 2.83 (1.0H, d, J=12.09 Hz), 2.77-2.69 (1.0H, m), 2.25 (3.0H, s), 2.04-1.96 (2.0H, m), 1.77-1.65 (1.0H, m), 1.60-1.47 (1.0H, m), 1.44-1.28 (1.0H, m), 0.90-0.83 (6.0H, m).


Example 900






1H-NMR (DMSO-d6) δ: 8.22 (1H, s), 7.59-7.53 (2H, m), 6.75 (1H, s), 6.68 (1H, s), 6.54 (1H, s), 4.21-3.89 (2H, m), 3.55-3.30 (3H, m), 2.92-2.75 (2H, m), 2.24 (3H, s), 2.18-2.02 (2H, m), 1.83 (1H, m), 1.65-1.38 (2H, m), 1.51 (6H, s), 0.93-0.91 (6H, m).


Example 901






MS (ESI) m/z 442 [M+H]+


Example 902






MS (ESI) m/z 462 [M+H]+


Example 903






MS (ESI) m/z 442 [M+H]+


Example 904






1H-NMR (DMSO-d6) δ: 1.01 (6H, d, J=5.5 Hz), 2.70-2.87 (4H, m), 3.22 (3H, s), 3.47 (2H, d, J=10.2 Hz), 3.55 (2H, s), 3.71-3.83 (4H, m), 4.15-4.24 (2H, m), 7.04-7.45 (8H, m).


Example 905






1H-NMR (DMSO-d6) δ: 1.03 (6H, d, J=5.2 Hz), 2.70-2.88 (4H, m), 3.45 (2H, d, J=11.0 Hz), 3.55 (2H, s), 3.60 (3H, s), 3.81 (2H, s), 7.04-7.42 (8H, m).


Example 906






1H-NMR (DMSO-d6) δ: 1.04 (6H, d, J=6.0 Hz), 2.66-2.79 (2H, m), 3.01 (2H, t, J=11.7 Hz), 3.54 (3H, s), 3.76-3.88 (4H, m), 7.02-7.31 (6H, m), 7.44 (1H, d, J=8.0 Hz), 7.75 (1H, d, J=7.7 Hz).


Example 907






1H-NMR (DMSO-d6) δ: 1.04 (6H, d, J=6.0 Hz), 2.63-2.76 (2H, m), 2.93-3.04 (2H, m), 3.53 (2H, s), 3.78 (2H, s), 3.90-3.98 (2H, m), 6.98-7.41 (8H, m).


Example 908






1H-NMR (DMSO-d6) δ: 1.01 (6H, d, J=6.0 Hz), 2.50-2.58 (2H, m), 2.80 (2H, dd, J=12.6, 10.4 Hz), 3.52 (2H, s), 3.75 (2H, s), 4.34 (2H, dd, J=12.6, 1.6 Hz), 7.05-7.27 (4H, m), 8.44 (2H, s).


Example 909






1H-NMR (DMSO-d6) δ: 1.02 (6H, d, J=6.0 Hz), 2.47-2.55 (2H, m), 2.61-2.74 (2H, m), 3.52 (2H, s), 3.60-3.67 (2H, m), 3.76 (2H, s), 7.07-7.45 (6H, m), 8.07 (1H, d, J=3.3 Hz).


Example 910






1H-NMR Acetone) δ: 7.76 (1.0H, s), 7.50 (1.0H, d, J=9.06 Hz), 7.41 (1.0H, s), 7.35 (1.0H, d, J=7.42 Hz), 7.30-7.22 (2.0H, m), 7.16 (1.0H, d, J=7.42 Hz), 3.94 (2.0H, dd, J=12.71, 2.33 Hz), 3.86 (2.0H, s), 3.62 (2.0H, s), 3.10 (2.0H, dd, J=12.71, 10.16 Hz), 2.87-2.77 (2.0H, m), 1.12 (6.0H, d, J=6.00 Hz).


Example 911






1H-NMR Acetone) δ: 8.27 (1.0H, d, J=1.80 Hz), 7.82 (1.0H, dd, J=8.46, 1.80 Hz), 7.58 (1.0H, d, J=8.46 Hz), 7.41 (1.0H, s), 7.35 (1.0H, d, J=7.42 Hz), 7.27 (1.0H, dd, J=7.42, 7.42 Hz), 7.17 (1.0H, d, J=7.42 Hz), 4.00 (2.0H, d, J=12.64 Hz), 3.87 (2.0H, s), 3.63 (2.0H, s), 3.21-3.07 (5.0H, m), 2.89-2.78 (2.0H, m), 1.13 (6.0H, d, J=6.32 Hz).


Example 912






1H-NMR Acetone) δ: 7.81 (1.0H, s), 7.47-7.33 (4.0H, m), 7.26 (1.0H, dd, J=7.54, 7.54 Hz), 7.16 (1.0H, d, J=7.54 Hz), 3.96 (2.0H, d, J=12.91 Hz), 3.86 (2.0H, s), 3.62 (2.0H, s), 3.15-3.01 (8.0H, m), 2.92-2.78 (2.0H, m), 1.12 (6.0H, d, J=6.04 Hz).


Example 913






1H-NMR (Acetone) δ: 8.23 (1.0H, s), 7.82 (1.0H, d, J=8.52 Hz), 7.64 (1.0H, br s), 7.48-7.23 (4.0H, m), 7.16 (1.0H, d, J=7.14 Hz), 3.96 (2.0H, d, J=12.64 Hz), 3.86 (2.0H, s), 3.62 (2.0H, s), 3.11 (2.0H, dd, J=11.40, 11.40 Hz), 2.93-2.76 (5.0H, m), 1.12 (6.0H, d, J=6.32 Hz).


Example 914






1H-NMR Acetone) δ: 7.42-7.31 (4.0H, m), 7.26 (1.0H, dd, J=7.42, 7.42 Hz), 7.16 (1.0H, d, J=7.42 Hz), 6.90 (1.0H, dd, J=8.79, 2.75 Hz), 3.90-3.84 (4.0H, m), 3.80 (3.0H, s), 3.60 (2.0H, s), 3.01 (2.0H, dd, J=12.77, 10.30 Hz), 2.83-2.72 (2.0H, m), 1.11 (6.0H, d, J=6.00 Hz).


Example 915






1H-NMR Acetone) δ: 7.83 (1.0H, d, J=8.24 Hz), 7.73 (1.0H, d, J=8.24 Hz), 7.42 (1.0H, s), 7.36 (1.0H, d, J=7.55 Hz), 7.27 (1.0H, dd, J=7.55, 7.55 Hz), 7.17 (1.0H, d, J=7.55 Hz), 4.05 (2.0H, d, J=13.05 Hz), 3.88 (2.0H, s), 3.63 (2.0H, s), 3.21 (2.0H, dd, J=13.05, 10.30 Hz), 1.14 (6.0H, d, J=6.32 Hz).


Example 916






1H-NMR (DMSO-d6) δ: 7.70 (1.0H, dd, J=8.52, 2.75 Hz), 7.43 (1.0H, dd, J=9.06, 4.94 Hz), 7.28-7.20 (3.0H, m), 7.16-7.05 (2.0H, m), 3.83-3.78 (4.0H, m), 3.52 (2.0H, s), 3.01 (2.0H, dd, J=11.54, 11.54 Hz), 2.77-2.69 (2.0H, m), 1.04 (6.0H, d, J=6.04 Hz).


Example 917






1H-NMR (Acetone) δ: 8.30 (1.0H, d, J=5.22 Hz), 7.31 (1.0H, d, J=7.97 Hz), 7.13 (1.0H, d, J=1.92 Hz), 7.05 (1.0H, s), 6.89 (1.0H, dd, J=7.97, 1.92 Hz), 6.80 (1.0H, d, J=5.22 Hz), 4.32 (2.0H, d, J=13.73 Hz), 4.16 (2.0H, dd, J=6.04, 6.04 Hz), 3.23 (2.0H, dd, J=6.04, 6.04 Hz), 2.89-2.79 (2.0H, m), 2.70-2.61 (2.0H, m), 1.25 (6.0H, d, J=6.04 Hz).


Example 918






1H-NMR (DMSO-d6) δ: 1.05 (7H, d, J=6.0 Hz), 2.58-2.87 (4H, m), 3.54 (2H, s), 3.77 (2H, s), 4.23-4.34 (2H, m), 7.05-7.53 (8H, m), 7.90-8.06 (3H, m).


Example 919






1H-NMR (Acetone) δ: 7.50 (1.0H, dd, J=7.97, 7.97 Hz), 7.40 (1.0H, s), 7.34 (1.0H, d, J=7.42 Hz), 7.25 (1.0H, dd, J=7.42, 7.42 Hz), 7.15 (1.0H, d, J=7.42 Hz), 6.75 (1.0H, d, J=7.97 Hz), 6.59 (1.0H, d, J=7.97 Hz), 4.13 (2.0H, d, J=11.54 Hz), 3.82 (2.0H, s), 3.61 (2.0H, s), 2.80-2.62 (4.0H, m), 1.08 (6.0H, d, J=5.77 Hz).


Example 920






MS (ESI) m/z 428 [M+H]+


Example 921






1H-NMR (DMSO-d6) δ: 1.03 (6H, d, J=6.0 Hz), 2.27 (3H, s), 2.63-2.80 (2H, m), 2.85-2.97 (2H, m), 3.49 (2H, s), 3.69-3.78 (4H, m), 6.86-7.61 (9H, m).


Example 922






1H-NMR (DMSO-d6) δ: 1.04 (6H, d, J=6.0 Hz), 2.52-2.62 (2H, m), 2.84 (2H, dd, J=12.9, 10.4 Hz), 3.54 (2H, s), 3.77 (2H, s), 4.44-4.52 (2H, m), 7.07-7.64 (9H, m), 8.69 (2H, s).


Example 923






1H-NMR (DMSO-d6)) δ: 7.77 (1H, s), 7.59-7.53 (1H, m), 7.37-7.29 (1H, m), 7.14-7.06 (3H, m), 6.89 (1H, s), 3.78-3.73 (4H, m), 3.49 (2H, s), 2.94 (2H, t, J=12.6 Hz), 2.74-2.68 (2H, m), 2.27 (3H, s), 1.0.3 (6H, d, J=6.3 Hz).


Example 924






1H-NMR (DMSO-d6)) δ: 7.77 (1H, s), 7.59-7.53 (1H, m), 7.37-7.29 (1H, m), 7.14-7.06 (3H, m), 6.76 (2H, s), 6.54 (1H, s), 4.60 (2H, s), 3.79-3.70 (4H, m), 2.93 (2H, t, J=10.5 Hz), 2.70 (2H, brs), 2.25 (3H, s), 1.02 (6H, d, J=6.0 Hz).


Example 925






1H-NMR (Acetone) δ: 8.43 (1.0H, d, J=2.54 Hz), 7.81 (1.0H, dd, J=9.00, 2.54 Hz), 7.61-7.58 (2.0H, m), 7.45-7.24 (6.0H, m), 7.16 (1.0H, d, J=7.69 Hz), 6.91 (1.0H, d, J=9.00 Hz), 4.25 (2.0H, d, J=11.81 Hz), 3.84 (2.0H, s), 3.63 (2.0H, s), 2.90-2.63 (4.0H, m), 1.10 (6.0H, d, J=5.22 Hz).


Example 926






1H-NMR (Acetone) δ: 8.09-8.07 (2.0H, m), 7.60 (1.0H, dd, J=7.76, 7.76 Hz), 7.48-7.34 (5.0H, m), 7.26 (1.0H, dd, J=7.76, 7.76 Hz), 7.20-7.13 (2.0H, m), 6.79 (1.0H, d, J=8.79 Hz), 4.32 (2.0H, d, J=11.81 Hz), 3.83 (2.0H, s), 3.62 (2.0H, s), 2.93-2.67 (4.0H, m), 1.10 (2.0H, d, J=5.70 Hz).


Example 927






1H-NMR (DMSO-d6) δ: 1.00 (6H, d, J=6.0 Hz), 2.35 (3H, t, J=10.7 Hz), 2.61-2.73 (2H, m), 3.53 (2H, s), 3.75 (2H, s), 5.90 (2H, s), 6.32 (1H, dd, J=8.5, 1.6 Hz), 6.65-6.78 (2H, m), 7.05-7.28 (4H, m).


Example 928






1H-NMR (DMSO-d6) δ: 1.03 (7H, d, J=6.0 Hz), 2.35-2.46 (2H, m), 2.68-2.81 (2H, m), 3.55 (2H, s), 3.72 (3H, s), 3.79 (2H, s), 6.27 (1H, d, J=2.2 Hz), 6.90-7.31 (8H, m).


Example 929






1H-NMR (DMSO-d6) δ: 1.03 (6H, d, J=5.2 Hz), 2.61-2.76 (4H, m), 2.92-3.00 (2H, m), 3.53 (2H, s), 3.75 (2H, s), 3.83 (2H, d, J=10.7 Hz), 6.93-7.28 (6H, m), 7.42 (1H, d, J=8.5 Hz).


Example 930






1H-NMR (DMSO-d6) δ: 1.04 (6H, d, J=6.0 Hz), 2.50-2.58 (2H, m), 2.66-2.78 (2H, m), 3.54 (2H, s), 3.66 (2H, d, J=11.5 Hz), 3.78 (2H, s), 7.06-7.31 (5H, m), 7.59 (1H, d, J=2.2 Hz), 7.87 (1H, d, J=9.1 Hz), 9.07 (1H, s).


Example 931






1H-NMR (DMSO-d6) δ: 1.04 (6H, d, J=6.0 Hz), 2.45-2.75 (7H, m), 3.54 (2H, s), 3.61 (2H, d, J=10.7 Hz), 3.78 (2H, s), 7.06-7.39 (6H, m), 7.78 (1H, d, J=8.8 Hz).


Example 932






1H-NMR (Acetone) δ: 7.49 (2.0H, d, J=8.66 Hz), 7.40 (1.0H, s), 7.35 (1.0H, d, J=7.42 Hz), 7.26 (1.0H, dd, J=7.42, 7.42 Hz), 7.16 (1.0H, d, J=7.42 Hz), 7.08 (2.0H, d, J=8.66 Hz), 3.83 (2.0H, s), 3.75 (2.0H, d, J=10.71 Hz), 3.62 (2.0H, s), 2.84-2.66 (4.0H, m), 1.09 (6.0H, d, J=5.77 Hz).


Example 933






1H-NMR (Acetone) δ: 7.53-7.49 (2.0H, m), 7.41 (1.0H, s), 7.37-7.32 (3.0H, m), 7.29 (1.0H, d, J=4.39 Hz), 7.25 (1.0H, d, J=7.42 Hz), 7.20-7.13 (3.0H, m), 6.17 (1.0H, d, J=3.85 Hz), 3.85 (2.0H, s), 3.63 (2.0H, s), 3.43 (2.0H, d, J=9.61 Hz), 2.86-2.83 (2.0H, m), 2.70-2.66 (2.0H, m), 1.09 (6.0H, d, J=6.32 Hz).


Example 934






1H-NMR (DMSO-d6) δ: 8.72 (2H, s), 7.59-7.40 (2H, m), 7.13 (1H, t, J=8.1 Hz), 6.75 (1H, s), 6.66 (1H, s), 6.54 (1H, s), 4.86 (1H, br-s), 4.56 (1H, d, J=12.9 Hz), 3.48-3.13 (3H, m), 2.86-2.72 (2H, m), 2.23 (3H, s), 2.10-1.90 (2H, m), 1.39 (1H, m), 0.91-0.87 (6H, m).


Example 935






1H-NMR (DMSO-d6) δ: 8.72 (2H, s), 6.75 (1H, s), 6.66 (1H, s), 6.54 (1H, s), 4.86 (1H, br-s), 4.56 (1H, d, J=12.9 Hz), 3.48-3.13 (3H, m), 2.86-2.72 (2H, m), 2.23 (3H, s), 2.10-1.90 (2H, m), 1.39 (1H, m), 0.91-0.87 (6H, m).


Example 936






1H-NMR (DMSO-d6) δ: 8.23 (1.0H, d, J=7.22 Hz), 7.42 (1.0H, d, J=12.42 Hz), 6.73 (1.0H, s), 6.65 (1.0H, s), 6.54 (1.0H, s), 4.15-3.86 (2.0H, m), 3.53-3.20 (3.0H, m), 2.92-2.75 (2.0H, m), 2.24 (3.0H, s), 2.20-2.05 (2.0H, m), 1.92-1.70 (2.0H, m), 1.52-1.48 (6.0H, m), 1.30-1.14 (2.0H, m), 0.90 (3.0H, t, J=7.30 Hz).


Example 937






MS (ESI) 534[M−H]−


Example 938






MS (ESI) 494[M−H]−


Example 939






MS (ESI) 508[M−H]−


Example 940






MS (ESI) 536[M−H]−


Example 941






1H-NMR (300 MHz, DMSO-d6) δ 0.85 (3H, t, J=7.2 Hz), 1.13-1.35 (4H, m), 1.50 (6H, s), 1.75-1.94 (2H, m), 2.12-2.17 (2H, m), 2.24 (3H, s), 2.78-2.90 (2H, m), 3.33-3.53 (3H, m), 4.02 (2H, m), 6.54 (1H, s), 6.65 (1H, s), 6.74 (1H, s), 7.43 (1H, d, J=12.0 Hz), 8.23 (1H, d, J=7.2 Hz), 12.97 (1H, br s)


Example 942






MS (ESI) m/z 428 [M+H]+


Example 943






TLC_Rf=0.55 (MeOH:CHCl3=1:10)


Example 944






1H-NMR (300 MHz, DMSO-d6) δ 0.83 (3H, t, J=7.2 Hz), 1.06-1.33 (4H, m), 1.51 (6H, s), 1.61-1.91 (2H, m), 1.98-2.05 (2H, m), 2.26 (3H, s), 2.78-2.90 (2H, m), 3.11-3.55 (3H, m), 4.55 (1H, d, =12.3 Hz), 4.72 (1H, m), 6.54 (1H, s), 6.66 (1H, s), 6.75 (1H, s), 7.14 (1H, m), 7.45-7.55 (3H, m), 8.72 (2H, s)


The present invention includes the following compounds synthesized by similar methods as above.


Compound I-1







Compound I-2






Compound I-3






Compound I-4






Compound I-5






Compound I-6






Compound I-7






Compound I-8






Compound I-9






Compound I-10






Compound I-11






Compound I-12






Compound I-13






Compound I-14






Compound I-15






Compound I-16






Compound I-17






Compound I-18






Compound I-19






Compound I-20






Compound I-21






Compound I-22






Compound I-23






Compound I-24






Compound I-25






Compound I-26






Compound I-27






Compound I-28






Compound I-29






Compound I-30






Compound I-31






Compound I-32






Compound I-33






Compound I-34






Compound I-35






Compound I-36






Compound I-37






Compound I-38






Compound I-39






Compound I-40






Compound I-41






Compound I-42






Compound I-43






Compound I-44






Compound I-45






Compound I-46






Compound I-47






Compound I-48






Compound I-49






Compound I-50






Compound I-51






Compound I-52






Compound I-53






Compound I-54






Compound I-55






Compound I-56






Compound I-57






Compound I-58






Compound I-59






Compound I-60






Compound I-61






Compound I-62






Compound I-63






Compound I-64






Compound I-65






Compound I-66






Compound I-67






Compound I-68






Compound I-69






Compound I-70






Compound I-71






Compound I-72






Compound I-73






Compound I-74






Compound I-75






Compound I-76






Compound I-77






Compound I-78






Compound I-79






Compound I-80













TABLE 1

























No.
A







X-1












X-2












X-3












X-4












X-5






















TABLE 2

























No.
A







X-6












X-7












X-8












X-9












X-10












X-11












X-12












X-13












X-14












X-15






















TABLE 3


























No.
R1
B







Y-1
H












Y-2
H












Y-3
H












Y-4
H












Y-5
H












Y-6
H












Y-7
H












Y-8
H












Y-9
H












Y-10
H












Y-18
5-Me












Y-19
5-Me












Y-20
5-Me












Y-21
5-Me












Y-22
5-Me












Y-23
5-Me












Y-24
5-Me












Y-25
5-Me












Y-26
5-Me












Y-27
5-Me






















TABLE 4


























No.
R1
B







Y-11
H












Y-12
H












Y-13
H












Y-14
H












Y-15
H












Y-16
H












Y-17
H












Y-28
5-Me












Y-29
5-Me












Y-30
5-Me












Y-31
5-Me












Y-32
5-Me












Y-33
5-Me












Y-34
5-Me






















TABLE 5


























No.
R1
B







Y-35
H












Y-36
H












Y-37
H












Y-38
H












Y-39
H












Y-40
H












Y-41
H












Y-42
H












Y-43
H












Y-44
H












Y-52
4-Cl












Y-53
4-Cl












Y-54
4-Cl












Y-55
4-Cl












Y-56
4-Cl












Y-57
4-Cl












Y-58
4-Cl












Y-59
4-Cl












Y-60
4-Cl












Y-61
4-Cl






















TABLE 6


























No.
R1
B







Y-45
H












Y-46
H












Y-47
H












Y-48
H












Y-49
H












Y-50
H












Y-51
H












Y-62
4-Cl












Y-63
4-Cl












Y-64
4-Cl












Y-65
4-Cl












Y-66
4-Cl












Y-67
4-Cl












Y-68
4-Cl






















TABLE 7

























No.
C







Z-1












Z-2












Z-3












Z-4












Z-5












Z-6












Z-7












Z-8












Z-9












Z-10












Z-11












Z-12












Z-13












Z-14












Z-15






















TABLE 8

























No.
C







Z-16












Z-17












Z-18












Z-19












Z-20












Z-21












Z-22












Z-23












Z-24












Z-25












Z-26












Z-27












Z-28












Z-29












Z-30















Test Example 1
Test for Transcriptional Activity of PPARδ and α

A chimeric transcription factor assay, which is commonly used to detect nuclear receptor activity, was employed to measure PPAR transcriptional activity. Specifically, two plasmids, one that expresses the fusion protein of DNA binding domain of yeast transcription factor GAL4 and a ligand binding domain of a receptor, and a reporter plasmid were transiently transfected to CHO cells. The activity of the promoter containing a recognition sequence of GAL4 coded on the reporter plasmid was used as a parameter to estimate the activity of the receptor.


Plasmid: The ligand binding domain of human PPARδ (hPPARδ) or a (hPPARα) (δ: aa 139-C-end; α: aa 167-C-end) is obtained by PCR amplification using Human Universal Quick-Clone cDNA (CLONTECH). Each amplified cDNA was subcloned into pCR2.1-TOPO vector (Invitrogen) and the identity of the cDNA clones was confirmed by the DNA sequence. Then, each obtained cDNA fragment was subcloned into pBIND vector (Promega) to construct a plasmid expressing the fusion protein with DNA binding domain of yeast transcription factor GAL4. pG5luc vector (Promega) was used as a reporter plasmid.


Cell culturing and transfection: CHO cells were cultured in 10% FBS-aMEM. With a 96-well plate (Costar), CHO cells, that were dispersed with trypsin treatment, 20000 cells per well and the two plasmids obtained by the above procedure, 25 ng per well, were transfected with FuGene Reagent (Roche) by following the instruction of the manufacture.


Measurement of the transcriptional activity: CHO cells 100 μl per well, which were transfected as above, were dispensed into the wells in which a test compound dissolved in DMSO 0.5 μl was spotted in advance. After the cells and a test compound were cultured together for 24 hours in a CO2 incubator, the luciferase activity was measured by adding luciferase substrates, PicaGene LT2.0 (Toyo ink) 100 μl per well. LUMINOUS CT-9000D (DIA-IATRON) is used to measure the activity.


As to PPARδ, the concentration of a test compound which shows ½ of maximum luciferase activity was calculated using an Excel program to obtain the EC50 value for PPARδ activity of a test compound. The result is shown in Table 9.











TABLE 9









EC50 (μM)












Example No.
hPPARδ
hPPARα
hPPARγ
















474
0.0045
0.35
0.20



503
0.91
1.5
>10



519
0.02
0.54
0.8



562
0.029
>10
1.9



590
0.026
>10
>10



597
0.0075
0.27
0.69



612
0.049
0.57
2.2



630
0.023
2.6
4.2



652
0.28
>10
>10



679
0.013
0.96
0.58



699
0.041
1.00
0.76



707
0.019
2.50
3.30



854
0.0044
>10
>10










Test Example 2
Test for Inhibition of CYP2C9 Enzyme

The test for inhibition of CYP2C9 enzyme was carried out with human liver microsomes and hydration activity of 4-position of tolbutamide that is a typical reaction of CYP2C9 as a parameter.


The reaction condition was as below: A substrate, 5 μM Tolbutamide (14C labeled compound); the reaction time, 30 minutes; the reaction temperature, 37° C.; the protein concentration, 0.25 mg/ml (human liver microsomes, 15 pol, Lot. 210296, XenoTech).


To the HEPES Buffer (pH 7.4), was added the protein (human liver microsomes), a drug solution and a substrate with the composition as the above. NADPH, which is a coenzyme of the reaction, was added thereto to start the reaction. After reacting for the fixed hours, 2N hydrochloric acid solution was added thereto and the reaction was stopped by removing protein. The remaining substrate drug and the generating metabolite were extracted with chloroform. The solvent was removed and the residue was redissolved in methanol. This solution was spotted on TLC, developed with chloroform:methanol: acetic acid=90:10:1, contacted on the imaging plate for about 14-20 hours and analyzed by BAS2000. As to the generation activity of the metabolite, Tolbutamide 4-position hydration body, the activity in case that the solvent dissolving a drug was added to the reaction assay was used as a control (100%). The residual activity (%) in case that the test drug solution was added to the reaction was calculated to confirm the compounds of the present invention had little effect on inhibition of CYP2C9 enzyme.


Test Example 3
Test for Metabolic Stability

Test for Metabolic Stability in Hepatic Microsomes: To trishydrochloric acid buffer (pH 7.4), were added NADPH (the final concentration was 1 mM in case of oxidative metabolism), Hepatic Microsomes (the final concentration was 0.5 mg protein/ml) and each compound (the final concentration was 2 μM). The mixture was reacted at 37° C. for 0 and 30 minutes. In case of conjugated glucuronic acid, UDPGA (the final concentration is 5 mM) was added instead of NADPH. The reaction was stopped by adding acetonitrile/methanol=1/1 (v/v) which is 2 parts by volume based on 1 part by volume of the reaction solution and then compounds in the centrifugal supernatant were measured by HPLC. By comparing the values between 0 and 30 minutes the disappearance volume of the compounds by the metabolic reaction was calculated to confirm metabolic stability of the compounds of the present invention.


Test Example 4
Test for Solubility

The compounds of the present invention and test solvents (JP-2 solution, and JP-2 solution containing 20 mM sodium taurocholate) were stirred at 37° C. for 3 hours. The mixture was filtrated with a 0.45 μm filter and the concentration of the filtrate was measured with HPLC method to confirm solubility of compounds of the present invention.


Test Example 5
Test for Toxicity

The compounds of the present invention (30 to 300 mg/kg/day) were administered to rats. After administration, number of deaths, conditions, food intake and body weight of rats were checked and histopathological examination and the like were performed.


Additionally, as a hematological examination, after few days from administration, the blood was collected and PT, APTT and Fbg were measured after blood treatment. The activities of extrinsic blood coagulation factors (F-III, F-V, F-VII, F-X) and intrinsic blood coagulation factors (F-VIII, F-IX, F-XI, F-XII) were measured. The coagulation times of extrinsic or intrinsic blood coagulation factors were measured by a method for measurement of PT (extrinsic) or APTT (intrinsic) after adding plasma which is deficient a factor of each measuring object (Dade Boehringer Marburg) to plasma of rat and preincubating. Plasma of control rats was mixed and calibration curve was made with diluent which the plasma was sequentially double-diluted with Owren's Veronal Buffer as a reference material. Activity percentage was calculated with coagulation time measured by a method for coagulation time with factor deficient plasma and calibration curve and activities of each coagulation factor were evaluated by activity percentage compared to plasma of intact rat.


As the above, toxicities of compounds of the present invention were confirmed.

Claims
  • 1-27. (canceled)
  • 28. A compound of the formula (I):
  • 29. The compound, pharmaceutically acceptable salt or solvate thereof according to claim 28, wherein Ring Q is substituted fused heteroaryl.
  • 30. The compound, pharmaceutically acceptable salt or solvate thereof according to claim 28, wherein Ring Q is substituted benzofuryl, substituted benzothienyl, substituted benzopyrolyl, substituted benzoxazolyl, substituted benzoisoxazolyl, substituted benzothiazolyl, substituted benzoisothiazolyl, substituted benzoimidazolyl or substituted benzopyrazolyl.
  • 31. The compound, pharmaceutically acceptable salt or solvate thereof according to claim 28, wherein a group of the formula:
  • 32. The compound, pharmaceutically acceptable salt or solvate thereof according to claim 28, wherein a group of the formula:
  • 33. The compound, pharmaceutically acceptable salt or solvate thereof according to claim 28, wherein a group of the formula:
  • 34. The compound, pharmaceutically acceptable salt or solvate thereof according to claim 28, wherein a group of the formula: -Y2Z1- is a group of the formula:
  • 35. The compound, pharmaceutically acceptable salt or solvate thereof according to claim 28, wherein Ring B is optionally substituted phenylene, optionally substituted indolediyl, optionally substituted benzofurandiyl, optionally substituted benzothiophenediyl, optionally substituted furandiyl or optionally substituted thiophenediyl.
  • 36. The compound, pharmaceutically acceptable salt or solvate thereof according to claim 28, wherein Y3 is a bond, optionally substituted lower alkylene, —O-optionally substituted lower alkylene or optionally substituted lower alkenylene.
  • 37. The compound, pharmaceutically acceptable salt or solvate thereof according to claim 28, wherein Z2 is COOR3 wherein R3 is hydrogen or optionally substituted lower alkyl.
  • 38. The compound, pharmaceutically acceptable salt or solvate thereof according to claim 28, wherein a group of the formula:
  • 39. The compound, pharmaceutically acceptable salt or solvate thereof according to claim 28, wherein a group of the formula:
  • 40. The compound, pharmaceutically acceptable salt or solvate thereof according to claim 28, wherein Y1 is a bond, a group of the formula: -Y2Z1- is a group of the formula:
  • 41. A pharmaceutical composition comprising the compound, pharmaceutically acceptable salt or solvate thereof according to claim 28 as an active ingredient.
  • 42. A pharmaceutical composition for prevention and/or treatment for a disease concerning peroxisome proliferator-activated receptor(s), which comprises the compound, pharmaceutically acceptable salt or solvate thereof according to claim 28 as active ingredient.
Priority Claims (2)
Number Date Country Kind
2005-246297 Aug 2005 JP national
2006-154607 Jun 2006 JP national
PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/JP2006/316564 8/24/2006 WO 00 4/8/2008